BACKGROUND OF THE INVENTION Factor Xa and Factor Xa assembled in the prothrombinase complex (Factor Xa, Factor Va, calcium and phospholipid) activates prothrombin to generate thrombin. Factor Xa is strategically located at the intersection of extrinsic and intrinsic pathways of the blood coagulation system. Thus, an inhibitor of Factor Xa inhibits the formation of thrombin and therefore is useful for preventing or treating disorders related to blood coagulation in mammals.

Anticoagulant therapy is indicated for the treatment and prophylaxis of a variety of thrombotic conditions of both the venous and arterial vasculature. In the arterial system, abnormal thrombus formation is primarily associated with arteries of the coronary, cerebral and peripheral vasculature. The diseases associated with thrombotic occlusion of these vessels principally include acute myocardial infarction (AMI), unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy and percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication and bypass grafting of the coronary (CABG) or peripheral arteries. Chronic anticoagulant therapy may also be beneficial in preventing the vessel luminal narrowing (restenosis) that often occurs following PTCA and CABG, and in the maintenance of vascular access patency in long- term hemodialysis patients. With respect to the venous vasculature, pathologic thrombus formation frequently occurs in the veins of the lower extremities following abdominal, knee and hip surgery (deep vein thrombosis, DVT). DVT further predisposes the patient to a higher risk of pulmonary thromboembolism. A systemic, disseminated intravascular coagulopathy (DIC) commonly occurs in both vascular systems during septic shock, certain viral infections and cancer. This condition is characterized by a rapid consumption of coagulation factors and their plasma inhibitors resulting in the formation of life-threatening clots throughout the microvasculature of. several organ systems.

In addition to their use in anticoagulant therapy, Factor Xa inhibitors are useful in the treatment or prevention of other diseases in which the generation of thrombin has been implicated as playing a physiologic role. For example, thrombin has been proposed to contribute to the morbidity and mortality of such chronic and degenerative diseases as arthritis, cancer, atherosclerosis and Alzheimer's disease by

virtue of its ability to regulate many different cell types through specific cleavage and activation of a cell surface thrombin receptor, mitogenic effects, diverse cellular functions such as cell proliferation, for example, abnormal proliferation of vascular cells resulting in restenosis or angiogenesis, release of PDGF and DNA syntheses. Inhibition of Factor Xa will effectively block thrombin generation and therefore neutralize any physiologic effects of thrombin on various cell types.

The representative indications discussed above include some, but not all, of the possible clinical situations amenable to treatment with a Factor Xa inhibitor.

Oxoazaheterocyclyl Factor Xa inhibitors are disclosed in International Patent Numbers PCT/US98/07158, published Oct. 22,1998; PCT/US98/07159, published Oct. 22,1998; PCT/JS98/07160, published Oct. 22,1998; PCT/US98/07161, published Oct. and PCT/US96/09290, published Dec. 19,1996. Oxoazaheterocyclyl fibrinogen antagonists are disclosed in International Patent Application Number PCT/US92/09467, published May 13,1993.

SUMMARY OF THE INVENTION This invention is directed to a compound of formula I or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof wherein G, and G, are L,-Cy, or L2-Cy2, provided that when R, and R, a or R4 and R4a taken together form O or S, then G, is L2-Cy2 and G, is L,-Cy,, or when R, and Rlaor R3 and R3a taken together form O or S, then G, is L,-Cy, and G2 is L,-Cy2; Cy, and CY2 are independently selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted

heterocyclyl, optionally substituted heterocyclenyl, optionally substituted fused arylcycloalkyl, optionally substituted fused arylcycloalkenyl, optionally substituted fused arylheterocyclyl, optionally substituted fused arylheterocyclenyl, optionally substituted fused heteroarylcycloalkyl, optionally substituted fused heteroarylcycloalkenyl, optionally substituted fused heteroarylheterocyclyl and optionally substituted fused heteroarylheterocyclenyl; O,NR5,-S(O)p-,-S(O)pNR5-,L1is -C(X)Y- -L3-Q-L4-Q'-L5-, <BR> <BR> <BR> <BR> <BR> <BR> L3 and L5 are independently absent, optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene; <BR> <BR> <BR> <BR> <BR> <BR> L4 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted<BR> <BR> <BR> <BR> <BR> <BR> alkynylene;<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Q and Q'are independently absent, O, S, NRS,-S (O) p-,-S (O) PNRs- or-C (X) Y- ;<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> A is CH or N; R1, R1a, R2, R2a, R3, R3a, R4 and R4a are independently selected from hydrogen, carboxy, alkoxycarbonyl, Y'Y2NCO, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, <BR> <BR> <BR> <BR> optionally substituted heteroaryl and optionally substituted heteroaralkyl, or R, and Ria, R, and R2a, R3 and R3a, or R4 and R4a taken together form O or S; m and n are independently 0,1 or 2, provided that m and n are not both 0 and further provided that when <BR> <BR> <BR> <BR> R, and Ri. take together form O or S, n is 1 and when R4 and R4a taken together form O or S, m is I; L2 is absent or a group of formula

R5 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, R60 (CH2) v-, R602C (CH2) X-, YlY2NC (O) (CH2) x-, or Y1Y2N (CH2) v- ; R6 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl; Y1 and Y2 are independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or Y2and taken together with the N through which Y1 andY2 are linked form a monocyclic heterocyclyl; R7, R8, R9 and R, o are independently selected from hydrogen, hydroxy, alkoxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl and optionally substituted heteroaralkyl, provided that only one of R, and R8 or one of R9 and R, o is hydroxy or alkoxy, and further provided when R"R8, R9 and R, o is hydroxy or alkoxy, then the hydroxy or alkoxy is not a substituted to a N, O or S in Z; X is 0 or S; Y is absent or is selected from O, S and NR5; Z is absent or is selected from optionally substituted lower alkenylene, optionally substituted lower alkynylene, O, S (O) p, NR5,-NR5C (O)-and-C (O) NR5-; x is 1,2,3 or 4; v is 2,3 or 4; 1or2;andpis q and r are independently 0, 1, 2 or 3, provided that q and r are not both 0.

In another aspect, this invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula I and a pharmaceutically acceptable carrier.

In another aspect, this invention is directed to a method of treating a physiological disorder capable of being modulated by inhibiting Factor Xa comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I.

In another aspect, this invention is directed to a compound of formula 11

wherein P is H or a nitrogen protecting group; R"Rla, R2, R2a, R3, R3a, R4 and Rg are independently selected from hydrogen, carboxy, alkoxycarbonyl, Y'Y2NCO, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; L2 is a group of formula

Cy2 is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclenyl, optionally substituted fused arylcycloalkyl, optionally substituted fused arylcycloalkenyl, optionally substituted fused arylheterocyclyl, optionally substituted fused arylheterocyclenyl, optionally substituted fused heteroarylcycloalkyl, optionally substituted fused heteroarylcycloalkenyl, optionally substituted fused heteroarylheterocyclyl and optionally substituted fused heteroarylheterocyclenyl; R5 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, R60 (CH2) v-, R602C (CH2) X-, YlY2NC (O) (CH2) x-, or YlY2N (CH2) v- ;

R6is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl; Y1 and Y2 are independently hydrogen, optionally substituted alkyl,optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or Y2takenand together with the N through which Y and Y are linked form a monocyclic heterocyclyl; R"R8, R9 and R, o are independently selected from hydrogen, hydroxy, alkoxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl and optionally substituted heteroaralkyl, provided that only one of R, and R8 or one of R, and R, o is hydroxy or alkoxy, and further provided when R"R8, R9 and R, o is hydroxy or alkoxy, then the hydroxy or alkoxy is not a substituted to a N, O or S in Z; Z is absent or is selected from optionally substituted lower alkenylene, optionally substituted lower alkynylene, O, S (O) p, NR5,-NR5C (O)-and-C (O) NR5-; x is 1,2,3 or 4; v is 2,3 or 4; and q and r are independently 0,1,2 or 3, provided that q and r are not both 0, which is an intermediate useful in the preparation of the compound of formula I.

DETAILED DESCRIPTION OF THE INVENTION Definitions As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings: "Patient"includes both human and other mammals.

"Alkyl"means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups have 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain."Lower alkyl"means about 1 to about 4 carbon atoms in the chain which may be

straight or branched. The alkyl may be substituted with one or more"alkyl group substituents"which may be the same or different, and include halo, cycloalkyl, hydroxy, alkoxy, amino, carbamoyl, acylamino, aroylamino, carboxy, alkoxycarbonyl, aralkyloxycarbonyl and heteroaralkyloxycarbonyl.

Representative alkyl groups include methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonylethyl, benzyloxycarbonylmethyl, and pyridylmethyloxycarbonylmethyl.

"Alkenyl"means a straight or branched aliphatic hydrocarbon group containing a carbon-carbon double bond and having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 6 carbon atoms in the chain. Branched means that one or more tower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkenyl chain."Lower alkenyl"means about 2 to about 4 carbon atoms in the chain which may be straight or branched. The alkenyl group may be substituted by one or more alkyl group substituents as defined herein. Representative alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, decenyl, and the like.

"Alkylene"means a straight or branched bivalent hydrocarbon chain having from 1 to about 20 carbon atoms. The preferred alkylene groups are the lower alkylene groups having from 1 to about 6 carbon atoms. Alkylene may be substituted with I or more alkyl group substituents as defined herein.

Representative alkylene groups include methylene, ethylene, and the like.

"Alkenylene"means a bivalent group derived from a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. The preferred alkenylene groups are the lower alkenylene groups having from 1 to about 6 carbon atoms. Alkenylene may be substituted by one or more alkyl group substituents as defined herein. Representative alkenylene include-CH=CH-,- CH2CH=CH-,-C (CH3) =CH-,-CH2CH=CHCH2-, and the like.

"Alkynylene"means a bivalent group derived from a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. Preferred alkynylene groups are the lower alkynylene groups having from I to about 6 carbon atoms. Alkynylene may be substituted by one or more alkyl group substituents as defined herein. Representative akynylene include -CH= CH-,-CH : CH-CH2-,-CH= CH-CH (CH3), and the like.

"Amidino"or"amidine"means a group of formula wherein R,, is selected from hydrogen, R602C-, R6O-, R6C (O)-, cyano, optionally substituted lower alkyl, nitro or Y'YN-and R, 2 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted aralkyl and optionally substituted heteroaralkyl. Preferred amidino groups are those in which R,, is hydrogen, R6O, or optionally substituted lower alkyl and R, 2 is as defined above. Most preferred amidino groups are those in which R"and R, 2 are hydrogen.

"Basic nitrogen atom"means an sp or sp'hybridized nitrogen atom having a non-bonded pair of electrons which is capable of being protonated. Examples of basic nitrogen atoms, which may be optionally substituted where possible, include those in heteroaryl, heterocyclyl, heterocyclenyl, fused arylheterocyclyl, fused arylheterocyclenyl, fused heteroarylcycloalkyl, fused heteroarylcycloalkenyl, fused heteroarylheterocyclyl, fused heterocyclylheterocyclenyl, imino, amino and amidino groups.

"Cycloalkyl"means a non-aromatic mono-or multicyclic hydrocarbon ring system of about 3 to about 10 carbon atoms. Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl, cycloheptyl, and the like. Representative multicyclic cycloalkyl rings include decalinyl, norbornyl, adamantyl, and the like. The cycloalkyl group is optionally substituted with one or more cycloalkyl group substituents which may be the same or different, where"cycloalkyl group substituent"includes oxo, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo. nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, amidino, amino, carbamoyl, or sulfamoyl. Preferred cycloalkyl group substituents are amino and amidino.

"Cycloalkenyl"means a non-aromatic monocyclic or multicyclic hydrocarbon ring system containing a carbon-carbon double bond and having about 3 to about 10 carbon atoms. The cycloalkenyl group is optionally substituted by one or more cycloalkyl group substituents as defined herein.

Representative monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl, and the like. A representative multicyclic cycloalkenyl ring is norbornylenyl. Preferred cycloalkenyl group substituents are amino and amidino.

"Heterocyclyl"means a non-aromatic saturated monocyclic or multicyclic ring system of about 3 to about 10 ring atoms wherein the ring system contains one or more element (s) other than carbon.

"Azaheterocyclyl"means heterocyclyl wherein one or more of the atoms in the ring system is/are nitrogen. Preferred heterocyclyl comprise about 5 to about 6 ring atoms wherein one or two of the ring atoms is/are independently selected from oxygen, nitrogen or sulfur. "Aza","oxo"or"thia", when used as a prefix before heterocyclyl means that the ring system contains at lease one nitrogen, oxygen or sulfur atom. The heterocyclyl is optionally substituted with one or more heterocyclyl group substituents which may be the same or different, where"heterocyclyl group substituent"includes oxo, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aryloxycarbonyl, aralkoxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, amino, carbamoyl, or sulfamoyl. Preferred heterocyclyl group substituents include amino, amidino, halogen, hydroxy, alkoxycarbonylalkyl and carboxyalkyl. Representative heterocyclyl include piperidyl,

pyrrolidinyl, piperazinyl, pyrazolidinyl, imidazolinyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dithianyl, 1,3,5-triathianyl, tetrahydrothienyl, tetrahydrothiopyranyl, quinuclidinyl, and the like. The thio or nitrogen moiety of the heterocyclyl may also be optionally oxidized to the corresponding S-oxide, S, S-dioxide or N-oxide.

"Heterocyclenyl"means a heterocyclyl as defined herein which contains at least one carbon- carbon or carbon-nitrogen double bond. "Aza","oxo"or"thia", when used as a prefix before heterocyclenyl means that the ring system contains at lease one nitrogen, oxygen or sulfur atom. The heterocyclenyl is optionally substituted with one or more heterocyclyl group substituents as defined herein. Representative heterocyclenyl include 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, 2H-pyranyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,4- tetrahydropyridyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like. Preferred heterocyclyl group substituents include amino, amidino, halogen, hydroxy, alkoxycarbonylalkyl and carboxyalkyl. The thio or nitrogen moiety of the heterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S, S-dioxide.

"Aryl"means a 6 to 10 membered aromatic monocyclic or multicyclic hydrocarbon ring system.

The aryl is optionally substituted with one or more aryl group substituents which may be the same or different, where"aryl group substituent"includes hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aryldiazo, heteroaryldiazo, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroaryisulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, arylazo, heteroarylazo, amino, alkylamino, carbamyl and sulfamyl. Preferred aryl groups are optionally substituted phenyl or optionally substituted naphthyl. Preferred aryl group substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino.

"Heteroaryl"means about a 5-to about a 10-membered aromatic monocyclic or multicyclic ring system wherein one or more of the atoms in the ring system is/are element (s) other than carbon.

Preferred heteroaryl contain one to about 4 heteroatoms selected from oxygen, nitrogen and sulfur.

"Aza","oxo"or"thia", when used as a prefix before heteroaryl means that the ring system contains at lease one nitrogen, oxygen or sulfur atom. The heteroaryl is optionally substituted with one or more aryl group substituents as defined herein. Representative heteroaryl groups include pyrrolyl, pyrazinyl, furyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thienopyridyl, pyrrolopyridyl, furanopyridyl, furazanyl, quinoxalinyl, quinazolinyl, quinolizinyl, imidazo [1,2-a] pyridyl, phthalazinyl, imidazo [2,1-b] thiazolyl, benzofuranyl, indolyl, isoindolyl, indolizinyl, indazolyl, azaindolyl, benzimidazolyl, benzothienyl, benzisoxazolyl,

benzothiazolyl, purinyl, benzotriazolyl, 1,8-naphthyridinyl, pteridinyl, quinolinyl, imidazolyl, isoquinolinyl, cinnolinyl, triazinyl, benzotriazinyl, and the like. Preferred heteroaryl group substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. When heteroaryl contains a nitrogen atom, the nitrogen atom may be oxidized to the N-oxide.

"Fused arylcycloalkyl"means a fused aryl and cycloalkyl as defined herein. Preferred fused arylcycloalkyls are those wherein the aryl thereof is phenyl and the cycloalkyl consists of about 5 to about 6 carbon atoms. Representative fused phenylcycloalkyl groups include 1,2,3,4-tetrahydronaphthyl, indanyl, and the like. The fused arylcycloalkyl is optionally substituted with one or more fused arylcycloalkyl group substituents selected from, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aryldiazo, heteroaryidiazo, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, arylazo, heteroarylazo, amino, alkylamino, carbamyl and sulfamyl. The cycloalkyl moiety is further optionally substituted with oxo. Preferred fused phenylcycloalkyl group substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino.

"Fused arylcycloalkenyl"means a fused aryl and cycloalkenyl as defined herein. Preferred fused arylcycloalkyenl are those wherein the aryl thereof is phenyl and the cycloalkenyl consists of about 5 to about 6 carbon atoms. The fused arylcycloalkenyl is optionally substituted with one or more fused arylcycloalkyl group substituents as defined herein. Representative fused phenylcycloalkenyls include 1,2-dihydronaphthylenyl, indenyl, and the like. The cycloalkyl moiety is further optionally substituted with oxo. Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino.

"Fused arylheterocyclyl"means a fused aryl and heterocyclyl as defined herein. Preferred fused arylheterocyclyl are those wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to about 6 ring atoms wherein one or two of the ring atoms is/are independently selected from oxygen, nitrogen and sulfur. "Aza","oxo"or"thia", when used as a prefix before the heterocyclyl portion of the fused arylheterocyclyl means that the heterocyclyl contains at lease one nitrogen, oxygen or sulfur atom.

Representative preferred fused phenylheterocyclyl ring systems include indolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, I H-2, 3-dihydroisoindolyl, 2,3-dihydrobenz [fisoindolyl, 1,2,3,4-tetrahydrobenz [g] isoquinolinyl, and the like. The fused phenylheterocyclyl is optionally substituted with one or more fused phenylcycloalkyl group substituents

as defined herein. The heterocyclyl moiety is further optionally substituted with oxo. Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. The nitrogen or sulphur atom of the heterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S, S-dioxide.

"Fused arylheterocyclenyl"means a fused aryl and heterocyclenyl as defined herein."Aza", "oxo"or"thia", when used as a prefix before the heterocyclenyl portion of the fused arylheterocyclenyl means that the heterocyclenyl contains at lease one nitrogen, oxygen or sulfur atom. Preferred fused arylheterocyclyl are those wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to about 6 ring atoms wherein one or two of the ring atoms is/are independently selected from oxygen, nitrogen and sulfur. Representative preferred fused arylheterocycloalkenyl ring systems include 3H-indolinyl, I H-2-oxoquinolyl, 2H-I-oxoisoquinolyl, and the like. The fused arylheterocyclenyl is optionally substituted with one or more fused arylcycloalkyl group substituents as defined herein. The heterocyclyl moiety is further optionally substituted with oxo. Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. The nitrogen or sulphur atom of the heterocyclenyl is optionally oxidized to the corresponding N-oxide, S-oxide or S, S-dioxide.

"Fused heteroarylcycloalkyl"means a fused heteroaryl and cycloalkyl as defined herein."Aza", "oxo"or"thia", when used as a prefix before the heteroaryl portion of the fused heteroarylcycloalkyl means that the heteroaryl contains at lease one nitrogen, oxygen or sulfur atom. Preferred fused heteroarylcycloalkyls are those wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms in which one or two of the ring atoms are independently selected from oxygen, nitrogen and sulfur and the cycloalkyl consists of about 5 to about 6 ring atoms. Representative preferred fused heteroaryicycloalkyl include 5,6,7,8-tetrahydroisoquinolyl, 5,6,7,8-tetrahydroquinoxalinyl, 5,6,7,8-tetrahydroquinazolyl, 4,5,6,7-tetrahydro-1H-benzimidazolyl, 4,5,6,7-tetrahydrobenzoxazolyl, IH-4-oxa-1, 5-diazanaphthalen-2-onyl, 1, 3-dihydroimidizole- [4, 5]-pyridin-2-onyi, and the like. The fused heteroarylcycloalkyl is optionally substituted with one or more fused phenylcycloalkyl group substituents as defined herein. The cycloalkyl moiety is further optionally substituted with oxo.

Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. The nitrogen atom of the heteroaryl portion of the fused heteroarylcycloalkyl is optionally oxidized to the N- oxide.

"Fused heteroarylcycloalkenyl"means a 5-or 6-membered heteroaryl fused with a cycloalkenyl ring."Aza","oxo"or"thia", when used as a prefix before the heteroaryl portion of the fused heteroarylcycloalkenyl means that the cycloalkenyl contains at lease one nitrogen, oxygen or sulfur

atom. Preferred fused heteroarylcycloalkenyls are those wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms in which one or two of the ring atoms are independently selected from oxygen, nitrogen and sulfur and the cycloalkenyl consists of about 5 to about 6 ring atoms. Representative preferred fused heteroarylcycloalkenyl include 5,6-dihydroisoquinolyl, 5,6-dihydroquinoxalinyl, 5,6-dihydroquinazolinyl, 4,5-dihydro-lH-benzimidazolyl, 4,5-dihydrobenzoxazolyl, and the like. The fused heteroarylcycloalkenyl is optionally substituted with one or more fused phenylcycloalkyl group substituents as defined herein. The cycloalkenyl moiety is further optionally substituted with oxo.

Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. The nitrogen atom of the heteroaryl portion of the fused heteroarylcycloalkyl is optionally oxidized to the N-oxide.

"Fused heteroarylheterocyclyl"means a fused heteroaryl and heterocyclyl as defined herein.

"Aza","oxo"or"thia", when used as a prefix before the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl means that the heteroaryl or heterocyclyl contains at lease one nitrogen, oxygen or sulfur atom. Preferred fused heteroarylheterocyclyls are ring systems wherein one or two of the ring atoms of the heteroaryl are independently selected from oxygen, nitrogen and sulfur and the heterocyclyl portion consists of about 5 to about 6 ring atoms in which one or two of the ring atoms are independently selected from oxygen, nitrogen and sulfur. Representative fused heteroarylheterocyclyl include 2,3-dihydro-IH pyrrol [3,4-b] quinolin-2-yl, 1,2,3,4-tetrahydrobenz [b] [1,7] naphthyridin-2-yl, 1,2,3,4-tetrahydrobenz [b] [1,6] naphthyridin-2-yl, 1,2,3,4-tetrahydro-9H-pyrido [3,4-b] indol-2yl, 1,2,3,4-tetrahydro-9H-pyrido [4,3-b] indol-2yl, 2,3,-dihydro- I H-pyrrolo [3,4-b] indol-2-yl, I H-2,3,4,5-tetrahydroazepino [3,4-b] indol-2-yl, I H-2,3,4,5-tetrahydroazepino [4,3-b] indol-3-yl, I H-2,3,4,5-tetrahydroazepino [4,5-b] indol-2 yl, 5,6,7,8-tetrahydro [1,7] napthyridinyl, 1,2,3,4-tetrhydro [2,7] naphthyridyl, 2,3-dihydro [1,4] dioxino [2,3-b] pyridyl, 2,3-dihydro [1,4] dioxino [2,3-b] pyridyl, 4,5,6,7-tetrahydro-3H-imidazo [4,5-c] pyridyl, 6,7-dihydro-5,8-diazanaphthalenyl, and the like. The fused heteroarylheterocyclyl is optionally substituted with one or more fused arylcycloalkyl group substituents as defined herein. The heterocyclyl moiety is further optionally substituted with oxo. Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. The nitrogen atom of the heteroaryl portion is optionally oxidized to the N-oxide. The nitrogen or sulphur atom of the heterocyclyl is optionally oxidized to the corresponding N-oxide, S-oxide or S, S-dioxide.

"Fused heteroarylheterocyclenyl"means a fused heteroaryl and heterocyclenyl as defined herein.

"Aza","oxo"or"thia", when used as a prefix before the heteroaryl or heterocyclenyl portion of the fused heteroarylheterocyclenyl means that the heteroaryl or heterocyclenyl contains at lease one nitrogen,

oxygen or sulfur atom. Preferred fused heteroarylcycloalkenyls are ring systems wherein the heteroaryl portion thereof consists of about 5 to about 6 ring atoms in which one or two of the ring atoms are independently selected from oxygen, nitrogen and sulfur and the heterocyclenyl portion consists of about 5 to about 6 ring atoms in which one or two of the ring atoms are independently selected from oxygen, nitrogen and sulfur. Representative fused heteroarylheterocyclenyl include 7,8-dihydro [1,7] naphthyridinyl, 1,2-dihydro [2,7] naphthyridinyl, 6,7-dihydro-3H-imidazo [4,5-c] pyridyl, and the like. The fused heteroarylheterocyclenyl is optionally substituted with one or more fused arylcycloalkyl group substituents as defined herein. The heterocyclenyl moiety is further optionally substituted with oxo. Preferred substituents include hydrogen, alkyl, aryl, heteroaryl, hydroxy, acyl, aroyl, halo, nitro, cyano, alkoxycarbonyl, acylamino, alkylthio, alkylamino, amino, carbamyl, thiocarbamyl and amidino. The nitrogen atom of the heteroaryl portion is optionally oxidized to the N-oxide. The nitrogen or sulphur atom of the heterocyclenyl is optionally oxidized to the corresponding N-oxide, S-oxide or S, S-dioxide.

"Aralkyl"means an aryl-alkyl-group in which the aryl and alkyl are as defined herein. Preferred aralkyls contain a lower alkyl moiety. Representative aralkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

"Heteroaralkyl"means a heteroaryl-alkyl-group in which the heteroaryl and alkyl are as defined herein. Preferred heteroaralkyls contain a lower alkyl moiety. Representative heteroaralkyl groups may contain thienyimethyl, pyridylmethyl, imidazolylmethyl and pyrazinylmethyl.

"Aralkenyl"means an aryl-alkenyl-group in which the aryl and alkenyl are as defined herein.

Preferred aralkenyls contain a lower alkenyl moiety. An representative aralkenyl group is 2-phenethenyl.

"Heteroaralkenyl"means a heteroaryl-alkenyl-group in which the heteroaryl and alkenyl are as defined herein. Preferred heteroaralkenyls contain a lower alkenyl moiety. Representative heteroaralkenyl groups may contain thienylethenyl, pyridylethenyl, imidazolylethenyl and pyrazinylethenyl.

"Hydroxyalkyl"means a HO-alkyl-group in which alkyl is defined herein. Preferred hydroxyalkyls contain lower alkyl. Representative hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

"Acyl"means an H-CO-or alkyl-CO-group in which alkyl is defined herein. Preferred acyls contain a lower alkyl. Representative acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, butanoyl and palmitoyl.

"Aroyl"means an aryl-CO-group in which aryl is defined herein. Representative aroyl groups include benzoyl and 1-and 2-naphthoyl.

"Aryldiazo"means an aryl-N=N-group in which aryl is defined herein. Representative aryldiazo groups include phenyldiazo and naphthyldiazo.

"Heteroaroyl"means an means a heteroaryl-CO-group in which heteroaryl is defined herein.

Representative heteroaryl groups include thiophenoyl and pyridinoyl.

"Heteroaryldiazo"means a heteroaryl-N=N-group in which heteroaryl is defined herein.

Representative heteroaryldiazo groups include pyridyldiazo and thienyldiazo.

"Alkoxy"means an alkyl-O-group in which alkyl is defined herein. Representative alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.

"Aryloxy"means an aryl-O-group in which aryl is defined herein. Representative aryloxy groups include phenoxy and naphthoxy.

"Aralkyloxy"means an aralkyl-O-group in aralkyl is defined herein. Representative aralkyloxy groups include benzyloxy and 1-or 2-naphthalenemethoxy.

"Alkylthio"means an alkyl-S-group in which alkyl is defined herein. Representative alkylthio groups include methylthio, ethylthio, i-propylthio and heptylthio.

"Arylthio"means an aryl-S-group in which the aryl group is defined herein. Representative arylthio groups include phenylthio and naphthylthio.

"Aralkylthio"means an aralkyl-S-group in which aralkyl is defined herein. A representative aralkylthio group is benzylthio.

"Amino""Amino"means a group of formula Y1andY2wherein are defined herein. Preferred amino groups include amino (H2N-), methylamino, dimethylamino, diethylamino, benzylamino, or phenethylamino.

"Aminoalkyl"means a Y Y Y2N-alkylene-group wherein Y, Y and alkylene are defined herein.

"Alkoxycarbonyl"means an alkyl-O-CO-group wherein alkyl is defined herein. Representative alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, or t-butyloxycarbonyl.

"Alkoxycarbonylalkyl"means an alkyl-O-CO-alkylene-group wherein alkyl and alkylene are defined herein.

"Aryloxycarbonyl"means an aryl-O-CO-group wherein aryl is defined herein. Representative aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

"Aralkoxycarbonyl"means an aralkyl-O-CO-group wherein aralkyl is defined herein. A representative aralkoxycarbonyl group is benzyloxycarbonyl.

"Carbamyl"means a group of formula Yr4CO-wherein Y andY are defined herein.

Representative carbamyl groups are carbamyl (H2NCO-) and dimethylaminocarbamyl (Me2NCO-).

"Sulfamyl" meansa group of formula Y1andY2wherein are defined herein.

Representative sulfamyl groups are aminosulfamoyl (H2NS02-) and dimethylaminosulfamoyl <BR> <BR> <BR> <BR> (Me2NS02-).<BR> <BR> <BR> <BR> <BR> <BR> <P> "Acylamino"means an acyl-NH-group wherein acyl is defined herein.

"Aroylamino"means an aroyl-NH-group wherein aroyl is defined herein.

"Alkylsulfonyl"means an alkyl-S02- group wherein alkyl is defined herein. Preferred alkylsulfonyl groups are those in which the alkyl group is lower alkyl.

"Alkylsulfinyl"means an alkyl-SO-group wherein alkyl is defined herein. Preferred alkylsulfinyl groups are those in which the alkyl group is lower alkyl.

"Arylsulfonyl"means an aryl-S02-group wherein aryl is defined herein.

"Arylsulfinyl"means an aryl-SO-group wherein aryl is defined herein.

"Halo"or"halogen"means fluoro, chloro, bromo, or iodo. Preferred are fluoro, chloro or bromo, and more preferred are fluoro or chloro.

"Nitrogen protecting group"means an easily removable group which is known in the art to protect an amino group against undesirable reaction during synthetic procedures and to be selectively removable. The use of N-protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known, CF, for example, T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991), incorporated herein by reference. Preferred N-protecting groups are acyl, including formyl, acetyl, chloroacetyl, trichloroacetyl, o-nitrophenylacetyl, o-nitrophenoxyacetyl, trifluoroacetyl, acetoacetyl, 4-chlorobutyryl, isobutyryl, o-nitrocinnamoyl, picolinoyl, acylisothiocyanate, aminocaproyl, benzoyl and the like, and acyloxy including methoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 2-trimethylsilylethxoycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, t-butyloxycarbonyl (BOC), 1,1-dimethylpropynyloxycarbonyl, benzyloxycarbonyl (CBZ), p-nitrophenylsulfinyl, p-nitrobenzyloxycarbony, 2,4-dichlorobenzyloxycarbonyl, allyloxycarbonyl (Alloc), and the like.

"Oxo"means a carbonyl (>C=O) group.

"Compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (I) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e. g. hydrates, where the context so permits. It is understood that the activity of individual compounds of formula (I) will vary depending on the individual compound and assay employed. Compounds of the invention as used herein includes all compounds of formula (I) having an in-vitro activity of greater than 10% at 3.9 u. M in the Factor Xa in vitro enzyme assay described herein. Similarly, reference to intermediates, whether or not they themselves are

claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

"Prodrug"means a form of the compound of formula I which may or may not itself be biologically active but which may be converted, for example by metabolic, solvolytic, or other physiological means, to a biologically active chemical entity, and is suitable for administration to a patient without undue toxicity, irritation, allergic response, and the like, and effective for their intended use, including ketal, ester and zwitterionic forms. A prodrug is transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Deliverv Systems, Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drus Design American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

"Solvate"means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid."Solvate" encompasses both solution-phase and isolable solvates. Representative solvates include ethanolates, methanolates, and the like."Hydrate"is a solvate wherein the solvent molecule (s) is/are H2O.

Where the compound of this invention is substituted with a basic moiety, acid addition salts may be formed. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.

Pharmaceutically acceptable salts within the scope of the invention are those derived from the following acids: mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesufonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like. The corresponding acid addition salts comprise the following: hydrohalides, e. g. hydrochloride and hydrobromide, sulfate, phosphate, nitrate, sulfate, acetate, citrate, lactate, tartrate, malonate, oxalate, salicylate, propionate, succinate, fumarate, maleate,

methylene-bis->hydroxynaphthoates, gentisates, mesylates, isethionates and di-p-toluoyltartratesmethanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.

Acid addition salts of the compounds of this invention are prepared by reaction of the free base with the appropriate acid by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention are prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e. g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

Where the compound of the invention is substituted with an acidic moiety, base addition salts may be formed. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the animal organism in pharmaceutical doses of the salts, so that the beneficial effects inherent in the free acid are not vitiated by side effects ascribable to the cations.

Pharmaceutically acceptable salts, including for example alkali and alkaline earth metal salts, within the scope of the invention are those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, trimethylammonia, triethylammonia, ethylenediamine, n-methylglucamine, lysine, arginine, ornithine, choline, N, N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, n-benzylphenethylamine, diethylamine, piperazine, tris (hydroxymethyl) aminomethane, tetramethylammonium hydroxide, and the like.

Metal salts of compounds of the present invention may be obtained by contacting a hydride, hydroxide, carbonate or similar reactive compound of the chosen metal in an aqueous or organic solvent with the free acid form of the compound. The aqueous solvent employed may be water or it may be a mixture of water with an organic solvent, preferably an alcohol such as methanol or ethanol, a ketone such as acetone, an aliphatic ether such as tetrahydrofuran, or an ester such as ethyl acetate. Such reactions are normally conducted at ambient temperature but they may, if desired, be conducted with heating.

Amine salts of compounds of the present invention may be obtained by contacting an amine in an aqueous or organic solvent with the free acid form of the compound. Suitable aqueous solvents include water and mixtures of water with alcohols such as methanol or ethanol, ethers such as

tetrahydrofuran, nitriles such as acetonitrile, or ketones such as acetone. Amino acid salts may be similarly prepared.

The base addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e. g. hydrochloric acid.

As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

Compounds of this invention may exhibit stereoisomerism by virtue of the presence of one or more asymmetric or chiral centers in the compounds. The present invention contemplates the various stereoisomers and mixtures thereof. Desired enantiomers are obtained by chiral synthesis from commercially available chiral starting materials by methods well known in the art, or may be obtained from mixtures of the enantiomers by resolution using known techniques.

Compounds of this invention may also exhibit geometrical isomerism. Geometrical isomers include the cis and trans forms of compounds of the invention having alkenyl or alkenylenyl moieties.

The present invention comprises the individual geometrical isomers and stereoisomers and mixtures thereof.

Preferred Embodiments Compounds contemplated as falling within the scope of this invention, include, but are not limited to 4- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxo-piperazine-1-ylmethyl] benzamidine, 4- [4- (4-Methoxy-benzenesulfonyl)-2-oxo-piperazin-1-ylmethyl]-benz amidine, 4- [4- (5-Chloro-thieno [3,2-b] pyridine-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-benzamidine , 4- [4- (6-Chloro-thieno [2,3-b] pyridine-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-benzamidine , 4- [2-Oxo-4- (thieno [2,3-c] pyridine-2-sulfonyl)-piperazin-1-ylmethyl]-benzamidine, 4- [4- (7-Chloro-thieno [2,3-c] pyridine-2-sulfonyl)-2-oxo-piperazin-I-ylmethyl]-benzamidine , 4- [4- (5'-Chloro- [2,2'] bithiophenyl-5-sulfonyl)-2-oxo-piperazin-l-ylmethyl]-benzami dine, 4- [4- (4-Chloro-thieno [3,2-c] pyridine-2-sulfonyl)-2-oXo-piperazin-l-ylmethyl]-benzamidine , <BR> <BR> <BR> <BR> 4- [2-Oxo-4- (toluene-4-sulfonyl)-piperazin-1-ylmethyl]-benzamidine,.< BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>4- [4- (Benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-ylmethyl]-benzamidin e, 4-Amino-3- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-l-ylmethyl]-benzamidin e, 3- [2-Oxo-4-(toluene-4-sulfonyl)-piperazin-1-ylmethyl]-benzamid ine, 3- [4- (6-Fluoro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-ylmethyl]-benzamidin e,

3-[4-(4-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-ylmethyl]-benzamidine, 3- [4- (5-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-benzamidin e, 3- [4- (6-Methoxy-naphthalene-2-sulfonyl)-2-oxo-piperazin- I-yimethyl]-benzamidine, 3-{4-[5-(5-Nitro-pyridine-2-sulfonyl)-thiophene-2-sulfonyl]- 2-oxo-piperazin-1-ylmethyl}-benzamidine, 3- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]- benzamidine, <BR> <BR> <BR> <BR> 3- {4- [2- (3-Chloro-phenyl)-ethenesulfonyl]-2-oxo-piperazin-1-ylmethyl }- benzamidine,<BR> <BR> <BR> <BR> <BR> 3- [2-Oxo-4- (4-phenylazo-benzenesulfonyl)-piperazin-1-ylmethyl]-benzamid ine, 3- [4- (Benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]- benzamidine, 4-[4-(6-Chloro-1H-benzoimidazol-2-ylmethyl)-2-oxo-piperazin- 1-ylmethyl]-benzamidine, 4- {4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-2-oxopiperazin-1-ylmethyl} benzamidine, 3-{4-[3-(5-Chloro-thiophen-2-yl)-(E)-acryloyl]-2-oxopiperazi n-1-ylmethyl}benzamidine, 3-[4-(6-Chloro-1H-benzoimidazo-2-ylmethyl)-2-oxopiperazin-1- ylmethyl}-benzamidine, 1- (2-Aminoquinolin-6-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-sulfonyl) piperazin-2-one, 6- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1-ylmethyl]-1 H-quinolin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-thieno [2,3-c] pyridin-3-ylmethyl-piperazin-2-one, 1-(2-Amino-quinoxalin-6-ylmethyl)-4-(6-chloro-benzo[b]thioph ene-2-sulfonyl)-piperazin-2-one, 4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-thieno [2,3-c] pyridin-2-ylmethyl-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-thieno [3,2-c] pyridin-2-ylmethyl-piperazin-2-one, 1-(2-Amino-quinolin-6-ylmethyl)-4-(6-chloro-thieno [2,3-b] pyridine-2-sulfonyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-hydroxy-isoqu inolin-6-ylmethyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-chloro-isoqui nolin-6-ylmethyl)-piperazin-2-one, 7- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-2H-isoquin olin-1-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-chloro-isoqui nolin-7-ylmethyl)-piperazin-2-one, 1- (7-Amino-thieno [2,3-c] pyridin-2-ylmethyl)-4- (6-chloro-benzo [b] thiophne-2-sulfonyl)-piperazin-2- one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)- I- (2-chloro-quinolin-6-ylmethyl)-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)- I-quinolin-6-ylmethyl-piperazin-2-one, 7- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-I H-quinolin-2-one, 1- (2-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 1- (4-Amino-thieno [3,2-c] pyridin-2-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2- one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(1, 2,3,4-tetrahydro-isoquinolin-6-ylmethyl)-piperazin-2- one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-isoquinolin-6-ylmethyl-piperazin-2-o ne, 1- (2-Am'mo-quinolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one,

4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)- I- (decahydro-isoquinolin-6-yimethyl)-piperazin-2-one, I- (I-Amino-isoquinolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(decahydro-isoqu inolin-7-ylmethyl)-piperazin-2-one, I-(I-Am (1-Amino-isoquinolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 1- (4-Amino-thieno [3, 2-c]pyridin-3-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2- one, (+/-)- [1- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-3-oxo-4-thieno [3,2-c] pyridin-2-ylmethyl-piperazin-2- yl]-acetic acid, (+/-)- [1- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-3-oxo-4-thieno [2,3-c] pyridin-2-ylmethyl-piperazin-2- yl]-acetic acid, 1-(1-Amino-isoquinolin-6-ylmethyl)-4-[3-(5-chloro-thiophen-2 -yl)-(E)-acryloyl]-3-(S)-methoxymethyl- piperazin-2-one, 1- (I-Amino-isoquinolin-6-yimethyl)-4- [ (5-chloro-thiophen-2-yioxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, (3S)-1-(7-Chloro-isoquinolin-3-ylmethyl)-4-[(5-chloro-thioph en-2-yloxy)-acetyl]-3-methoxymethyl- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> (3S)-I- (7-Chloro-isoquinolin-3-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- (E)-acryloyl]-3- methoxymethyl-piperazin-2-one, (S)-4- [3- (5-Chloro-thiophen-2-yl)-acryloyl]-3-ethyl-1- (4-hydroxy-quinolin-7-ylmethyl)-piperazin-2- one, I- (2-Amino-quinolin-6-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- (E)-acryloyl]-piperazin-2-one, 1-(2-Aminoquinolin-6-ylmethyl)-4-(4-methoxybenzyl)piperazin- 2-one, 1-(2-Aminoquinolin-6-ylmethyl)-4-6-chlorobenzo[b]thiophen-2- ylmethyl)piperazin-2-one, 1-(2-Aminoquinolin-6-ylmethyl)-4-(5-methoxy-1H-benzoimidazol -2-ylmethyl)piperazin-2-one, 1- (2-Aminoquinolin-6-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-ylmethyl) piperazin-2-one, 1- (2-Aminoquinolin-6-yimethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-piperazin-2-one, 1- (2-Aminoquinolin-6-ylmethyl)-4- [3- (3, 5-dibromo-4-methoxy-phenyl)- [ 1,2,4] oxadiazol-5- ylmethyl] piperazin-2-one, 3-[4-(2-Aminoquinolin-6-ylmethyl)-3-oxo-piperazin-1-ylmethyl ]-7-fluoro-1H-quinolin-2-one, 1- (2-Aminoquinolin-6-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-piperazin-2-one, 3- idine,.

4- (5-Chloro-1 H-indol-2-ylmethyl)-1- (4-chloro-quinolin-7-ylmethyl)-piperazin-2-one, 1,4-Bis-(5-chloro-1H-indol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-piperazin-2-one,

1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2- one, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4-[3-(5-chloro-thiophen-2-yl)-allyl]-p ipeazin-2-one, <BR> <BR> <BR> <BR> I- (3-Amino-I H-indazol-6-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (3-Amino- I H-indazol-6-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-thieno [2,3-d] pyrimidin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-, 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2-oxo-piperazin-1-ylmethyl]-benzamidine , 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-3-oxo-piperazin-1-ylmethyl]-benzamidine , 4- (4-Cyclohexylmethyl-2-oxo-piperazin-1-ylmethyl)-benzamidine, I- (1-Amino-isoquinolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1-(1-Amino-isoquinolin-6-ylmethyl)-4-[3-(5-chloro-thiophen-2 -yl)-allyl]-3-(S)-methoxybenzyl- piperazin-2-one, <BR> <BR> <BR> <BR> 4- [3- (5-Chloro-thiophen-2-yl)-allyl]-1- [4- (6-methoxy-pyridin-3-yl)-benzyl]-3- (S)-methyl-piperazin-2- one, 4- [3- (5-Chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-1- [4- (6-oxo-1, 6-dihydro-pyridin-3-yl)-benzyl]- piperazin-2-one, (S)-4-(5-Chloro-1H-indol-2-ylmethyl)-1-(4-chloro-quinolin-7- ylmethyl)-3-methoxymethyl-piperazin-2- one, (S)-4-(5-Chloro-1H-indol-2-ylmethyl)-1-(4-chloro-quinolin-7- ylmethyl)-3-methyl-piperazin-2-one, 1- (4-Aminoquinazolin-7-yimethyl)-4- (6-chlorobenzo [b] thiophene-2-sulfonyl) piperazin-2-one, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-sulfonic acid 3-chloro-benzylamide, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2,3-b] pyridine-2-sulfonyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-sulfonyl)-piperazin-2-one, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-sulfonic acid 4-chloro-benzylamide, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-isoxazol-3-yl-thiophene-2-sulfonyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (thieno [3,2-b] pyridine-2-sulfonyl)-piperazin-2-one, [2-(3-chloro-phenyl)-ethyl]-amide,4-(4-Amino-quinazolin-7-yl methyl)-3-oxo-piperazine-1-sulfonicacid 4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-sulfoni c acid [2-(4-chloro-phenyl)-ethyl]-amide, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-1 H-benzoimidazole-2-sulfonyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one, 4-(3-Amino-benzenesulfonyl)-1-(4-amino-quinazolin-7-ylmethyl )-piperazine-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3- (S)-ethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-3- (S)-ethyl-piperazin-2- one,

1- (4-Amino-quinazolin-7-ylmethyl)-4-(5'-chloro- [2,2'] bithiophenyl-5-sulfonyl)-3- (S)-ethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-sulfonyl)-3- (S)-methyl-piperazin- 2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-3- (S)-methyl-piperazin- 2-one, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b] thiophene-2-sulfonyl)-6-methyl- piperazin-2-one, (+/-)- [4- (4-Amino-quinazolin-7-ylmethyl)- I- (6-chloro-benzo [b] thiophene-2-sulfonyl)-3-oxo-piperazin- 2-yl]-acetic acid, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]- piperazin-2-one, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2- one, 1- (4-Amino-thieno [2,3-d] pyrimidin-6-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2- one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(4-hydroxy-quina zolin-6-ylmethyl)-piperazin-2-one, 1- (4-Amino-thieno [3,2-d] pyrimidin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2- one, I- (4-Amino-quinazolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(4-hydroxy-quina zolin-7-ylmethyl)-piperazin-2-one, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-piperazin-2- one, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-piperazin-2- one, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, 4-(6-Chlorobenzo [b] thiophene-2-sulfonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, 4-(6-Chlorobenzo [b] thiophene-2-sulfonyl)-1- (5-oxy-I H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2- one, 4-(l6-Chlorobenzo[b]thiophene-2-sulfonyl)-1-(1-methyl-1H-pyr rolo[3, 2-c] pyridin-2-ylmethyl) piperazin- 2-one, 4- (3-Chlorobenzo [b] thiophene-2-sulfonyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, 4-(6-Chlorothieno [2,3-b] pyridine-2-sulfonyl)-1-[1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, 4- (6-Bromobenzo [b] thiophene-2-sulfonyl)-1-(1H-pyrrolo[3, 2-c] pyridin-2-ylmethyl) piperazin-2-one,

2-[3-Oxo-4-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazine-1-sulfonyl]-benzo [b] thiophene-6- carbonitrile, 4- (5'-Chloro- [2,2'] bithiophenyl-5-sulfonyl)- I- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, 4-[2-(4-Chlorophenyl)ethenesulfonyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, {2-[4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazin- 1-ylmethyl]pyrrolo[3,2-c]pyridin-1-yl} acetic acid, 4-(5-Pyridin-4-ylthiophene-2-sulfonyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, {2-[4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazin- 1-ylmethyl]pyrrolo[3,2-c]pyridin-1-yl} acetic acid ethyl ester, 4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-1-[1-(2-methoxyethy l)-1H-pyrrolo[3,2-c]pyridin-2- ylmethyl] piperazin-2-one, 4- (6-Chlorothieno [3,2-b] pyridine-2-sulfonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, {2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1-ylmethyl] pyrrolo [2,3-c] pyridin-I-yl} acetic acid methyl ester, 2-[3-Oxo-4-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazine-1-sulfonyl] benzo [b] thiophene-5- carbonitrile, 4- (5-Aminomethylbenzo [b] thiophene-2-sulfonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2- one, 2- {2- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1-ylmethyl] pyrrolo [3,2-c] pyridin-1- yl} acetamide, 4-(6-Chlorobenzo [b] thiophene-2-sulfonyl)-I- [I- (2-hydroxyethyl)-1 H-pyrrolo [3,2-c] pyridin-2- ylmethyl] piperazin-2-one, 4-(6-Chloro-1H-benzoimidazole-2-sulfonyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- (1 H-Benzoimidazole-2-sulfonyl)-1- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- (6-Aminomethyl-benzo [b] thiophene-2-sulfonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2- one, 1-(1H-Pyrrolo [3,2-c] pyridin-2-ylmethyl)-4- (thieno [2,3-b] pyridine-2-sulfonyl)-piperazin-2-one, 1-(1H-Pyrrolo [3,2-c] pyridin-2-ylmethyl)-4- (thieno [3,2-b] pyridine-2-sulfonyl)-piperazin-2-one, 4-[2-(5-Chloro-thiophen-2-yl)-ethanesulfonyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- (2-Benzo [b] thiophen-2-yl-ethenesulfonyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-[2-(5-Chloro-4-methoxy-thiophen-2-yl)-ethenesulfonyl]-1-(1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, 4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-furo [3,2-c] pyridin-2-ylmethyl-piperazin-2-one, 4- (6-Fluoro-benzo [b] thiophene-2-sulfonyl)-1-furo(6-Fluoro-benzo [b] thiophene-2-sulfonyl)-1-furo [3,2-c] pyridin-2-ylmethyl-piperazin-2-one, 4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-1-(1H-pyrrolo[2,3-c ]pyridin-2-ylmethyl)piperazin-2-one,

4- (6-Chlorothieno [2,3-b] pyridine-2-sulfonyl)-1- (I H-pyrrolo [2,3-c] pyridin-2-ylmethyl) piperazin-2-one, {2-[4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-pyrrolo [2,3-c] pyridin-1- yl}-acetic acid methyl ester, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1H-pyrrolo[3,2- b]pyridin-2-ylmethyl)-piperazin-2-one, 1-(4-Amino-I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl) piperazin- 2-one, 4- [2-(5-Chloro-thiophene-2-yl)-ethenesulfonyl]-5-(~)-hydroxyme thyl-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, ()-I- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-5-oxo-4-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, (~)-1-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-oxo-4-(1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, ()-1- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-5-oxo-4- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid, (~)-4-(6-Chloro-benzo[b]thiophene-2-sulfonyl]-5-hydroxymethy l-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, (-)-I-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-oxo-4-(1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, (+)-1- [2- (5-Chloro-thiophen-2-yi)-ethenesulfonyl]-5-oxo-4- (l H-pyrrolo ['3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-(R)-hydroxym ethyl-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-6-(R)-hydroxymethy l-1-(1H-pyrrolo[3,2-c]pyridin-2- ylmethyl)-piperazin-2-one, (~)-4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-oxo-1-(1 H-pyrrolo[3,2-c]pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, ()-4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-I- ( 1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, (~)-4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-oxo-1-(1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid, (~)-4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-1-(1H-py rrolo[3,2-c]pyridin-2-ylmethyl)- piperazine-2-carboxylic acid, ()-4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-hydroxymethyl-1- ( 1 H-pyrro lo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one,

(~)-4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-hydroxym ethyl-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, ()-4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid amide, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-3-(S)-methoxym ethyl-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-3- (S)-methoxymethyl-I-(1 H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, 4- (5'-Chloro-[2, 2'] bithiophenyl-5-sulfonyl)-3-(S)-methoxymethyl-I-(I H-pyrrolo(5'-Chloro-[2, 2'] bithiophenyl-5-sulfonyl)-3-(S)-methoxymethyl-I-(I H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, 4-[2-(4-Chloro-phenyl)-ethenesulfonyl]-3-(S)-methoxymethyl-1 -(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, 1- (4-Aminoquinazolin-7-ylmethyl)-4- (6-chlorobenzo [b] thiophene-2-ylmethyl) piperazin-2-one, l- (4-Aminoquinazolin-7-ylmethyl)-4-(6-chloro-l H-benzoimidazol-2-ylmethyl)(4-Aminoquinazolin-7-ylmethyl)-4- (6-chloro-l H-benzoimidazol-2-ylmethyl) piperazin-2-one, <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzothioazol-2-ylmethyl)-piperazin-2-one,<BR&g t; <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzooxazol-2-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzothioazol-2-ylmethyl)-piperazin-2-one,<BR&g t; <BR> <BR> <BR> <BR> <BR> <BR> 3- [4- (4-Aminoquinazoline-7-ylmethyl)-3-oxopiperazin-1-ylmethyl]-7 -chloro-1 H-quinolin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-chloro- I H-indol-6-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- (E)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-but-2- (E)-enyl]-piperazin-2-one ditrifluoroacetate, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yi)-2-methyl- (E)-allyi]-piperazin-2-one ditrifluoroacetate, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-furan-2-yl)- (E)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (6-methoxy-pyridin-3-yl)- (E)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- (E)-allyl]-4-oxy-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-prop-2-ynyl]-piperazin-2-one,<BR > <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yi)-propyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4-prop-2-ynyi-piperazin-2-on e,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-biphenyl-2-yl-prop-2-ynyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(1H-pyrrolo[3,2-c]pyridi n-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yloxy)-ethyl]-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1-methyl-1H-in dol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (4-chloro-thiophen-2-yl)-allyl]-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (6-chloro-benzo [b] thiophen-2-yl)-allyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-4-methyl-thiophen-2-yl)-allyl]-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzofuran-2-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-chloro- I H-indol-5-yimethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro- I H-indol-2-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5,7-dichloro-1H-indol-2 -ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-1H-indol-2-ylm ethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-p-tolyi-prop-2-ynyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-m-tolyl-prop-2-ynyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)-prop-2-ynyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (3-chloro-phenyl)-prop-2-ynyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (2-chloro-phenyl)-prop-2-ynyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-biphenyl-4-yl-prop-2-ynyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4, 5-dibromo-thiophen-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-biphenyl-3-yl-prop-2-ynyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(2,5-dichloro-thiophe n-3-yl)-prop-2-ynyl]-piperazine-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-chloro-phenyl)-propyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1,4-Bis- (4-am ino-quinazolin-7-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- ( 1 H-pyrrolo [2,3-c] pyridin-2-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (5-nitro-thiophen-2-yl)-al lyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (6-chloro-pyridin-3-yl)-allyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (l H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-3- yl)-allyl]-piperazine-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-furan-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (5-methyl-thiophen-2-yl)-penta-2, 4-dienyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro-benzo [b] thiophen-5-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-methyl-thiophen-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-methoxy-thiophen-2-yl)-allyl]-piperazin-2-one, 4-(1-Amino-7-chloro-isoquinolin-3-ylmethyl)-1-(4-amino-quina zolin-7-ylmthyl)-piperazine-2-one, <BR> <BR> <BR> <BR> 2- [4- (4-Amino-quinazolin-7-yimethyl)-3-oxo-piperazin-1-yl]-N- (5-chloro-thiophen-2-yl)-acetamide,<BR> <BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[2-(3-chloro-phenyl)-2-( S)-hydroxy-ethyl]-piperazine-2-one, I- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (3-chloro-phenylsulfanyl)-ethyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-methyiene-I, I-dioxo-2, 3-dihydro-IH-11 6-benzo [b] thiophen-3- yl)-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-nitro-phenyl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazol in-7-ylmethyl)-4- (2-chloro-benzo [b] thiophen-6-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin- I-yi]-N- (4-chloro-phenyl)-acetamide,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [1- (4-chloro-phenyl)-pyrrolidin-3-yl]-piperazin-2-one,<BR> ; <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Am ino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)-propyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 2- [4- (4-Aminoquinazoline-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 3- (4-chlorophenyl)-acrylic acid,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-1-hydroxy-isoquinolin-3-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-yimethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1-ino-quinazolin-7-ylmethyl)-4-isoquinolin-3-ylmethyl-pipera zin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[1-(3-chloro-phenyl)-pyr rolidin-3-yl]-piperazine-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(1,7-dichloro-isoquinoli n-3-ylmethyl)-piperazine-2-one, 4- (2-Amino-7-chloro-quinolin-3-ylmethyl)- 1- (4-amino-quinazolin-7-ylmethyl)-piperazin-2-one, 1- (4-Aminoquinazolin-7-ylmethyl)-4- (5-chloro-benzo [b] thiophene-2-ylmethyl) piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (4-chloro-phenyisulfanyl)-ethyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (6-chloro-benzo [b] thiophen-2-yl)-ethyl]-piperazin-2-one, 1-(4-Aminoquinazolin-7-ylmethyl)-4-[2-(4-chloro-phenoxy)-eth yl]-piperazine-2-one, 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 6-chloro-4H-benzo [1,4] thiazin-3- one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(2,7-dichloro-quinolin-3 -ylmethyl)-piperazin-2-one, 2-[[4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]- (4-chloro-phenyl)-methyl]-acrylicacid ethyl ester, <BR> <BR> <BR> <BR> 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 3- (4-chloro-phenyl)-acrylic acid ethyl ester, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-chloro-phenyl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 7-fluoro-1 H-quinolin-2-one,<BR> <BR> <BR> <BR> <BR> 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 6-chloro-1 H-quinoxalin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1-methyl-1H-be nzoimidazol-2-ylmethyl)-piperazin-2- one, 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 6-chloro-3H-quinazolin-4-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- (3-thiophen-2-yi-propyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-quinolin-3-ylmethyl)-piperazin-2-one,

3-[4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmet hyl]-5,7-dichloro-1H-quinolin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6,7-dichloro-benzo[b]th iophen-2-ylmethyl)-piperazin-2-one, 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 5-chloro-I H-quinolin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-[2,3']bithioph enyl-5'-ylmethyl)-piperazin-2-one, 4- (6-Amino-benzo [b] thiophen-2-ylmethyl)- I- (4-amino-quinazolin-7-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro-quinolin-6-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-bromo- I H-benzoimidazol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-nitro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (3-chloro-phenyl)-thiophen-2-ylmethyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-3-methoxy-benzo [b] thiophen-2-ylmethyl)-piperazin-2- one, 3-[4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmet hyl]-6-chloro-1H-quinolin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-trifluoromethyl-1H-be nzoimidazol-2-ylmethyl)-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-methyl- [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-methyl-benzo[b]thioph en-2-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro-3, 3'-dimethyl- [2, 2'] bithiophenyl-5-ylmethyl)-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3, 5-dibromo-4-methoxy-phenyl)- [ 1,2,4] oxadiazol-5-<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> ylmethyl]-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-methyl-benzo[b]thioph en-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-methyl-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro-3'-methyl- [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- ( 1 H-benzoimidazol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-bromo- [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (2,3-dihydro-benzo [1, 4] dioxin-6-yl)-oxazol-2-ylmethyl]- <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5, 6-dichloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4, 5-dichloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzooxazol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-5-fluoro-benzo [b] thiophen-2-ylmethyl)-piperazin-2- one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-chloro-5-fluoro-benzo [b] thiophen-2-ylmethyl)-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro-3-methyl- [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2- one, I- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-thieno [3,2-b] pyridin-2-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5,6-dichloro-1H-benzoim idazol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-benzooxazol-2-yl-benzyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[5-(4-chloro-phenyl)-thi ophen-2-ylmethyl]-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-methyl-1H-benzoimidaz ol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2,2'] bithiophenyl-5-ylmethyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-fluoro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, l- (4-Aminoquinazolin-7-ylmethyl)-4-(6-fluoro-benzo(4-Aminoquin azolin-7-ylmethyl)-4-(6-fluoro-benzo [b] thiophene-2-ylmethyl) piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (l-methyl-5-trifluoro-methyl-I H-pyrazol-3-yl)-thiophen-2- ylmethyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3, 4-dimethyl-thieno [2,3-b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-chloro-3-methyl-benzo [b] thiophen-2-ylmethyl)-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-3-methyl-benzo [b] thiophen-2-ylmethyl)-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl) thiophen-2- ylmethyl] piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (3-nitro-phenyl)-furan-2-ylmethyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-thieno [3,2-b] pyridin-6-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (4-methoxy-phenyl)-thiophen-2-ylmethyl]-piperazin-2-one,< BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-hydroxy-2-pyridin-2-yl-pyrimidin-5-ylmethyl)-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-fluoro-phenoxy)-benzyl]-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (4-chloro-phenyl)-thiazol-4-ylmethyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-bromo-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-benzo[b]thiophen-2-ylmet hyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3, 5-bis-trifluoromethyl-benzyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4-biphenyl-4-ylmethyl-pipera zin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4-naphthalen-2-ylmethyl-pipe razin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzo [b] thiophen-3-ylmethyl)-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2,3-b] pyridin-2-ylmethyl)-piperazin-2-one, 1- (4-Aminoquinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- (E)-acryloyl] piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-chloro-thiophene-2-carbonyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- [3- (3-Amino-4-chloro-phenyl)- (E)-acryloyl]- I- (4-amino-quinazolin-7-yimethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-chloro-1 H-indole-6-carbonyl)-piperazin-2-one, 1 (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl] piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)- (E)-acryloyl]-piperazin-2-one, 5-Chloro-thiophene-2-carboxylic acid {2- [4- (4-amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]-2- <BR> <BR> <BR> <BR> oxo-ethyl}-amide,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)- (E)-acryloyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-1 H-indole-2-carbonyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(6-chloro-benzo[b]thi ophen-2-yl)-(E)-acryloyl]-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- (E)-acryloyl]-piperazin-2-one, 5-Chloro-thiophene-2-carboxylic acid {2- [4- (4-amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]-l- methyl-2-oxo-ethyl}-amide, 5-Chloro-thiophene-2-carboxylic acid {3- [4- (4-amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]-3- oxo-propyl}-amide, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenoxy)-acetyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-2-methyl-phenoxy)-acetyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-carbonyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-propionyl]-piperazin-2-one,<BR&g t; <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-chloro-phenyl)- (E)-acryloyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> N- [2- [4- (4-Amino-quinazolin-7-yimethyl)-3-oxo-piperazin-1-yl]-I- (5-chloro-thiophen-2-ylmethyl)-2- oxo-ethyl]-benzamide, <BR> <BR> <BR> <BR> N- [l- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carbonyl] -2- (5-chloro-thiophen-2-yl)- vinyl]-benzamide, N-[1-[4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-c arbonyl]-2-(5-chloro-thiophen-2-yl)- vinyl]-acetamide, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)- (E)-acryloyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yl)-acetyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-piperazin-2-one, 2-[4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carb onyl]-6-chloro-4H-benzo[1,4]thiazin-3- one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(6-chloro-benzo[b]thiop hen-2-yl)-acetyl]-piperazin-2-one,

4- (4-Aminoquinazolin-7-ylmethyl)-3-oxopiperazine-1-carboxylic acid 4-chloro-benzylamide, 4- (4-Aminoquinazolin-7-ylmethyl)-3-oxopiperazine-1-carboxylic acid (5-chloro-thiophen-2- ylmethyl) amide, 4- (4-Aminoquinazolin-7-ylmethyl)-3-oxopiperazine-1-carboxylic acid (5-chloro-thiophen-2-yl) amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid (4-chloro-thiophen-2-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid (5-bromo-thiophen-2-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-I-carboxyli c acid (3-amino-4-chloro-phenyl)- amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-I-carboxyli c acid (4-bromo-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid (4-chloro-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid (4-methoxy-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid (3,4-dichloro-phenyl)-amide, 4- (4-Amino-quinazolin-7-yimethyl)-3-oxo-piperazine-1-carboxyli c acid 5-chloro-thiophen-2-ylmethyl ester, 6-chloro-benzooxazol-2-4-(4-Amino-quinazolin-7-ylmethyl)-3-o xo-piperazin-1-carboxylicacid ylmethyl ester, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid 1- (3-chloro-phenyl)-pyrrolidin- 3-yl ester, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3- (S)-methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- (4-Amino-quinazolin-7-ylmethyl)- 4- (3-chloro- I H-indol-6-ylmethyl)-3- (S)-methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(6-chloro-benzo[b]thi ophen-2-yl)-allyl]-3-(S)-methyl- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-propyl]-3- (S)-methyl-piperazin-2- one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-indol-2-ylm ethyl)-3-(S)-methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-but-2-enyl]-3- (S)-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2']bithiophenyl-5-ylmethyl)-3- (S)-methyl-piperazin- 2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-benzoimidaz ol-2-ylmethyl)-3-(S)-methyl-piperazin- 2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-3- (S)-methyl-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2,3-b] pyridin-2-ylmethyl)-3- (S)-methyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-3-(S)-methyl-piperazin- 2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-benzo[b]thioph en-2-ylmethyl)-3-(S)-methyl-piperazin- 2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzo [b] thiophen-2-ylmethyl)-3- (R)-methyl-piperazin- 2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-3- (R)-methyl-piperazin- 2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-chloro-thiophen-2- yl)-acryloyl]-3-(S)-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazoiin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methyl-piperazin-2- one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-1H-indole-6-ca rbonyl)-3-(S)-methyl-piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinoline-3-carbonyl)-3- (S)-methyl-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-2-yl oxy)-acetyl]-3-(S)-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methyl-piperazin-2- one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(4-chloro-phenoxy)-acet yl]-3-(S)-methyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-carbonyl)-3- (S)-methyl-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-but-2-enoyl]-3- (S)-methyl-piperazin- 2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-3- (S)-methyl-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methyl-piperazin-2- one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-propyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-allyl]-3- (S)-ethyl-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-but-2-enyl]-3- (S)-ethyl-piperazin-2- one, <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-3- (S)-ethyl-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]thioph en-2-ylmethyl)-3-(S)-ethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2,3-b] pyridin-2-ylmethyl)-3- (S)-ethyl-piperazin- 2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2- yl)-acryloyl]-3-(S)-ethyl-piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2-yloxy)-acetyl]- (S)-3-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]- (S)-3-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-3-yl)-acryloyl]- (S)-3-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 2- (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-ethyl-3-oxo-piperazin-1-yl]-2-oxo-ethoxy}-5-chloro- thiophen-3-yl)-acetamide, (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-ethyl-3-oxo-piperazin-1-yl]-2-oxo-ethoxy}-5-chloro- thiophen-3-yl)-acetic acid, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2, 3-dichloro-benzo [b] thiophene-6-carbonyl)- (S)-3-ethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro-benzo [b] thiophene-6-carbonyl)- (S)-3-ethyl-piperazin-2- one, (2-{2-[4-(4-Amino-quinazolin-7-ylmethyl)-(S)-2-ethyl-3-oxo-p iperazin-1-yl]-2-oxo-ethoxy}-5-chloro- thiophen-3-yl)-acetic acid ethyl, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3, 5-dichloro-thiophen-2-yloxy)-acetyl]- (S)-3-ethyl-piperazin-2- one, <BR> <BR> <BR> <BR> (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-ethyl-3-oxo-piperazin-1-yl]-2-oxo-ethoxy}-5-chloro- thiophen-3-yl)-acetic acid methyl ester, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-1H-indole-6-ca rbonyl)-(3S)-ethyl-piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinoline-3-carbonyl)-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-ethyl-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-bromo-thiophen-2-y l)-acryloyl]-3-(S)-ethyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yi)-acryloyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-piperazin-2- one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-propionyl]-3- (S)-ethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [I- (4-chloro-phenyl)- I H-pyrroie-2-carbonyl]-3- (S)-ethyl- piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [ (4-chloro-phenyisulfanyi)-acetyl]-3- (S)-ethyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyt)-4- [3- (5-chloro-thiophen-2-yl)-but-2-enoyl]-3- (S)-ethyl-piperazin-2- one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenoxy)-acetyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)-acryloyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-I H-indole-2-carbonyl)-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)-propionyl]-3- (S)-ethyi-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-3-(S)-ethyl-4-[3-(4-methox y-phenyl)-propionyl]-piperazin-2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-3- (S)-ethyl-piperazin-2- one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 4- [3- (6-Amino-pyridin-3-yl)-acryloyl]-1- (4-amino-quinazolin-7-ylmethyl)-3- (S)-propyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (2, 5-dichloro-thiophen-3-yloxy)-acetyl]-3- (S)-propyl-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yi)-acryloyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenoxy)-acetyl]-3- (S)-propyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-5-methoxy-phenoxy)-acetyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (5-chloro-thiophen-3-yi)-acryloyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-propyl-piperazin-2- one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> l-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-l H-indol-6-ylmethyl)-3-(S)-methoxymethyl-piperazin- 2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[2-(5-chloro-thiophen-2- yloxy)-ethyl]-3-(S)-methoxymethyl- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-I H-indol-2-ylmethyl)-3- (S)-methoxymethyl-piperazin- 2-one, 1- (4-Amino-quinazolin-7-yimethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3- (R)-methoxymethyl- piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(7-chloro-isoquinolin-3- ylmethyl)-3-(S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-3- (S)-methoxymethyl- piperazin-2-one, I- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-1H-benzoimidaz ole-2-carbonyl)-3-(S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2-yloxy)-acetyl]-3- (S)- methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 4- [3- (4-Amino-phenyl)-acryloyl]-I- (4-amino-quinazolin-7-ylmethyl)-3- (S)-methoxymethyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-3H-imidazol-4-yl-acryloyl)-3- (S)-methoxymethyl-piperazin-2- one, <BR> <BR> <BR> <BR> I-(4-Amino-quinazolin-7-ylmethyl)-4- [(2, 5-dichloro-thiophen-3-yloxy)-acetyl]-3-(S)-methoxymethyl- piperazin-2-one, (1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-1H-benzoimida zole-2-carbonyl)-3-(S)-methoxymethyl- piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-thiophene-2-ca rbonyl)-3-(S)-methoxymethyl-piperazin- 2-one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-furan-2-yl)-acryloyl]-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-phenyl)-acryloyl]-3- (S)-methoxymethyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)-acryloyl]-3- (S)-methoxymethyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-bromo-phenyl)-acryloyl]-3- (S)-methoxymethyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-chloro-phenyl)-acryloyl]-3- (S)-methoxymethyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)--methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-pyridin-3-yloxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, 1-ino-quinazolin-7-ylmethyl)-4-[(6-chloro-pyridin-2-yloxy)-a cetyl]-3-(S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 4- [3- (6-Amino-pyridin-3-yl)-acryloyl]-1- (4-amino-quinazolin-7-ylmethyl)-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-5-methoxy-phenoxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-3-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (2, 5-dichloro-phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin- 2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-fluoro-thiophen-2-yloxy)-acetyl]-3- (S)- methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-fluoro-phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (3-chloro-phenoxy)-propionyl]-3- (S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (6-chloro-pyridin-3-yloxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-methoxymethyl-4- [ (4-trifluoromethylsulfanyl-phenoxy)- acetyl]-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenylamino)-acetyl]-3- (S)-methoxymethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenylamino)-acetyl]-3- (S)-methoxymethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2- one, (2-{2-[4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-methoxymethyl -3-oxo-piperazin-1-yl]-2-oxo-ethoxy}- 5-chloro-thiophen-3-yl)-acetic acid, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-ylsulfanyl)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, I-(4-Amino-quinazolin-7-ylmethyl)-4-[(6-chloro-pyridin-3-yla mino)-acetyl]-3-(S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 2- (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazin-1-yl]-2-oxo-<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethoxy}-5-chloro-thiophen-3-yl)-, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro-benzo [b] thiophene-6-carbonyl)-3- (S)-methoxymethyl- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2, 3-dichloro-benzo [b] thiophene-6-carbonyl)-3- (S)- methoxymethyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3, 5-dichloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazin-1-yl]-2-oxo-ethoxy}- 5-chloro-thiophen-3-yl)-acetic acid methyl ester, (2-{2-[4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-methoxymethyl -3-oxo-piperazin-1-yl]-2-oxo-ethoxy}- 5-chloro-thiophen-3-yl)-acetic acid ethyl ester, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(2-chloro-pyridin-3-yla mino)-acetyl]-3-(S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> I-(4-Amino-quinazolin-7-ylmethyl)-4-[(2, 3-dichloro-phenoxy)-acetyl]-3-(S)-methoxymethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-fluoro-phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-2-methyl-phenoxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(2,4-dichloro-phenoxy)- acetyl]-3-(S)-methoxymethyl-piperazin- 2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinoline-3-carbonyl)-3- (S)-methoxymethyl- piperazin-2-one, (1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-bromo-thiophen-2- yl)-acryloyl]-3-(S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (R)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (6-chloro-pyridin-3-yloxy)-acetyl]-3- (S)-ethoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-3- (S)-ethoxymethyl-4- [ (3-fluoro-phenoxy)-acetyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-ethoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [ (2-chloro-pyridin-3-yiamino)-acetyl]-3- (S)-ethoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (6-chloro-pyridin-3-ylamino)-acetyl]-3- (S)-ethoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-ethoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyi-4- [3- (5-chloro-thiophen-2-yl)-allyl]-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- [ (4-chloro-phenoxy)-acetyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> l-(4-Amino-quinazolin-7-ylmethyl)-3-(S)-benzyl-4-(6-chloro-n aphthalen-2-ylmethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-3-(S)-benzyl-4-[3-(5-chlor o-thiophen-2-yl)-propyl]-piperazin-2-one,

I-(4-Amino-quinazol in-7-ylmethyl)-4- [(5-chloro-thiophen-2-yloxy)-acetyl]-3-(S)-((R)-I-methoxy- ethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)- ( (R)-1-methoxy-ethyl)-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2- yl)-acryloyl]-3-(S)-((R)-1-methoxy- ethyl)-piperazin-2-one, I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)- ( (R)-1-methoxy- ethyl)-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-(7-chloro-isoquinolin-3- ylmethyl)-3-(S)-((R)-1-methoxy-ethyl)- piperazin-2-one, 1-ino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophen-2-ylmethyl)-3-(S)-isopropyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-3,3-dimethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 3-dimethyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3, 3-dimethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-3,3-dimethyl-piperazin- 2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-2-yl oxy)-acetyl]-3-(S)-(2-methoxy-ethyl)- piperazin-2-one, (4-4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-(2-methoxy-ethyl) -3-oxo-piperazine-1-carboxylicacid chloro-phenyl)-amide, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)- (2-methoxy-ethyl)- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-3- (S)- (2-methoxy- ethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-3- (S)-methoxymethyl-6- (S)- methyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yi)-propyl]-3- (S)-ethyl-6-methyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-yimethyl)-3- (S)-methoxymethyl-6- (R)- methyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methoxymethyl-6- methyl-piperazin-2-one,

(I- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3- (S)-methoxymethyl-6-<BR> <BR> <BR> <BR> <BR> <BR> methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-6-dimethyl-piperazin-2- one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-6-methyl-piperazin-2-one,&l t;BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-methyl-piperazin-2-one,< ;BR> <BR> <BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3 (S)-methoxymethyl-6- methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2-yloxy)-acetyl]- (S)-3-methoxymethyl-6- methyl-piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-3-yl oxy)-acetyl]-(S)-3-methoxymethyl-6- methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-4-fluoro-phenoxy)-acetyl]-3 (S)-methoxymethyl-6- methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3, 5-dichloro-phenoxy)-acetyl]-3 (S)-methoxymethyl-6-methyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (2, 5-dichloro-phenyl)-acryloyl]-3 (S)-methoxymethyl-6- methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [ (5-chloro-2-methyl-phenoxy)-acetyl]-3 (S)-methoxymethyl-6- methyl-piperazin-2-one, 1-($-Amino-quinazolin-7-ylmethyl)-4-[(2,5-dichloro-phenoxy)- acetyl]-3(S)-methoxymethyl-6-methyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenoxy)-acetyl]-3- (S)-methoxymethyl-6-methyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-propionyl]-3 (S)-ethyl-6-methyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3 (S)-ethyl-6-methyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3 (S)-ethyl-6-methyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3 (S)-ethyl-6-methyl- piperazin-2-one, <BR> <BR> <BR> <BR> (S)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3-methoxymethyl-6- methyl-piperazin-2-one,

(S)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3-methoxymethyl-6- methyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-yimethyl)-4- (6-chloro-benzo [b] thiophene-2-carbonyl)-3 (S)-6-dimethyl- piperazin-2-one, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-bromo-thiophen-2-y l)-acryloyl]-3(S)-6-dimethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3 (S)-6-dimethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-6-methyl-piperazin-2-one, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4-chloro- phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methyl-3-oxo-piperazine-l-carboxylic acid (5-chloro- thiophen-2-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo-piperazine-I-carboxylic acid (5-chloro- thiophen-2-yl)-amide, (4-4-(4-Amino-quinazolin-7-ylmethyl)-2(S)-(2-methoxy-ethyl)- 3-oxo-piperazine-1-carboxylicacid chloro-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-butyl-3-oxo-piperazine-1-carboxylic acid (4-chloro-phenyl)- amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (5-bromo- thiophen-2-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo-piperazine-I-carboxylic acid (5-chloro- thiophen-3-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4-chloro- thiophen-2-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo- (S)-2-propyl-piperazine-1-carboxylic acid (4-chloro-phenyl)- amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (3-bromo- phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo- (2S)-propyl-piperazine-1-carboxylic acid (4-chloro-thiophen- 2-yl)-amide, (5-chloro-2-4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-(S)-2-pr opyl-piperazine-1-carboxylicacid methoxy-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4- bromo-2-chloro-phenyl)-amide,

4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4- trifluoromethoxy-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4-fluoro- phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-l-carboxylic acid (2,4- dichloro-phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-l-carboxylic acid (2,4- difluoro-phenyl)-amide, (3-chloro-4-(4-Amino-quinazolin-7-ylmethyl)-(2S)-methoxymeth yl-3-oxo-piperazine-1-carboxylicacid phenyl)-amide, (5-chloro-thiophen-4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-( 2S)-propyl-piperazine-1-carboxylicacid 2-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methyl-3-oxo-piperazine-1-carboxylic acid (6-chloro-pyridin- 3-yl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4-bromo- phenyl)-amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methyl-3-oxo-piperazine-1-carboxylic acid (4-bromo-phenyl)- amide, 4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-methoxymethyl-5-(R, S)-methyl-3-oxo-piperazine-l- carboxylic acid (4-chloro-phenyl)-amide, (4-bromo-phenyl)-4-(4-Amino-quinazolin-7-ylmethyl)-(2S)-ethy l-3-oxo-piperazine-1-carboxylicacid amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methyl-3-oxo-piperazine-I-carboxylic acid (4-chloro-phenyl)- amide, 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-ethyl-3-oxo-piperazine-1-carboxylic acid (4-chloro-phenyl)- amide, 4- (4-Amino-quinazolin-7-ylmethyl)-(S)-2-methoxymethyl-3-oxo-pi perazine-l-carboxylic(4-Amino-quinazolin-7-ylmethyl)-(S)-2-m ethoxymethyl-3-oxo-piperazine-l-carboxylic acid (5-chloro- 4-methoxy-thiophen-2-yl)-amide, (3S, 5RS)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-3,5-dimethyl- piperazin-2-one, (3S, 5S)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 5-dimethyl- piperazin-2-one, (3S, 5R)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 5-dimethyl- piperazin-2-one,

(3S, 5R)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3,5- dimethyl-piperazin-2-one, (3S, 5S)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3,5- dimethyl-piperazin-2-one, (3S, 5S)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-sulfonyl)-3, 5-dimethyl- piperazin-2-one, (3S, 5S)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3, 5-dimethyl- piperazin-2-one, acid(4-bromo-(3S,5R)-4-(4-Amino-quinazolin-7-ylmethyl)-2,6-d imethyl-oxo-piperazine-1-carboxylic phenyl)-amide, (3S, 5S)-4-(4-Amino-quinazolin-7-ylmethyl)-2,6-dimethyl-oxo-piper azine-1-carboxylic acid (4-bromo- phenyl)-amide, (3S, 5S)-4- (4-Amino-quinazolin-7-ylmethyl)-2, 6-dimethyl-oxo-piperazine-l-carboxylic acid (4-chloro- phenyl)-amide, 1- (4-Aminoquinolin-7-ylmethyl)-4- (6-chlorobenzo [b] thiophen-2-sulfonyl)-piperazin-2-one, I-(4-Amino-quinolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one, (S)-1-(4-Amino-quinoline-7-ylmethyl)-4-(6-chloro-benzo[b]thi ophene-2-sulfonyl)-3-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> <BR> (3S, 5 S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3, 5-dimethyl-<BR> <BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> (3S, 5R)-1- (4-Amino-quinolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3, 5-dimethyl- piperazin-2-one, (S, R)- 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid methylamide, I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid ethylamide, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid dimethylamide, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6- (morpholine-4- carbonyl)-piperazin-2-one, <BR> <BR> <BR> (S)-I- (4-Aminoquinolin-7-ylmethyl)-4- [3- (5-chlorothiophen-2-yl)-allyl]-3-methylpiperazin-2-one,<B R> <BR> <BR> <BR> <BR> <BR> 1- (4-Amint-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-piperazin-2-one,

(3S, S, 5R)-I- (4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophen-2-ylmethyl)-3,5-dimethyl- piperazin-2-one, <BR> <BR> <BR> <BR> (3S, 5S)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-3, 5-dimethyl-<BR> <BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3-methyl-piperazin-2-one, (S)-1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-naphthalen-2 -ylmethyl)-3-methyl-piperazin-2-one, <BR> <BR> <BR> <BR> (3 S, 5 S)-1- (4-Am ino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 5-dimethyl-piperazin-2- one, <BR> <BR> <BR> <BR> (3S,5R)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 5-dimethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- (5-chloro-1 H-indol-2-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-naphthalen-2-ylmethyl)-3-ethyl-piperazin-2-one,< ;BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]- (S)-3- ( (R)-1-methoxy-ethyl)- piperazin-2-one, 1-(4-Amino-quinolin-7-ylmethyl)-4-(7-chloro-isoquinolin-3-yl methyl)-(S)-3-((R)-1-methoxy-ethyl)- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- (5-chloro-I H-indol-2-ylmethyl)-3-methoxymethyl-piperazin-2- one, (S)-1-(4-Amino-quinoline-7-ylmethyl)-4-(5-chloro-1H-indol-2- ylmethyl)-3-methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 4- (5-Chloro- I H-indol-2-ylmethyl)-1- [4- (2-hydroxy-ethylamino)-quinolin-7-yimethyl]-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> <BR> <BR> (S)-4- (5-Chloro-I H-indol-2-ylmethyl)-1- (4-ethylamino-quinolin-7-ylmethyl)-3-methyl-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> <BR> <BR> (S)-4-(5-Chloro-I H-indol-2-ylmethyl)-1-(4-ethylam ino-quinol in-7-ylmethyl)-3-methoxymethyl- piperazin-2-one, (S)-4-(5-Chloro-1H-indol-2-ylmethyl)-3-methyl-1-(4-methylami no-quinolin-7-ylmethyl)-piperazin-2- one, (S)-4-(5-Chloro-1H-indol-2-ylmethyl)-3-methoxymethyl-1-(4-me thylamino-quinolin-7-ylmethyl)- piperazin-2-one, <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3-methyl-4-oxy-piperazin-2- one, <BR> <BR> <BR> <BR> (S)-I- (4-Aminoquinolin-7-ylmethyl)-4- [3- (4-bromothiophen-2-yl) acryloyl]-3-methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yi)-acryloyl]-3 (S)-ethyl-6-methyl-<BR> <BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 4- [3- (5-Chloro-thiophen-2-yl)-acryloyl]- (S)-3-ethyl-I- (4-hydroxyamino-quinolin-7-ylmethyl)-piperazin- 2-one, 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-piperazin-2-one,

(S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3-ethyl-piperazin-2-one,& lt;BR> <BR> <BR> <BR> <BR> <BR> (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3-methyl-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3-ethyl-piperazin-2-one,&l t;BR> <BR> <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3-ethyl-piperazin-2-one, <BR> <BR> <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3-methoxymethyl-6- methyl-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-yimethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]- (S)-3- ( 1- (R)-methoxy-ethyl)- piperazin-2-one, 1-(4-Aminoquinolin-7-ylmethyl)-4-[3-(4-bromothiophen-2-yl)-a cryl-oyl]-3-(S)-(1-(R)-methoxyethyl)- piperazin-2-one trifluoroacetate, 1- (4-Aminoquinolin-7-ylmethyl)-4- [ (5-chlorothiophen-2-yloxy-acetyl]-3- (S)- (l- (R)-methoxyethyl)- piperazin-2-one trifluoroacetate, <BR> <BR> <BR> <BR> (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3-ethyl-piperazin-2-one,& lt;BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Aminocinnolin-7-yimethyl)-4- [2- (5-chlorothiophen-2-yi)-ethenesulfonyl]-piperazin-2-one, 4- (6-Chloro-thieno [2,3-b] pyridine-2-sulfonyl)-1-[2-(pyridin-4-ylamino)-ethyl]-piperaz in-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-[2-(methyl-pyrid in-4-yl-amino)-ethyl]-piperazin-2-one, <BR> <BR> <BR> <BR> 4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1- [2- (3-methyl-pyridin-4-ylamino)-ethyl]-piperazin-2- one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-[2-(pyridin-4-yl amino)-ethyl]-piperazin-2-one, 1- [2- (Pyridin-4-ylamino)-ethyl]-4- (thieno [2,3-b] pyridine-2-sulfonyl)-piperazin-2-one, 4-(5'-Chloro-[2,2']bithiophenyl-5-sulfonyl)-1-[2-(pyridin-4- ylamino)-ethyl]-piperazin-2-one, 1- [2- (Pyridin-4-ylamino)-ethyl]-4- (thieno [3,2-b] pyridine-2-sulfonyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1- [2- (pyridin-4-ylamino)-ethyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1- [2- (methylpyridin-4-ylamino)-ethyl]-piperazin-2-one, 4-(2-Benzo[b]thiophen-2-yl-ethenesulfonyl)-1-[2-(pyridin-4-y lamino)-ethyl]-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- [2- (3-methyl-pyridin-4-ylamino)-ethyl]-piperazin-2-one, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(2-pyrrolo [3,2-c] pyridin-1-yl-ethyl)-piperazin-2-one, 1- [2- (2-Amino-3-chloro-pyridin-4-ylamino)-ethyl]-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]- piperazin-2-one, 1- [2- (2-Amino-5-chloro-pyridin-4-ylamino)-ethyl]-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]- piperazin-2-one,

4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1- [2- (2,3,5,6-tetrachloro-pyridin-4-ylamino)-ethyl]- piperazin-2-one, 1-[2-(2-Amino-3,5,6-trichloro-pyridin-4-ylamino)-ethyl]-4-[2 -(5-chloro-thiophen-2-yl)-ethenesulfonyl]- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- [3- (5-Chloro-thiophen-2-yl)-acryloyl]-1- [2- (pyridin-4-ylamino)-ethyl]-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-[2-(pyridazin-4- yl-amino)-ethyl]-piperazin-2-one, <BR> <BR> <BR> <BR> 1- [3- (4-Amino-pyridin-3-yi)-propenyl]-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one, 1- [3- (4-Amino-pyridin-3-yl)-propenyl]-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 1- [3-(4-Amino-pyridin-3-yl)-allyl]-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 1- [3- (4-Amino-pyridin-3-yl)-allyl]-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one, 1- [3- (4-Amino-pyridin-3-yl)-propyl]-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- [3- (4-Amino-pyridin-3-yl)-propyl]-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one, 4- [2- (5-Chlorothiophen-2-yl)-ethenesulfonyl]-1- (2-pyrrolo [3,2-c] pyridin-I-ylethyl)-piperazin-2-one, 4-Prop-2-ynyl-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one.

1, 4-Bis-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- (6-Chloro- I H-benzoimidazol-2-ylmethyl)-I- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [3- (5-Chloro-thiophen-2-yl)-allyl]-1- ( 1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-(5-Chloro-1H-indol-2-ylmethyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-(6-Chloro-naphthalen-2-ylmethyl)-1-(1H-pyrrolo[3,2-c]pyrid in-2-ylmethyl)-piperazin-2-one, 4-(7-Chloro-isoquinolin-3-ylmethyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-6-oxo-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine- 2- ()-carboxylic acid methyl ester, 1-(5-Chloro-1H-indol-2-ylmethyl)-5-oxo-4-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()- carboxylic acid methyl ester, 1- [ (5-Chloro-thiophen-2-yloxy)-acetyl]-5-oxo-4- (l H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- carboxylic acid methyl ester, 1- (6-Chloro-benzo [b] thiophene-2-carbonyl)-5-oxo-4-(1H-pyrrolog[3, 2-c] pyridin-2-ylmethyl)-piperazine- 2-carboxylic acid methyl ester, 1- [1- (3, 5-Dichloro-phenyl)-2, 5-dimethyl-I H-pyrrole-3-carbonyl]-5-oxo-4- (1 H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazine-2-carboxylic acid methyl ester, 1-(1H-Pyrrolo[3,2-c]pyridin-2-ylmethyl)-4-(1H-pyrrolo[2,3-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-(3-Phenyl-prop-2-ynyl)-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmet hyl)-piperazin-2-one, 4-[3-(5-Chloro-thiophen-2-yl)-prop-2-ynyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one,

4-[3-(5-Chloro-thiophen-2-yl)-allyl]-3-(S)-methoxymethyl-1-( 1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, 4-(5-Chloro-1H-indol-2-ylmethyl)-3-(S)-methoxymethyl-1-(1H-p yrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-3-(S)-methoxymethyl-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-carbonyl)-3-(S)-methoxymethy l-1-(1H-pyrrolo[3,2-c]pyridin-2- ylmethyl)-piperazin-2-one, 4-[1-(3,5-Dichloro-phenyl)-2,5-dimethyl-1H-pyrrole-3-carbony l]-3-(S)-methoxymethyl-1-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-[3-(4-Chloro-phenyl)-(E)-acryloyl]-3-(S)-methoxymethyl-1-( 1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)- piperazin-2-one, (4-(S)-2-Methoxymethyl-3-oxo-4-(1H-pyrrolo[3,2-c]pyridin-2-y lmethyl)-piperazine-1-carboxylicacid chloro-phenyl)-amide, (S)-4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-3-methoxymethyl-1- ( I H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-carbonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2-one, 4- [3- (6-Chloro-benzo [b] thiophen-2-yl)- (E)-acryloyl]-I-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin- 2-one, 4-[(5-Chloro-thiophen-2-yloxy)-acetyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [1- (3, 5-Dichloro-phenyl)-2, 5-dimethyl-1 H-pyrrole-3-carbonyl]-1- (1 H-pyrrolo [3,2-c] pyrid : n-2- ylmethyl)-piperazin-2-one, 4- (5'-Chloro- [2,2'] bithiophenyl-5-carbonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-(5-Chloro-1H-indole-2-carbonyl)-1-(1H-pyrrolo[3,2-c]pyridi n-2-ylmethyl)-piperazin-2-one, 4-[4-(6-Methoxy-pyridin-3-yl)-benzoyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-(4-Pyridin-3-yl-benzoyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-[3-(4-Bromo-thiophen-2-yl)-(E)-acryloyl]-1-(1H-pyrrolo[3,2 -c]pyridin-2-ylmethyl)-piperazin-2-one, 4- [3- (5-Chloro-thiophen-2-yl)-propionyl]- 1- (l H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [ (5-Chloro-3-methyl-benzo [b] thiophen-2-yl)-acetyl]-I- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, <BR> <BR> <BR> <BR> 4- [2- (4-Chloro-phenyl)-2-methyl-propionyl]- I- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [3- (3, 4-Dichloro-phenyl)- (E)-acryloyl]- I- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [ (4-Chloro-phenyl)-acetyl]- I- (I H-pyffolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [3- (4-Chloro-phenyl)- (E)-acryloyl]-1- ( 1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-I- ( 1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one,

(_)-I-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid methyl ester, (~)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-indol-2 -ylmethyl)-6-oxo-piperazine-2- carboxylic acid, (~)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-indol-2 -ylmethyl)-6-oxo-piperazine-2- carboxylic acid methylamide, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-indol -2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid ethylamide, (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-IH-indol-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid dimethylamide, (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-1 H-indol-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid benzylamide, (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-1 H-indol-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid (2-hydroxy-ethyl)-amide, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid bis- (2-hydroxy-ethyl)-amide, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-indol -2-ylmethyl)-6-(morpholine-4-carbonyl)- piperazin-2-one, (+/-)-I-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid methylcarbamoylmethyl-amide, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-oxo-piperazme-2- carboxylic acid, (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-oxo-piperazine-2- carboxylic acid methyl ester, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-oxo-piperazine-2- carboxylic acid amide, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-oxo-piperazine-2- carboxylic acid ethylamide, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiop hen-2-yl)-allyl]-6-(4-methyl-piperazine-1- carbonyl)-piperazin-2-one, ()-1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid methyl ester, ()-1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid,

(+)-l-(4-Am ino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid amide, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine- 2-carboxylic acid ethyl ester, (+/-)-1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid, (+/-)-1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid methylamide, (+/-)-l-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid ethylamide, <BR> <BR> <BR> <BR> (+/-)-I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid dimethylamide, (+/-)-1-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-6-(morpholine-4- carbonyl)-piperazin-2-one, (+)-1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen- 2-yloxy)-acetyl]-6-oxo-piperazine-2- carboxylic acid methyl ester, ()-1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-6-oxo-piperazine-2- carboxylic acid methylamide, <BR> <BR> <BR> <BR> (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-6-oxo-piperazine-2- carboxylic acid ethylamide, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophe n-2-yloxy)-acetyl]-6-oxo-piperazine-2- carboxylic acid, 4-Prop-2-ynyl-I- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one. <BR> <BR> <BR> <BR> <P> 1,4-Bis-(1 H-pyrrolo [3, 2-c] pyridin-2-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 2-Amino-4- [4- (6-chloro-1 H-benzoimidazol-2-ylmethyl)-2-oxo-piperidin-I-ylmethyl]-benz onitrile,<BR> <BR> <BR> <BR> <BR> 4- [4- (6-Chloro- I H-benzoimidazol-2-ylmethyl)-2-oxo-piperidin-I-ylmethyll-benz amidine,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethly)-4- (6-chloro-1 H-benzoimidazol-2-ylmethyl)-piperidin-2-one, 4-(6-Chloro-1H-benzoimidazol-2-ylmethyl)-1-(2,4-dimaino-quin azolin-7-ylmethyl)-piperidin-2-one, <BR> <BR> <BR> <BR> I-(4-Amino-2-methyl-quinazolin-7-ylmethly)-4-(6-chloro-I H-benzoimidazol-2-ylmethyl)-piperidin-2- one, (3S, 5R)-4-[4-(6-Chloro-benzo [b] thiophen-2-ylmethyl)-3, 5-dimethyl-2-oxo-piperazin-1-ylmethyl]- benzamidine, (3S, 5S)-4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-3, 5-dimethyl-2-oxo-piperazin-1-ylmethyl]- benzamidine, 4- {4- [3- (5-Chloro-thiophen-2-yl)-acryloyl]-3, 5-dimethyl-2-oxo-piperazin-1-ylmethyl}-benzamidine,

(3R,5S)-4-[4-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-3,5-dime thyl-2-oxo-piperazin-1-ylmethyl]- benzamidine, 820.2- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1-yl]-N-[2-(3H-imidazol -4-yl)- ethyl] acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-pyridin-4-yl-a cetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-pyridin-3-ylme thyl-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-piperidin-4-yl -acetamide, N-(1-Carbamimidoyl-piperidin-4-yl)-2-[4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-2-oxo-piperain-1-yl]- acetamide, 5-(2-{2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-pip erazin-1-yl]acetylamino}-ethyl)- imidazole-1-carboxylic acid ethyl ester, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-pyrimidin-4-yl -acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-phenyl-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(9H-purin-6-yl)-acetamide, N- (4-Amino-2-methyl-pyrimidin-5-ylmethyl)-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo- piperazin-1-yl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- (3-imidazol-1-yl-propyl)- acetamide, <BR> <BR> <BR> <BR> 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- [2- (l-methyl-I H-imidazol-4-yl)- ethyl]-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(2-pyridin-4-yl-ethyl)-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- [2- (3-methyl-3H-imidazol-4-yl)- ethyl]-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(2-pyridin-2-yl-ethyl)-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(2-pyridin-3-yl-ethyl)-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(2-imidazol-1-yl-ethyl)- acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-[2-(1-methyl-1H-pyrrol-2-yl)- ethyl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- [2- (5-methyl-I H-imidazoi-4-yl)- ethyl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-yl]-N- (4-dimethylamino- [ 1,3,5] triazin- 2-yl)-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-methyl-N-pyrid in-4-yl-acetamide,

N-[2-(2-Amino-pyridin-4-yl)-ethyl]-2-[4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- acetamide, <BR> <BR> <BR> <BR> 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- [2- (4-methyl-thiazol-5-yl)-ethyl]- acetamide, <BR> <BR> <BR> <BR> 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-yl]-N- (2-thiazol-4-yl-ethyl)-acetam ide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(3-guanidino-propyl)-acetamide trifluoroacetic acid salt, N- (3-Amino-propyl)-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-yl]-N- [2- (2-mercapto- I H-imidazol-4- yl)-ethyl]-acetamide, N- [2- (2-Amino-thiazol-4-yl)-ethyl]-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-methyl-N- (2-pyridin-4-yl-ethyl)- acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-l-yl]-N-[2-(2-methylsu lfanyl-I H- imidazol-4-yl)-ethyl]-acetamide, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-[3-(3H-imidazol- 4-yl)-propyl]-piperazin-2-one, 4- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-piperidine -l-carboxamidine, <BR> <BR> <BR> <BR> 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (3-piperazin-1-yl-propyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- (6-Chloro-benzo [b] thiophene-2-sulfonyi)-1- (3-pyridin-4-yl-propyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (4-piperidin-4-yl-butyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(2-piperidin-4-y l-ethyl)-piperazin-2-one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(3-piperidin-4-y l-propyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 4- [ (5-Chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl- 1- [4- (6-methoxy-pyridin-3-yl)-benzyl]-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one, 4'- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-ylmethyl]-biphenyl-2 -carbonitrile, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(4-chloro-3-hydr oxy-benzyl)-piperazin-2-one, I-Benzyl-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (4-chloro-benzyl)-piperazin-2-one, 4-[(4-Chloro-thiophen-2-yloxy)-acetyl]-3-(S)-methoxymethyl-1 -[4-(6-methoxy-pyridin-3-yl)-benzyl]- piperazin-2-one, 4- [ (5-Chloro-thiophen-3-yloxy)-acetyl]-1- [4- (6-hydroxy-pyridin-3-yl)-benzyl]-3- (S)-methoxymethyl- piperazin-2-one, 4- [ (5-Chloro-thiophen-3-yloxy)-acetyl]-3- (S)-methoxymethyl-1- [4- (6-methoxy-pyridin-3-yl)-benzyl]- piperazin-2-one,

4- [ (5-Chloro-thiophen-2-yloxy)-acetyl]-1- [4- (6-hydroxy-pyridin-3-yl)-benzyl]-3- (S)-methoxymethyl- piperazin-2-one, 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-1- [4- (6-methoxy-pyridin-3-yl)-benzyl]-3- (S)-methyl- piperazin-2-one, 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-3- (S)-methyl-1- [4- (6-oxo-1, 6-dihydro-pyridin-3-yl)- benzyl]-piperazin-2-one, <BR> <BR> <BR> <BR> I-Biphenyl-4-ylmethyl-4- [3- (5-chloro-thiophen-2-yl)- (E)-acryloyl]-3 (S)-ethyl-6-methyl-piperazin-2- one, 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-I- [4- (6-hydroxy-pyridin-3-yl)-benzyl]-3- (S)- methoxymethyl-piperazin-2-one, 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-3- (S)-methoxymethyl-1- [4- (6-methoxy-pyridin-3-yl)- benzyl]-piperazin-2-one, 1- (3-Amino- I H-indazol-6-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, 1- (3-Amino-1 H-indazol-6-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)]-piperazin-2-one, 1- (3-Amino- I H-indazol-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 4-[4-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-2-(S)-methyl-3,6 -dioxo-piperazin-1-ylmethyl]- benzamidine, 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2- (R)-methyl-3, 6-dioxo-piperazin-I-ylmethyl]- benzamidine, 3- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2, 5-dioxo-piperazin-1-ylmethyl]-benzamidine and 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2, 5-dioxo-piperazin-1-ylmethyl]-benzamidine.

Preferred compounds have formula I wherein Cy2 contains at least one nitrogen atom and when CY2 is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted fused phenylcycloalkyl or optionally substituted fused phenylcycloalkenyl, then said nitrogen atom is a basic nitrogen atom.

Other preferred compounds have formula I wherein Z is absent or is selected from O, S (O) p and NR5.

Other preferred compounds have formula I wherein Z is-NR5C (O)- or-C (O) NR,-.

Preferred compounds wherein Z is -NR5C(O)- or -C(O)NR5- are selected from 2- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin- I-yi]-N- [2- (3H-imidazol-4-yl)- ethyl] acetamide,

2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-pyridin-4-yl-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-yi]-N-pyridin-3-ylmethyl-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-yl]-N-piperidin-4-yl -acetamide, N-(1-Carbamimidoyl-piperidin-4-yl)-2-[4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-2-oxo-piperazin-1- yl]-acetamide, 5-(2-{2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-pip erazin-1-yl]-acetylamino}-ethyl)- imidazole-I-carboxylic acid ethyl ester, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-pyrimidin-4-yl -acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-phenyl-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(9H-purin-6-yl)-acetamide, N- (4-Amino-2-methyl-pyrimidin-5-ylmethyl)-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo- piperazin-1-yl]-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(3-imidazol-1-yl-propyl)- acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-[2-(1-methyl-1H-imidazol-4-yl)- ethyl]-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(2-pyridin-4-yl-ethyl)- acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-[2-(3-methyl-3H-imidazol-4-yl)- ethyl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-(2-pyridion-2- yl-ethyl)- acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-l-yl]-N-(2-pyridin-3-y l-ethyl)- acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- (2-imidazol-1-yl-ethyl)- acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-[2-(1-methyl-1H-pyrrol-2-yl)- ethyl]-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-[2-(5-methyl-1H-imidazol-4-yl)- ethyl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-(4-dimethylami no-[1, 3,5] triazin- 2-yl)-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N-methyl-N-pyrid in-4-yl- acetamide,

N-[2-(2-Amino-pyridin-4-yl)-ethyl]-2-[4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-2-oxo-piperazin-1- yl]-acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- [2- (4-methyl-thiazol-5-yl)- ethyl]-acetamide, 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-(2-thiazol-4-yl-ethyl)-acetamide, <BR> <BR> <BR> <BR> 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- (3-guanidino-propyl)-acetamide trifluoroacetic acid salt, N- (3-Amino-propyl)-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-acetamide, <BR> <BR> <BR> <BR> <BR> 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-N- [2- (2-mercapto-1 H-imidazol-4- yl)-ethyl]-acetamide, N- [2- (2-Amino-thiazol-4-yl)-ethyl]-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-l-yl]- acetamide, 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-yl]-N-methyl-N- (2-pyridin-4-yi-ethyl)- acetamide, or 2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin -1-yl]-N-[2-(2-methylsulfanyl-1H- imidazol-4-yl)-ethyl]-acetamide, or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

Other preferred compounds have formula I wherein m is 1; and n is 1.

Other preferred compounds have formula I wherein A is N.

Other preferred compounds have formula I wherein R3 and R3a taken together are 0 ; and R,, Rla, R,, R2a, R4 and R4a are hydrogen.

Other preferred compounds have formula I wherein R3 and R3a taken together are O; R1, R1a, R2, R,. and R, are hydrogen; and R4a is optionally substituted alkyl.

Other preferred compounds have formula I wherein R3 and R3a taken together are O; RI, Ria, R2 and R4 are hydrogen; and R2a and R4a are optionally substituted alkyl.

Other preferred compounds have formula I wherein R3 and R3a taken together are O; R1, R2, R2a and R4 are hydrogen; and Rla and R4a are optionally substituted alkyl.

Other preferred compounds have formula I wherein R3 and R3a taken together are O; R,, R2, R2a, R4 and Rua are hydrogen; and Rla is carboxy, alkoxycarbonyl, Y1Y2NCO or optionally substituted alkyl.

Other preferred compounds have formula I wherein R3 and R3a taken together are O; and R,, Rla, R2, R4 and R4a are hydrogen; and R2a is carboxy, alkoxycarbonyl, Y'Y2NCO or optionally substituted alkyl.

Other preferred compounds have formula I wherein L, is-S (O) p-,-C (X) Y- or-L3-Q-L4-Q'-L5-.

Other preferred compounds have formula I wherein Cy, is optionally substituted aryl or optionally substituted heteroaryl.

More preferred compounds have formula I wherein L, is alkylene of one to three carbon atoms.

Other more preferred compounds have formula I wherein L, is-CH,-.

Other more preferred compounds have formula I wherein L, is a group of formula wherein Z is NR5 ; q is 2; r is 0; R, is hydrogen or optionally substituted alkyl; and R, and R8 are hydrogen.

Other more preferred compounds have formula I wherein R5 is hydrogen.

Other more preferred compounds have formula I wherein Cy2 is optionally substituted aryl or optionally substituted heteroaryl.

Other more preferred compounds have formula I wherein L, is -S(O)2-.

Other more preferred compounds have formula I wherein L, is-C (X) Y- ; X is O; and Y is NH.

Other more preferred compounds have formula I wherein L, is-L3-Q-L4-Q'-L5-; Q is-S (O) 2-or -C (O)- ; and L4 is optionally substituted alkenylene.

Other more preferred compounds have formula I wherein L, is-L3-Q-L4-Q'-L5- ; and L4 is optionally substituted alkylene.

Other more preferred compounds have formula I wherein L, is-L3-Q-L4-Q'-L5- ; Q is-C (O)- ; Q'is O; and L4 is optionally substituted alkylene.

Other more preferred compounds have formula I wherein L, is-L3-Q-L4-Q'-L5- ; L3 is optionally substituted alkylene; and L4 is optionally substituted alkenylene.

Other more preferred compounds have formula I wherein Cy, is optionally substituted phenyl, optionally substituted thienyl, optionally substituted benzothienyl, optionally substituted isoquinolinyl, optionally substituted indolyl, optionally substituted thienopyridyl, optionally substituted furanyl, optionally substituted pyridyl, or optionally substituted benzimidazolyl.

Other more preferred compounds have formula I wherein Cy2 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted imidazolyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted cinnolinyl, optionally substituted azaindolyl, or optionally substituted thienopyridyl.

Still more preferred compounds are selected from <BR> <BR> <BR> <BR> 4- [3- (6-Amino-pyridin-3-yi)-acryloyl]- 1- (4-amino-quinazolin-7-ylmethyl)-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one, 1-(1-Amino-isoquinolin-7-ylmethyl)-4-(6-chloro-benzo[b]thiop hene-2-sulfonyl)-piperazin-2-one, 4- (5'-Chloro-[2, 2'] bithiophenyl-5-ylmethyl)-3-(S)-methoxymethyl-I-(I H-pyrrolot3,(5'-Chloro-[2, 2'] bithiophenyl-5-ylmethyl)-3-(S)-methoxymethyl-I-(I H-pyrrolot3, 2-c] pyridin-2- ylmethyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-piperazin-2-one, <BR> <BR> <BR> <BR> (S)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3-methyl-piperazin-2- one, <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-al lyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-chloro- I H-indol-6-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3- (S)-methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-4-oxy-piperazin-2-one,

4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1- [2- (pyridin-4-ylamino)-ethyl]-piperazin-2-one, <BR> <BR> <BR> <BR> I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-piperazin-2-one, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4-chloro- phenyl)-amide, I-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-I H-benzoimidazol-2-ylmethyl)-piperazin-2-one, 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4-[2-(5-chloro-thiophen-2-yl)-ethenesu lfonyl]- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methoxymethyl- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-furan-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-4-oxy-piperazin-2- one, <BR> <BR> <BR> <BR> I- (I-Amino-isoquinolin-6-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-ethoxymethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- ( (S)-l- (R)-methoxy-ethyl)- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- (R)- carboxylic acid ethyl ester, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin- I-ylmethyl]-7-chloro-I H-quinolin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-butyl-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-piperazin-2-one,<BR&g t; <BR> <BR> <BR> <BR> 4- [3- (6-Amino-pyridin-3-yl)-acryloyl]-1- (4-amino-quinazolin-7-ylmethyl)-3- (S)-propyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> I-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-I H-indol-6-ylmethyl)-3-(S)-methyl-piperæin-2-one, 1-(4-Amino-quinolin-7-ylmethyl)-4-(5-chloro-1H-indol-2-ylmet hyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo- I- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine- 2-carboxylic acid methyl ester,

(3S,5R)-1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thi ophen-2-yl)-allyl]-3,5-dimethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5-sulfonyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)-propyl-piperazin-2- one, <BR> <BR> <BR> <BR> <BR> 4- [ (5-Chloro-thiophen-2-yloxy)-acetyl]-1- [4- (6-hydroxy-pyridin-3-yl)-benzyl]-3- (S)-methoxymethyl-<BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-ethoxymethyl- piperazin-2-one, 1- (4-Amino-quinolin-7-ylmethyl)-4- (5-chloro-IH-indol-2-ylmethyl)-3- (S)-methyl-piperazin-2-one, 1-(4-Amino-quinolin-7-ylmethyl)-4-(5-chloro-1H-indol-2-ylmet hyl)-3-(S)-methoxymethyl-piperazin-2- one, 1-(4-Amino-quinolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2-yl )-acryloyl]-3-(S)-ethyl-6-methyl- piperazin-2-one, (3S, 5S)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-3,5-dimethyl- piperazin-2-one, (3S, 5R)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3,5- <BR> <BR> <BR> <BR> dimethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-piperazin-2- one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-6-dimethyl-piperazin- 2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3-ylmethyl)-3- (S)-methyi-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(1-ethyl-1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin- 2-one, 4-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piprazin- 1-ylmethyl]-piperidine-1-caboxamidine, 4- (6-Chloro-thieno [2,3-b] pyridine-2-sulfonyl)-1-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one,

4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(I H-pyrrolo(6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4-[(5-Chloro-thiophen-3-yloxy)-acetyl]-3-(S)-methoxymethyl-1 -[4-(6-methoxy-pyridin-3-yl)-benzyl]- <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-2- (S)-propyl-piperazine-I-carboxylic acid (5-chloro- thiophen-2-yl)-amide, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-3- yl)-acryloyl]-3-(S)-propyl-piperazin-2- one, 4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-hydroxymethyl-1- ( I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methyl-3-oxo-piperazine- 1-carboxylic acid (5-chloro- thiophen-2-yl)-amide, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-2-yl oxy)-acetyl]-3-(S)-ethyl-6-methyl- piperazin-2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yi)-acryloyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methyl-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-methyl-piperazin-2- one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro- I H-benzoimidazole-2-sulfonyl)-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- [I-(2-hydroxy-ethyl)-I H-pyrrolo [3,2-c] pyridin-2- ylmethyl]-piperazin-2-one, 4- (6-Bromo-benzo [b] thiophene-2-sulfonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-yimethyl)-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(1-methyl-1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)-methoxymethyl-6- methyl-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo- I- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine- 2-carboxylic acid, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-6-methyl-<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-6-methyl-<BR> <BR> <BR> <BR> <BR> <BR> <BR> piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl-6-<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl-6-<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, (3S, 5R)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 5-dimethyl-piperazin- 2-one, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-oxo-1-(1H-py rrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- (R)- carboxylic acid methyl ester, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- (S)- carboxylic acid methyl ester, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-ethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-6- (R)-hydroxymethyl-3- (S)- methoxymethyl-piperazin-2-one, 1- (I-Amino-isoquinolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, 4- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-benzamidin e, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)- propyl-piperazin-2- one, 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-1-(1H-pyrrol o [3,2-c] pyridin-2-ylmethyl)-piperazine- 2-carboxylic acid amide 4- [2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-hydroxymethyl- 1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one, (+/-)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl-6-<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyl-piperazin-2-one, (5-4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-methoxymethyl-3-o xo-piperazine-1-carboxylicacid bromo-thiophen-2-yl)-amide, 4-[4-(6-Chloro-thieno[2,3-b]pyridine-2-sulfonyl)-2-oxo-piper azin-1-ylmethyl]-benzamidine, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one,

1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)-acryloyl]-3- (S)- propyl-piperazin-2- one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-ethyl-piperazin-2-one, 4- (4-Amino-quinazolin-7-yimethyl)-2- (S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (5-chloro- thiophen-2-yl)-amide, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)-acryloyl]-3- (S)- propyl-piperazin-2- one, (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b] thiophene-2-sulfonyl)-6-oxo-piperazine- 2-carboxylic acid amide, 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-2-yl oxy)-acetyl]-3-(S)-methoxymethyl- piperazin-2-one, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)- propyi-piperazin-2- one, 1-(4-Amino-cinnolin-7-ylmethyl)-4-[2-(5-chloro-thiophen-2-yl )-ethenesulfonyl]-piperazin-2-one, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6- (morpholine-4- carbonyl)-piperazin-2-one, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid dimethylamide, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid ethylamide, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid methylamide, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yioxy)-acetyl]-3- (S)-methoxymethyl-6-<BR> <BR> <BR> <BR> <BR> methyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- (S)- carboxylic acid ethyl ester, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-(R)-hydroxym ethyl-1-(1H-pyrrolo [3,2-c] pyridin-2- <BR> <BR> <BR> <BR> ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one, (3S, 5-dimethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2,3-b] pyridine-2-sulfonyl)-piperazin-2-one, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one,

(3S, 5S)-I- (4-Amino-quinazolin-7-yimethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesulfonyl]-3,5-<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> dimethyl-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-yimethyl)-4- [2- (5-chloro-thiophen-2-yl)-ethenesuffonyl]-piperazin-2-one, (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine- 2-carboxylic acid, 1- (4-Amino-quinolin-7-yimethyl)-4- (5-chloro- I H-indol-2-yimethyl)-3- (S)-methyl-piperazin-2-one, 4-(5-Chloro-1H-indol-2-ylmethyl)-3-(S)-methyl-1-(4-methylami no-quinolin-7-ylmethyl)-piperazin-2- one, 4-(5-Chloro-1H-indol-2-ylmethyl)-3-(S)-methyoxymethyl-1-(4-m ethylamino-quinolin-7-ylmethyl)- piperazin-2-one, 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid dimethylamide, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- (S)- carboxylic acid methyl ester, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine- 2-carboxylic acid amide, 1- (4-Amino-quinazolin-7-ylmethyl)-4- (IH-5 3-chloro-l-aza-inden-2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid, (+/-)-1-(4-Amino-quinazolin-7-ylmetyl)-4-(5-chloro-1H-indol- 2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid methylamide, (+/-)-1-(4-Amino-quinazolin-7-ylmetyl)-4-(5-chloro-1H-indol- 2-ylmethyl)-6-oxo-piperazine-2- carboxylic acid ethylamide, <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-I H-indol-2-ylmethyl)-6-oxo-piperazine-2-carboxylic acid (2-hydroxy-ethyl)-amide, (+/-)-1-(4-Amino-quinazolin-7-ylmetyl)-4-[(5-chloro-thiophen -2-yloxy)-acetyl]-6-oxo-piperazine-2- carboxylic acid methyl ester, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-oxo-piperazine-2- carboxylic acid methyl ester, (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-6-oxo-piperazine-2- carboxylic acid, 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-6-oxo- 1- (IH-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine- 2-carboxylic acid methyl ester, 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-hydroxymethy l-1-(1H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one,

I-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-oxo-4-(1 H-pyrrolo[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-oxo-4 -(1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- piperazine-2-carboxylic acid methyl ester, or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

Still yet more preferred compounds are selected from 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl- piperazin-2-one, I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl-6- methyl-piperazin-2-one, 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, 4- [2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(I H-pyrrolo[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one, I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-acryloyl]-3- (S)-methoxymethyl- piperazin-2-one, 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-piperazin-2-one, 4- [2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-(R)-hydroxymet hyl-I-(I H-pyrrolo[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-(R)-h ydroxymethyl-I-(I H-pyrrolo [3,2-c] pyridin-2- ylmethyl)-piperazin-2-one and <BR> <BR> <BR> 4- [3- (6-Amino-pyridin-3-yl)-acryloyl]-1- (4-amino-quinazolin-7-ylmethyl)-3- (S)-propyl-piperazin-2-one, or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

Preferred intermediates according to this invention have formula II wherein Cy2 contains at least one nitrogen atom and when Cy2 is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted fused phenylcycloalkyl or optionally substituted fused phenylcycloalkenyl, then said nitrogen atom is a basic nitrogen atom.

Other preferred intermediates according to this invention have formula 11 wherein Z is absent.

Other preferred intermediates according to this invention have formula 11 wherein R"Rla, R2, R2a, R4 and R4a are hydrogen.

More preferred intermediates according to this invention are selected from (2S, 6RS)-4- (4-chloro-quinolin-7-ylmethyl)-2, 6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester,

(3S,5RS)-1-(4-chloro-quinolin-7-ylmethyl)-3,5-dimethyl-piper azin-2-one, (3S, SR)-1- (4-chloro-quinolin-7-ylmethyl)-3, 5-dimethyl-piperazin-2-one, (3S,5S)-1-(4-chloro-quinolin-7-ylmethyl)-3,5-dimethyl-pipera zin-2-one, (3S, 5S)-1-(4-chloro-quinolin-7-ylmethyl)-3,5-dimethyl-piperazin- 2-one, (2S, 6R)-4- (4-chloro-quinolin-7-ylmethyl)-2, 6-dimethyl-3-oxo-piperazine-l-carboxylic acid benzyl ester, (3S,5S)-1-(4-chloro-quinolin-7-ylmethyl)-4-[3-(5-chloro-thio phen-2-yl)-allyl]-3,5-dimethyl-piperazine- 2-one, (3S, 5S)-1-(4-chloro-quinolin-7-ylmethyl)-4-[3-(5-chloro-thiophen -2-yl)-allyl]-3,5-dimethyl-piperazine- 2-one, 4- (2-Oxopiperazin- I-ylmethyl) benzamidine, 1- (2-Aminoquinolin-6-ylmethyl) piperazin-2-one, I- (I-Aminoisoquinolin-6-ylmethyl) piperazin-2-one, 2- (2-Oxopiperazin- I-ylmethyl) pyrrolo [3,2-c] pyridin-1-carboxylic acid tert-butyl ester, 2- (5- ()-Methoxycarbonyl-2-oxo-piperazin-1-ylmethyl)-pyrrolo [3, 2-c]pyridine-1-carboxylic acid tert- butyl ester, 2- (2- ()-Methoxycarbonyl-6-oxo-piperazin-I-ylmethyl)-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert- butyl ester, 1- (4-Aminoquinazoline-7-ylmethyl) piperazine-2-one, 1- (4-Amino-thieno [2,3-d] pyrimidin-6-ylmethyl)-piperazin-2-one, 4-[3-(2-Oxo-piperazin-1-yl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester, <BR> <BR> <BR> <BR> 1- (4-Amino-quinazoline-7-ylmethyl)-3-methoxymethyl-piperazine- 2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Aminoquinazoline-7-ylmethyl)-3-butyl-piperazine-2-one,< ;BR> <BR> <BR> <BR> <BR> <BR> I- (4-Aminoquinazoline-7-ylmethyl)-3-ethyl-piperazine-2-one,< ;BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Aminoquinazoline-7-ylmethyl)-3-propyl-piperazine-2-one,&l t;BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazoline-7-ylmethyl)-3-ethoxymethyl-piperazine-2 -one,<BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazoline-7-ylmethyl)-3-methyl-piperazine-2-one,& lt;BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazoline-7-ylmethyl)-3-benzyl-piperazine-2-one,& lt;BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Amino-quinazoline-7-ylmethyl)-3- (I-methoxyethyl)-piperazine-2-one, 1-(4-Amino-quinazoline-7-ylmethyl)-3,3-dimethyl-piperazine-2 -one, 1-(4-Amino-quinazoline-7-ylmethyl)-3-isopropyl-piperazine-2- one, 1- (4-Amino-quinazoline-7-ylmethyl)-3-isobutyl-piperazine-2-one , 1-(4-Amino-quinazoline-7-ylmethyl)-3-(2-methoxyethyl)1-piper azine-2-one, 1-(4-Amino-quinazoline-7-ylmethyl)-3-methoxymethyl-6-methyl- piperazine-2-one, (3S,5RS)-1-(4-amino-quinazolin-7-ylmethyl)-3,5-dimethyl-pipe razin-one,

1-(4-Chloroquinolin-7-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Chlorocinnolin-7-ylmethyl)-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 1- (4-Chloroquinolin-7-ylmethyl)-3- (S)-methylpiperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1-[2- (Pyridin-4-ylamino)-ethyl]-piperazin-2-one, 1-[2-{(Methyl)-(pyridin-4-yl)-amino}-ethyl]-piperazin-2-onet rifluroacetate, <BR> <BR> <BR> <BR> 1- [2- (3-Methylpyridin-4-yl-amino)-ethyl]-piperazin-2-one,<BR&g t; <BR> <BR> <BR> <BR> <BR> <BR> 1- [2- (Pyridazin-4-ylamino)-ethyl]-piperazin-2-one,<BR> <BR> <BR> <BR> <BR> <BR> 4- [3- (4-tert-Butoxycarbonylamino-pyridin-3-yl)-propenyl]-3-oxo-pi perazine-1-carboxylic acid tert-butyl ester, 4-[3-(4-tert-butoxycarbonylamino-pyridin-3-yl)-allyl]-3-oxo- piperazine-1-carboxylic acid tert-butyl ester 4- [3- (4-tert-Butoxycarbonylamino-pyridin-3-yl)-propyl]-3-oxo-pipe razine-1-carboxylic acid tert-butyl ester.

4-(Benzyloxycarbonyl)-1-(2-pyrrolo [3,2-c] pyridin-1-ylethyl)-piperazin-2-one, ()-I- (3-Amino-4-cyano-benzyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid methyl ester and ()-1- (3-Amino-4-cyano-benzyl)-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxylic acid.

Preparation of the Compounds of the Invention A general route to the compounds of this invention wherein A is N and R1, R1a, R2, R2a, R3, R3a, R4, R4a, L,, L,, Cy,, Cy2, m and n are defined herein is outlined in Scheme 1.

Scheme 1 As shown in Scheme 1, coupling of a compound of formula 11 with a sulfonyl chloride, an alkyl halide, an acid or an activated derivative thereof such as an anhydride or acid chloride, an isocyanate, chloroformate or activated sulfamyl ester in an appropriate solvent generates the compound of formula I

in which the L,-Cy, portion is a sulfonamide, alkyl amine, amide, urea, carbamate or sulfamyl urea respectively. Sulfonamide formation is accomplished with a base such as a trialkylamine in an inert solvent such as dichloromethane, THF or acetonitrile at about 0 °C to about 100 °C in the presence or absence of an activating agent such as dimethylaminopyridine (DMAP). Alkyl amine formation can be achieved with a suitable base such as K, C03 or trialkylamine in an appropriate solvent such as DMF or acetonitrile at about 0 °C to about 100 °C. Amide, urea, carbamate and sulfamyl urea formation can be conducted with acids and coupling reagents such as EDC or TBTU or with any variant of reactive acid derivatives and the use of an appropriate base additive such as triethylamine, N-methylmorpholine or diisopropylethylamine.

The preparation of the compound of formula Il wherein RI, Rla, R2, R2a, R3, R3a R4, R4as L2, Cy2, m and n are defined herein is outlined in Scheme 2.

Scheme 2 As shown in Scheme 2, the compound of formula 11 is prepared by removing a nitrogen protecting group P from the compound of formula 1. In a preferred aspect, P is an alkyl, aralkyl or aryl carbamate moiety which is removed using strong acid, strong base or catalytic hydrogenation in an appropriate solvent such as methanol or ethanol.

The preparation of the compound of formula I wherein R"Rla, R2, R2a, R3, R3a R4, R4a Ll, L2, Cy,, Cy2, m and n and P are defined herein is outlined in Scheme 3.

Scheme 3

As shown in Scheme 3, the compound of formula 1 is obtained by coupling a compound of formula 2 with an appropriate Cy2-L2-LG group wherein LG is a leaving group such as chloro, bromo, iodo, or optionally substituted lower alkylsulfonyloxy or arylsulfonyloxy in an inert organic solvent such as THF, Et, O or DMF in the presence of a strong base such as NaH, lithium hexamethyidisilylazide or lithium diisopropylamine. In a preferred aspect, P is an alkyl, aralkyl or aryl carbamate group.

The preparation of intermediate compounds of formula 7 and 10 are outlined in Scheme 4.

Scheme 4 0 ci Br -r Ar Ar I NH A I N CHO COR 3 4 5 1 6 e 6 3 4 S Ar = monocyclic aryl or heteroaryl Rua NMR R9'N A I N boc Rz Rl Rla 7 H N ci 0 N O gr N C1 4 N\ C1 air 9 R1 Rla 10 C r /\ R2 $ Rl Rla As shown in Scheme 4, reacting a compound of formula 3 with an appropriate malonic acid in a polar solvent such as pyridine or ethanol and a base such as piperidine or pyridine at reflux provides a compound of formula 4 wherein R is H. Alternatively, a compound of formula 3 may be reacted with a suitable Wittig or Horner-Emmons reagent in an inert solvent such as THF to give a compound of formula 4 wherein R is lower alkyl. When R is lower alkyl, the ester is hydrolyzed to the corresponding carboxylic acid (R is H) by an appropriate strong acid or alkali base. The corresponding acid is

converted to the acid chloride using standard methods such as thionyl chloride or is converted to the mixed anhydride in a polar solvent such as acetone or THF to form an activated acyl compound. The activated acyl compound is then treated with a solution of NaN3 in water at about-10 °C to about 25 °C to yield the corresponding acyl azide. The acyl azide compound is then heated slowly in an inert solvent such as benzene or toluene at about 60 °C to about 110 °C then concentrated in vacuo and heated in a higher boiling inert solvent such as 1,2-dichlorobenzene or phenyl ether at about 180 °C to about 240 °C with a catalyst such as iodine or tributylamine to obtain a compound of formula 5. Alternatively the acyl azide compound can be added directly to a high boiling inert solvent such as phenyl ether at about 190 °C to about 240 °C with a catalyst such as iodine or tributylamine to obtain the compound of formula 5.

A compound of formula 8, prepared as described in Syn., 739 (1975), which is incorporated herein by reference, or formula 5 above may be chlorinated using standard methods such as POCI3 or POCl3/PCl5 and halogenated using standard conditions such as N-halosuccinimide and benzoyl peroxide in an inert solvent such as carbon tetrachloride to give the corresponding chloro-halomethyl compounds 6 and 9, respectively.

The preparation of aminoquinazoline, quinazolinone or amino-thienopyrimidine intermediates is outlined in Scheme 5.

Scheme 5 Ar = monocyclic aryl or heteroaryl As shown in Scheme 5, an aminoheteroaryl carboxylic acid or an aminoarylcarboxylic acid 11 in which the amino and carboxylic acid are adjacent is treated with formamidine under heat to form the corresponding quinazolinone or thienopyrimidinone 12. The quinazolinone or thienopyrimidinone 12 is

then converted to the chloroquinazoline or chlorothienopyrimidine using a chlorinating reagent such as P (O) Cl3 and heat. The chloroquinazoline or chlorothienopyrimidine is brominated at the benzylic carbon using radical bromination conditions. Alternatively, a chloroquinazoline or chlorothienopyrimidine, containing a hydroxy-methylene group is converted to the corresponding bromide using CBr,/PPh,; or PBr3 conditions. The bromide 13 is then reacted with the anion of the ring nitrogen of compounds of formula 2, formed using NaH, LiN (SiMe3) 3, NaN (SiMe3) 3, LDA, lithium alkoxides, sodium alkoxides or an appropriate base, in an inert solvent such as THF, DMF, ether, or DME. This yields compounds of formula 14 in which Cy2 is a chloro-quinazoline or a chloro-thienopyrimidine. The chloro group is converted to an amino group using NH3 in ethanol in the presence of a catalytic acid source.

Alternatively, the chloro group is converted to a substituted amino using a primary or secondary amine in a solvent. Alternatively, the chloro group is converted to a hydroxy group using acetic acid in water with heating or using a hydroxide source. Alternatively, the chloro is converted to an alkoxy group using an alcoholic solvent with heated in the presence of a base.

An alternative synthesis of quinazolines and thienoquinazolines is outlined in Scheme 6.

Scheme 6. Pu pu NHZ N-- 3--y Ar Ph 7 CN CN 18 CN Ar = monocyclic aryl or heteroaryl o o 0 R4 R4 Rae NNHz Rea NN Ar-- Ar P N p, N4R2RN R1R 20 R1 R, az 21 0 NH2 R4, R4a N N Au I !! Ar t R2 N) R1 R1a 22 As shown in Scheme 6, an amino-aryl nitrile or an amino heteroaryl nitrile 17 is treated with an aldehyde or ketone under imine forming conditions. The corresponding aryl or heteroaryl imine is brominated using radical bomination with NBS. The bromide is then reacted with the anion of the ring nitrogen of compounds of formula 2, formed using NaH, LiN (SiMe3) 3, NaN (SiMe3) 3, LDA, lithium alkoxides, sodium alkoxides or an appropriate base, in an inert solvent such as THF, DMF, ether, or DME. This yields compounds of formula 20 in which Cy2 is an imino-aryl nitrile or an imino heteroaryl

nitrile. The imine is deprotected using an acid such as HCI to give the corresponding aniline. The aniline-aryl-nitrile or the aniline-heteroaryl nitrile is converted to the amino-quinazoline or thienopyrimidine using triazine or formamidine. The quinazolinone or thienopyrimidinone 21 is formed using formamide.

The preparation of cinnoline (X = N) and quinoline (X = CH) intermediates is outlined in Scheme 7.

Scheme 7 As shown in Scheme 7, halogenated azaarenes exemplified by 4-chloro-7- trifluoromethylquinoline or cinnoline are treated with H, S04 (70-95 %) at 180-220 °C for about 16 to 48 hours in a sealed reaction vessel. The solution is cooled, poured into water and neutralized with base to pH The product is dissolved in aqueous base and precipitated by acidification to yield 7-carboxy- 4-chloroquinoline or cinnoline. This material is converted to the alkyl ester (such as methyl or ethyl) by standard methods. 7-Alkyloxycarbonyl-4-chloroquinoline or cinnoline is dissolved in an anhydrous, aprotic solvent (THF or ether). The solution is cooled (-60 to-95 °C) and treated with a reducing agent such as lithium aluminum hydride. The solution is warmed (approximately-40 to-50 °C) for about 15 to 30 minutes and quenched with a solvent such as ethyl acetate. Standard workup gives the product 7- hydroxymethyl-4-chloroquinoline or cinnoline. This material is treated with 45-50 % HBr and heated to about 100-140 °C for about 45 to 90 minutes. After cooling and standard workup 7-bromomethyl-4- chloroquinoline or cinnoline is obtained.

The preparation of pyrrolopyridine derivatives is outlined in Scheme 8.

Scheme 8

As shown in Scheme 8 pyrrolopyridine derivatives are prepared by alkylation of a suitably protected oxopiperazine with propargyl bromide in the presence of a base such as sodium hydride. The resulting alkyne is heated (100-120 °C) with a halopyridine optionally substituted with hydroxy, alkoxycarbonylamino, or sulfhydryl, a catalyst such as Pd (PPh3) copper iodide and triethylamine in a suitable solvent such as acetonitrile in a sealed vessel or in DMF for 2-20 hours. When the pyridine is substituted with a hydroxyl moiety furopyridines are isolated directly. If the pyridine is substituted with an alkoxycarbonylamino moiety, additional treatment with DBU at about 60 °C in DMF yields pyrrolopyridines. Subsequent carbamate deprotection using transfer hydrogenation conditions such as Pd black in formic acid yields the desired oxopiperazine furopyridines or pyrrolopyridine-l-carboxylic acid alkyl ester derivatives. After further reaction with the L,-Cy, group, an additional deprotection step such as Boc removal using, for example, TFA, HCI is required for generating the oxopiperazine pyrrolopyridines.

The preparation of the compound of formula 40 are shown in Scheme 9.

Scheme 9

As shown in Scheme 9, compounds of formula 40 are prepared from an appropriately protected mono-or di-substituted amino-acid. To this is added an amino-acetaldehyde, protected as an acetal derivative, under standard peptide coupling procedures, employing activating reagents such as EDC, TBTU, or BOP. The resulting dipeptidyl moiety is subjected to conditions which remove the acetal, such as acidic conditions (TsOH). The resulting cyclic material is reduced using hydrogenating conditions to yield compounds of formula 40. This reduction, alternatively can be carried out using a reagent which acts as a hydride source.

The preparation of compounds of formula 46a and b is shown scheme 10.

Scheme 10.

As shown in Scheme 10, a protected amino acid is coupled to a beta-aminoalcohol using standard peptide coupling procedures as describe above. The alcohol is then oxidized to a ketone using, for example, Swern oxidation conditions. The protecting group is removed and the resulting compound

is reduced under hydrogenation conditions to give the 2-piperidinone. The free amine can be reprotected and diastereomers are separated by chromatographic methods, or in some cases by recrystallization.

A chiral synthesis of compounds of formula 46 is shown in Scheme 11.

Scheme l l

As shown in Scheme 11, an amino acid is protected as its trifluoroacetate derivative using trifluoroacetic anhydride and a base. An amino-alcohol is derivatized via reductive amination conditions using a benzaldehyde derivative, such as 2,4-dimethoxybenzaldehyde. The resulting secondary amine is then coupled to an amino-acid protected as a trifluoroacetate using standard peptide coupling procedures.

Ring closure is then accomplished by utilizing Mitsinobu conditions. The trifluoroacetate group is removed under basic conditions, and the amide of the ring is deproteced using an aqueous solution of potassium persulfate and sodium phosphate and heat. All possible enantiomers of piperazin-2-one can be made from the corresponding amino-alcohol and amino acid as shown in scheme 2c.

The preparation of the compound of formula 58 wherein R,, R2, R2a R4 and R4a are hydrogen and Riais carbomethoxy, methoxymethyl, or a protected hydroxymethyl group is shown in Scheme 12.

Scheme 12

As shown in Scheme 12, alkylating a compound of formula 55 with propargyl bromide in the presence of an amine base such as triethylamine provides the compound of formula 56. Coupling with bromoacetic acid using a standard reagent such as DCC gives the compound of formula 57 which can be cyclized using a non-nucleophilic strong base such as NaH in a solvent such as THF to yield the desired compound of formula 58.

The preparation of a compound of formula 59 is outlined in Scheme 13.

Scheme 13 As shown in Scheme 13, protection of (Aebischer, 6-oxopiperazine-2-carboxylate Helv. Chim. Acta 1989,72,1043-1051) using, for example, benzyl chloroformate or allyl chloroformate under standard conditions provides compound 59. Alkylation of 59 with propargyl bromide using a strong base such as NaH in polar solvents as THF or DMF provides the compound of formula 58.

The preparation of a compound of formula 61 wherein R,, R,, R4 R,., L, and Cy, are defined as above and Rla or R2a are independently carboxy, acetamido or hydroxymethyl is outlined in Scheme 14.

Scheme 14 As shown in Scheme 14, the compound of formula 61 is prepared by hydrolysis of the ester using a base such as NaOH or LiOH to yield the acid, coupling the corresponding acid with a primary or secondary amine or ammonia using standard coupling reagents such as TBTU or EDC and reduction of the ester using a reducing agent such as NaBH4 to yield hydroxymethyl. <BR> <BR> <P> The preparation of diketopiperazine compounds formula 66 in which R, and Rla together and R3<BR> and R3a together are oxygen are prepared as outlined in Scheme 15.

Scheme 15 As shown in Scheme 15, an aldehyde containing the Cy2 group is condensed with an amino acid ester under reductive amination conditions. The resulting secondary amine is then coupled to an N- protected amino acid. The resulting dipeptide is deprotected which in general results in cyclization to the CY2 diketopiperazine. Alternatively for cases which do not cyclize, diketopiperazine formation can be achieved using a peptide coupling reagent such as EDC, TBTU, or BOP.

The preparation of sulfonyl chloride intermediates is outlined in Scheme 16.

Scheme 17 As shown in Scheme 16, Cy, substituted sulfonyl chlorides are prepared by treatment of the appropriate aryl and heteroaryl compounds with a strong base such as n-BuLi at-78 °C followed by the addition of SO2 gas and treatment of the lithium heteroaryl sulfate with a chlorinating agent such as NCS or SO, CL, or, alternately, by homologation of the appropriate aryl and heteroaryl aldehydes using, for example, ethylmethanesulfonate and ethylchlorophosphonate.

The preparation of intermediate compounds of formula Cy,-CO2H is outlined in Scheme 17.

Scheme 17 As shown in Scheme 17, the requisite Cy, acids as defined above can be obtained by oxidation of the corresponding alcohols or the aldehydes using, for example, MnO,, PDC or AgNO3 in an appropriate solvent such as CH2C12 or H2O/EtOH. The Cy, substituted aryl and heteroaryl groups can be functionalized by deprotonation methods using an appropriate non-nucleophilic base such as n-BuLi in an appropriate solvent such as Et, O or THF and quenching with an appropriate carbonyl electrophile such as DMF, CO, or alkyl chloroformate. Alternatively, the acids can also be generated by hydrolysis of the corresponding esters using, for example, NaOH or LiOH. For example, in the acrylic esters, the Cy,- (alkenylene)- groups as defined above are generated by homologation of the Cy, aldehydes using the usual Wittig type or Horner-Emmons type reagents in an appropriate solvent such as CH, C1, or THF.

The preparation of Cy, alkyl and alkenyl halides is outlined in Scheme 18.

Scheme 18 As shown in Scheme 18, Cy, alkyl and alkenyl halides as defined above can be prepared by halogenation of the corresponding alcools using either NBS, CBr4 or PBr3 under standard solvent conditions. The alcohols are generated by reduction of the corresponding aldehydes or esters using NaBH4 or DIBAL in an appropriate solvent.

The preparation of Cy, isocyanate intermediates is outlined in Scheme 19.

Scheme 19 As shown in Scheme 19, Cy, isocyanates are obtained by chlorocarbonylation methods using phosgene or triphosgene in an appropriate solvent such as CH2Cl2 with an appropriate base additive such as triethylamine or pyridine on the corresponding primary or secondary amines. Alternatively, the isocyanates can also be generated by Curtius rearrangement in an appropriate solvent such as toluene, p- dioxane or DMF of the corresponding Cy, carbonyl azides. The carbonyl azides, in turn, are derived

from the corresponding carboxylic acids using either DPPA reagent or by proceeding through the mixed anhydride via an alkyl chloroformate reagent in an appropriate solvent such as DMF or acetone and using an appropriate base additive such as treithylamine.

The preparation of Cy, chloroformate intermediates is outlined in Scheme 20.

Scheme 20 As shown in Scheme 20, Cy, chloroformates are obtained by chlorocarbonylation methods using reagents such as phosgene, triphosgene or 1,1'-carbonyldiimidazole in an appropriate solvent such as CH, CL, on the corresponding alcools. Activated sulfamyl esters are prepared from the corresponding amines using catechol sulfate in an appropriate solvent.

The preparation of acetamido compounds of this invention is outlined in Scheme 21.

Scheme 21

As shown in Scheme 21, alkylation of piperazin-2-one 96 is achieved with a strong base such as NaH and a t-butyl ester of haloacetic acid to give the acetate 97. Pd-catalyzed hydrogenation effectes removal of the CBZ group from the acetate 97 to give amine 98 which is converted to the compound 99 as described in Scheme 1 above. Hydrolysis of t-butyl ester 99 is accomplished using, for example, TFA/CH2Cl2. The resulting acid 100 is coupled with the optionally protected amine HNCy2 under typical amide bond formation conditions to give the acetamide 101.

The preparation of compounds of this invention wherein Cy, is benzimidazol-2-yl is outlined in Scheme 22.

Scheme 22

Piperidin-2-one 102 is alkylated as described above to give the ester 103 which is hydrolyzed to give the acid 104 or reduced to give aldehyde 105. Coupling of the acid 104 and amines affords amide 106 which is cyclized with acetic anhydride to give the compound 108. Wittig-coupling of aldehyde 105 produces compound 107.

This invention is further exemplified but not limited by the following examples which further illustrate the preparation of the compounds of this invention. The starting materials and intermediates are prepared by the application or adaptation of known methods, for example methods described herein or their obvious equivalents.

EXAMPLE 1.6-Chlorobenzofblthiophene-2-sulfonyl chloride.

A. l-Chloro-3-(22-dimethoxvethvlsulfanyl) benzene.

To a solution of 3-chlorothiophenol (2.4 g, 16.6 mmol) in THF (200 mL) at 0°C is added bromoacetaldehyde dimethyl acetal (2.8 g, 16.6 mmol). To the solution is added sodium hydride (60% mineral oil dispersion, 0.70 g, 17.4 mmol). The reaction is stirred for 16 hours, and then is quenched by the addition of saturated NH4Cl (aq.). The solution is diluted with EtOAc. The organic layer is washed with a saturated NaCI (aq.). The organic layer is dried over MgS04, filtered and concentrated. The crude product is purified by column chromatography eluting with hexanes. The title compound (3.7 g, 15.9 mmol) is obtained as an oil. 'H NMR (CDCl3, 300MHz) 6 7.32 (m, I H), 7.25 (m, IH), 7.12 (m, IH), 4.47 (m, IH), 3.07 (s, 3H), 3.02 (s, 3H).

B. 4-Chlorobenzofblthiophene and 6-Chlorobenzofblthiophene.

A solution containing polyphosphoric acid (8 g) and chlorobenzene (50 mL) is heated at reflux.

A solution containing I-chloro-3- (2, 2-dimethoxyethylsulfanyl) benzene (2.7 g, 11.6 mmol) in chlorobenzene (5 mL) is added dropwise to the refluxing polyphosphoric acid solution. After 6 hours, the solution is cooled to ambient temperature. The solution is diluted with CH, C12 and washed with water and saturated NaCl (aq.). The organic layer is dried over MgSO4, filtered and concentrated. The crude product is purified by column chromatography eluting with hexanes to yield the title compounds <BR> <BR> <BR> <BR> (2.4 g, 9.0 mmol) as a 1: 1 isomeric mixture. 'H NMR (CDCI3, 300MHz) 6 7.88 (m, 1H), 7.75 (m, 2H), 7.42 (m, 2H). MS (EI) : m/z 168,170 (M+), Cl pattern.

C. 4-Chlorobenzorblthiophene-2-sulfonvl chloride and 6-Chlorobenzorb1thiophene-2-sulfonvl chloride To a solution of 4-chloro-benzo [b] thiophene and 6-chlorobenzo [b] thiophene (11.8 g, 88.1 mmol), in 400 mL of THF at-78°C is added n-BuLi (55 mL of a 1.6M solution in hexanes, 88.1 mmol). <BR> <BR> <BR> <BR> <P>After 15 minutes, the solution is added by cannula to a precooled (-78°C) solution of SO (200 g) in 100 mL of THF. After addition, the solution is allowed to warm to ambient temperature. After 0.5 hour, the solution is concentrated. The residue is suspended in hexanes (400 mL) and is cooled to 0°C. To the solution is added SOO (12.5 g, 92.5 mmol). After stirring for 15 minutes, the solution is concentrated.

The residue is dissolved in EtOAc. The organic solution is washed with saturated NH, CI (aq.), H, O and saturated NaCI (aq.). The organic layer is dried over MgSO4, filtered and concentrated. The crude product is dissolved in CH, CL, and filtered through a plug of silica gel. The crude product is purified by column chromatography eluting with hexanes to yield the title compound as well as 4- chlorobenzo [b] thiophene-2-sulfonyl chloride as white solids.

4-Chiorobenzo [b] thiophene-2-sulfonyl chloride:'H NMR (CDCl3, 300MHz) 8 8. 32 (m, 1H), 7.81 (m, 1H), 7.53 (m, 2H).

6-Chlorobenzo [b] thiophene-2-sulfonyl chloride :'H NMR (CDCl3,300MHz) 8 8.11 (s, 1H), 7.88 (m, 2H), 7.50 (m, I H).

EXAMPLE 2.5'-Chloro-f2, 2'lbithiophenvl-5-sulfonvl chloride.

A. 5-Chloro-12*2'1bithiophene.

The title compound is prepared from 2-chloro-thiophene according to the procedure described in Bull. Chem. Soc. Japan, 1979,1126. The crude product is purified by column chromatography eluting with a gradient of 5% EtOAc/hexanes to 10% EtOAc/hexanes to afford a white solid.'H NMR (CDCl 300MHz) 8 7.24 (m, 1H), 7.11 (d, 1H), 7.03 (dd, 1H), 6.94 (d, I H), 6.83 (d, 1 H). MS (EI) [M+] = 200, 202, Cl pattern.

B. 5'-Chloro-f2, 2'lbithiophenvl-5-sulfonvl chloride.

The title compound is prepared as described in Example 1, Part C using 5-chloro- [2,2'] bithiophene in place of 6-chloro-benzo [b] thiophene. The crude product is purified by column chromatography eluting with a gradient of 5% EtOAc/hexanes to 10% EtOAc/hexanes to give a white solid.'HNMR (CDCI3, 300MHz) 67.76 (d, IH), 7.14 (d, IH), 7.09 (d, 1H), 6.92 (d, IH). MS (EI) : m/z 298,300 (M+), Cl pattern.

EXAMPLE 3.2- (5-Chloro-thiophen-2-yi)-ethenesulfonvi chloride.

A. 2- (5-Chloro-thiophen-2-vl)-ethenesulfonic acid ethyl ester. n-Butyllithium (53.1 mL, 2.5M solution in hexanes) is added dropwise to a solution of ethylmethanesulfonate (12.9 mL, 0.12 mol) in THF (300 mL) at-78°C. The reaction mixture is stirred for 15 min then ethylchlorophosphonate (9.9 mL, 0.07 mol) is added dropwise. The solution is stirred at -78°C for 30 minutes and then heated to 50°C for 1 hour. The reaction mixture is then cooled to-78°C and stirred for I h then 5-chlorothiophenecarboxaldehyde (7.1 mL, 0.07 mol) is added dropwise. The reaction mixture is allowed to slowly warm to RT overnight. Water (30 mL) is added to the mixture and stirred for 15 min then concentrated in vacuo. The residue is taken up in CH, CL, and washed with water, brine, dried over MgSO4, filtered and concentrated to dryness. The crude product is purified by column chromatography eluting with 5% EtOAc/hexanes to give title product (11. 3 g, 0.04 mol) as an oil.'H NMR (CDCI3,300MHz) 8 7.51 (d, I H), 7.10 (d, 1H), 6.91 (d, I H), 6.42 (d, I H), 4.20 (q, 2H), 1.40 (t, 3H).

B. 2- (5-Chloro-thiophen-2-yl)-ethenesulfonvl chloride.

Tetrabutylammonium iodide (16.3 g, (44.2 mmol) is added to a solution of 2- (5-chloro-thiophen- 2-yl)-ethenesulfonic acid ethyl ester (11. 3 g, 40.2 mmol) in acetone (100 mL) at room temperature. The mixture is heated to reflux and stirred overnight then cooled to RT and conconcentrated in vacuo. The residue is taken up in CH2CI2then washed with water and brine. The organic layer is dried over MgSO4, filtered and concentrated to dryness to give an oil (18.74 g, 40.2 mmol) which is taken on to the next step without further purification. Sulfuryl chloride (7.1 mL, 88.5 mmol) is added to a solution of triphenylphosphine (21.0 g, 86.42 mmol) in CH, CL, at 0°C. The ice bath is then removed and the product (18.74 g, 40.2 mmol) from the above reaction is added. After 2 h, the reaction mixture is concentrated in vacuo and the product purified by column chromatography eluting with 10% EtOAc/Hexanes to give the title compound (6.4 g, 26.3 mmol) as an off-white solid.'H NMR (CDCI3, 300 MHz) 8 7.70 (d, I H), 7.23 (d, I H), 7.00 (d, 1H), 6.91 (d, 1H).

EXAMPLE4. catechol.sulfamyl To a solution of 3-chlorobenzylamine (0.14 g, 1.0 mmol) in 3 mL of DMF is added Et3N (0.10 g, 1.5 mmol). The solution is cooled to 0°C. Catechol sulfate (0.172 g, 1.0 mmol) is added. The solution is warmed to ambient temperatures. After 2.5 h, 30 mL of EtOAc is added. The solution is washed with 5% HCI, HO and saturated NaCI. The organic layer is dried over MgSO4, filtered and concentrated to give the title compound (0.30 g, 0.97 mmol).'H NMR (d6-DMSO, 300 MHz) 8 9.94 (s, 1H), 8.82 (m, 1H), 7.41 (m, 4H), 7.19 (d, 1H), 7.10 (m, 1H), 6.95 (d, 1H), 6.79 (m, 1H), 4.32 (AB, 2H).

2-Bromomethyl-6-chlorobenzo[b]thiophene.EXAMPLE5.

A. 6-Chlorobenzorb1thiophene-2-carboxaldehvde.

To a solution of 6-chlorobenzo [b] thiophene (1.0 g, 5.93 mmol) in THF (60 mL) at-78°C is added a 1.6 M solution of n-BuLi in THF (3.9 mL, 6.23 mmol). After 10 minutes, 0.5 mL of DMF is added. The solution is stirred for 0.5 hours, then allowed to warm to ambient temperature. The solution is poured into a solution of saturated NH, CL. The solution is diluted with ether and the layers are separated. The organic layer is washed with H, O and saturated NaCl. The organic layer is dried over MgSO4, filtered and concentrated. The title compound is obtained as a white solid. MS (El): m/z 196 (M+).

B. 6-Chlorobenzofblthiophen-2-vl) methanol.

To a solution of 6-chlorobenzo [b] thiophene-2-carboxaldehyde in THF at 0°C is added NaBH4.

After I hour, the solution is diluted with saturated NHQCI and ether. The organic layer is washed with <BR> <BR> <BR> <BR> H, O and saturated NaCl, dried over MgS04, filtered and concentrated.'H NMR (CDCI,, 300 MHz) 6 7.82 (s, 1H), 7.60 (d, 1H), 7.40 (m, 2H), 4.91 (AB, 2H).

C. 2-Bromomethvl-6-chlorobenzof blthiophene.

To a solution of 6-chlorobenzo [b] thiophen-2-yl)-methanol (0.2 g, 1. 01 mmol) in THF (10 mL) is added triphenyl phosphine (0.34 g, 1. 31 mmol) followed by CBr4 (0.42g, 1.26 mmol). After 3 hours, the solution is concentrated. The product is purified by column chromatography eluting in a gradient of 5% EtOAc/hexanes to 10% EtOAc/hexanes. The product is obtained as a white solid (0.25 g, 0.53 mmol).

'H NMR (CDC13,300 MHz) 8 7.82 (s, IH), 7.62 (d, 1H), 7.40 (m, 2H), 4.76 (s, 2H).

EXAMPLE A. (5'-Chloro- (2, 2'lbithiophenvl-5-vl)-methanol.

To a solution of 5-chloro- [2,2'] bithiophenyl (3.00 g, 14.9 mmol) in 30 mL of THF at 0°C is added n-BuLi (9.8 mL of a 1.6M solution in hexanes, 15.7 mmol) dropwise. DMF (2. 30 mL, 30 mmol) is added dropwise and the resulting solution is heated at reflux for 1 hour. The solution is diluted with H, O and extracted with Et, O. The organic layer is washed with HO and saturated NaCI solution, then dried over MgSO4, filtered and concentrated. The crude aldehyde is dissolved in 40 mL of anhydrous MeOH and sodium borohydride (0.85 g, 22.5 mmol) is added portionwise. The mixture is stirred at room temperature for 10 min, then quenched with water. The mixture is diluted with Et, O and the layers separated. The organic layer is washed with H, O, then dried over MgSO4, filtered and concentrated to yield the title compound (2.23 g, 9.66 mmol) which is used in the subsequent step without further <BR> <BR> <BR> purification.'H NMR (CDCI3, 300MHz) 6 6.95 (d, 1H), 6.90 (m, 2H), 6.86 (d, 1H), 4.82 (s, 2H), 1.88 (bs, I H).

B. 5-Bromomethvl-5'-chloro-r2, 2'lbithiophenyl.

To a solution of (5'-chloro- [2,2'] bithiophenyl-5-yl)-methanol (2.23 g, 9.66 mmol) in 65 mL of CH, CL, is added bromotrimethylsilane (3.82 mL, 29.0 mmol). After 4 h, the solution is concentrated in vacuo. The crude product is stirred in hot hexanes and filtered. The filtrate is concentrated and the title <BR> <BR> <BR> compound (1.67 g, 5.69 mmol) is obtained as a green solid. H NMR (CDCI3,300MHz) 8 7.00 (d, 1H), 6.94 (m, 2H), 6.85 (d, 2H), 4.71 (s, 2H).

EXAMPLE 7.7-Bromomethvl-4-chloroquinazoline.

A. 7-Methvl-3H-quinazolin-4-one.

A solution of 2-amino-4-methylbenzoic acid (31.6 g, 206 mmol) in formamide (60mL) is heated to 130°C for I hour, then at 175°C for 3 hours. The solution is poured into 500 mL of ice water. The resulting solid is collected by filtration and further dried under reduced pressure. The title compound (26.2 g, 170 mmol) is obtained as a white solid. MS (EI) : m/z 159 (M+).

B.4-Chloro-7-methvl-quinazoline.

To a solution of 7-methyl-3H-quinazolin-4-one (10.6 g, 69 mmol) in toluene (350mL) is added triethylamine (17.5 g, 173 mmol) followed by phosphorous oxychloride (12.3 g, 80 mmol). The resulting solution is heated to 80°C. After 4 hours, the solution is cooled to ambient temperature. The reaction mixture is poured into 500 mL of water. The layers are separated and the organic layer is washed with H20, saturated NaHC03, and saturated NaCI, dried over MgSO4, filtered and concentrated.

The resulting crude product is purified by recrystallization from EtOAc. The title compound is obtained

asawhitesolid (10g, 56mmol).'HNMR (CDC ! 300 MHz) 8 9.02 (s, I H), 8.16 (d, 1H), 7.87 (s, 1H), 7.55 (d, 1H), 2.62 (s, 3H).

C. 7-Bromomethvl-4-chloroquinazoline.

To a solution of 4-chloro-7-methylquinazoline (7.0 g, 39 mmol) in carbon tetrachloride (140 mL) is added N-bromosuccinimide (8.0 g, 45 mmol), and benzoyl peroxide (0.8 g, 3.3 mmol). The solution is refluxed for 8 hours. After this time, the solution is filtered. The filtrate is concentrated and the residue is stirred with ether to give the title compound as an off-white solid (5.1 g, 20 mmol).'H NMR (CDCI3, 300 MHz) 8 9.10 (s, 1H), 8.30 (d, 1H), 8.10 (s, 1H), 7.82 (d, 1H), 4.68 (s, 2H). MS (El) : m/z 237 (M+).

EXAMPLE 8.3-Bromomethvl-7-chloro-I H-quinolin-2-one.

A.N- (3-Chlorophenvl)-2-methvl-3-phenvlacrylamide.

To a solution of 3-chloroaniline (0.98 mL, 9.3 mmol) in CH, C12 (25 mL) at 0°C is added pyridine (0.78mL, 9.5 mmol). To the resulting solution is added dropwise a solution of α-methyl cinnamic acid chloride (1.6 g, 9.3 mmol) in CH, CL, (8 mL). After 3 hours, the solution is concentrated.

The crude product is purified by column chromatography eluting with 5% EtOAc/hexanes to 10% EtOAc/hexanes. The title compound is obtained as a solid (2.5 g, 9.2 mmol).'H NMR (CDCI3,300 MHz) 8 7.95 (m, 1H), 7.73 (s, 1H), 7.46 (m, 1H), 7.33 (m, 6H), 7.22 (m, 1H), 7.03 (m, 1H), 2.13 (s, 3H).

B. 7-Chloro-3-methvl-I H-quinol in-2-one.

To a solution of N- (3-chlorophenyl)-2-methyl-3-phenylacrylamide (2.5 g, 9.2 mmol) in chlorobenzene (50 mL) is added AlCl3 (6.2 g, 46 mmol). The solution is heated to 1 20°C. After 4 hours, the solution is poured onto ice. The solution is filtered. The organic layer is washed with IN HCI, H, O and saturated NaCI. The crude product is purified by column chromatography eluting with 2% MeOH/CH, The title compound is obtained as a white solid (1.5 g, 7.74 mmol).'H NMR (d6- DMSO, 300 MHz) 8 11.82 (bs, IH), 7.73 (s, IH), 7.52 (m, 1H), 7.21 (m, 2H), 2.08 (s, 3H).

C. 3-Bromomethvl-7-chloro-IH-quinolin-2-one.

The title compound is prepared as described in Example 7, Part C, substituting 7-chloro-3- methyl-lH-quinoline-2-one for 7-methyl-4-chloroquinazoline. The title compound is obtained as a white solid.'HNMR (d6-DMSO, 300 MHz) 8 12.00 (bs, 1H), 8.17 (s, 1H), 7.72 (d, 1H), 7.29 (m, 2H), 4.58 (s, 2H).

EXAMPLE 4.6-Bromomethvl-2-chloro-quinoline.

A. 6-Methyl-I H-quinolin-2-one.

The title compound is prepared from p-toluidine and cinnamoyl chloride according to the procedure described in Synthesis 1975,739. The crude product obtained is triturated in EtO/hexanes and filtered to give the title compound as a beige solid.'H NMR (DMSO-d6,300 MHz) 8 11.60 (bs, IH), 7.82 (d, IH), 7.41 (s, IH), 7. 30 (d, IH), 7.18 (d, 1H), 6.45 (d, 1H), 2.30 (s, 3H).

B. 2-Chloro-6-methvlquinoline.

6-Methyl-lH-isoquinolin-2-one (14.6 g, 91.7 mmol) in phosphorus oxychloride (160 mL) is heated at 60°C for 17 hours. The mixture is cooled to room temperature, then concentrated to a beige residue. The residue is diluted with ice water and the pH is adjusted to about 8 by slow addition of 10 N NaOH. The crude product is precipitated out during neutralization of the aqueous solution and the solid is filtered, washed with water and dried. The solid is recrystallize from MeOH to afford the title <BR> <BR> <BR> <BR> compound (12.0 g, 67.5 mmol) as a beige solid. 'H NMR (CDCI3,300 MHz) 8 8.02 (d, 1H), 7.92 (d, IH), 7.60 (s, IH), 7.58 (d, 1H), 7.33 (d, IH), 2.53 (s, 3H).

C. 6-Bromomethyl-2-chloro-quinoline.

N-Bromosuccinimide (12.9 g, 72.5 mmol) and benzoyl peroxide (0. 33 g, 1. 30 mmol) are added to a solution of 2-chloro-6-methyl-quinoline (12.0 g, 67.5 mmol) in carbon tetrachloride (300 mL). The mixture is heated at reflux for 6 hours. At this time, the resulting mixture is cooled to room temperature, filtered, washed with CH, CL, and concentrated in vacuo. The crude residue is recrystallized from 50% EtOAc/hexanes to yield the title compound (8.80 g, 34.3 mmol) as a beige crystalline solid.'H NMR (CDC13,300 MHz) 8 8.08 (d, IH), 8.02 (d, 1H), 7.83 (s, 1H), 7.77 (dd, 1H), 7.40 (d, 1H), 4.65 (s, 2H).

MS (El) : m/z 256,258 (M+), Cl pattern.

EXAMPLE 10.3-Bromomethyl-I 7-dichloro-2H-isoquinoline.

A. 3- (4-Chlorophenvl)-2-methvl-acrvlovl azide.

To a solution of 3- (4-chlorophenyl)-2-methyl-acrviic acid (11.2 g, 57 mmol) in 500 mL of acetone at 0°C is added triethyl amine (9.6 mL, 68 mmol) followed by ethyl chloroformate (6.2 mL, 63 mmol). The solution is allowed to warm to ambient temperatures. After 2 h, sodium azide (5.6 g, 86 mmol) in 35 mL of H, O is added. After addition, the solution is stirred for 2 hours. The solution is diluted with HO (100 mL). The resulting solid is collected by filtration giving the title compound as a white solid (11. 1 g, 50mmol).'H NMR (CDC13,300 MHz) 8 7.67 (s, IH), 3.38 (m, 4H), 2.10 9s, 3H).

B. 7-Chloro-3-methvl-2H-isoquinoline-I-one.

3- (4-Chlorophenyl)-2-methyl-acryloyl azide (11.0 g, 50 mmol) is dissolved in 80 mL of diphenyl ether. The solution is added dropwise to a solution of tributyl amine (11. 8 mL, 50mmol) in 170 mL of diphenyl ether at 210°C. After 4 hours., the solution is cooled 50°C and diluted with 1.5 L of hexanes.

The resulting solid is collected by filtration giving the title compound as a white solid (7.2 g, 37 mmol). <BR> <BR> <BR> <P>'H NMR (d6-DMSO, 300 MHz) 6 11.4 (bs, 1H), 8.02 (s, 1H), 7.67 (d, 1H), 7.55 (d, 1H), 6.34 (s, 1H), 2.18 (s, 3H).

C. 1.7-Dichloro-3-methvl-isoquinoline.

A solution of 7-chloro-3-methyl-2H-isoquinoline-I-one (7.1 g, 36. 7 mmol) in 100 mL of phosporous oxychloride is heated to 100°C. After 5 h, the solution is concentrated to dryness. The residue is dissolved in CH2CI2. The solution is washed with H2O. The organic layer is dried over MgSO4, filtered and concentrated. The crude product is purified by column chromatography eluting with a gradient of 3% EtOAc/hexanes to 5% EtOAc/hexanes. The title compound is obtained as a white solid (6.0g, 28 mmol).'H NMR (CDCI3,300 MHz) 8 8.23 (s, 1H), 7.68 (m, 1H), 7.63 (m, 1H), 7.40 (s, 1H), 2.64 (s, 3H).

D. 3-Bromomethyl-1.7-dichloro-2H-isoquinoline.

The title compound is prepared as described in Example 7, part C, substituting 1,7-dichloro-3- methyl-isoquinoline for 4-chloro-7-methylquinazoline.'H NMR (CDCl3, 300 MHz) 8 8.29 (s, 1H), 7.82 (m, 1H), 7.76 (m, 2H), 4.68 (s, 2H).

EXAMPLE 11.3-Bromomethvl-7-chloroisoquinoline.

A. 7-Chloro-3-metheI-isoquinoline.

To a solution of 1,7-dichloro-3-methyl-isoquinoline (0.50 g, 2.36 mmol), Example 10, part C, in 5.5 mL of 9: 1 acetic acid: H, O at 75°C is added zinc (0.23 g, 3.54 mmol) After 75 minutes, the solution is cooled to ambient temperatures. The solution is diluted with a 4: 1 EtOAc: CH, CI2 solution. To the solution is added 100mL of a IN NaOH solution. The aqueous solution is extracted with 4: 1 EtOAc: CH2CI2. The combined organic layers are washed with a saturated NaCI solution. The organic layer is dried over MgSO4, filtered and concentrated. The crude product is purified by column chromatography eluting with a gradient of 5% EtOAc/hexanes to 15% EtOAc/hexanes. The title <BR> <BR> <BR> compound is obtained as a white solid (0.36 g, 1.97 mmol). tH NMR (CDCI3,300 MHz) 6 9.09 (s, 1H), 7.89 (s, 1H), 7.61 (d, 1H), 7.55 (d, 1H), 7.44 (s, 1H) 2.68 (s, 3H). MS (EI) : m/z 177,179 (M+), Cl pattern.

B. 3-Bromomethvl-7-chloroisoquinoline.

The title compound is prepared as described in Example 7, part C, substituting 7-chloro-3- methyl-isoquinoline for 4-chloro-7-methylquinazoline.'H NMR (CDCl3, 300 MHz) 8 9.18 (s, I H), 7.97 (s, 1H), 7.75 (m, 2H), 7.67 (m, 1H), 4.71 (s, 2H).

EXAMPLE 12. 2-Bromomethvl-6-chloronaphthalene.

A. 6-Chloro-34-dihvdro-I H-naphthalene-2-one.

To a solution of (4-chlorophenyl)-acetyl chloride (17.3 g, 92 mmol) in 50 mL of CH, CI, at-20°C is added a solution of AIC13 (24.4 g, 184 mmol) in 200 mL CH, CL, dropwise. After 20 minutes, ethylene (g) is bubbled through the solution for 30 minutes. The solution is stirred at-10°C for 15 minutes. The reaction mixture is poured into 300 g of ice. The layers are separated. The organic layer is washed with H, O, saturated NaHC03 and saturated NaCI. The organic layer is dried over MgS04, filtered and concentrated. The resulting solid is triturated with pentane (2x20mL). The solid is then dried to give the title compound as a solid (15.2 g, 84.2 mmol).'H NMR (CDCI3,300 MHz) 8 7.28 (m, 2H), 7.06 (m, 1H), 3.52 (s, 2H), 3.04 (m, 2H), 2.56 (m, 2H).

B. 6-Chloro-2-methyl-1,2,3,4-tetrahydronaphthalene-2-ol.

To a solution of TiCl4 (95 mL, 1 M in toluene) at-45°C is added a solution of CH3MgBr (4.2 mL 3M in THF). The solution is stirred for 20 minutes. After this time, 6-chloro-3, 4-dihydro-1H- naphthalene-2-one (11.3 g, 63 mmol) in 80 mL of CH2CI2 is added dropwise over 15 minutes. The reaction is stirred for an additional 15 min at-45°C. The solution is warmed to 0°C. After 2 h, the solution is diluted with H2O and CH2CI2. The organic layer is dried over MgSO4, filtered and concentrated. The title compound is obtained as an oil (11.3 g, 57.5 mmol).'H NMR (CCDl3, 300 MHz) 8 7.10 (m, 2H), 6.97 (m, 1H), 3.02 (m, 2H), 2.80 (s, 3H), 1.85 (m, 2H), 1.80 (m, 2H).

C. 2-Chloro-6-methyl naphthalene.

A solution of 6-chloro-2-methyl-1,2,3, 4-tetrahydronaphthalene-2-ol (11.3 g, 57.5 mmol) and Ph3COH (16.5 g, 63 mmol) in 80 mL of TFA is stirred for 2.5 days. After this time, the solution is concentrated to dryness. The residue is dissolved in CH2C12. The organic layer is washed with H, O, saturated NaHC03, and saturated NaCI. The organic layer is dried over MgSO4, filtered and concentrated. The crude product is purified by column chromatography eluting with hexanes. The title <BR> <BR> <BR> compound is obtained as a white solid (4.05 g, 22.9 mmol).'H NMR (CDCl3, 300 MHz) 6 7.78 (s, 1H), 7.69 (m, 2H), 7.58 (s, 1H), 7.50 (m, 2H), 2.49 (s, 3H).

D. 2-Bromomethyl-6-chloronaphthalene.

The title compound is prepared as described in Example 7, part C, substituting 2-chloro-6-methyl naphthalene for 4-chloro-7-methylquinazoline.'H NMR (CDC13,300 MHz) 8 7.82 (m, 2H), 7.78 (s, 1H), 7.76 (m, 2H), 7.52 (d, 1H), 7.42 (d, 1H), 4.62 (s, 2H).

EXAMPLE 13.2- ino)-4-bromomethvl-benzonitrile.

A. 2- (Benzhvdrvlidene-amino)-4-methvl-benzonitrile.

To a solution of 2-amino-4-methyl benzonitrile (20 g, 151 mmol) in 1000mL of dichloroethane is added benzophenone imine (30g, 166mmol). The solution is refluxed for 48 hours After this time, the solution is cooled to ambient temperatures. The solution is washed with sat. NaHC03, water and sat.

NaCI. The organic layer is dried over MgS04, filtered and concentrated under vacuum. The product is further purified by recrystallization from t-butyl ether. The title compound (25.5g, 118mmol) is obtained <BR> <BR> <BR> as a yellow solid.'H NMR (CDCI3, 300MHz) 6 7.88 (m, 2H), 7.42 (m, 3H), 7. 32 (m, 7H), 6.79 (d, 1H), 6.58 (s, 1H), 2.23 (s, 3H).

B. 2- (enzhvdrylidene-amino)-4-bromomethyl-benzonitrile.

To a solution of 2- (benzhydrylidene-amino)-4-methyl-benzonitrile (11. 2g, 37.8mmol) in 500mL of CC14 is added N-bromosuccinimide (7.06g, 39.7mmol), and benzoyl peroxide (0.92g, 3.8mmol). The solution is heated to reflux for 16 hours. After this time, the solution is filtered and the organic solution is concentrated under vacuum. The residue is purified by column chromatography eluting with a gradient of 20% t-butyl ether/hexanes to 25% t-butyl ether/hexanes. The product is obtained as an oil containing a mixture of the desired monobromide, dibromide and unreacted starting material. The mixture is assayed by proton NMR and is found to have a purity between 60-75%.'H NMR (CDCI3, 300MHz) 8 7.82 (m, 2H), 7.42 (m, 9H), 6.92 (d, I H), 6.81 (s, I H), 4.29 (s, 2H).

EXAMPLE 14. 7-Bromomethvl-4-chloroquinoline.

A. 7-Methvloxvcarbonvl-4-chloroquinoline.

4-Chloro-7-trifluoromethylquinoline (5.0 g, 21.6 mmol) in 100 mL 80% H, SO, is heated to 200°C for 24 hours in a sealed tube. The solution is cooled, poured into water and neutralized with sodium hydroxide to pH-3-4. The precipitated solid is collected, washed with water and dissolved in 2 N sodium hydroxide. The aqueous solution is washed with ethyl acetate then acidified to pH-3-4. The precipitate is collected, washed with water and dried in a vacuum oven overnight to yield 7-carboxy-4-

chloroquinoline as a solid (5.1 g, 24.6 mmol). A portion of this material (2.0 g, 9.6 mmol) is treated with anhydrous THF (200 mL) and DMF (2 mL) and 2 M oxalyl chloride in methylene chloride (14.5 mL, 29 mmol). The resulting suspension is stirred at room temperature for 2 h then treated with methanol (10 mL). After stirring 30 minutes the solution is concentrated and the residue is taken up in methylene chloride. The solution is washed with saturated sodium bicarbonate and dried (sodium sulfate) and concentrated to yield the title compound as a solid (2.1 g, 9.5 mmol). MS m/z: M+= 221;'H NMR (CDC13,300 MHz) 8 8.6 (s, 1H), 8.2 (s, IH), 7.9 (d, 1H), 7.65 (d, 1H), 7.45 (s, IH), 3.95 (s. 3H).

B. 7-Hvdroxymethvl-4-chloroquinoline.

7-Methyloxycarbonyl-4-chloroquinoline (2.1 g, 9.5 mmol) is dissolved in anhydrous THF (25 mL) and anhydrous ether (200 mL). The solution is cooled in a dry ice/acetone bath and treated 1M lithium aluminum hydride in THF (11.0 mL, 11 mmol). The solution is warmed (approximately-45°C) for 20 minutes and quenched with ethyl acetate. The solution is diluted with ether (100 mL) and treated with water (36 mL), 15% NaOH (36 mL) and water (36 mL) in succession. The mixture is filtered and evaporated to yield the title compound as a residue (2.0 g, 9.7 mmol) which is dried under vacuum and used without further purification. MS m/z: M+ = 193;'H NMR (CDCI3,300 MHz) 8 8.65 (d, 1H), 8.15 (d, 1H), 8.0 (d, 1H), 7.6 (d, 1H), 7.45 (d, 1H), 4.8 (s, 2H).

C. 7-Bromomethvl-4-chloroauinoline.

7-Hydroxymethyl-4-chloroquinoline (0.2 g, 0.97 mmol) is treated with 48 % HBr and heated to 120°C for 1 hours. The resulting solution is cooled with ice, diluted with water and treated with ethyl acetate and sodium bicarbonate until basic to pH paper. The layers are separated and the organic layer is washed with water, dried (Na2SO4) and concentrated to give 7-bromomethyl-4-chloroquinoline (0.23 g, 0.9 mmol). MS m/z: M+ = MHz) 8 8.75 (d, I H), 8.25 (d, 1H), 8.1 (s, 1H), 7.7 (d, 1H), 7.5 (d, I H), 4.7 (s. 2H).

EXAMPLE 15.7-Bromomethyl-4-chlorocinnoline.

A. 4-methyl-2-nitrophenvlethanone.

4-Fluro-3-nitrotoluene (7.5 g, 48.4 mmol) is treated with a solution of nitroethane (15.2 mL, 200 mmol) in ethyl acetate (100 mL) and DBU (21 mL, 145 mmol) and stirred overnight at ambient temperature. The solution is concentrated under vacuum, diluted with methanol, treated with 30% HO (25 mL) and 10% sodium bicarbonate (25 ml) and stirred overnight at ambient temperature. The reaction mixture is concentrated in vacuo, acidified with 5% HC1 and extracted with methylene chloride.

The organic layer is dried (sodium sulfate) and chromatographed (35% ethyl acetate/hexane) to give the

title compound (7.2 g, 40.2 mmol). MS m/z: M"= 279;'H NMR (CDC13,300MHz) S 7.8 (s, IH), 7.48 (d, I H), 7.32 (d, IH), 2.5 (s, 3H), 2.4 (s, 3H).

B. 2-Amino-4-methvlphenvlethanone.

A solution of 4-methyl-2-nitrophenylethanone (5.0 g, 28 mmol) in methanol (100 mL) is treated with ammonium formate (9.6 g, 140 mmol) and 5% palladium on carbon (1.5 g). The mixture is heated to 60°C for 6 h then stirred at ambient temperature for 16 hours. The reaction mixture is filtered through Celite and the filtrate is concentrated in vacuo. The concentrate is treated with sodium bicarbonate and partitioned between water and ethyl acetate. The organic layer is separated, dried with sodium sulfate and concentrated to give crude title compound (4.5 g, 30.2 mmol) which is used without further purification. MS m/z: M+= 149;'H NMR (CDCI3, 300MHz) 6 8.05 (d, IH), 7.4 (d, I H), 7.25 (s, I H), 2.8 (s, 3H), 2.45 (s, 3H).

C. 7-Methvl-I-H-cinnolin-4-one.

A solution of 2-amino-4-methylphenylethanone (5.0 g, 33.6 mmol) in concentrated HCI (100 mL) is treated, in portions, with a solution of sodium nitrite (5.7 g, 82.6 mmol) in water (-10 mL). The resulting solution is stirred at 60°C for 2 hr, cooled to ambient temperature and diluted with a saturated solution of sodium acetate (-200 mL). Solid sodium acetate is added portionwise until the solution tested basic to pH paper. Upon stirring, the title compound precipitated as a white solid which is collected and air dried (2.3 g, 14. 3 mmol). MS m/z: [M+H]'= 161;'H NMR (CDC13,300MHz) 8 8.1 (d, 1H), 7.85 (s, 1H), 7.45 (s, IH) 7.3 (d, IH), 2.55 (s, 3H).

D. 4-Chloro-7-methvlcinnoline.

7-Methyl-l-H-cinnolin-4-one (1.3 g, 8.1 mmol) is treated with about 80 mL of chlorobenzene and heated until the solid dissolves. The resulting solution is cooled and treated with pyridine (0.16 mL, 2 mmol) and POC13 (1.13 mL, 12.2 mmol). The solution is heated to reflux for I h then concentrated to dryness. The residue is chromatographed (20 % ethyl acetate/hexane) to yield the title compound as a tan solid (-I g, 5.6 mmol). MS m/z (M+=178) ;'H NMR (CDC13,300MHz) 8 9.3 (s, 1H), 8.35 (s, 1H), 8.1 (d, IH), 7.7 (d, 1H), 2.68 (s, 3H).

E. 7-Bromomethvl-4-chlorocinnoline.

A solution of 4-chloro-7-methylcinnoline (0. 6 g, 3. 37 mmol) in carbon tetrachloride (30 mL) is treated with N-bromosuccinimide (0.64 g, 3.4 mmol) and a catalytic amount of 70 % benzoyl peroxide (0.22 g, 0.63 mmol). The solution is heated to 80 °C overnight, then filtered. The filtrate is concentrated in vacuo and the resulting residue is chromatographed (20 % ethyl acetate/methyl chloride) to give the

title compound (0.3 g, 1.2 mmol) and some unreacted starting material (0.1 g, 0.56 mmol). MS m/z: <BR> <BR> <BR> <BR> [M+Hr=257 ;'H NMR (CDCI,, 300MHz) S 9.35 (s, 1H), 8.55 (s, 1H), 8.2 (d, 1H), 8.85 (d, 1H), 4.75 (s, 2H).

EXAMPLE 16.6-Bromomethvl-3-chloro-l- H-indole.

A. IH-lndole-6-carboxylic acid methvl ester.

To a solution of 6-indole carboxylic acid (0.91 g, 5.67 mmol) in 33 mL of 2: 1 THF/MeOH is added (trimethylsilyl) diazomethane (5.0 mL of a 2.0M solution in hexanes, 10.0 mmol). The mixture is stirred for 3 h and concentrated in vacuo to give the title compound (0.87 g, 4.97 mmol). The crude <BR> <BR> <BR> <BR> product is used in the next step without further purification.'H NMR (CDCl3, 300 MHz) 6 8.70 (bs, 1 H), 8.20 (s, 1H), 7.82 (dd, 1H), 7.67 (d, 1H), 7.45 (m, 1H), 6.60 (m, 1H), 3.95 (s, 3H).

B. 3-Chloro-1H-indole-6-carboxylic acid methyl ester.

To a solution of 1H-indole-6-carboxylic acid methyl ester (5.86 g, 33.5 mmol) in 30 mL of CH, C1, is added N-chlorosuccinimide (0.58,4.33 mmol) portionwise over 1.5 hours. The mixture is stirred for 2 h, then diluted with water. The layers are separated and the organic phase is washed with water and saturated NaCI solution. The organic layer is dried over MgS04, filtered and concentrated in vacuo to give the title compound (5.74 g, 27.3 mmol). The crude product is used in the next step without furtherpurification. lHNMR (CDCI3, 300MHz) o8.46 (bs, 1H), 8.19 (s, IH), 7.90 (dd, 1H), 7.69 (d, IH), 7.36 (d, 1H), 3.97 (s, 3H).

C. 3-Chloro-I-(toluene-4-sulfonyl)-I H-lndole-6-carboxylic acid methvl ester.

To a solution of 3-chloro-I H-indole-6-carboxylic acid methyl ester (3.00 g, 17.1 mmol) in 40 mL of THF at-78°C is added LDA (8.55 mL of a 2.0M solution in hexanes, 17.1 mmol) dropwise. The solution is stirred at-78°C for 30 minutes p-Toluenesulfonyl chloride (3.43 g, 18.0 mmol) in 15 mL of THF is added dropwise and the resulting solution is stirred at-78°C for 3 hours. The mixture is warmed to 0°C, quenched with saturated NaHC03 solution and diluted with H, O and Et, O. The layers are separated. The organic phase is washed with saturated NaHCO3 solution, H2O and saturated NaCI solution, then dried over MgS04, filtered and concentrated. The crude residue is purified via flash column chromatography eluting with a gradient of 10% EtOAc/hexanes to 30% EtOAc/hexanes to <BR> <BR> <BR> <BR> provide the title compound (3.64 g, 10.0 mmol).'H NMR (CDCI3, 300MHz) 8 8.70 (s, IH), 8.01 (dd, 1H), 7.80 (d, 2H), 7.70 (s, 1H), 7.60 (d, 1H), 7. 38 (m, 2H), 4.00 (s, 3H), 2.49 (s, 3H).

D. f3-Chloro-1- H-indol-6-vll-methanol.

To a solution of 3-chloro-1- (toluene-4-sulfonyl)-I H-lndole-6-carboxylic acid methyl ester (3.10 g, 8.53 mmol) in 50 mL of toluene at-78°C is added DIBAL (13.8 mL of a 1.5M solution in toluene, 20.8 mmol) dropwise. The mixture is stirred at-78°C for 2 h, then warmed to room temperature and stirred for 2 hours. The reaction mixture is quenched by the addition of MeOH and washed with saturated disodium tartrate solution. The aqueuos layer is extracted with Et2O. The combined organics are washed with saturated disodium tartrate solution, water and saturated NaCI solution. The organic phase is then dried over anhydrous MgSO4, filtered and concentrated to give the title compound (2.88 g). <BR> <BR> <BR> <P>The crude product is used in the next step without further purification.'H NMR (CDC13,300 MHz) 8 8.01 (s, 1H), 7.79 (d, 2H), 7.56 (s, 1H), 7.53 (d, 1H), 7. 31 (d, IH), 7.25 (d, 2H), 4.84 (s, 2H), 2. 37 (s, 3H), 1.88 (bs, I H).

E. 6-Bromomethvl-3-chloro-1-(toluene-4-sulfonyl)-I H-indole.

To a solution of [3-chloro-I- H-indol-6-yl]-methanol (0.45 g, 1. 34 mmol) in 13 mL of Et, O at 0°C is added phosphorous tribromide (0.04 mL, 0.40 mmol). The mixture is stirred at 0°C for 15 min, then at room temperature for 2 hours. The mixture is quenched by the addition of water/ice and diluted with Et, O. The layers are separated and the organic phase is washed with saturated NaHCO3 solution, water and saturated NaCI solution. The organic layer is dried over anhydrous MgSO4, filtered and concentrated to provide the title compound (0.47 g, 1.18 mmol) as an oil. The crude product is used in the subsequent step without further purification.'H NMR (CDCl3, 300 MHz) 8 8.09 (s, 1H), 7.79 (d, 2H), 7.59 (s, 1H), 7.50 (d, 1H), 7.35 (d, 1H), 7.27 (m, 2H), 4.66 (s, 2H), 2. 39 (s, 3H).

EXAMPLE 17.2- (3-Bromo- (E)-propenvl)-5-chloro-thiophene.

A. 3- (5-Chloro-thiophen-2-yl)- (E)-acrylic acid methyl ester.

To a solution of 5-chloro-2-thiophene-carboxaldehyde (5.10 g, 34.8 mmol) in 100 mL of dry CH2CI2 is added methyl (triphenylphosphoranylidene) acetate (11.8 g, 35.3 mmol). The resulting brown- green mixture is stirred for 19 h at room temperature. The mixture is filtered through a Celite pad, concentrated in vacuo and triturated with hexane. The white precipitate (triphenylphosphine oxide) is filtered off and the filtrate is concentrated. The crude residue is purified via flash column chromatography eluting with a gradient of 5% EtOAc/hexanes to 10% EtOAc/hexanes to provide the <BR> <BR> <BR> title compound (6.20 g, 30.6 mmol) as a yellow solid. 'H NMR (CDC13, 300MHz) 6 7.65 (d, 1H), 7.05 (d, 1H), 6.89 (d, 1H), 6.10 (d, I H), 3.80 (s, 3H).

B. 3-(5-Chloro-thiophen-2-vl)-ProD-2-(E)-en-I-ol.

To a solution of 3- (5-chloro-thiophen-2-yl)- (E)-acrylic acid methyl ester (5.00 g, 24.7 mmol) in 80 mL of CH, CI, at 0°C is added slowly a solution of DIBAL (36.2 mL of a 1. 5M solution in toluene, 54. mmol). The mixture is stirred at 0°C for 15 min, then quenched by the addition of 6 mL of MeOH.

The mixture is allowed to warm to room temperature, diluted with water/ice and stirred for 15 minutes.

The mixture is filtered through a pad of Celite and washed with CH, CI,. The layers are separated and the aqueous layer is extracted with CH2CI2. The combined organics are washed with saturated NaCI solution, dried over anhydrous Na, S04, filtered and concentrated. The residue is purified via flash column chromatography eluting with a gradient of 15% EtOAc/hexanes to 25% EtOAc/hexanes to afford the title compound (4.18 g, 23.9 mmol) as an oil. 'H NMR (CDCI3,300 MHz) 8 6.77 (d, 1H), 6.71 (d, 1H), 6.60 (d, 1 H), 6.10 (m, IH), 4. 30 (d, 2H), 1.79 (bs, 1 H).

C. 2- (3-Bromo- (E)-propenvl)-5-chloro-thiophene.

To a solution of 3- (5-chloro-thiophen-2-yl)-prop-2-(E)-en-l-ol (4.18 g, 23.9 mmol) in 140 mL of Et2O at 0°C is added phosphorous tribromide (1. 34 mL, 14.3 mmol) in 10 mL of Et2O. The mixture is stirred at 0°C for 45 min, then at room temperature for 1.5 hours. The mixture is quenched by the addition of water/ice and diluted with Et20. The layers are separated and the organic phase is washed with water until neutral (3x) and once with saturated NaCI solution. The organic layer is dried over anhydrous MgSO4, filtered and concentrated to provide the title compound (5.46 g, 23.0 mmol) as an oil.

The crude material solidified upon storage in the freezer and can be used in the subsequent step without further purification. 'HNMR (CDC13, 300 MHz) 6 6.80 (m, 2H), 6.65 (d, 1H), 6.10 (m, 1H), 4.10 (d, 2H).

EXAMPLE 18.3-(4-Bromo-furan-2-vl)-(E)-propenal.

To a solution of 4-bromo-2-furfuraldehyde (0.5 g, 2.86 mmol) in 30 mL of dry CH, C12 is added (triphenylphosphoranylidene) acetaldehyde (0.87 g, 2.86 mmol). The resulting mixture is stirred for 16 h at room temperature. The crude mixture is concentrated in vacuo and the residue is purified via flash column chromatography eluting with CH, CI, to provide the title compound (0.15 g, 0.75 mmol) as a <BR> <BR> <BR> <BR> whitesolid.'HNMR (CDC13, 300MHz) o9.62 (d, 1H), 7.59 (s, 1H), 7.18 (d, 1H), 6.81 (s, 1H), 6.60 (m, 1H).

EXAMPLE 19. Acetic acid 3-(6-methoxv-neridin-3-yl)-(E)-allvl ester.

To a solution of 3-(6-methoxy-pyridin-3-yl)-prop-2-(E)-en-1-ol (0.39 g, 2.36 mmol, prepared as described in PREPARATION MB from 6-methoxy-pyridine-3-carbaldehyde (J. Org. Chem. 1990,72)) in 8 mL of CH2Cl2 at 0°C is added triethylamine (0.66 mL, 4.72 mmol), DMAP (0.05 g, 0.40 mmol) and Ac2O (0.33 mL, 3.54 mmol). The mixture is stirred at 0°C for 45 min, then at room temperature for 16

hours. The mixture is diluted with Et20 and washed with IN HCI, water, saturated NaHC03 solution and saturated NaCI solution. The organic layer is dried over anhydrous MgSO4, filtered and concentrated.

The residue is purified via flash column chromatography eluting with a gradient of 10% EtOAc/hexanes to 20% EtOAc/hexanes to afford the title compound (0.25 g, 1.21 mmol) as an oil.'H NMR (CDC13, 300 MHz) 5 8.12 (d, IH), 7.68 (dd, I H), 6.72 (d, IH), 6.60 (d, I H), 6.18 (dt, I H), 4.73 (d, 2H), 3.95 (s, 3H), 2.10 (s, 3H).

EXAMPLE 20. 2- (3-Bromo-prop-1-ynyl)-5-chloro-thiophene.

A. 3- (5-Chloro-thiophen-2-vl)-prop-2-vn-1-ol.

Nitrogen (g) is bubbled through a solution of 5-bromo-2-chloro-thiophene (1.00 g, 5.06 mmol) in 8 mL of piperidine. After 5 min, propargyl alcohol (0.32 mL, 5.56 mmol), tetrakis (triphenylphosphine) palladium (0) (0.06 g) and Cul (catalytic amount) are added to the solution. The mixture is heated at 80°C for 1 h in a sealed glass vessel. At this time, the mixture is cooled and diluted with EtOAc/Et, O.

The organic layer is washed 3N HCI, water, saturated NaHC03 solution and saturated NaCI solution.

The organic layer is dried, filtered and concentrated. The crude residue is purified via flash column chromatography eluting with a gradient of 10% EtOAc/hexanes to 20% EtOAc/hexanes to give the title compound (0.8 g, 0.46 mmol) as an oil.'H NMR (DMSO-d,, 300 MHz) 8 6.99 (d, 1H), 6.80 (d, 1H), 4.49 (s, 2H), 1.90 (bs, IH). EI MS, [M] +=172,174 (Cl pattern).

B. 2- (3-Bromo-prop-1-ynyl)-5-chloro-thiophene.

The title compound is prepared as described in EXAMPLE 17, Part C, using 3- (5-chloro- thiophen-2-yl)-prop-2-yn-I-ol in place of 3- (5-chloro-thiophen-2-yl)-prop-2-(E)-en-I-ol. The crude product is used in the subsequent step without further purification.

'H NMR (CDCI3,300 MHz) 8 7.04 (d, 1H), 6.80 (d, IH), 4.98 (d, 2H).

EXAMPLE 21. 2-Bromomethyl-5-chloro-indole-1-carboxvlic acid tert-butvl ester.

A. 5-Chloro-2-methvl-indole-1-carboxylic acid tert-butvl ester.

A solution containing 5-chloro-2-methylindole (4.0 g, 24.1 mmol) and DMAP (295 mg, 2.42 mmol) in anhydrous THF (100 mL) is cooled to 0°C. A solution containing (Boc) 2O (5.27 g, 24.1 mmol) in anhydrous THF (100 mL) is then added over a 20 min period. The reaction mixture is stirred for 2 h at 0°C and then at ambient temperature for 16 hours. The reaction mixture is concentrated and the crude residue is purified by flash silica gel chromatography (2% EtOAc/hexane to 5% EtOAc/hexane) to provide 5.2 g (81%) of title compound as a pale yellow solid.'H NMR (300 MHz, CDCl3) 8 1.67 (s,

9H), 2.57 (s, 3H), 6.24 (t, J = 0. 9 Hz, 1H), 7.16 (dd, J = 8.8,2.1 Hz, 1H), 7. 38 (d, J = 2. 1 Hz, 1H), 8.01 (d, J = 8.8 Hz, I H) ppm; MS (EI): m/z 265 (M+).

B. 2-Bromomethvl-5-chloro-indole-1-carboxylic acid tert-butyl ester.

A solution containing 5-chloro-2-methyl-indole-1-carboxylic acid tert-butyl ester (3.0 g, 11.3 mmol), NBS (1.33 g, 11. 3 mmol), and benzoyl peroxide (0.4 g, 1.13 mmol) in CC14 (100 mL) is heated at 80°C for 3 hours. An additional portion of NBS (0.65 g, 5.65 mmol), and benzoyl peroxide (0.2 g, 0.56 mmol) is then added and the reaction mixture is heated for an additional 3 hours. After cooling to ambient temperature, the reaction mixture is filtered. The filtrate is concentrated to a brown oil which is triturated with hexane to remove residual succinimide, filtered, and concentrated. The resultant oil (4.5 g, >100%) is used directly in the next reaction without further purification.'H NMR (300 MHz, CDC13) 8 1.72 (s, 9H), 4.88 (s, 2H), 6.63 (s, 1H), 7.27 (dd, J = 9.0,2.0 Hz, 1 H), 7.46 (d, J = 2.0 Hz, IH), 8.09 (d, J = 9.0 Hz, I H) ppm; MS (EI): m/z 343 (M+).

EXAMPLE 22.3-Bromomethvl-5-iodo-2-methoxy-pvridine A. 5-lodo-3-methyl-2-methoxv-pyridine.

To a solution containing 2-bromo-5-iodo-3-methyl-pyridine (4.80 g, 16.0 mmol) in DMSO (15 mL) is added methanolic NaOMe (3. 33 M, 5.3 mL, 17.7 mmol) at 0 °C. The solution is allowed to warm to ambient temperature and then heated at 70°C for 1 hour. The reaction mixture is diluted with diethyl ether (300 mL) and water (200 mL) and the layers are separated. The organic phase is washed with brine, dried over anhydrous Na, SO4, filtered and concentrated. The crude product is purified by silica gel flash column chromatography (hexane/diethyl ether, 19: 1) to provide 2.86 g (71 %) of the title compound as a white solid.'H NMR (300 MHz, CDC13) 8 2.12 (s, 3H), 3.90 (s, 3H), 7.60 (d, J = 2.1 Hz, I H), 8.14 (d, J = 2.1 Hz, I H) ppm; MS (EI): m/z 249 (M+).

B. 3-Bromomethvl-5-iodo-2-methoxv-pvridine.

A solution containing 5-iodo-3-methyl-2-methoxy-pyridine (1.00 g, 4.00 mmol) and NBS (0.78 g, 4.40 mmol) in CC14 (20 mL) is warmed to reflux. AIBN is added in 5 mg portions (0.03 mmol) every hour. After 3 h, the reaction mixture is cooled and then concentrated in vacuo. The residue is dissolved in EtOAc (150 mL) and washed successively with aqueous Na, S'03 (1. 00 mL), water (100 mL), brine then dried over anhydrous Na, S04, filtered and concentrated. The crude product ispurified by silica gel flash column chromatography (hexane/diethyl ether, 19: 1) to provide 0.72 g (55%) of the title compound as a white solid.'H NMR (300 MHz, CDC13) 8 3.97 (s, 3H), 4.38 (s, 2H), 7.83 (d, J = 2.2 Hz, 1H), 8.27 (d, J = 2.2 Hz, 1H) ppm; MS (EI) : m/z 327 (M+).

EXAMPLE 23.5-Bromomethvl-6-methoxv-nicotinic acid methvl ester.

A. 6-Methoxy-5-methvl-nicotinic acid methvl ester.

A solution containing 5-iodo-3-methyl-2-methoxy-pyridine (10.0 g, 40.0 mmol), Et3N (8.0 g, 80.0 mmol), and (Ph3P) 4PdCI2 (2.80 g, 4.00 mmol) in 1: 1 DMF/MeOH (100 mL) is cooled to 0°C.

Carbon monoxide is bubbled into the cooled solution for approx. 5 min at which time the reaction mixture is sealed under a balloon of CO. The reaction mixture is allowed to warm to ambient temperature and then stirred for 16 hours. The reaction mixture is concentrated in vacuo and the residue is partitioned between water (300 mL) and EtOAc (300 mL) and the layers are separated. The organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated. The crude product is purified by silica gel flash column chromatography (hexane/diethyl ether, 19: 1) to provide 4.10 g (57%) of the title compound as a white solid.'H NMR (300 MHz, CDC13) 8 2.20 (s, 3H), 3.88 (s, 3H), 4.00 (s, 2H), 7.96 (d, J = 2.2 Hz, 1H), 8.65 (d, J = 2.2 Hz, IH) ppm; MS (ISP loop): m/z 182 (M+H).

B. 5-Bromomethvl-6-methoxy-nicotinic acid methyl ester.

A solution containing 6-methoxy-5-methyl-nicotinic acid methyl ester (4.00 g, 22.1 mmol), NBS (5.11 g, 28.7 mmol), and AIBN (0.90 g, 5.5 mmol) in CC14 (100 mL) is warmed to reflux. After 5 h, the reaction mixture is cooled and then concentrated in vacuo. The residue is dissolved in EtOAc (500 mL) and washed successively with aqueous Na2S203 (300 mL), water (100 mL), brine then dried over anhydrous Na, S04, filtered and concentrated. The crude product is purified by silica gel flash column chromatography (hexane/diethyl ether, 9: 1) to provide 3.10 g (54%) of the title compound as a white solid.'H NMR (300 MHz, CDC13) S 3.90 (s, 3H), 4.07 (s, 3H), 4.46 (s, 2H), 8.19 (d, J = 2.2 Hz, 1H), 8.79 (d, J = 2.2 Hz, I H) ppm; MS (EI): m/z 259 (M+).

EXAMPLE 24.5-Chloro-2-thienvioxvacetic acid.

A. 2-Hvdroxv-thiophene.

Thiophene (42g, 500mmol) is dissolved in ether (250mL). To the solution is added n-BuLi (200mL of a 2. 5N solution in hexanes, 500mmol) at a rate which maintains a gentle reflux. After addition, the solution is stirred for 0.5 hour. The solution is then cooled to-78°C and triethyl borate (102 g, 700mL) is added dropwise. The solution is stirred for 3 hours. The cold bath is removed and 130mL of a 30% HO is added dropwise with rapid stirring. After addition, the solution is allowed to refluxed for an additional 20 minutes. The solution is then cooled to 0°C and acidified to pH=3 with 6N HCI.

The resulting solution is extracted with ether. The organic solution is washed with 10% ferric

ammonium sulfate, water and saturated NaCI. The solution is dried over MgSO4, filtered and concentrated under vacuum. The title compound (32g, 320mmol) is obtained as an oil.'H NMR (CDCI3, 300MHz) # 7.60 (m, IH), 6. 35 (m, 1H), 4.12 (d, 2H).

B. Ethvl 2-thienoxvacetate.

To a solution of 2-hydroxy-thiophene (32g, 320 mmol) in CHC13 (500mL) is added ethyl bromoacetate (53.4 g, 320 mmol). To the resulting solution is added a solution containing n-Bu4NHSO4 (25g, 74mmol) and NaOH (15.8g, 394 mmol) in water (500mL). After addition, the solution is stirred vigorously using mechanical stirring. The reaction is stirred for 12 hours. After this time, the layers are separated. The aqueous layer is extracted with CHCl3. The combined organic layers are washed with water and saturated NaCI. The organic layer is dried over MgS04, filtered and concentrated under vacuum. The resulting crude product is purified by column chromatography eluting with a gradient of 30% CH, Cl,: hexanes to 60% CH, CI,: hexanes. The title compound (11. 5g, 62mmol) is obtained as an oil.

'HNMR (CDCI3, 300MHz) â6.68 (dd, 1H), 6.60 (d, IH), 6.22 (d, 1H), 4.62 (s, 2H), 4. 30 (q, 2H), 1. 31 (t, 3H).

C. Ethvl 5-chloro-2-thienvloxvacetate.

To a solution of ethyl 2-thienyloxyacetate (I. lg, 5.9mmol) in acetic acid (I 5mL) is added N- chlorosuccinimide (0.78g, 5.9mmol). The solution is stirred for 1.5 hour. After this time the solution is concentrated. The resulting oil is dissolved in ether and washed with IN NaOH, water and sat. NaCI.

The organic layer is dried over MgS04, filtered and concentrated under vacuum. The title compound (1.26g, 5.7mmol) is obtained as an oil.'H NMR (CDC13,300MHz) 8 6.52 (d, 1H), 6.06 (d, 1H), 4.60 (s, 2H), 4.24 (q, 2H), 1.31 (t, 3H).

D. 5-Chloro-2-thienvloxyacetic acid.

To a solution of ethyl 5-chloro-2-thienyloxyacetate (0. 39g, 1.77mmol) in 9mL of a 1: 1: 1 mixture of CH30H: THF: water is added LiOH (0. 38g, 9.0 mmol). The solution is stirred for 16 hours. After this time, the solution is concentrated to 1/3 its volume. The resulting solution is acidified to pH=3 with IN HCI. The aqueous solution is extracted with CH2C12. The organic layer is dried over MgS04, filtered and concentrated under vacuum. The title compound (0. 32g, 1.66mmol) is obtained as a white solid.'H NMR (CDC1 ;, 300MHz) 8 6.50 (d, 1H), 6.07 (d, IH), 4.66 (s, 2H).

EXAMPLE 25.3- (5-Chloro-thioi) hen-2-vl)- (E)-acrylic acid.

To a mixture of 3- (5-chloro-thiophen-2-yl)- (E)-acrylic acid methyl ester (0.60 g, 2.96 mmol) in 15 mL of 1: 1: 1 THF/MeOH/H2O at 0°C is added lithium hydroxide monohydrate (0.62 g, 14.7 mmol).

The mixture is stirred at 0°C for 1 h, then at room temperature for 1 h and concentrated in vacuo. The residue is diluted with EtOAc and washed with IN HCI. The aqueous layer is extracted with EtOAc and the combined organics are washed with water (2x), dried, filtered and concentrated to provide the title compound (0.54 g, 2.86 mmol) as a white solid. The crude material can be used in the subsequent step without further purification.'H NMR (CDCI ;, 300MHz) 8 7. 300MHz) 8 7. 65 (d, 1H), 7.05 (d, 1H), 6.90 (d, 1H), 6.10 (d, 1H).

EXAMPLE 26.3- (4-Chloro-thiophen-2-vl)- (E)-acrvlic acid.

A. 4-Chloro-2-thiophene-carboxaldehvde.

To a solution of 2-thiophene-carboxaldehyde (6. 33 g, 56.4 mmol) in 100 mL of CHC13 at 0°C is added aluminum trichloride (16.8 g, 126 mmol) portionwise over a few minutes. In a separate vessel, chlorine gas (4.00 g) is bubbled for about 2 min into 100 mL of CCI4 at 0°C and then added to the former mixture slowly at 0°C. The resulting mixture is stirred at 0°C for 45 min, then allowed to warm to room temperature and stirred overnight. After 16 h, the reaction mixture is poured slowly into 6N HCI at 0°C, then stirred at room temperature for 2 hours. The layers are separated. The aqueous layer is extracted with CHCl3. The combined organic layers are washed with H2O and saturated NaCI solution, then dried over MgSO4, filtered and concentrated. The crude product is purified by column chromatography eluting with 10% EtOAc/hexanes to yield the title compound (6.70 g, 45.9 mmol).'H NMR (CDCI3, 300 MHz) 8 9.87 (s, 1H), 7.64 (s, 1H), 7.63 (s, 1H).

B. 3- (4-Chloro-thiophen-2-vl)- (E)-acrvlic acid methyl ester.

The title compound is prepared as described in EXAMPLE 1, Part A from 4-chloro-2-thiophene- carboxaldehyde.'H NMR (CDC13,300 MHz) 8 7.69 (d, 1H), 7.15 (s, 1H), 7.11 (s, 1H), 6.25 (d, 1H), 3.82 (s, 3H).

C. 3- (4-Chloro-thiophen-2-yl)- (E)-acrylic acid.

The title compound is prepared as described in EXAMPLE 1, Part B from 3- (4-chloro-thiophen- 2-yl)- (E)-acrylic(E)-acrylic acid methyl ester.'H NMR (CDC13,300 MHz) 8 7.77 (d, 1H), 7.19 (d, 2H), 6.25 (d, 1H).

EXAMPLE 27. (5-Chloro-thiophen-2-vl)-acetic acid.

A. f2- (5-Chloro-thiophen-2-yl)-1-dimethylaminovinvilphosphonic acid diethyl ester.

To a suspension of sodium hydride (0.25 g, 6.25 mmol, 60% mineral oil dispersion) in 10 mL of THF is added slowly a solution of tetraethyl dimethylaminomethylenediphosphonate (2.03 g, 6.14 mmol, prepared according to the procedure described in Psaume, Montury, and Cosmetic Comm. 1982,12,415) in 10 mL of THF. After stirring I h, a solution of 5-chloro-2-thiophene carboxaldehyde (0.90 g, 6.14 mmol) in 10 mL of THF is added. The resulting mixture is heated at reflux for 1 h, then cooled to room temperature. The reaction mixture is partitioned between Et, and water. The organic layer is washed sequentially with IN HCI, water and saturated NaCI, then dried over MgSO4, filtered and concentrated.

The crude product is purified via flash column chromatography eluting with a gradient of 40% EtOAc/hexanes to 50% EtOAc/hexanes to afford the title compound (1.52 g, 4.69 mmol) as an oil.'H NMR (CDC13,300 MHz) 8 7.20 (d, I H), 6.95 (d, I H), 6.82 (d, I H), 4.15 (m, 4H), 2.62 (s, 6H), 1.60 (t, 6H).

B. (5-Chloro-thiophen-2-yl)-acetic acid.

A mixture of [2- (5-chloro-thiophen-2-yl)-1-dimethylaminovinyl] phosphonic acid diethyl ester (1.52 g, 4.69 mmol) and 30 mL of 6N HCI is heated at reflux for 2 hours. After cooling to room temperature, ice water is added and the mixture is partitioned between Et, O and water. The organic layer is washed with water (2x), dried over MgS04, filtered and concentrated to give the title compound (0.62 g, 3.51 mmol) as a brown solid. The crude material can be used in the subsequent step without further purification.'H NMR (CDC13,300 MHz) 5 8. 30 (bs, IH), 7.79 (d, IH), 6.71 (d, 1H), 3.81 (s, 2H).

EXAMPLE 28.3-(5-Chloro-thiophen-2-vl)-propionic acid.

A. 3- (5-Chloro-thiophen-2-yi)-propionaldehyde.

To a mixture of Pd (OAc) 2 (0.12 g, 0.53 mmol), NaHC03 (0.52 g, 6.19 mmol) and NaI (0.28 g, 1.87 mmol) in 5 mL of HMPA is added 5-bromo-2-chloro-thiophene (1.00 g, 5.06 mmol) and allyl alcohol (1.03 mL, 15.2 mmol). The mixture is heated to 90°C and stirred for 16 hours. The reaction mixture is cooled to room temperature, diluted with Et, and washed with water. The organic layer is dried over MgSO4, filtered and concentrated in vacuo. The crude residue is purified by flash column chromatography eluting with a gradient of 10% Et2O/hexanes to 20% Et2O/hexanes to provide the product (0.18 g, 1.03 mmol) as an oil. 'H NMR (CDC13,300 MHz) S 9.81 (s, 1H), 6.71 (d, IH), 6.58 (d, I H), 3.07 (t, 2H), 2.81 (t, 2H).

B. 3-(5-Chloro-thiophen-2-vl)-propionic acid.

Silver nitrate (117 mg, 0.69 mmol) in I mL of H, O is added to 1.36 mL of IN NaOH at 0°C and stirred for 5 minutes. To the brown suspension is added 3- (5-chloro-thiophen-2-yl)-propionaldehyde (60

mg, 0. 34 mmol) and the resulting mixture is allowed to warm to room temperature over 2 hours. The precipitate is filtered and washed with hot water (2x). The combined aqueous layers are acidified with 6 N HCI and extracted with EtOAc (2x). The combined organic layers are washed with water (2x), then dried over MgS04, filtered and concentrated in vacuo to give the title compound (50 mg, 0.26 mmol) as a beige solid. The crude material can be used in the subsequent step without further purification.'H NMR (CDC13,300 MHz) 8 6.72 (d, 1H), 6.60 (d, 1H), 3.07 (t, 2H), 2.71 (t, 2H).

EXAMPLE 29.3-Fluorophenoxy-acetic acid.

A. 3-Fluorophenoxy-acetic acid ethyl ester.

To a solution of 3-fluorophenol (1.2g, 11. 8mmol) in 20mL of DMF at 0°C is added sodium hydride (0.47g, 10.7mmol). After stirring for 10 minutes Ethyl bromoacetate (1.2g, 10.7 mmol) is added dropwise. The reaction is allowed to warm to ambient temperatures and is stirred for 16 hours. To the reaction is added a saturated solution NHCl (aq.). The resulting mixture is diluted with EtOAc and H2O.

The layers are separted. The organic layer is washed with H2O and a saturated solution NaCI (aq.). The organic layer is dried over MgS04, filtered and concentrated to give the product (2g, l Ommol) as an oil.

'H NMR (CDC13, 300MHz) â 7.22 (m, 1H), 6.65 (m, 3H), 4.61 (s, 2H), 4.27 (q, 2H), 1.24 (t, 3H).

B. 3-Fluorophenoxy-acetic acid.

To a solution of ethyl 3-fluorophenoxy-acetate (2g, l Ommol) in 24mL of a 1: 1: 1 solution of MeOH: H, O : THF is added lithium hydroxide monohydrate (2.25g, 54mmol). The solution is stirred for 16 hours. After this time, the solution is concentrated under reduced pressure to 1/3 of its volume. The remaining solution is acidified to pH=3 with IN HCI (aq.). The aqueous solution is extracted with EtOAc. The organic layer is washed with a saturated solution NaCI (aq.). The organic layer is dried over MgSO4, filtered and concentrated to give the product (1.65g, 9.7mmol) as a white solid.'H NMR (CDC13,300MHz) 8 9.8 (bs, 1H), 7.28 (m, 1H), 6.69 (m, 3H), 4.70 (s, 2H).

EXAMPLE 30.2-Chloropvrdin-3-vlamino-acetic acid.

To a solution of 3-amino-2-chloropyridine (I. 0g, 7.8mmol) in 20mL of MeOH is added glyoxylic acid (0.86mL of a 50% by weight solution in H20,7.8mmol). After stirring for 10 minutes, NaCNBH3 (1.54 g, 23mmol) is added. The reaction is stirred for 16 hours., then is concentrated under reduced pressure. The resulting residue is dissolved in H, O. The solution is acidified to pH=3 with IN HCI (aq.). The solution is extracted with EtOAc/CH2CI2 (2: 1). The organic layer is dried over MgSO4, filtered and concentrated. The resulting product is obtained as a white solid (0.95g, 5.1mmol).'H NMR

(d6-DMSO, 300MHz) 8 12.7 (bs, IH), 7.62 (m, 1H), 7.44 (m, 1H), 6.90 (m, 1H), 5.8 (bs, IH), 3.95 (AB, 2H). 4.70 (s, 2H).

EXAMPLE 31.5-Chlorothiophen-2-yl-sulfanvl acetic acid.

A. Thiophen-2-vl-sulfanvi acetic acid ethyl ester.

To a solution of thiophene-2-thiol (1.49g, 116mmol) in 40mL of CH3CN is added ethyl bromoacetate (2.14g, 167mmol) followed by K, C03 (3.54g, 138mmol). The solution is stirred for 16 hours. After this time, the solution is filtered. The solvent is evaporate to give the product as an oil (2.4g, 118mmol). 1H NMR (CDCl3, 300MHz) # 7.37 (m, IH), 7.21 (m, 1H), 6.94 (m, IH), 4.15 (q, 2H), 3.48 (s, 2H), 1.20 (t, 3H). MS (El) : m/z 202 (M+).

B. 5-Chlorothiophen-2-yl sulfanyl acetic acid.

To a solution of thiophen-2-yl-sulfanyl acetic acid ethy (0.52g, 2.6mmol) in 25 mL of CH2CI2 is added N-chlorosuccinimide (0.35g, 2.6mmol). The solution is stirred for 10 minutes. After this time, 1 drop of TFA is added. The solution is stirred for 16 hours. The reaction mixture is then diluted with 25 mL of CH2CI2. The resulting solution is washed with IN NaOH and a saturated NaCI solution. The organic layer is dried over MgSO4, filtered and concentrated. The resulting product is obtained as an oil which is determined to contain 45% of the desired product. The oil is then dissolved in 60 mL of 1: 1: 1 THF: MeOH: H, O. To the solution is added lithium hydroxide monohydrate (1.26g, 30mmol). The solution is stirred for 16 hours. After this time, the solution is acidified to pH=3 with IN HCI. The aqueous solution is washed with H, O and saturated NaCI solution. The solution is extracted with EtOAc/CH, Cl, (2: 1). The organic layer is dried over MgS04, filtered and concentrated. The resulting crude product is purified by column chromatography eluting with 20% MeOH: Et, O to give the product as a white solid (0.4g, 1.9mmol). MS (El): m/z 208,210 (M+), Cl pattern.

EXAMPLE 32.5'-Chloro-f2, 2'lbithiophenyl-5-carboxylic acid.

A. 5'-Chloro-r2, 2'lbithiophenvl-5-carbaldehvde.

To a solution of 5-chloro- [2,2'] bithiophene (1.06 g, 5.28 mmol) in 12 mL of THF at-78°C is added n-BuLi (4.4 mL of a 1.6M solution in hexanes, 6.99 mmol). After 15 minutes, DMF (0.97 mL, 14 mmol) is added and the resulting solution is allowed to warm to 0°C. After 15 min, the solution diluted with EtOAc and quenched with saturated NaHCO3 solution. The organic solution is washed with H2O and saturated NaCI solution, then dried over MgS04, filtered and concentrated. The crude product is purified by flash column chromatography eluting with a gradient of 10% Et2O/hexanes to 20%

Et2O/hexanes to yield the title compound (0.89 g, 3.89 mmol) as a white solid.'H NMR (CDCL,, 300 MHz) 8 9.87 (s, 1H), 7.70 (d, 1H), 7.20 (d, 1H), 7.15 (d, IH), 6.91 (d, IH).

B. 5'-Chloro-f2, 2'lbithiophenvl-5-carboxylic acid.

The title compound is prepared as described in EXAMPLE 28, Part B using 5'-chloro- [2,2'] bithiophenyl-5-carbaldehyde.'H NMR (CDCI3,300 MHz) 8 7.69 (d, 1H), 7.09 (d, 1H), 7.06 (d, 1H), 6.89 (d, IH). El MS, [M] +=243,245 (Cl pattern).

EXAMPLE 33.7-Chloro-isoQuinoline-3-carboxvlic acid.

A. 7-Chloro-isoquinoline-3-carbaldehvde.

A 20mL of 80% H, SO, is added 7-chloro-3,3-dibromomethyl isoquinoline (0.69g, 2.06mmol) is heated to 150°C for 16 hours. The solution is then cooled to ambient temperatures and diluted with 40 mL of H, O. The resulting solution is basified to pH=11 with IN NaOH. The aqueous solution is extracted with CH2Cl2. The organic solution is washed with H, O and a saturated NaCI solution. The organic layer is dried over MgSO4, filtered and concentrated to give the product as an oil (0.25g, 1.3 mmol).'H NMR (CDCl3, 300MHz) 8 10.0 (s, I H), 9. 30 (s, 1H), 8.36 (s, IH), 8.07 (s, 1H), 7.95 (d, 1H), 7.78 (d, 1H), MS (El): m/z 191,193 (M+), Cl pattern.

B. 7-Chloro-isoquinoline-3-carboxvlic acid.

To 4.5 mL of a IN NaOH solution at 0°C is added a solution of AgNO3 (0. 31g, 1. 8mmol) in 3 mL of H, O, followed by a solution of of 7-chloro-isoquinoline-3-carbaldehyde (0.25g, 1.3mmol) in 3 mL of EtOH. The solution is stirred at 0°C for 10 minutes, then at room temp. For 3 hours. The solution is acidified to pH=3 with 1H) HCI. The resulting solution is extracted with CHCl3. The organic layer is dried over MgSO4, filtered and concentrated to give the product as a white solid (0.2g, 0. 96mmol). 1H NMR (CD30D, 300MHz) 8 9.18 (s, 1H), 8.. 63 (s, 1H), 8.18 (m, 1H), 7.80 (m, 2H). 6.94 (m, 1H), 4.15 (q, 2H), 3.48 (s, 2H), 1.20 (t, 3H). MS (EI): m/z 208,210 (M+), Cl pattern.

EXAMPLE 34.2-Acetvlamino-3- (5-chloro-thiophen-2-yl)-acrvlic acid.

A. 4-(5-ChIoro-thiophen-2-v)methytene)-2-methvi-4H-oxazot-5-one .

A mixture consisting of 5-chlorothiophene-2-carboxaldehyde (1.00 g, 6.82 mmol), N- acetylglycine (0.96 g, 8.18 mmol), NaOAc (0.67 g, 8.18 mmol) in Ac, O (5 mL) is warmed at reflux for 16 hours. The reaction mixture is cooled to ambient temperature and diluted with dilute aqueous NaOH (0.5 M, 100 mL) and CH, C12 (100 mL). The layers are separated and the organic phase is washed with

aqueous NaHC03, brine, dried over anhydrous Na2SO4, filtered and concentrated to provide 1.5 g (100%) of the title compound as a colorless oil which is used without further purification in the next reaction.'H NMR (300 MHz, CDCI3) 8 2.39 (s, 3H), 6.94 (d, J = 4.0 Hz, IH), 7.21 (s, 1H), 7.26 (d, J = 4.0 Hz, 1H) ppm.

B. 2-Acetvlamino-3- (5-chloro-thiophen-2-yl)-acrvlic acid.

To a solution containing 4- (5-chloro-thiophen-2-ylmethylene)-2-methyl-4H-oxazol-5-one (1.5 g, 6.82 mmol) in MeOH (18 mL) is added 1.0 M NaOH (12.0 mL, 12 mmol) at ambient temperature. After 3 h, the reaction mixture is diluted with water (100 mL) and CH, CL, (100 mL) and the layers are separated. The basic, aqueous layer is washed with CH, C1, and then acidified using 1.0 M HCI (20 mL) to provide a crude solid which is collected on a Buchner funnel. Drying in vacuo provided 1.2 g (75%) of the title compound as a pale brown solid which is used without further purification.'H NMR (300 MHz, DMSO-d6) S 2.00 (s, 3H), 7.14 (d, J = 4.01 Hz, 1H), 7.38 (d, J = 4.01 Hz, 1H), 7.63 (s, 1H), 9.28 (s, I H), 12.73 (br s, I H) ppm; MS (El): m/z 245 (M+).

EXAMPLE 35. 2-Acetvlamino-3- (5-chloro-thiophen-2-yl)-propionic acid.

To a solution containing 2-acetylamino-3- (5-chloro-thiophen-2-yl)-acrylic acid (1.00 g, 4.08 mmol) and K, C03 (1.70 g, 12.1 mmol) in DMF (20 mL) is added MeI (0.87 g, 6.12 mmol) at ambient temperature. After 2 h, the reaction mixture is diluted with water (100 mL) and EtOAc (100 mL) and the layers are separated. The aqueous layer is extracted with EtOAc (50 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated to provide 0.92 g (83%) of the methyl ester which is used without further purification.'H NMR (300 MHz, CDCI3) å 2.19 (s, 3H), 3.77 (s, 3H), 6.86 (d, J = 4.02 Hz, 1H), 6.99 (m, 1H), 7.05 (d, J = 4.02 Hz, IH), 7.64 (s, IH) ppm.

A small Parro vessel is charged with the crude ester (0.85 g, 3.13 mmol) and (Ph3P), RhCI (0.10 g, 0.10 mmol) in MeOH (50 mL). The vessel is pressurized to 50 PSI H, pressure and agitated for 7 h at ambient temperature. The reaction mixture is then filtered and concentrated to provide the desired compound, which is used without further purification. MS (El): m/z 261 (M+).

The above-prepared saturated ester is dissolved in a 1: 1: 1 solution of water/THF/MeOH (15 mL). LiOH monohydrate (0.14 g, 3.23 mmol) is added and the heterogeneous mixture is stirred for 16 hours. The reaction mixture is diluted with water (100 mL) and EtOAc (100 mL) and the layers are separated. The aqueous layer is extracted with EtOAc (50 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated to provide 0.62 g (81 %) of the title compound as a colorless oil.'H NMR (300 MHz, CDCl3) 5 2.02 (s, 3H), 3.30 (m, 2H), 4.81 (m, 1H), 6.45 (br d, J = 6.45 Hz, 1H), 6.58 (d, J = 3.68 Hz, 1H), 6.71 (d, J = 3.68 Hz, 1H), 9.79 (br s, IH) ppm; MS (El): m/z 247 (M+).

EXAMPLE 36.3- (6-Amino-pyridin-3-vl)-acrvlic acid.

A. N- (5-Bromo-pyridin-2-yl)-acetamide.

Triethylamine (17.7mL, 75 mmol) is added to a mixture of 2-amino-5-bromopyridine (5.0 g, 29 mmol) and acetic acid (7.1 mL, 75 mmol). The solution is heated to reflux for 48 hours. After this time, the solution is concentrated. The reside is dissolved in water and the pH is adjusted to 10 with IN NaOH. The solids are collected by filtration. The crude product is recrystallized from boiling water to give the title compound (2.6 g 12.0 mmol) as a white solid.'H NMR (300 MHz, CDCI3) 8 10.62 (IH, bs), 8.42 (s, IH), 8.01 (m, 2H), 2.05 (s, 3H).

B. 3- (6-Acetvlamino-pyridin-3-vl)-acrvlic(6-Acetvlamino-pyridin-3 -vl)-acrvlic acid To a mixture ofN- (5-bromo-pyridin-2-yi)-acetamide (1.26 g, 5.86 mmol) and tri-n-butylamine in xylenes (10 mL) is added Pd (OAc) 2 (1.4 mg, 0.006 mmol) and triphenyl phosphine (15.4mg, 0.06 mmol). Acrylic acid (0.48 mL, 7.03 mmol) is then added dropwise over 5 minutes. The mixture is heated to reflux for 5 hours. The solution is cooled to ambient temperatures. The mixture is diluted with water and the pH is adjusted to 4 with IN HCI. The solution is extracted with EtOAc/CH, Cl, (2: 1). The resulting suspension is filtred to give the title compound (0.80 g, 3.88 mmol) as a white solid. MS (ion spray) 207, (M+H).

C. 3- (6-Aminopyridin-3-yl)-acrylic acid To 3- (6-acetylamino-pyridin-3-yl)-acrylic acid (0.80 g, 3.88 mmol) in ethanol (10 mL) is added IN NaOH (20mL). The solution is heated to reflux. After 16 h, the solution is concentrated to 1/3 its volume. The aqueous solution is diluted with water and acidified to pH=2 with 6N HCI. The solution is concentrated to dryness. The residue is dissolved in methanol. The solution is filtered. The organic solution is concentrated. The crude product is purified by RP-HPLC eluting with a gradient of 5% CH3CN/H20 (0.1% TFA) to 30% CH3CN/H20 (0.1% TFA) to give the product as a white solid (0.54 g, 1.93 mmol).'H NMR (300 MHz, CD30D) 8 8. 34 (d, IH), 8.07 (s, 1H), 7.54 (d, 2H), 7.06 (d, 1H), 6.47 (d, 1H). MS (ion spray) 165, (M+H).

EXAMPLE 37.4-Chloro-benzvl isocvanate.

To a solution of triphosgene (0.54 g, 1.85 mmol) in 10 mL of dry CL, CI at 0°C is added 4- chloro-benzylamine (0.61 mL, 5.00 mmol) dropwise as a white precipitate forms. Et3N (1. 39 mL, 10.0 mmol) in 5 mL of CH, CL, is added immediately and the resulting mixture is stirred at 0°C for 5 min, then at room temperature for 3 hours. The mixture is concentrated in vacuo and triturated with EtOAc.

The white precipitate (triethylamine hydrochloride) is filtered off and the filtrate is concentrated. The title compound (6.20 g, 30.6 mmol) is isolated as a crude yellow residue and used in the subsequent step without further purification. 'H NMR (CDC13,300 MHz) 8 7. 35 (d, 2H), 7.25 (d, 2H), 4.50 (s, 2H).

EXAMPLE 38.5-Chloro-thiophene-2-carbonvl azide.

To a solution of 5-chloro-2-thiophene-carboxylic acid (5.00 g, 30.7 mmol) in 130 mL of acetone is added Et3N (4.29 mL, 30.7 mmol). The mixture is cooled to 0°C and ethyl chloroformate (3.23 mL, 33.8 mmol) is added. The mixture is stirred at 0°C for Ih and sodium azide (3.40 g, 52.3 mmol) is added. The mixture is stirred at 0°C for 2 h, then poured into 300 mL of ice water and the aqueous layer is extracted with CH, CL, (2x). The combined organics are washed with water (2x) and brine, then dried, filtered and concentrated. The crude residue is purified via flash column chromatography eluting with 10% EtOAc/hexanes to provide the title compound (3.00 g, 16.0 mmol) as a white solid.'H NMR (CDC13,300 MHz) 8 7.67 (d, IH), 6.99 (d, IH).

EXAMPLE Pentachloropyridine (80 g, 320 mmol) is treated with benzyl amine (104 mL, 96 mmol), dissolved in dioxane (I L) and refluxed for 16 hours. The reaction mixture is cooled to ambient temperature and the precipitated white solid is removed by filtration. The filtrate is concentrated to a brown residue and triturated with 4 % ethyl acetate in hexane (3 X 250 mL) to give 4-benzylamino- 2,3,5,6-tetrachloropyridine as an off-white solid (40 g, 124 mmol). This material is dissolved in chloroform (400 mL), cooled in an ice bath and treated with trifluoroacetic acid (500 mL) and 30% hydrogen peroxide (100 mL). The reaction mixture is warmed to room temperature overnight and treated with additional trifluoroacetic acid (500 mL) and 30% hydrogen peroxide (100 mL). After stirring 24 hours the reaction is treated with water (IL). The lower organic layer is separated and the aqueous layer is extracted with chloroform. The combined organic layers are concentrated to a solid residue and redissolved in ethyl acetate/hexane (30 mL). The suspended orange solid is removed and the filtrate is loaded on a silica flash column. The column is eluted with hexane and the title compound is collected as a white solid (15.6 g, 60 mmol). El MS m/z 260,262,264 [M+].

EXAMPLE40. 4-(tert-ButvloxYcarbonYI)-piperazin-2-one 4- (Benzyloxycarbonyl)-piperazin-2-one (2.2 g, 9.4 mmol) and-Boc anhydride (2.5 g, 11.3 mmol) are dissolved in methanol (100 mL), treated with 5% Pd/C and shaken 16 h under hydrogen gas (30 PSI). The reaction vessel contents are filtered through Celite and the filtrate is concentrated to yield 4- (tert-Butyloxycarbonyl)-2-oxopiperazine (1.9 g, 9.4 mmol) which is used without further purification. El

MS m/z 200, M+ ;'H NMR (CDCI3,300 MHz) 8 6.17 (br, I H), 4.20 (s, 2H), 3.55 (t, 2H), 3.38 (m, 2H), 1.48 (s, 9H).

EXAMPLE 41. 2-Methoxvmethvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

A. N-Cbz-O-methvlserine-aminoacetaldehyde dimethvl acetal.

To a solution of N-Cbz-O-methylserine (10.8g, 41. 8mmol) in 500mL of CH2CI2 is added Et3N (12.7 g, 125mmol). The solution is cooled to 0°C and TBTU (13. 5g, 42mmol) and aminoacetaldehyde dimethyl acetal (4.83g, 46mmol) are added. The solution is stirred for 16 hours. The solution is diluted with 500mL of ether. The resulting solution is washed with water, IN KHSO4, and sat. NaCI. The title compound (13.7g, 41.8mmol) is obtained as a white foam. 'H NMR (CDCI, 300MHz) 8 7.40 (m, 5H), 6.55 (bs, 1H), 5.66 (bs, IH), 5. 32 (m, IH), 5.13 (s, 2H), 4.32 (m, 2H), 3.79 (dd, 1H), 3.44 (m, 2H), 3.40 (m, 9H).

B. N-Cbz-2-Oxo-3- (S)-methoxvmethvl- (4,5-dihvdro) piperazine.

To a solution of N-Cbz-0-methylserine-aminoacetaldehyde dimethyl acetal 13.7g, 41.8mmol) in 300mL of toluene is added TsOH. H20 (0.80g, 4.2mmol). The solution is heated to 60°C. After 5h, the solution is diluted with ether. The resulting organic solution is washed with water, sat. NaHC03, and sat. NaCI. The organic layer is dried over MgS04, filtered and concentrated under vacuum. The resulting crude product is purified by column chromatography eluting with a gradient of 10% EtOAc: CH2Cl2 to 20% EtOAc: CH, CI,. The title compound (10.7g, 38mmol) is obtained as a white solid.'H NMR (CDCl3, 300MHz) 8 7.36 (m, 5H), 6.45 and 6. 30 (d, IH rotational isomers), 5.61 and 5.50 (d, 1H rotational isomers), 5.20 (s, 2H), 4.92 and 4.83 (bs, 1H rotational isomers), 3.63 (m, 3H), 3.32 and 3.20 (s, 1 H rotational isomers).

C. 2-Methoxymethyl-3-oxo-piperazine-I-carboxylic acid benzyl ester.

To a solution of N-Cbz-2-oxo-3-(S)-methoxymethyl-(4, 5-dihydro) piperidine (10.7g, 38mmol) in 50mL of methanol is added Pt/C (Igm, 10% by weight). The atmosphere above the reaction is replaced by hydrogen. After 24h, the solution is filtered and the filtrate is washed with methanol. The collected organic solutions are concentrated under vacuum. The resulting crude product is purified by column chromatography eluting with a gradient of 2%MeOH/CH2Cl2 to 5% MeOH/CH2CI,. The title compound (6.0g, 22mmol) is obtained as a white solid. IH NMR (CDC13, 300MHz) â 7.35 (m, 5H), 6.42 (bs, 1H), 5.20 (AB, 2H), 4.58 (m, 1H), 4.18 (m, 1H), 3.95 (m, 1H), 3.50 (m, 4H), 3.27 (s, 3H).

EXAMPLE 42.2-Butvl-3-oxo-piperazine-l-carboxvlic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-norleucine for Cbz-O- methyl-serine.'H NMR (CDC13, 300mHz) 87. 32 (m, 5H), 5.13 (AB, 2H), 4.60 (m, IH), 4.13 (m, 1H), 3. 38 (m, 2H), 3.23 (m, 2H), 1.90 (m, IH), 1.66 (m, 1H), 1.29 (m, 4H), 0.89 (m, 3H). MS (ion spray) m/z 291, (M+H).

EXAMPLE 43.2-Ethyl-3-oxo-piperazine-l-carboxvlic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-2-amino-butric acid for Cbz-O-methyl-serine.'H NMR (CDC13, 300mHz) 8 737 (m, 5H), 6.55 (bs, 1H), 5.10 (AB, 2H), 4.57 (m, 1H), 4.24 (m, 1H), 3.42 (m, 1H), 3.26 (m, 2H), 2.20 (m, 1H), 1.81 (m, 1H), 0.96 (m, 3H).

EXAMPLE 44.2-Propyl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-norvaline for Cbz-O- methyl-serine.'H NMR (CDCI3, 300mHz) 87. 32 (m, 5H), 7.00 (bs, 1H), 5.12 (AB, 2H), 4.58 (m, IH), 4.21 (m, 1H), 3.40 (m, 1H), 3.19 (m, 2H), 1.88 (m, 1H), 1.73 (m, IH), 1. 37 (m, 2H), 0.91 (m, 3H). MS (ion spray) m/z 277, (M+H).

EXAMPLE 45.2-Ethoxvmethvl-3-oxo-niperazine-I-carboxvlic acid benzyl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-O-ethyl-serine for Cbz-O- methyl-serine.'H NMR (CDCl3, 300MHz) 8 7. 32 (m, 5H), 6.96 (bs, 1H), 5.17 (AB, 2H), 4.58 (m, 1H), 4.18 (m, 1H), 4.03 (m, 1H), 3.66 (m, 2H), 3.44 (m, 3H), 3.27 (s, 1H), 1.06 (m, 3H). MS (ion spray) m/z 293, (M+H).

EXAMPLE 46.2-Methvl-3-oxo-piperazine-1-carboxvlic acid benzv) ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-alanine for Cbz-O-methyl- <BR> <BR> <BR> <BR> serine.'H NMR (CDCI3, 300MHz) â 7.34 (m, 5H), 7.02 (bs, 1H), 5.17 (AB, 2H), 4.65 (m, 1H), 4.17 (m, 1H), 3.42 (m, 1H), 3.23 (m, 2H), 1.41 (d, 3H). MS (El) m/z 248, (M+).

EXAMPLE 47.2-Benzyl-3-oxo-piperazine-1-carboxvlic acid benzvl ester The title compound is prepared as in EXAMPLE 41, substituting Cbz-phenylalanine for Cbz-O- methyl-serine. lHNMR (CDCI3, 300MHz) â7.22 (m, IOH), 7.00 (bs, 1H), 5.10 (AB, 2H), 4.10 (m, 1H), 3.27 (m, 2H), 3.10 (m, 2H), 2.55 (m, 2H). MS (EI) m/z 324, (M+).

EXAMPLE 48. 2-(1-Methoxyethyl)-3-oxo-piperazine-1-carboxylic acid benzyl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-O-methyl-threonine for Cbz-O-methyl-serine.'H NMR (CDCl3, 300MHz) 8 7.52 (bs, I H), 7.22 (m, 5H), 5.12 (AB, 2H), 4.33

(m, 1H), 4.05 (m, 2H), 3.60 (m, 1H), 3.14 (s, 3H), 3.10 (m, 1H), 2.82 (m, 1H), 1. 10 (d, 3H). MS (ion spray) m/z 293, (M+H).

EXAMPLE 49.2,2-Dimethvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-2-amino-isobutryic acid for Cbz-O-methyl-serine.'H NMR (CDCI3, 300MHz) â 7.36 (m, 5H), 6.52 (bs, 1H), 5.12 (s, 2H), 3.72 (m, 2H), 3. 33 (m, 2H), 1.68 (s, 3H), 1.64 (s, 3H). MS (El) m/z 262, (M+).

EXAMPLE 50. 2-Isopropyl-3-oxo-piperazine-1-carboxylic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-valine for Cbz-O-methyl- serine. 1H NMR (CDCl3, 300MHz) # 7.36 (m, 5H), 5.88 (bs, IH), 5.10 (s, 2H), 4. 35 (m, IH), 3.44 (m, 1H), 3.27 (m, 2H), 2. 31 (m, IH), 1.00 (d, 3H), 0.94 (d, 2H).

EXAMPLE 51.2-Isobutyl-3-oxo-piperazine-l-carboxylic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-leucine for Cbz-O-methyl- serine. 'HNMR (CDC13, 30OMHz) 87. 35 (m, 5H), 6.50 (m, IH), 5.15 (s, @H), 4.18 (m, 1H), 3.42 (m, 2H), 3.21 (m, 2H), 1.50 (m, 3H), 0.90 (m, 6H).

EXAMPLE 52.2- (2-Methoxvethvl)-3-oxo-piperazine-1-carboxylic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting Cbz-O-methyl-homo-serine for Cbz-O-methyl-serine.'H NMR (CDCl3, 300MHz) 8 7.32 (m, 5H), 6.85 (bs, 1H), 5.14 (s, 2H), 4.75 (m, 2H), 4.20 (m, 2H), 3.42 (m, 1H), 3.21 (m, 3H), 2.12 (m, 4H).

EXAMPLE 53.2-Methoxvmethvl-5-methvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

The title compound is prepared as in EXAMPLE 41, substituting 2-amino-propionaldehyde dimethyl acetal for aminoacetaldehyde dimethyl acetal.'H NMR (CDCl3, 300MHz) 8 7.42 (m, 5H), 6.96 (bs, IH), 5.12 (AB, 2H), 4.52 (m, IH), 4.21 (m, IH), 3.92 (m, IH), 3.58 (m, 2H), 3.22 (s, 3H), 3.10 (m, 1H), 0.95 (m, 3H).

EXAMPLE 54.3- (R)- (tert-Butyl-dimethv (-silanvloxvmethvl)-5-oxo-piperazine-I-carboxvlic acid benzvl ester.

A. 2-tert-Butoxvcarbonylamino-3-(tert-butvl-dimethvl-silanvloxv )-DroPionic acid. tert-Butyldimethylchlorosilane (32.3 g, 0.214 mol) in THF (50 mL) is added dropwise via cannula to a solution of BOC serine (20.0g, 0.098 mol) and imidazole (15.3 g, 0.224 mol) in THF (360

mL) at RT. The resulting slurry is stirred for 2.5 h then the solvent is removed in vacuo. The crude product is dissolved in MeOH (180 mL) and 5N NaOH (58 mL) is slowly added at RT. The mixture is stirred for 3 h then diluted with water (180 mL) after which time the aqueous layer is washed with ether (180 mLx2). The aqueous layer is acidified to pH 4-5 with 2N HCI and extracted with diethyl ether. The organic layer is washed with saturated NaHC03 and brine then dried over MgSO,, filtered and concentrated to dryness. The crude product (12.67g, 0.040 mol) is used in the subsequent step without further purification. 'H NMR (CDCI,, 300 MHz) 8 5.35 (bs, IH), 4.30 (bs, 1H), 4.13 (dd, 1H), 3.80 (dd, 1H), 1.45 (s, 9H), 0.98 (s, 9H), 0.10 (s, 6H). EI MS, [M+H] +=320. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>B. r2- (tert-Butvl-dimethyl-silanvloxy)-I- (methoxv-methvl-carbamovi)-ethvll-carbamic acid tert-but ester.

N, N-Dimethylaminopyridine (2.60 g, 21.3 mmol) and BOP reagent (18.15 g, 41.0 mmol) are added to a solution of 2-tert-butoxycarbonylamino-3- (tert-butyl-dimethyl-silanyloxy)-propionic acid (12.37 g, 38.7 mmol), diisopropylethylamine (8.1 mL, 46.4 mmol) and N, O-dimethylhydroxylamine hydrochloride (4.53 g, 46.4 mmol) in THF (260 mL) at RT. The resulting suspension is stirred at RT overnight then concentrated to dryness. The residue is diluted with EtOAc and washed with saturated NH4CI, saturated NaHC03 and brine. The organic layer is dried over MgS04, filtered and concentrated in vacuo to give the crude product which is purified by flash chromatography eluting with 10-30% EtOAc/Hexanes to yield the title compound (11.86 g, 30. 37 mmol) as an oil.'HNMR (CDC13,300 MHz) 8 5. 35 (bd, IH), 4.71 (bs, 1H), 3.78-3.85 (m, 2H), 3.72 (s, 3H), 3.20 (s, 3H), 1.42 (s, 9H), 0.90 (s, 9H), 0.05 (s, 6H).

C. [I- (tert-Butvl-dimethvl-silanvloxvmethvl)-2-oxo-ethvll-carbamic acid tert-butyl ester.

A solution of [2-(tert-butyl-dimethyl-silanyloxy)-1-(methoxy-methyl-carbam oyl)-ethyl]- carbamic acid tert-butyl ester (11.86,30. 37 mmol) in Et20 (100 mL) is added dropwise to a I. OM solution of LAH in ether (35.5 mL) at-5°C-0°C. The resulting mixture is stirred for 2.5 h then an aqueous solution of KHS04 is slowly added. The reaction mixture is stirred for 30 minutes and then washed with saturated NH4CI, saturated NaHC03 and brine. The organic layer is dried over MgSO4, filtered and concentrated in vacuo to give the crude product which is purified by flash chromatography eluting with 30% EtOAc/Hexanes to yield the title compound (6.04 g, 19.9 mmol) as an oil.'H NMR (CDCl3, 300 MHz) 8 9.65 (s, 1H), 5.30 (bs, 1H), 4.20 (m, 1H), 3.65 (4, 90 (m, 2H), 1.48 (s, 9H), 0.90 (s, 9H), 0.05 (s, 6H). Ion spray MS, [M+H] +=304.

D. j2-tert-Butoxvcarbonvlamino-3- (tert-butyl-dimethvl-silanvloxv)-propvlaminol-acetic acid methyl ester.

Sodium cyanoborohydride (2.63 g, 41.9 mmol) is added to a solution of [1-(tert-butyl-dimethyl- silanyloxymethyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (6.04 g, 19.9 mmol) and glycine methyl ester hydrochloride (2.75 g, 32.9 mmol) in MeOH (500 mL). The mixture is stirred for 2 days at RT then concentrated to dryness. The crude product is purifed by flash chromatography eluting with 1-5% MeOH/CH2CI2 to yield the title compound (3.06,8.12 mmol) as a colorless oil.'H NMR (CDCI3,300 MHz) S 5.00 (bs, 1H), 3.75 (s, 3H), 3.60-3.70 (m, 4H), 3.40 (d, 1H), 2.80 (dd, 1H), 2.68 (dd, 1H), 1.40 (s, 9H), 0.90 (s, 9H), 0.05 (s, 6H). Ion spray MS, [M+H] +=377.

E. (Benzvloxvcarbonvl-f2-tert-butoxvcarbonylamino-3- (tert-butvl-dimethvl-silanvloxv)-propvll-amino)- acetic acid methyl ester.

Benzylchloroformate (1.4 mL, 9.81 mmol) is added dropwise to a solution of N, N- dimethylaminopyridine (1.09 g, 8.93 mmol) and [2-tert-butoxycarbonylamino-3- (tert-butyl-dimethyl- silanyloxy)-propylamino]-acetic acid methyl ester (3.06 g, 8.12 mmol) in CH, CL, at RT. The resulting mixture is stirred overnight then concentrated to dryness. The crude product is purifed by flash chromatography eluting with 1% MeOH/CH, Cl, to yield the title compound (3.52 g, 6.89 mmol) as a colorless oil. Ion spray MS, [M+H] 1.

F. 3- (tert-Butvl-dimethvl-silanvloxvmethvl)-5-oxo-piperazine-l-ca rboxc acid benzyl ester (Benzyloxycarbonyl- [2-tert-butoxycarbonylamino-3- (tert-butyl-dimethyl-silanyloxy)-propyl]- amino)-acetic acid methyl ester (3.52 g, 6.89 mmol) is stirred in 50% TFA/CH2CI2 (40 mL) at RT for 40 minutes. The reaction mixture is concentrated in vacuo and the crude product is purifed by flash chromatography eluting with 1 % MeOH/CH, CI, to yield the title compound (1.1 g, 2.9 mmol) as a colorless oil. Ion spray MS, [M+H]'=379.

EXAMPLE (R or S)-dicarboxvlic acid 1-benzyl ester 3-methyl ester.

N, N-Dimethylaminopyridine (0.43 g, 3.5 mmol) and benzylchloroformate (0.55 g, 3.8 mmol) are added to a solution of methyl 6-oxopiperazine-2-carboxylate (0.50 g, 3.2 mmol) (Aebischer, B., Helv.

Chim. Acta 1989,72,1043-1051) in CH2C12 at RT. After I h, the reaction mixture is poured into EtOAc and washed with saturated NaHC03 and brine then dried over MgSO4, filtered and concentrated to dryness to give a solid (0.90 g, 3.1 mmol) which is used in subsequent reactions without further purification.'H NMR (CDCI 13,300 MHz) 5 7.40 (bs, 5 H), 6. 32 (bs, 1H), 5.15 (s, 2H), 4.00-4. 30 (m, 3H), 4.23 (s, 3H), 3.70-3.80 (m, 2H). MS (EI) m/z 292 (M+).

EXAMPLE 56. (S)-5-Oxo-piperazine-1, 3-dicarboxylic acid 1-allvl ester 3-methvl ester.

To a solution containing methyl (S)-6-oxopiperazine-2-carboxylate (1. 32 g, 8.35 mmol), prepared by the method of Aebischer, in anhydrous dichloromethane (30 mL) at 0 °C is added triethylamine (1.26 g, 12.5 mmol) followed by allylchloroformate (1.20 g, 10.0 mmol). After 1 h, the reaction mixture is poured onto a 1: 1 mixture of CH2CI2/water (200 mL), acidified using 1 N HCl and the layers are separated. The organic phase is washed with brine, dried over anhydrous Na, SO4, filtered and concentrated. The crude residue is chromatographed on silica gel (CFLCL to 1% MeOFUCH, C12) to provide 1.22 g (60%) of EXAMPLE 35 as a viscous oil.'H NMR (300 MHz, CDC13) 8 6.43 (bs, 1H), 5.90 (m, 1H), 5.26 (m, 2H), 4.61 (m, 2H), 4.05-4.26 (m, 3H), 3.80 (s, 3H), 3.72 (m, 2H); MS (ISP loop): m/z 243 (M+H).

EXAMPLE 57. (2S, 6R)-4- (2, 6-dimethvl)-3-oxo-piperazine-1-carboxylic acid benzvl ester. and EXAMPLE 58. (2S, 6S)-2.6-dimethvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

A. (2RS, 1S)- [I- (2-hvdroxv-propvlcarbamvl)-ethvll-carbamic acidtert-butyt ester N- (tert-Butoxycarbonyl)-L-alanine (10.0 g, 52.8 mmol) is dissolved in 150 mL of THF. Once the triethylamine (11.0 mi, 79.2 mmol) is added, the solution is cooled to 0°C. Isopropyl chloroformate in toluene (IM) (52.8 ml, 52.8 mmol) is added slowly followed by the addition of (2RS) I-amino-2- propanol (6.1 mi, 79.2 mmol). After stirring overnight, the mixture is washed with IN sodium hydroxide and IN hydrochloric acid. Concentration of the organic solvent afforded (2RS, IS)- [I- (2-hydroxy- propylcarbamyl)-ethyl]-carbamic acid tert-butyl ester (9.92 g, 76% yield) as a clear oil.

B. (IS)- I- (2-oxo-propvlcarbamovl)-ethvll-carbamic acid tertbuty) ester Dimethylsulfoxide (7.16 ml, 100.8 mmol) is added to a solution of oxalyl chloride (4.41 mi, 50.4 mmol) in 126 mL of methylene chloride at-78 °C. The mixture is left to stir for fifteen minutes, and a solution of (2RS, I S)- [I- (2-hydroxy-propylcarbamyl)-ethyl]-carbamic acid tert-butyl ester (9.92 g, 40. 32 mmol) in 100 mL of CH, C12 is added dropwise. After stirring for 15 minutes at-78 °C, the reaction is quenched with triethylamine (28 mL, 381 mmol), and the temperature is allowed to rise to room temperature. The volatile solvents are removed, and the residue is purified by flash column (SiO2,60% EtOAc/Hexane). The product (IS)- [1- (2-oxo-propylcarbamoyl)-ethyl]-carbamic acid tertbutyl ester (5.93 g, 60 %) is isolated as a white solid. MS C"H2oN204 MS m/z : 245.

C: (3S. 5RS)-3, 5-dimethvl-piperazin-2-one.

(IS)- [1- (2-oxo-propylcarbamoyl)-ethyl]-carbamic acid tertbutyl ester (5.93 g, 24.3 mmol) is stirred in a solution of 30 % trifluoroacetic acid in methylene chloride (100 mL) for three hours. The

solvents are removed in vacuo. The residue is dissolved in 50 mL of MeOH and transferred to a par bottle. Palladium on carbon (10 %, 1.0 g) is added, and the mixture is hydrogenated under pressure for 24 hours. The catalyst is filtered off; the MeOH is removed in vacuo to afford (3S, 5RS)-3,5-dimethyl- piperazin-2-one which is directly protected with a benzyl carbamate without further purification.

D: (2S. 6RS)-2,6-Dimethvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

To a solution of (3S, 5RS)-3,5-dimethyl-piperazin-2-one (24.3 mmol) in 100 mL of methylenechloride is added triethylamine (8.45 mL, 60.75 mmol) and N- (benzyloxycarbonyloxy) succinimide (12.1 g, 48.6 mmol). After stirring overnight, the CH, is removed, and the crude mixture is chromatographed (50 % EtOAc/Hexane). (2S, 6RS)-2,6-Dimethyl-3- oxo-piperazine-1-carboxylic acid benzyl ester (3.3 g, 52 % yield over three steps) is isolated as a white powder. MS C, 4H, 8N203 MS m/z: 263.

E. (2S. 6R)-2,6-dimethvl-3-oxo-piperazine-l-carboxvlic acid benzvl ester and (2S, 6S)-2.6-dimethvl-3- oxo-piperazine-I-carboxvlic acid benzvl ester The two single enantiomers [ (2S, 6R)-2,6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester and (2S, 6S)-2,6-dimethyl-3-oxo-piperazine-I-carboxylic acid benzyl ester] can be seperated by column chromatography from (2S, 6RS)-2,6-dimethyl-3-oxo-piperazine-I-carboxylic acid benzyl ester, which can also be used directly in combination or separation of its derivatives as shown below.

EXAMPLE 59. (2S, 6R)-4- (2, 4-Dimethoxv-benzyl)-2, 6-dimethvl-3-oxo-piperazine-l-carboxvlic acid benzvi ester.

A. (2S, 2S)-N-(2. 4-dimethoxv-benZvl)-N-(2-hydroxy-propel)-2-(22*2-trifluoroac etylamino) propionamide.

To a slurry of (2S)-2- (2,2,2-trifluoroacetylamino)-propionic acid (15.3 g, 53.4 mmol) in 120 mL of methylene chloride is added triethylamine (5.6 mL, 40.0 mmol). The heterogeneous mixture is cooled to 0°C and isopropyl chloroformate (27 mL, 27.0 mmol) is added slowly. After stirring for 20 minutes at room temperature, a solution of the (2S)-1- (2,4-dimethoxy-benzylamino)-propan-2-ol (6.0 g, 26.7 mmol, obtained from the reductive amination of the corresponding aldehyde and aminoalcohol) in 5mL of methylene chloride is added. The resulting mixture is left to stir overnight. Ethyl acetate (500 mL) is added, and the organic solution is washed with IN hydrochloric acid (50 mL) and IN sodium hydroxide (50 mL). The ethyl acetate is dried with magnesium sulfate, filtered and condensed. The resulting residue is chromatographed on silica gel (25% ethyl acetate/hexane) to give (2S, 2S)-N- (2,4-dimethoxy- benzyl)-N- (2-hydroxy-propyl)-2-(2,(2-hydroxy-propyl)-2-(2, 2,2-trifluoroacetylamino)-propionamide (6.29g, 60% yield) as a clear oil. MS C"H, 3F3N205 MS m/z: 393.

B. (3S. 5R)-1- (2, 4-dimethoxv-benzvl)-3, 5-dimeth, Yl-4-trifluoroacetvl-piperazin-2-one.

(2S, 2S)-N- (2, 4-Dimethoxy-benzyl)-N- (2-hydroxypropyl)-2- (2,2,2-trifluoroacetylamino)- propionamide (3.64 g, 9.29 mmol) is dissolved in 25 mL of tetrahydrofuran. Triphenylphosphate (3.65 g, 14.0 mmol) is added, and the resulting mixture is cooled to 0 °C before diethyl azodicarboxylate (2.2 mL, 14 mmol) is added slowly. The resulting mixture is left to stir overnight. The reaction mixture is condensed, and the residue is purified by column chromatography (SiO, 25% ethyl acetate/hexane). The desired product, (3S, 5R)-1- (2, 4-dimethoxy-benzyl)-3, 5-dimethyl-4-trifluoroacetyl-piperazin-2-one (1.5 g, 43% yield), is isolated as a clear oil.

C. 5R)-1-(2,4-Dimethoxy-benzyl)-3,5-dimethyl-piperazin-2-one.

(3S, 5R)-1- (2, 4-Dimethoxy-benzyl)-3, 5-dimethyl-4-trifluoroacetyl-piperazin-2-one (575 mg, 1.54 mmol) is dissolved in 30 mL of methanol and 3 mL of H, O. Potassium carbonate (883 mg, 6.4 mmol) is added to the solution, and the reaction is refluxed for one and half hours before concentration.

Ethyl acetate (3x 50 mL) is used to extract the aqueous layer. Removal of Ethyl acetate afforded the crude amine (387 mg, 91% yield) as a clear oil. C15H, 2N201 MS m/z: 279.

D. (2S, 6R)-4- (2, 4-dimethoxv-benzyl)-2, 6-dimethvl-3-oxo-piperazine-1-carboxvlic acid benzyl ester.

Triethylamine (0.4 mL, 2.8 mmol) and N- (benzyloxycarbonyloxy)-succinimide (1. 04 g, 4.2 mmol) is added to a solution of the above crude amine (387 mg, 1.4 mmol) in 15 mL of methylene chloride. The reaction mixture is left to stir overnight. The residue after concentration is chromatographed on silica gel (30% ethyl acetate/hexane) to give (2S, 6R)-4- (2, 4-dimethoxy-benzyl)- 2,6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (450 mg, 78 % yield) as a clear oil.

E. (2S, 6R)-2.6-Dimethvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

(2S, 6R)-4- (2, 4-Dimethoxy-benzyl)-2, 6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (1. 13 g, 2.74 mmol) is dissolved in 20 mL of acetonitrile. An aqueous solution of potassium persulfate (2.2 g, 8.23 mmol) and sodium phosphate (2.3 g, 16.5 mmol) in 12 mL of H, O is added, and the resulting mixture is heated to 95-100 °C for two hours. After cooling to room temperature, ethyl acetate (200 mL) is used to extract the aqueous layer and dried over magnesium sulfate. The residue after filtration and concentration is chromatographed (SiO,, 60% ethyl acetate/hexane) to give (2S, 6R)-2,6-Dimethyl- 3-oxo-piperazine-1-carboxylic acid benzyl ester (480 mg, 67 % yield) as a yellow oil.

EXAMPLE 60. (2S, 6RS)-4- (4-chloro-quinolin-7-ylmethvl)-2, 6-dimethvi-3-oxo-piperazine-1- carboxylic acid benzvl ester.

(2S, 6RS)-2,6-Dimethyl-3-oxo-piperazine-I-carboxylic acid benzyl ester (380 mg, 1.45 mmol) is dissolved in 10 mL of THF and ImL of DMF. Sodium hydride (60%, 72 mg, 3.14 mmol) is added at 0 °C and left to stir at room temperature for thirty minutes before 7-bromomethyl-4-chloro-quinoline (257 mg, 1.0 mmol) is added. The reaction is stirred for four hours. Ethyl acetate is added to the mixture, and the reaction is quenched with 3 mL of H, O. The two layers are separated and ethyl acetate (2x 30 ml) is used to extract before dried over magnesium sulfate. The residue after filtration and concentration is chromatographed on silica gel (60% EtOAc/Hexane) to give (2S, 6RS)-4- (4-chloro-quinolin-7- ylmethyl)-2,6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (417 mg, 95 % yield).C22H20ClN3O3MS m/z: 438,440.

EXAMPLE 61. (3S,5RS)-1-(4-chloro-quinolin-7-ylmethyl)-3,5-dimethyl-piper azin-2-one. and EXAMPLE 62. (3S, 5R)-I- (4-chloro-quinolin-7-vlmethyl)-3, 5-dimethvl-piperazin-2-one. and EXAMPLE 63 (3S. 5S)-1- (4-chloro-quinolin-7-vlmethvl)-3,5-dimethyl-piperazin-2-one.

(2S, 6RS)-4- (4-Chloro-quinolin-7-ylmethyl)-2, 6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (417 mg, 1.0 mmol) is taken up in 7 mL of acetonitrile, and iodotrimethyl-silane (0.43 mL, 3.0 mmol) is added. The resulting mixture is stirred for one hour at room temperature before quenched with methanol (I mL). The residue after concentration is taken up in 2N hydrochloric acid (3 mL) and is extracted with ether (2x 30 mL). The aqueous layer is condensed to dryness and the residue is recrystalized from isopropanol and ether to give a mixture (1: 4 ratio) of (3S, 5RS)-I- (4-chloro-quinolin- 7-ylmethyl)-3,5-dimethyl-piperazin-2-one as a yellow solid (290 mg). The two epimers are separated using a flash column (SiO2, 1% triethylamine/3% methanol/methylene chloride). C, 6H, 8CIN3O MS m/z: 304,306. The minor isomer (3S, 5R)-1- (4-chloro-quinolin-7-ylmethyl)-3, 5-dimethyl-piperazin-2-one. is (3S, 5R)-1- (4-chloro-quinolin-7-ylmethyl)-3, 5-dimethyl-piperazin-2-one while the major isomer is (3S, SS)-1- (4-chloro-quinolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one. Alternatively, (3S,5R)-1-(4- chloro-quinolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one and (3S, 5S)-I- (4-chloro-quinolin-7- ylmethyl)-3, 5-dimethyl-piperazin-2-one can be made via the same chemistry shown below from pure (2S, 6S)-2,6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester and (2S, 6RS)-4- (4-chloro- quinolin-7-ylmethyl)-2, 6-dimethyl-3-oxo-piperazine-l-carboxylic acid benzyl ester, respectively.

Alternative synthesis of (3S. 5R)-1- (4-chloro-quinolin-7-vlmethvl)-3, 5-dimethvl-piperazin-2-one.

A. (2S, 6R)-4- (4-chloro-quinolin-7-vlmethYl !-2. 6-dimethyl-3-oxo-piperazine-l-carboxylic acid benzvl ester.

(2S, 6R)-2,6-Dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (750 mg, 2.86 mmol) is dissolved in 20 mL of THF and 2 mL of DMF. Sodium hydride (60%, 142.6 mg, 6.20 mmol) is added at 0 °C, and the reaction is left to stir at room temperature for thirty minutes at which time the 7- bromomethyl-4-chloro-quinoline (952 mg, 3.72 mmol) is added. The reaction is complete after stirring for four hours. Ethyl acetate (200 mL) is added to the mixture, and the reaction is quenched with 3 mL of H, O. The two layers are separated, and ethyl acetate (2x 30 mL) is used to extract and dried over magnesium sulfate. The residue after filtration and concentration is chromatographed on silica gel (60% EtOAc/Hexane) to give (2S, 6R)-4- (4-chloro-quinolin-7-ylmethyl)-2, 6-dimethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester (1. 04 g, 83 %).

B. (3S. 5R)-1- (4-chloro-quinolin-7-vlmethyl)-3. 5-dimethyl-piperazin-2-one.

A 33 % solution of hydrogen bromide in acetic acid (10 mL) is added to (2S, 6R)-4- (4-chloro- quinolin-7-ylmethyl)-2,6-dimethyl-3-oxo-piperazine-1-carboxy lic acid benzyl ester (1.04 g, 2. 38 mmol).

The reaction is left to stir at room temperature for one hour. The reaction mixture is diluted with ethyl acetate and stirred vigorously to force the product to precipitate out of solution. The ethyl acetate is decanted off and the precipitate is purified on a silica gel column (I % triethylamine/3 % methanol/methylene chloride) to 582 mg (81% yield) of (3S, 5R)-1- (4-chloro-quinolin-7-ylmethyl)-3,5- dimethyl-piperazin-2-one as a white solid.

EXAMPLE 64. (3S, 5S)-I- (4-chloro-quinolin-7-vlmethly)-4-r3- (5-chloro-thiophen-2-vl)-allvll-3,5- dimethvl-piperazine-2-one. and EXAMPLE 65. (3S, 5R)-I- (4-chloro-quinolin-7-vlmethlv)-4-f3- (5-chloro-thiophen-2-yl)-allyll-3,5- dimethvl-piperazine-2-one.

The crude (3S, 5RS)-1- (4-chloro-quinolin-7-ylmethyl)-3, 5-dimethyl-piperazin-2-one (69 mg, 0.20 mmol) obtained from above is dissolved in 1 mL of DMF. Potassium carbonate (76 mg, 0.60 mmol) is added followed by the addition of 2- (3-bromopropenyl)-5-chloro-thiophene (56 mg, 0.24 mmol). The reaction is left to stir overnight. The potassium carbonate is filtered off, and the crude material is purified. The two epimers are separated at this stage by preparative thin layer chromatography (80 % EtOAc/hexane) to give a major epimer (3S, 5R)-1- (4-chloro-quinolin-7- ylmethly)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3, 5-dimethyl-piperazine-2-one (25 mg, 26% yield) and a minor epimer (3S, 5S)-I- (4-chloro-quinolin-7-ylmethly)-4- [3- (5-chloro-thiophen-2-yl)-allyl]-3,5- dimethyl-piperazine-2-one (7 mg, 7.5% yield).

EXAMPLE 66.4- (2-Oxopiperazin-l-yimethvi) benzamidine.

A. 4- (4-Cyanobenzvl)-3-oxopinerazine-I-carboxvlic acid benzyl ester.

To a solution of 3-oxo-piperazine-1-carboxylic acid benzyl ester (3.0 g, 12.8 mmol) and 4- bromomethyl tolylnitrile (2.76 g, 14.1 mmol) in 135 mL of THF and 15 mL of DMF at 0°C is added a 60% dispersion in mineral oil of NaH (0.49 g, 12.8 mmol). After 5 hours, the solution is diluted with saturated NH4CI and EtOAc. The organic layer is washed with HO and saturated NaCI. The organic layer is dried over MgSO4, filtered and concentrated. The crude product is purified by column chromatography over silcia gel eluting with 20% EtOAc/CH2CI,. The title compound is obtained as a <BR> <BR> <BR> <BR> white solid (4.01 g, 11.4 mmol).'H NMR (CDCI3, 300MHz) 6 7.62 (d, 2H), 7. 39 (m, 7H), 5.14 (s, 2H), 4.68 (s, 2H), 4.27 (s, 2H), 3.73 (m, 2H), 3. 30 (m, 2H).

B. 4- 4-Carbamimidovlbenzyl)-3-oxo-piperazine-1-carboxylic acid benzvl ester.

A solution of 4- (4-cyanobenzyl)-3-oxopiperazine-I-carboxylic acid benzyl ester (2.4 g, 6.87 mmol) in 30mL of pyridine and 3 ml of Et3N is saturated with H, S. The resulting mixture is sealed and stirred for 16 hours. After this time, the solution is concentrated. The residue is dissolved in 30 mL of acetone and methyl iodide (19.4 g, 137 mmol) is added. The solution is refluxed for 2 hours. After this time, the solution is concentrated. The residue is dissolved in MeOH (40 mL) and NH40Ac (5.0 g, 65 mol) is added. The solution is reluxed for 3 hours. After this time, the solution is concentrated. The crude product is purified by RP-HPLC eluting in a gradient of CH3CN to 60% CH3CN/H2O (0. 1 % TFA).

The appropriate collected fractions are lyophilized to give the product as a white foam. MS (FAB) m/z 367, (M+H).

C.4 (2-Oxopiperazin-1-vlmethyl) benzamidine.

To a solution of 4- (4-carbamimidoylbenzyl)-3-oxopiperazine-I-carboxylic acid benzyl ester (2.0 g, 5.0 mmol) in 40 mL of MeOH and 4 mL of AcOH is added 10% Pd/C (0.4 g). The atmosphere above the reaction is replaced by hydrogen. After 4hours, the solution is filtered through a pad of Celite. The organic layer is concentrated. The resulting crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0. 1% TFA) to 40% CH3CN/H2O (0.1% TFA). The title compound is obtained as a white foam.'H NMR (d'-DMSO, 300 MHz) 8 9.3 (bs, 4H), 9.1 (bs, 2H), 7.83 (d, 2H), 7.42 (d, 2H), 4.78 (s, 2H), 3.80 (s, 2H), 3.44 (m, 2H), 3. 32 (m, 2H).

EXAMPLE 67.1-(2-Aminoquinolin-6-vlmethvl) piperazin-2-one.

A. 4- (2-Chloro-quinolin-6-vlmethvl)-3-oxo-piperazine-1-carboxvlic acid benzyl ester.

To a solution of 3-oxopiperazine-1-carboxylic acid benzyl ester (4.65 g, 19.8 mmol) and 6- bromomethyl-2-chloroquinoline (5.40 g, 21.0 mmol) in 80 mL of a 3: 1 mixture of THF: DMF at 0°C is added sodium hydride (0.81 g, 20.2 mmol, 60% mineral oil dispersion). The resulting mixture is stirred for 1 hour at 0°C then at room temperature for 18 hours. The reaction mixture is quenched with saturated NH4CI solution, then diluted with EtOAc. The organic layer is washed sequentially with IN HCI, water, saturated NaHC03 and saturated NaCI, then dried over MgSO4, filtered and concentrated.

The crude product is triturated in Et, O/hexanes/EtOAc and filtered to afford the title compound (6.96 g, 17.0 mmol) as a white solid. 'HNMR (CDC13, 300 MHz) 8 8.08 (d, I H), 8.00 (d, I H), 7.69 (s, I H), 7.63 (dd, 1H), 7.41 (d, IH), 7. 35 (s, 5H), 5.15 (s, 2H), 4.78 (s, 2H), 4.28 (s, 2H), 3.70 (m, 2H), 3. 32 (bs, 2H).

B. 4- (2-Phenoxvquinolin-6-vlmethvl)-3-oxopiperazine-1-carboxvlic acid benzyl ester.

A mixture of phenol (15.1 g, 160 mmol) and 4-(2-chloroquinolin-6-ylmethyl)-3-oxopiperazine- 1-carboxylic acid benzyl ester (6.60 g, 16.1 mmol) is melted together at 70°C until a homogeneous mixture is obtained. Potassium hydroxide (3.15 g, 56.1 mmol) is added and the resulting mixture is heated overnight at 120°C. After 24 hours, the brown/black residue is cooled to room temperature, diluted with CH2C12 and stirred with IN NaOH (100 mL) for 30 minutes. The two layers are separated and the aqueous layer is extracted with CH, C1,. The combined organic layers are washed with IN NaOH, saturated NaCI, dried over Na2SO4, filtered and concentrated. The crude title compound (6.92 g, 14.8 mmol) is obtained as a beige foam and used in the subsequent step without further purification. <BR> <BR> <BR> <BR> <P>'H NMR (CDCI3,300 MHz) 5 8.07 (d, 1H), 7.76 (d, 1H), 7.63 (s, 1H), 7.50 (dd, 1H), 7.42 (m, 2H), 7. 34 (m, 6H), 7.25 (m, 2), 7.09 (d, 1H), 5.14 (s, 2), 4.75 (s, 2H), 4.27 (s, 2H), 3.66 (m, 2H), 3. 30 (bs, 2H).

C. 4- (2-Aminoquinolin-6-vlmethyl)-3-oxopiperazine-1-carboxvlic acid benzvl ester A mixture of ammonium acetate (18.7 g, 242 mmol) and 4-(2-phenoxyquinolin-6-ylmethyl)-3- oxopiperazine-I-carboxylic acid benzyl ester (6.92 g, 14.8 mmol) is heated overnight at 150°C. After 21 hours, an additional 3 g of ammonium acetate is added and the heating is continued. After 5 hours, the mixture is cooled to room temperature, diluted with CH, CL, and stirred with IN NaOH (100 mL) for 30 minutes. The two layers are separated and the aqueous layer is extracted with CH, CI,. The combined organic layers are washed with IN NaOH, saturated NaCI, dried over Na, S04, filtered and concentrated.

The crude mixture of the title compounds (5.50 g, 14.1 mmol) is obtained as a beige foam and used in the subsequent step without further purification.

Major component (4-(2-aminoquinolin-6-ylmethyl)-3-oxopiperazine-1-carboxylic acid benzyl ester):'H NMR (CDC13,300 MHz) 8 7.86 (d, 1H), 7.63 (d, IH), 7.48 (d, 1H), 7.45 (d, 1H), 7. 35 (s, 5H), 6.74 (d, IH), 5.14 (s, 2H), 4.79 (bs, 2H), 4.71 (s, 2H), 4.26 (s, 2H), 3.66 (s, 2H), 3. 30 (s, 2H).

Minor component (3-oxo-4-(2-oxo-1, 2-dihydroquinolin-6-ylmethyl) piperazine-1-carboxylic acid benzyl ester):'H NMR (CDCl3, 300 MHz) 8 7.75 (d, 1H), 7.48 (m, 2H), 7. 37 (m, 6H), 6.70 (d, 1H), 5.14 (s, 2H), 4.66 (s, 2H), 4.26 (s, 2H), 3.66 (s, 2H), 3. 30 (s, 2H).

D. 1- (2-Aminoquinolin-6-vlmethvl)(2-Aminoquinolin-6-vlmethvl) piperazin-2-one.

To a solution of a mixture of 4-(2-aminoquinolin-6-ylmethyl)-3-oxopiperazine-1-carboxylic acid benzyl ester and 3-oxo-4- (2-oxo-1,2-dihydro-quinolin-6-ylmethyl) piperazine-1-carboxylic acid benzyl ester (5.50 g, 14.1 mmol) in 100 mL of 10: 1 MeOH/HOAc is added a catalytic amount of 10% palladium on activated carbon. The heterogenous mixture is hydrogenated at room temperature under a balloon of H, for 18 hours. The reaction mixture is filtered through a pad of Celite, washed with MeOH, and the filtrate is concentrated in vacuo. The crude mixture of products is purified by RP-HPLC eluting in a gradient of 2% CH, CN/H, O (0.1 % TFA) to 20% CH3CN/H2O (0. 1% TFA) and the appropriate product fractions are concentrated in vacuo to provide 1-(2-aminoquinolin-6-ylmethyl)-piperazin-2-one ditrifluoroacetate (2.64 g, 5.45 mmol) as the major product in the form of a white solid.'H NMR (d6- DMSO, 300 MHz) 8 8.78 (bs, 2H), 8.31 (d, 1H), 7.80 (s, 1H), 7.66 (m, 2H), 7.08 (d, 1H), 4.70 (s, 2H), 3.84 (s, 2H), 3.46 (bs, 4H). MS m/z 256, [M+]. Elemental analysis calculated with 0. 25 mol of H2O cal.

C=44.25%, H=3.82%, N=11.47%, found C=44.23%, H=3.76%, N=11.23%.

The minor by-product 6- (2-oxo-piperazin-1-ylmethyl)-lH-quinolin-2-one (0. 62 g, 1.28 mmol) is also <BR> <BR> <BR> isolated from the RP-HPLC separation as a white solid'H NMR (d'-DMSO, 300 MHz) 8 11.76 (bs, 1H), 9.30 (bs, 2H), 7.85 (d, 1H), 7.55 (s, 1H), 7.42 (d, 1H), 7.28 (d, 1H), 6.50 (d, 1H), 4.60 (s, 2H), 3.80 (s, 2H), 3. 38 (bs, 4H). MS m/z 257, [M+]. Elemental analysis calculated with 0.5 mol of H2O cal.

C=43.72%, H=3.68%, N=8.50%, found C=43.70%, H=3.62%, N=8. 61%.

EX MPLE 68. I-(I-Aminoisoquinolin-6-vlmethvl ! pinerazin-2-one.

The title compound is prepared as described in EXAMPLE 67 substituting 6-bromomethyl-1- chloroisoquinoline for bromomethyl-2-chloroquinoline.'H NMR (d6-DMSO, 300 MHz) 8 (9.18 (bs, 2H), 8.53 (d, 1H), 7.81 (s, 1H), 7.63 (m, 2H), 7.14 (d, 1H), 4.77 (s, 2H), 3.88 (s, 2H), 3.50 (m, 4H).

EXAMPLE 69.2- (2-Oxopiperazin-l-vlmethvl) pvrrolof3, 2-clpvridin-1-carboxvlic acid tert-butvl ester.

A.3-lodopyridin-4vlamine.

A solution of potassium iodide (19. 48 g, 117.4 mmol) and iodine (18.37 g, 72.3 mmol) in water (77 mL) is added dropwise via an addition funnel to a refluxing solution of 4-aminopyridine (9.21 g, 97.8 mmol) and sodium carbonate (6.12 g, 57.7 mmol) in water (35 mL). Upon complete addition the mixture is stirred for 2 hours at reflux then cooled to room temperature and extracted with ethyl acetate. The combined organic layers are washed with saturated sodium thiosulfate solution (3x) and brine then dried

over MgS04, filtered and concentrated to give the title product (8. 37 g, 38.0 mmol) and a trace of the di- iodo compound as an yellow/orange solid. This material is used in the subsequent step without further purification.'HNMR (CDC13, 300 MHz) 8 8.70 (s, IH), 8.10 (d, IH), 6.55 (d, 1H), 4.60 (bs, 2H).

B. (3-lodopvridin-4-vl)-carbamic acid tert-butvl ester.

Di-tert-butyl dicarbonate (20.7 g, 94.8 mmol) is added to a solution of 3-iodopyridin-4-ylamine (19.0 g, 86.4 mmol) in THF (86 mL). The resulting solution is stirred for 2 hours at room temperature then concentrated. The residue is diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and brine. The organic layer is dried over MgSO, filtered and concentrated. The residue is purified by column chromatography eluting with 1% EtOAc/CH2CI2 to give the title product and a small amount of the BOC-protected di-iodo compound. Trituration of the mixture with ether/hexane removes the undesired compound leaving the title product in the solution. Filtration of the solid and concentration of the filtrate yields the title product (18.95 g, 59.2 mmol).'H NMR (CDCI3, 300 MHz) 8 8.75 (s, IH), 8. 35 (d, 1H), 8.1 (d, 1H), 7.0 (bs, IH), 1.55 (s, 9H).

C. 3-Oxo-4-prop-2-vnvlpiperazine-1-carboxvlic acid benzvl ester.

Sodium hydride (0.82 g, 23.0 mmol, 60% mineral oil dispersion) is added to a solution of 4- benzyloxycarbonylpiperazin-2-one (5.13 g, 21.9 mmol) in THF/DMF (75 mL, 3/1 v/v) at 0°C. The mixture is stirred for 5 minutes, then propargyl bromide (3.7 mL, 41.5 mmol) is added dropwise. The resulting solution is stirred for 1 hour then brought to room temperature and stirred for 2 hours. The reaction is quenched with saturated ammonium chloride solution then diluted with ethyl acetate and washed with water (4x) and brine. The organic layer is dried over MgS04, filtered and concentrated to dryness. The residue is purified by column chromatography eluting with 5% MeOR/CH, Cl, to give the product (5.96 g, 21.9 mmol) as a white solid. 'H NMR (CDC13,300 MHz) 8 7.3 (m, 5H), 5.12 (s, 2H), 4.25 (s, 2H), 4.16 (s, 2H), 3.75 (m, 2H), 3.47 (m, 2H), 2.22 (s, I H). <BR> <BR> <BR> <BR> <BR> <BR> <P>D. 2- (4-Benzvloxvcarbonyi-2-oxopiperazin-1-ylmethvl pvrrolo3, 2-clpvridin-1-carboxylic acid tert-<BR> <BR> <BR> <BR> <BR> butvl ester.

Pd (PPh3) 2CI2 (0.29 g, 0.41 mmol), Cul (0.05 g, 0. 25 mmol) and triethylamine (4.6 mL, 32.9 mmol) is added to a solution of 3-oxo-4-prop-2-ynylpiperazine-1-carboxylic acid benzyl ester (2.24 g, 8.23 mmol) and (3-iodopyridin-4-yl)-carbamic acid tert-butyl ester (2.63 g, 8.23 mmol) in DMF (30 mL) at room temperature. The mixture is heated to 100°C and stirred for 1.5 hours. The reaction mixture is then cooled to 50°C and DBU (2.5 mL, 16.5 mmol) is added. After 30 minutes the solution is cooled to room temperature, diluted with ethyl acetate and washed with saturated ammonium chloride, water and brine. The organic layer is dried over MgS04, filtered and concentrated in vacuo. The resulting solid is

purified by column chromatography eluting with a gradient of 2% MeOH/CH2CI2to 5% MeOH/CH, Clto give the product (2.93 g, 6. 31 mmol) as a white solid.'H NMR (CDCl3, 300 MHz) 8 8.75 (s, 1H), 8.4 (d, IH), 7.85 (d, IH), 7.35 (m, 5H), 6.38 (s, IH), 5.2 (s, 2H), 5.00 (s, 2H), 4.29 (s, 2H), 3.85 (m, 2H), 3.52 (m, 2H), 1.7 (s, 9H). Ion spray MS, [M+H] += 465.

E. 2- (2-Oxopiperazin-l-ylmethvl) pvrrolof3, 2-clpvridin-l-carboxylic acid tert-butvl ester.

Palladium black (1.1 g, 10.3 mmol) is added to a solution of 2- (4-benzyloxycarbonyl-2-oxo- piperazin-I-ylmethyl) pyrrolo [3,2-c] pyridin-I-carboxylic acid tert-butyl ester (1.7 g, 3.7 mmol) in HCO, H/MeOH (45 mL, 4.4% solution). After 40 minutes the catalyst is filtered through Celite and washed with MeOH. The filtrate is concentrated in vacuo to remove methanol then the resulting solution is diluted with methylene chloride and washed with saturated sodium bicarbonate, and brine. The organic layer is dried over MgSO4, filtered and concentrated to dryness. The resulting solid is purified by column chromatography eluting with a gradient of 5% MeOH/CH2CI2 to 10% MeOH/CH2CI2 to give the product (0.8 g, 2.5 mmol) as a pale yellow foamy solid.'H NMR (CDCI3,300 MHz) 8 8.78 (s, 1H), 8.40 (d, 1H), 7.9 (d, 1H), 6.48 (s, 1H), 4.98 (s, 2H), 3.7 (s, 2H), 3.51 (t, 2H), 3.40 (t, 2H), 1.91 (bs, 1H), 1.70 (s, 9H).

EXAMPLE 70.2- (5- ()-Methoxvcarbonvl-2-oxo-piperazin-1-vlmethvl)-pvrrolo (3, 2-clpvridine-1- carboxylic acid tert-butvl ester.

A. 2-Benzvloxvcarbonviamino-3- (prop-2-vnvlamino)-propionic acid methyl ester.

Propargyl bromide (1.6 mL, 14.4 mmol) is added to a solution of 3-amino-2- benzyloxycarbonylamino-propionic acid methyl ester hydrochloride (4.0 g, 13.9 mmol) and triethylamine (4.1 mL, 29.4 mmol) in THF (46 mL). The resulting mixture is heated to 50°C and stirred overnight then cooled to RT and concentrated in vacuo. The crude residue is diluted with methylene chloride, washed with saturated NaHC03 and brine then the organic layer is dried over MgSO4, filtered and concentrated in vacuo. The crude material (4.0 g) is taken on to the subsequent step without further purification.'H NMR (CDC13,300 MHz) 8 7.25-7. 30 (m, 5H), 5.75 (bs, IH), 5.20 (s, 2H), 4.45 (bs, 1H), 3.80 (s, 3H), 3.75 (m, 1H), 3. 31 (s, 2H), 3.08 (dd, 1H), 2.98 (dd, IH), 2.20 (t, 1H). El MS, [M+H] +=291.

B. 2-Benzvloxvcarbonylamino-3- (bromoactvl-prop-2-vnvl-amino)-propionic acid methyl ester.

DCC (2.27 g, 11.0 mmol) and bromoacetic acid (1.48 g, 10.7 mmol) is added to a solution of 2- benzyloxycarbonylamino-3- (prop-2-ynylamino)-propionic acid methyl ester (3.10 g, 10.7 mmol) in CH, CL, at RT. The mixture is stirred overnight then diluted with ether. The white solid which precipitates out is filtered and the filtrate is concentrated to give a yellow oil. The crude product is

purified by chromatography eluting with a gradient of 40% EtOAc/hexanes to 50% EtOAc/hexanes to yield the title product (2. 1g, 5.12 mmol) as an oil. 'H NMR (CDCI3,300 MHz) 8 7. 30 (m, 5H), 5.70 (d, 1H), 5.10 (s, 2H), 4.63 (m, 1H), 4.15 (d, 2H), 4.00 (m, 1H), 3.80 (s, 3H), 3.75 (s, 2H), 3.70 (dd, 1H), 2.27 (bs, 1H). Ion spray MS, [M+H]+=411, 413, Br pattern.

C. 5-Oxo-4-prop-2-vnvl-piperazine-1, 2-dicarboxvlic acid 1-benzyl ester 2-methvl ester.

Sodium hydride (0.20 mg, 4.9 mmol) is added to a solution of 2-benzyloxycarbonylamino-3- (bromoactyl-prop-2-ynyl-amino)-propionic acid methyl ester (2.0 g, 4.8 mmol) in THF (50 mL) at 0°C.

The solution is stirred for 40 minutes then quenched with saturated NH4CI solution. The reaction mixture is concentrated in vacuo then diluted with CH, CI, and washed with brine. The organic layer is dried over, filtered and concentrated in vacuo. The crude product is purified by chromatography eluting with 50% EtOAc/hexanes to give the title product (1.4 g, 4.1 mmol).'H NMR (CDCl3, 300 MHz) 8 7. 30 (m, 5H), 5.20 (s, 2H), 5.10 (m, 1H), 4.30 (dd, 1H), 4.25 (d, 2H), 4.08 (m, 1H), 4.00 (dd, 1H), 3.78 (dd, 1H), 3.78 (s, 3H), 2.25 (t, 1H).

D. 2- (5- ()-Methoxvcarbonyl-2-oxo-piperazin-1-vlmethvl)-pyrrolof3, 2-clpvridine-l-carboxvlic acid tert-butylester.

'H NMR (CDC13,300 MHz) 8 8.75 (s, 1H), 8.41 (d, 1H), 7.90 (d, 1H), 6.42 (s, 1H), 5.00 (AB, 2H), 3.85-3.93 (m, 2H), 3.78 (s, 3H), 3.70-3.81 (m, 3H), 1.65 (s, 9H). Ion spray MS, [M+H]-=389.

EXAMPLE 71.2- (2- ()-Methoxycarvl-6-oxo-piperazin-1-vlmethvl)-pvrrolo (3, 2-clpyridine-1- carboxylic acid tert-bityl ester.

'H NMR (CDCl3, 300 MHz) 8 8.81 (s, I H), 8.43 (d, 1 H), 7.90 (d, 1 H), 6.48 (s, 1 H), 5.63 (d, 1 H), 4.40 (d, 1H), 4.20 (m, 1H), 3.78 (s, 3H), 3.70 (d, 1H), 3.52 (d, 1H), 3.33 (dd, 1H), 2.92 (s, 1H), 1.55 (s, 9H). Ion spray MS, [M+H] +=389.

EXAMPLE 72.1-(4-Aminoauinazoline-7-vlmethyl) piPerazine-2-one.

A. 4- (4-Chloroquinazoline-7-vlmethyl)-3-oxopiperazine-l-carboxyli c acid tert-butvl ester.

To a solution of 3-oxopiperazine-1-carboxylic acid tert-butyl ester (3.93 g, 19.6 mmol) and 7- bromomethyl-4-chloroquinazoline, EXAMPLE 7, (5.0 g, 19.6 mmol) in 150 mL of THF and 15 mL of DMF at 0°C is added a 60% dispersion in mineral oil of NaH (0.79 g, 19.6 mmol). The solution is stirred at 0°C for 0.5 hours and then is allowed to warm to ambient temperature. After 4 hours, the solution is poured into a saturated solution of NH4CI. The layers are separated and the organic layer is washed with

H20, and saturated NaCI, dried over MgSO4, filtered and concentrated. The title compound is obtained as a white solid (5.1 g, 13.4 mmol). MS (FAB) m/z 377,379, (M+H), chlorine pattern.

B. 4-(4-Aminoquinazoline-7-vlmethel-3-oxopiperazine-1-carboxYli c acid tert-butyl ester.

A solution of 4- (4-chloroquinazoline-7-ylmethyl)-3-oxopiperazine-1-carboxyli c acid tert-butyl ester (1.84 g, 4.9 mmol) in 120 mL of ethanol is saturated with NH3 gas. To the resulting solution is added acetic acid (0.03 mL). The solution is heated to reflux. After 16 hours, the solution is concentrated. The resulting solid is dissolved in CH, CL, and the inorganic salts are filtered off. The organic solution is concentrated. The resulting solid is triturated with EtOAc. The title compound is obtained a a white solid (1.59 g, 4.5 mmol). MS (FAB) m/z 356, (M+H).

C. 1- (4-Aminoquinazoline-7-ylmethyl) piperazine-2-one.

A solution of 4- (4-aminoquinazoline-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c acid tert-butyl ester (1.92 g, 5.4 mmol) in EtOAc (200 mL) at 0 °C is saturated with HCI gas. The solution is stirred at 0°C for 4 hours. After this time, the solution is concentrated. The title compound is obtained as a white solid (1. 79 g, 5.4 mmol).'H NMR (d6-DMSO, 300 MHz) S 9.9 (bs, 3H), 9.7 (bs, 2H), 8.8 (s, 1H), 8.46 (d, 1H), 7.72 (s, 1H), 7.61 (d, 1H), 4.78 (s, 2H), 3.83 (s, 2H), 3.4 (m, 4H).

Example 73.1- (4-Amino-thienof2, 3-dlpvrimidin-6-vlmethvl)-piperazin-2-one.

A. 1- (4-Amino-thienor2*3-dlpyrimidin-6-vlmethyl)-3-oxo-piperazine -1-carboXvlic acid tert-butyl ester.

The title compound is prepared as described in EXAMPLE 72, Part A, substituting 6- bromomethyl-4-chlorothieno [2,3-d] pyrimidine. for 7-bromomethyl-4-chloroquinazoline. Followed by treatment as described in EXAMPLE 72, Part B, the title compound is obtained.'H NMR (CD30D, 300 MHz) 8 8.22 (s, 1H), 7.35 (s, 1H), 5.48 (s, 2H), 4.10 (s, 2H), 3.60 (m, 2H), 3.40 (m, 2H), 1.45 (s, 9H).

MS (ion spray), 364, (M+H).

B.!- (4-Amino-thienor2, 3-d1pvrimidin-6-vlmethy))-piperazin-2-one.

The title compound is obtained by treatment of I- (4-amino-thieno [2,3-d] pyrimidin-6-ylmethyl)- 3-oxo-piperazine-1-carboxylic acid tert-butyl ester as described in EXAMPLE 72, Part C. MS (EI), 2634, (M+).

EXAMPLE 72. 4-f3- (2-Oxo-piperazin-1-vl)-propyll-piperidine-I-carboxvlic acid tert-butvl ester.

A. 4-I3- (l-tert-butoxvcarbonvl-piperidin-4-vl)-propvll-3-oxo-piperaz ine-I-carboxvlic acid benzyl ester.

The title compound is prepared as described in EXAMPLE 72, Part A, substituting 3- oxopiperazine-1-carboxylic acid benzyl ester for 3-oxopiperazine-1-carboxylic acid tert-butyl ester and 4- (3-bromopropyl)-piperidine-1-carboxylic acid tert-butyl ester for 7-bromomethyl-4-chloroquinazoline.

The title compound is obtained as a white foam. 1H NMR (CDCl3, 300MHz) # 7. 38 (m, 5H), 5.12 (s, 2H), 4.18 (m, 4H), 3.73 (m, 2H), 3. 33 (m, 4H), 2.66 (m, 2H), 1.58 (m, 6H), 1.42 (s, 9H), 1.38 (m, 3H).

B. 4-r3- (2-Oxo-piperazin-l-vl)-propyll-piperidine-l-carboxvlic acid tert-butyl ester.

4- [3- (1-tert-butoxycarbonyl-piperidin-4-yl)-propyl]-3-oxo-piperaz ine-1-carboxylic acid benzyl ester is treated as described in EXAMPLE 67, Part D, to give the title compound as an oil.

EXAMPLE 75.1- (4-Amino-quinazoline-7-ylmethyl)-3-methoxymethvl-piperazine- 2-one.

A. 2-Methoxymethvl-3-oxo-piperazine-1-carboxvlic acid benzvl ester.

To a solution of 2-oxo-3- (S)-methoxymethylpiperidine (5. 36g, 19.3mmol), EXAMPLE 41, in 200mL of 10: 1 THF: DMF is added 2- (benzhydrylidene-amino)-4-bromomethyl-benzonitrile (12.6g, 60% purity, 19. 3mmol), prepared as in EXAMPLE 13. The solution is cooled to 0°C. To the solution is added NaH (0.77g of a 60% dispersion in mineral oil, 19. 3mmol). The solution is stirred for 16 hours.

After this time, 1N HCl is added until the pH=1. The solution is stirred for 1 hour. After this time, the solution is diluted with EtOAc. The organic layer is washed with water and sat. NaCI. The organic layer is dried over MgSO4, filtered and concentrated under vacuum. The resulting crude product is purified by column chromatography eluting with a gradient of 20%EtOAc/CH2Cl2 to 40% EtOAc/CH2CL. The title compound (6.8g, 16.7mmol) is obtained as a white solid.'H NMR (CDC1,, 300MHz) 8 734 (m, 5H), 6.61 (m, 2H), 5.13 (AB, 2H), 4.76 (m, IH), 4.40 (AB, 2H), 4.08 (m, 5H), 3.74 (m, 2H), 3.32 (m, 1H), 3.30 (s, 3H), 3.10 (m, 1H).

B. 4- (4-Amino-quinazolin-7-vlmethyl)-2-methoxymethyl-3-oxo-pipera zine-1-carboxvlic acid benzvl ester.

To a solution of 2-methoxymethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (6.8g, 16.7mmol) in 100mL of ethanol is added triazine (2.2g, 26.4mmol) and acetic acid (1.6g, 26.4mmol).

The solution is heated to a reflux. After 36h, the solution is concentrated. The resulting crude product is purified by column chromatography eluting with a gradient of 2% MeOH/CHZCI, to 5% MeOH/CH2CI2.

The title compound (5.8g, 13. 3mmol) is obtained as a white solid.'H NMR (CDCI3, 300MHz) â 8.55 (s, 1H), 7.72 (m, 2H), 7.48 (m, 1H), 7.35 (m, 5H), 6.40 (bs, 2H), 5.16 (AB, 2H), 5.06 (m, 1H), 4.72 (m, IH), 4.59 (m, 1H), 4.09 (m, 2H), 3.74 (m, 2H), 3.44 (m, 1H), 3.30 (s, 3H), 3.12 (m, IH). MS (ion spray) m/z 436, (M+H).

C. 1- (4-Amino-quinazoline-7-vlmethyl)-3-methoxymethyl-piperazine- 2-one.

To a solution of 2-methoxymethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (5.8g, 13.3mmol) in 50mL of acetic acid is added dropwise, 20mL of a 30% HBr in AcOH solution. The solution is stirred for 1 hour. After this time, the solution is concentrated. The resulting crude product is purified by column chromatography eluting with CH, CI, : MeOH : NH4OH (20: 5: 1). The title compound (2.0g, 6.6mmol) is obtained as a white solid. 1H NMR (d6-DMSO, 300MHz) # 8. 60 (s, 1H), 7.72 (m, 2H), 7.48 (d, 1H), 5.60 (bs, 2H), 4.72 (AB, 2H), 3.87 (m, 2H), 3.71 (m, 1H), 3,42 (m, 1H), 3.40 (s, 3H), 3.19 (m, 2H), 3.02 (m, 1H), MS (ion spray) m/z 302, (M+H).

EXAMPLE 76.1- (4-Aminoquinazoline-7-vlmethyl)-3-butyl-pperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-butyl-3-oxo- piperazine-1-carboxylic acid benzyl ester, Example 42, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'H NMR (CD30D, 300MHz) â 8.35 (s, 1H), 8.09 (d, 1H), 7.54 (s, 1H), 7.41 (d, 1H), 4.74 (s, 2H), 3.43 (m, 2H), 3.28 (m, 1H), 3.09 (m, 1H), 2.95 (m, 1H), 1.92 (m, 1H), 1.70 (m, 1H), 1.39 (m, 4H), 0.93 (m, 3H). MS (ion spray) m/z 314, (M+H).

EXAMPLE 77.1- (4-Aminoquinazoline-7-vlmethyl)-3-ethvl-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-ethyl-3-oxo- piperazine-1-carboxylic acid benzyl ester r, Example 43, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester.'H NMR (CD30D, 300MHz) 88. 36 (s, 1H), 8.11 (d, 1H), 7.57 (s, 1H), 7.42 (d, 1H), 4.78 (s, 2H), 3.40 (m, 2H), 3.29 (m, 1H), 3.11 (m, 1H), 2.98 (m, 1H), 2.00 (m, 1H), 1.77 (m, 1H), 1.20 (m, 3H). MS (ion spray) m/z 286, (M+H).

EXAMPLE 78.1- (4-Aminoquinazoline-7-vlmethyl)-3-propyl-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-propyl-3-oxo- piperazine-1-carboxylic acid benzyl ester, Example 44, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'H NMR (CD30D, 300MHz) ã 8.36 (s, 1H), 8.13 (d, 1H), 7.60 (s, 1H), 7.47 (d, 1H), 4.78 (s, 2H), 3.44 (m, 2H), 3.30 (m, 1H), 3.11 (m, 1H), 2.97 (m, 1H), 1.98 (m, 1H), 1.72 (m, 1H), 1.50 (m, 2H), 0.97 (m, 3H). MS (ion spray) m/z 300, (M+H).

EXAMPLE 79.1- (4-Amino-quinazoline-7-ylmethvl)-3-ethoxvmethyl-piperazine-2 -one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-ethoxymethyl-3- oxo-piperazine-1-carboxylic acid benzyl ester, Example 45, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'HNMR (CD30D, 30OMHz) 88. 34 (s, 1H), 8.07 (d, 1H), 7.53 (s, 1H),

7.40 (d, 1H), 4.79 (AB, 2H), 3.90 (m, 1H), 3.72 (m, IH), 3.68 (m, 1H), 3.52 (m, 2H), 3.36 (m, 2H), 3.20 (m, 1H), 3.00 (m, 1H), 1.92 (m, 3H). MS (ion spray) m/z 316, (M+H).

EXAMPLE 80. 1- (4-Amino-quinazoline-7-vlmethyi)-3-methyl-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-methyl-3-oxo- piperazine-1-carboxylic acid benzyl ester, Example 46, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'H NMR (CD30D, 300MHz) 88. 36 (s, IH), 8.11 (d, 1H), 7.57 (s, 1H), 7.44 (d, I H), 4.79 (AB, 2H), 3.58 (m, 1H), 3.47 (m, 1H), 3.31 (m, 1H), 3.12 (m, 1H), 3.00 (m, 1H), 1.41 (d, 3H). MS (ion spray) m/z 272, (M+H).

EXAMPLE81.1-(4-Amino-quinazoline-7-ylmethyl)-3-benzyl-pip erazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-benzyl-3-oxo- piperazine-1-carboxylic acid benzyl, Example 47, ester for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester.'HNMR (CD30D, 300MHz) å 8.35 (s, 1H), 8.09 (d, 1H), 7.57 (s, IH), 7.38 (d, IH), 7.27 (m, 5H), 4.74 (AB, 2H), 3.76 (m, 1H), 3.47 (m, IH), 3. 30 (m, 3H), 3.08 (m, IH), 2.96 (m, IH). MS (ion spray) m/z 348, (M+H).

EXAMPLE 82.1- (4-Amino-quinazoline-7-vlmethyl)-3- (1-methoxvethyl)-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2- (1-methoxyethyl)- 3-oxo-piperazine-1-carboxylic acid benzyl ester, Example 48, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. This compound is isolated as the bis hydrobromide salt.'H NMR (CD30D, 300MHz) 8 8.70 (s, IH), 8.40 (d, IH), 7.88 (s, IH), 7.71 (d, IH), 4.94 (AB, 2H), 4.30 (m, 2H), 3.76 (m, IH), 3.68 (m, 3H), 3.36 (s, 3H), 1.42 (d, 3H). MS (ion spray) m/z 316, (M+H).

EXAMPLE 83. 1- (4-Amino-quinazoline-7-vlmethyl)-3, 3-dimethyi-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2,2-dimethyl-3-oxo- piperazine-1-carboxylic acid benzyl ester, Example 49, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester.'H NMR (d'-DMSO, 300MHz) 8 8.34 (s, 1H), 8.12 (d, 1H), 7.72 (bs, 2H), 7.41 (s, IH), 7.26 (d, IH), 4.60 (s, 2H), 3. 33 (m, 2H), 2.98 (m, 2H), 1. 27 (s, 6H).

EXAMPLE 84. 1- (4-Amino-quinazoline-7-yimethvl)-3-isopropvl-piperazine-2-on e.

The title compound is prepared as described in EXAMPLE 75, substituting 2-isopropyl-3-oxo- piperazine-1-carboxylic acid benzyl ester, Example 50, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'H NMR (d'-DMSO, 300MHz) b 8.32 (s, 1H), 8.12 (d, 1H), 7.66 (bs, 2H),

7.42 (s, 1H), 7.27 (d, 1H), 4.60 (AB, 2H), 3.23 (m, 2H), 3.05 (m, 1H), 2.79 (m, 1H), 2. 34 (m, 1H), 0.92 (s, 3H), 0.80 (s, 3H).

EXAMPLE 85.1- (4-Amino-quinazoline-7-vlmethvl)-3-isobutyl-piperazine-2-one .

The title compound is prepared as described in EXAMPLE 75, substituting 2-isobutyl-3-oxo- piperazine-I-carboxylic acid benzyl ester, Example 51, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'H NMR (d6-DMSO, 300MHz) ã 8.65 (s, 1H), 7.70 (m, 2H), 7.48 (m, IH), 5.61 (m, 2H), 4.82 (m, 1H), 4.65 (m, 1H), 3.52 (dd, 1H), 3.37 (m, 1H), 3.18 (m, 2H), 2.98 (m, 1H), 1.92 (m, 1H), 1.76 (m, 1H), 1.59 (m, 2H), 0.95 (m, 6H).

EXAMPLE 86. 1-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2- (2-methoxyethyl)- 3-oxo-piperazine-I-carboxylic acid benzyl ester, Example 52, for 2-methoxymethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester. 'H NMR (d'-DMSO, 300MHz) 88. 32 (s, 1 H), 8.13 (d, 1H), 7.70 (bs, 2H), 7.42 (s, 1H), 7.28 (m, 1H), 4.60 (m, 2H), 3.32 (m, 8H), 3.11 (m, 1H), 2.95 (m, 1H), 2.78 (m, 1H), 2.07 (m, 1H), 1.72 (m, 1H).

EXAMPLE 87. 1- (4-Amino-quinazoline-7-vlmethyi)-3-methoxvmethyl-6-methv !-piperazine-2-one.

The title compound is prepared as described in EXAMPLE 75, substituting 2-methoxymethyl-5- methyl-3-oxo-piperazine-1-carboxylic acid benzyl ester, Example 53, for 2-methoxymethyl-3-oxo- piperazine-1-carboxylic acid benzyl ester. 'H NMR (CD30D, 300MHz) 8 8.72 (s, 1H), 8. 32 (d, 1H), 7.78 (m, 2H), 5.11 (m, 1H), 4.81 (m, 1H), 4.42 (m, 1H), 4.13 (m, 1H), 4.04 (m, 1H), 3.74 (m, 2H), 3.52 (m, 1H), 3.43 (s, 3H), 1.34 (d, 3H).

EXAMPLE 88. (3S, 5RS)-l- (4-amino9uinazolin-7-vlmethvlZ3,5-dimethyl-piperazin-2-one.

A. (2S, 6RS)-4-j3- (benzhvdryl-amino)-4-cyano-benzyll-2, 6-dimethyl-3-oxo-piperazine-1-carboxvlic acid benzyl ester.

To a solution of the (2S, 6RS)-2,6-dimethyl-3-oxo-piperazine-I-carboxylic acid benzyl ester (1.98 g, 7.56 mmol in 20 mL of tetrahydrofuran and 2 mL of DMF is added sodium hydride (60%, 289 mg, 12.6 mmol) at 0°C. The reaction is stirred for one hour at room temperature and the 2- benzhydrylidene-amino)-4-bromomethyl-benonitrile (4.24 mg, 11.34 mmol), Example 13, is added.

After stirring at room temperature overnight, the tetrahydrofuran is removed. The residue is taken up in ethyl acetate. Excess sodium hydride is quenched with 5 mL of water, and normal aqueous work-up followed. The crude product is chromatographed on silica gel (50% EtOAc/Hexane) to give (2S, 6RS)-

4- [3- (benzhydryl-amino)-4-cyano-benzyl]-2, 6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (2.6 g, 65%). C35H37N403 MS m/z: 557.

B. (2S, 6RS)-4- (3-amino)-4-cvano-benzvl)-2, 6-dimethyl-3-oxo-piperazine-l-carboxylic acid benzvl ester.

(2S, 6RS)-4- [3- (Benzhydryl-amino)-4-cyano-benzyl]-2, 6-dimethyl-3-oxo-piperazine-1- carboxylic acid benzyl ester (2.6 g, 5.21 mmol) is dissolved in 100 mL of ethyl acetate and cooled to 0°C. A 12N solution of hydrochloric acid (0.5 ml, 6.0 mmol) is added dropwise. The deprotection is complete in thirty minutes. The reaction mixture is washed with 10 % sodium bicarbonate. The ethyl acetate layer is dried with magnesium sulfate, filtered and condensed. The resulting residue is purified by flash colunm (SiO,, 60 % ethyl acetate/hexane) to give the product (2S, 6RS)-4- (3-amino)-4-cyano- benzyl)-2,6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (2.03 g, 99 %).

C. (2S, 6RS)-4- (4-Amino-quinazolin-7-vlmethvl)-2, 6-dimethyl-3-oxo-piperazine-l-carboxylic acid benzvl ester.

Glacial acetic acid (0.9 ml, 15.54 mmol) and 1,3,5-triazine (840 mg, 10.36 mmol) is added to a solution of (2S, 6RS)-4- (3-amino-4-cyano-benzyl)-2, 6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (2.03 g, 5.18 mmol) in ethanol. The resulting mixture is heated to reflux overnight.

Replaced the ethanol with ethyl acetate and washed with saturated sodium bicarbonate (5 mL). The ethyl acetate layer is dried with magnesium sulfate, filtered and condensed. The resulting residue is purified by flash colunm (SiO,, 20% methanol/methylene chloride) to give the product (2S, 6RS)-4- (4-amino- quinazolin-7-ylmethyl)-2,6-dimethyl-3-oxo-piperazine-I-carbo xylic acid benzyl ester (1.85 g, 85%) as a yellow solid. C23H25N503 MS m/z: 420.

D. (3S. 5RS)-I- (4-amino-quinazolin-7-vimethyl)-3, 5-dimethyl-piperazin-2-one.

Palladium on carbon (10 %, 700 mg) is added to a solution of (2S, 6RS)-4- (4-amino-quinazolin- 7-ylmethyl)-2,6-dimethyl-3-oxo-piperazine-1-carboxylic acid benzyl ester (1.62 g, 3.87 mmol) in 20 mL of methanol and 2 mL of acetic acid. The reaction mixture is left to stir in an atmosphere of hydrogen for eight hours. The palladium is filtered off, and the volitale solvents are removed on the rotovap. The crude product (1.7 g, 95 %) is isolated as a white solid. The two epimers are separated on silica gel (1% triethylamine/15% methanol/methylene chloride). The minor epimer is assigned as (3S, 5R)-1-(4-amino- quinazolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one and the major epimer is assigned as (3S, 5S)-1- (4- amino-quinazolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one.

EXAMPLE 89.1- (4-Chloroquinolin-7-vlmethvl)-piperazin-2-one.

4- (Benzyloxycarbonyl)-piperazin-2-one (1.1 g, 4.6 mmol) is dissolved in THF (50 mL), cooled in an ice bath and treated with tretrabutylammonium iodide (0.18 g, mmol) and 60% sodium hydride (0.24 g, 6.0 mmol). The reaction mixture is stirred at 0 C for 30 minutes then treated dropwise with a solution of 7-bromomethyl-4-chloroquinoline (1.2 g, 4.6 mmol), Example 14, in THF (50 mL). The resulting solution is stirred at 0 C for 2 h then quenched with ammonium chloride solution and concentrated. Dilution with ethyl acetate is followed by a water wash; the organic layer is dried (sodium sulfate) and concentrated. The residue is chromatographed (4% methanol/methylene chloride) to yield solid 4- (benzyloxycarbonyl)-1- (4-chloroquinolin-7-ylmethyl)-piperazin-2-one (1.2 g, 2.9 mmol). A portion of this material (0.75 g, 1.8 mmol) is dissolved in acetonitrile (20 mL) and treated with iodo trimethylsilane (0.78 mL, 5.4 mmol) at room temperature for 3 hours. The reaction is quenched with methanol and concentrated to dryness. Methanol addition and concentration is repeated four times. The final residue is taken up is 2M aqueous HCI; the solution is washed with ether and concentrated. The residue is recrystallized from isopropanol and ether to yield the title compound (0.63 g, 2.3 mmol) MS m/z: M+ = 275;'HNMR (CD30D, 300 MHz) 8 9.1 (d, IH), 8.5 (d, IH), 8.2-8.3 (m, 2H), 8.0 (d, IH), 5.2 (s, 2H), 4.1 (s, 2H), 3.7-3.8 (m, 2H), 3.6-3.7 (m, 2H).

EXAMPLE 90.1- (4-Chlorocinnolin-7-ylmethyl)-piperazin-2-one.

4- (t-Butyloxycarbonyl)-piperazin-2-one (0.6 g, 3.0 mmol), EXAMPLE 40, is dissolved in THF (80 mL), cooled in an ice bath and treated with tretrabutylammonium iodide (0.23 g, 0.62 mmol) and 60% sodium hydride (0.12 g, 3.0 mmol). The reaction mixture is stirred at °C for 40 minutes then treated dropwise with a solution of 7-bromomethyl-4-chlorocinnoline (10.7g, 2.7 mmol), Example 15, in THF (20 mL). The resulting solution is warmed to ambient temperature over 2 hours. The solution is evaporated to dryness and the residue is taken up in ethyl acetate and 10 % aqueous sodium bicarbonate solution. The organic layer is separated, washed with water, dried (sodium sulfate) and concentrated. The residue is chromatographed (ethyl acetate) to yield the title compound (0.6 g, 1.6 mmol). A portion of this material (0.21 g, 1.26 mmol) is dissolved in THF (-4 mL) and treated with a saturated solution of HCI in ethyl acetate (50 mL) at room temperature for 2 hours. The solution is filtered and concentrated to a residue (0.14 g, 0.4 mmol). MS m/z: M+= 275;'H NMR (CD30D, 300 MHz) 8 9.15 (d, 1H), 8.5 (d, IH), 8.25 (s, 1H), 8.15 (d, 1H), 8.0 (d, 1H), 5.0 (s, 2H), 4.1 (s, 2H), 3.7-3.8 (m, 2H), 3.6-3.7 (m, 2H).

EXAMPLE 91. I- (4-Chloroquinolin-7-vlmethvl)-3- (S)-methvlpiperazin-2-one.

4- (Benzyloxycarbonyl)-3-(S)-methylpiperazin-2-one(Benzyloxycar bonyl)-3-(S)-methylpiperazin-2-one (1.0 g, 4.0 mmol), EXAMPLE 46, is dissolved in THF (60 mL), cooled in an ice bath and treated with tretrabutylammonium iodide (0.10 g, 0.27 mmol) and 60% sodium hydride (0.18 g, 4.4 mmol). The reaction mixture is stirred at 0°C for 30

minutes then treated dropwise with a solution of 7-bromomethyl-4-chloroquinoline (1. 12 g, 4.4 mmol), EXAMPLE 14, in THF (5 mL). The resulting solution warmed to room temperature over approximately 1 h then quenched with sodium bicarbonate solution and concentrated. The residue is partitioned between ethyl acetate and water; the organic layer is dried (sodium sulfate) and concentrated. The residue is chromatographed (5 % methanol/methylene chloride) to yield solid 4- (Benzyloxycarbonyl)-1- (4- chloroquinolin-7-ylmethyl)-3- (S)-methyl-piperazin-2-one (1. 32(S)-methyl-piperazin-2-one (1. 32 g, 3.1 mmol). A portion of this material (0.10 g, 0.23 mmol) is dissolved in acetonitrile (6 mL) and treated with iodotrimethyl-silane (0.1 mL, 0.75 mmol) at room temperature for 2 hours. The reaction is quenched with methanol and concentrated to dryness. Methanol addition and concentration is repeated six times. The final residue is taken up is 2M aqueous HCI; the solution is washed with ether and concentrated to yield the title compound. MS m/z: M+ = 289;'H NMR (CD30D, 300 MHz) 8 9.2 (d, 1H), 8.6 (d, IH), 2H), 8.0 (d, IH), 5.1 (q, 1H), 4.3-4.4 (m, 1H), 3.8-4.0 (m, 2H), 3.6-3.8 (m, 3H), 1.75 (d, 3H).

EXAMPLE 92.1-f2- (Pyridin-4-vlamino)-ethvll-piperazin-2-one.

A. 4-(tert-Butvloxecarbonvl)-I-(2-aminoethvl)-piperazin-2-one.

4- (tert-Butyloxycarbonyl)-piperazin-2-one (8.0 g, 40 mmol), EXAMPLE 40, is dissolved in THF (160 mL), cooled in an ice bath and treated with 60 % sodium hydride (1.9 g, 48 mmol). The reaction mixture is stirred 40 minutes, then treated with tetra-butylammonium iodide (0.35 g, 0.95 mmol) and bromoacetonitrile (3.4 mL, 48 mmol). After 2 h the reaction is quenched with water, concentrated to a small volume and extracted with methylene chloride (3 X). The combined organic extracts are concentrated and the residue is chromatographed (50 % ethyl acetate/hexane) to give 4- (tert- butyloxycarbonyl)-l-cyanomethyl-piperazin-2-one (5.2 g, 21.7 mmol). This material is dissolved in ethanol (140 mL) and treated with platinum oxide (0.83 g) at 50 PSI of hydrogen gas for 24 hours. The catalyst is removed by filtration and the solution is concentrated to yield 4-(tert-butyloxycarbonyl)-1-(2- aminoethyl)-piperazin-2-one (5.2 g, 21.6 mmol).'H NMR (CDCI3,300 MHz) S 4.08 (s, 2H), 3.62 (m, 2H), 3.44 (t, 2H), 3. 38 (t, 2H), 2.89 (t, 2H).

B. 4-(tert-ButvloxYcarbonYI)-l-r2-(23956-tetrachloroPyridin-4-y lamino)-ethyll-piperazin-2-one.

4- (tert-Butyloxycarbonyl)-1- (2-aminoethyl)-piperazin-2-one (4.0 g, 16 mmol) is dissolved in methylene chloride (150 mL) and treated with 4-nitro-2,3,5,6-tetrachloro-pyridine (4.8 g, 18 mmol) and N-methylmorpholine (4.0 mL, 36 mmol). The reaction mixture is stirred for 5 h, concentrated and the residue is purified by chromatography (50% ethyl acetate/hexane) to give the title compound (4.8 g, 10.5 mmol). Fab MS m/z: 457,469,461, [M+l] +;'H NMR (CDCl3, 300 MHz) 8 6.00 (t, 1 H), 4.10 (s, 2H), 3.97 (m, 2H), 3.66 (m, 2H), 3. 38 (m, 2H).

C. I- [2-(Pvridin-4-vlamino)-ethell-piperazin-2-one.<BR> <BR> <BR> <BR> <BR> <BR> <P> 4-(tert-Butyloxycarbonyl)-I-[2-(2,(tert-Butyloxycarbonyl)-I- [2-(2, 3,5,6-tetrachloropyridin-4-ylamino)-ethyl-piperazin-2-one (3.5 g, 7.6 mmol) is dissolved in methanol (20 mL) and 0.5 M sodium methoxide in methanol (150 mL, 75 mmol). The solution is treated with Pd/C (0.5 g) and agitated under 50 PSI of hydrogen gas for 16 hours. The solvent is removed and the residue is extracted with methylene chloride which is filtered. The filtrate is concentrated and loaded onto a silica flash column. The column is eluted with 5% MeOH/CH2CI2 followed by NH4OH/MeOH/CH2CI2 (1: 5: 95) and NH, OH/MeOlv CH, CL, (1: 10: 70) to yield 4- (tert-Butyloxycarbonyl)-1- [2- (pyridin-4-ylamino)-ethyl]-piperazin-2-one as a white foam (1.5 g, 4.7 mmol). This material (1.5 g, 4.7 mmol) is treated with 20% trifluoroacetic acid in methylene chloride (110mL) at ambient temperature for 2 hours. The solution is concentrated and the residue is treated with saturated bicarbonate solution and ammonium hydroxide until a basic solution is obtained. The solution is applied to a silica column and eluted with NH4OH/MeOH/CH2CI2 (1: 10: 60) and 1- [2- (pyridin-4- ylamino)-ethyl]-piperazin-2-one is isolated as a mixture of desired product and inorganic salts (estimate 25 % by weight) EI MS m/z: 220, M+;'H NMR (CD30D, 300 MHz) 5 8.07 (d, 2H), 6.96 (d, 2H), 3.77 (s, 2H), 3,65 (m, 6H), 3.44 (t, 2H).

EXAMPLE 93. 1-r2-f (Methvl)-(peridin-4-el)-aminoT-ethYll-piPerazin-2-one trifluroacetate.

4- (tert-Butyloxycarbonyl)-I- [2- (2,3,5,6-tetrachloropyridin-4-ylamino)-ethyl]-piperazin-2-on e (0.19 g, 0.41 mmol), Example 92, Part B, is dissolved in DMF (3 ml) and treated with 60 % NaH (20 mg, 0.5 mmol). After 10 minutes methyl iodide (0.025 ml, 0.40 mmol) is added and the yellow solution is stirred at r. t. overnight. The solution is diluted with EtOAc and washed with H, O (6 X). The organic layer is dried (MgS04) and concentrated to a residue (0.19 g, 0.40 mmol). The residue is dissolved in methanol (2 ml) and treated with 0.5 M NaOMe in MeOH (8 ml, 4.0 mmol)). The solution is treated with Pd/C and agitated under 60 PSI of hydrogen gas overnight and filtered. The filtrate is concentrated and extracted several times with CH, C1,; removal of solvent in vacuo gives 4-(tert-Butyloxycarbonyl)-1-[2- {(methyl)-(pyridin-4-yl)-amino}-ethyl]-piperazin-2-one as an amorphous residue (0.16 g). EI MS m/z: 335, [M+l];'H NMR (CDC13,300 MHz) 8 8.21 (d, 2H), 6.56 (d, 2H), 3.99 (s, 2H), 3.60 (t, 2H), 3.53 (t, 2H), 3.47 (t, 2H), 3.28 (t, 2H), 2.98 (s, 3H), 1.46 (s, 9H). Treatment of the above product with 20% TFA/CH2CI2 (10 mL) at r. t. for I h gives, after concentration, the title compound as a residue which is used without further purification.'H NMR (CD30D, 300 MHz) 8 8.14 (d, 2H), 7. 30 (br, 1H), 7.00 (br, 1H), 3.88-3.67 (m, 8H), 3.53 (t, 2H), 2.26 (s, 3H).

EXAMPLE 94.1-r2- (3-Methylpvridin-4-yl-amino)-ethylerazin-2-one.

A. 4-f2- (3-Methvipyridin-4-yiimino)-ethyll-3-oxo-piperazine-l-carbox iic acid benzol ester.

4- (Benzyloxycarbonyl)-piperazin-2-one (4.7 g, 20 mmol) is dissolved in THF (50 mL) and treated with 1.5M LDA (20 mL, 30 mmol) at 0°C. The reaction mixture is treated with condensed ethylene oxide (3 mL, 40 mmol) and stirred at r. t. overnight. The mixture is neutralized with 2N HCI, concentrated, and extracted with EtOAc. The EtOAc layer is washed with H, O and concentrated to a crude residue. Further extraction of the crude with Et, and concentration of the ethereal layer gives an oil (1.5 g). The above oil is dissolved in CH, CL, (25 mL) and added to the solution of 2M oxalyl chloride (7.5 mL, 15 mmol) and DMSO (2.3 mL, 29.7 mmol) in CHOC1, (25 mL) at-60°C. After 15 minutes, Et3N (2.1 ml, 15 mmol) is added. The mixture is stirred at-50 °C for 10 minutes then warmed to r. t for 10 minutes. The reaction is quenched with 0.5 N HCI and extracted with CH, Cl2. The CH, CI, layer is washed with 0.5 N HCI, brine (2 X), HO, and concentrated to a residue. The residue is purified by chromatography (2% MeOH/CH, C12) to give 4-amino-3-methyl pyridine as an oil (0.5 g, 1.6 mmol). A solution of the oil (0.2 g, 2 mmol), and (IR)-(-)-10-camphorsulfonic acid (15 mg) in toluene (100 ml) is refluxed with a Dean Stark set up overnight. The mixture is concentrated and the residue is purified by chromatography (2-4% MeOH/CH2C12) to give the title imine as a white foam (0.20 g, 0.54 mmol). Ion spray MS m/z: 367, [M+l] + ;'H NMR (CDCI3,300 MHz) 8 8.20 (d, IH), 8.14 (s, 1H), 7.35 (s, 5H), 6.60 (d, 1H), 6.18 (dd, IH), 5.15 (s, 2H), 4.97 (d, IH), 4. 30 (s, 2H), 3.78 (t, 2H), 3.50 (bm, 2H), 2.15 (s, 3H).

B. I-r2- (3-Methylpyridin-4-yi-amino)-ethyll-piperazin-2-one.

4- [2- (3-Methylpyridin-4-ylimino)-ethyl]-3-oxo-piperazine-1-carbox lic acid benzyl ester (0.20 g, 0.54 mmol) is dissolved in anhydrous ethanol (20 mL) and hydrogenated at 50 PSI with 10% Pd/C overnight. After filtration, the filtrate is concentrated. The residue is treated with Pd black in 5% HCO, H/CH, C12 (10 ml) for 10 minutes. Filtration and concentration gives crude residue, which is purified by chromatography using NH4OH/MeOH/CH2CI2 (1: 5: 95) to give the title compound as a clear syrup (0.078 g, 0.33 mmol).'H NMR (CDC13,300 MHz) 8 8.17 (d, I H), 8.03 (s, I H), 7. 35 (s, 5H), 6.36 (d, 1H), 5. 30 (b, 1H), 3.74 (t, 2H), 3.53 (s, 2H), 3.38 (m, 4H), 3.08 (t, 2H), 2.02 (s, 3H).

EXAMPLE 951-r2-(Pvridazin-4-Ylamino)-ethYll-piperazin-2-one.

1-(2-Aminoethyl)-4-(tert-butyloxycarbonyl)-piperazin-2-one(2 -Aminoethyl)-4-(tert-butyloxycarbonyl)-piperazin-2-one from EXAMPLE 92, Part A (1.0 g, 4.1 mmol) is treated with 3,4,5-trichloropyridazine (0.81 g, 4.1 mmol), triethylamine (0.57 mL, 4.1 mmol), THF (25 mL) and heated to 120°C in a sealed tube for 3 hours. Upon cooling, the solution is diluted with ethyl acetate and washed with aqueous sodium bicarbonate (25 mL), water and dried over sodium sulfate. The organic layer is concentrated and chromatographed (5% methanol/methylene chloride) to give a mixture of isomers (0.8 g, 20 mmol). The mixture is dissolved in 0.5 M sodium methoxide in methanol (200 mL), treated with 10% Pd/C (0.5 g) and agitated under 50 PSI of hydrogen

for 20 hours. The reaction mixture is filtered; the filtrate is concentrated to a residue which is chromatographed (NH4OH/H2O/MeOH/EtOAc, 1: 1: 2: 90) to give crude 4-(tert-butyloxycarbonyl)-1-[2- (pyridazin-4-ylamino)-ethyl]-piperazin-2-one. This material is dissolved in a minimal amount of THF and treated with a saturated solution of HCI in ethyl acetate (50 mL). The solution is stirred at ambient temperature for 2 h and diluted with diethyl ether (50 mL). The precipitated title compound is collected and air dried (0.5 g, 1.7 mmol). MS m/z: 367, [M+1]+ ;'H NMR (CD30D, 300 MHz) 8 8.8 (d, 1H), 8.5 (s, 1H), 7.4 (d, 1H), 4.1 (s, 2H), 3.5-3.8 (m, 8H).

EXAMPLE 96. 4- 3- (4-tert-Butoxvcarbonvlamino-p. ridin-3-vi)-propenyll-3-oxo-piperazine-1- carboxvlic acid tert-butvl ester and 4-f3- (4-tert-butoxvcarbonvlamino-pvridin-3-vi)-allyll-3-oxo- piperazine-l-carboxvlic acid tert-butvl ester.

A. I-Allvl-4- (tert-butvloxycarbonvl)-piperazin-2-one.

4- (tert-Butyloxycarbonyl)-piperazin-2-one (1.0 g, 5.0 mmol), EXAMPLE 40, is alkylated with allyl bromide (0.48 ml, 5.5 mmol) in THF (20 mi) using the procedure described in Example 92, PartA.

The title compound (0.92 g, 3.8 mmol) is obtained as a colorless liquid after chromatographed (50 % ethyl acetate/hexane). EI MS m/z 240 (M+);'H NMR (CDCl3, 300 MHz) 8 5.80-5.68 (m, 1H), 5.23-5.15 (m, 2H), 4.09 (s, 2H), 4.03 (d, 2H), 3.63 (t, 2H), 3,30 (t, 2H), 1.45 (s, 9H).

B. 4-f3- (4-tert-Butoxvcarbonvlamino-pvridin-3-vl)-propenyll-3-oxo-pi perazine-1-carboxvlic acid tert- butvi ester and 4-[3-(4-tert-butoxycarbonylamino-pyridin-3-yl)-alkyl]-3-oxo- piperazine-1-carboxylic acid tert-butvl ester l-Allyl-4- (tert-butyloxycarbonyl)-piperazin-2-one(tert-butyloxycarbony l)-piperazin-2-one (0.49 g, 2.0 mmol) is treated with (3-iodo- pyridin-4-yl)-carbamic acid tert-butyl ester (0.64 g, 2.0 mmol), Pd (OAc) 2 (14 mg, 0.06 mmol), P (o-tol) 3 (37 mg, 0.12 mmol), and Et3N (0.56 mmol) in a seal tube. The mixture is stirred at 100 °C overnight, then diluted with CHCL, and washed H, O (2 X). The CH, CL, layer is concentrated and the residue is chromatographed (5% MeOH/CH2Cl2) to give a mixture of two isomers (0.40 g, 0.92 mmol). The mixture is separated into its constituent isomers upon further chromatography (EtOAc) to give 4- [3- (4- tert-butoxycarbonylamino-pyridin-3-yl)-propenyl]-3-oxo-piper azine-1-carboxylic acid tert-butyl ester (90 mg, 0.21 mmol, higher R, value) and 4- [3- (4-tert-butoxycarbonylamino-pyridin-3-yi)-allyi]-3-oxo- piperazine-l-carboxylic acid tert-butyl ester (0. 24 g, 0.56 mmol, lower Rf value). For the former: MS m/z 433 (M+1) ;'H NMR (CDCl3, 300 MHz) 8 8. 38 (d, 1H), 8.28 (s, 1H), 7.93 (d, 1H), 7.48 (d, 1H), 6.67 (s, 1H), 5.10 (m, 1H), 4.15 (s, 2H), 3.70 (t, 2H), 3,46 (t, 2H), 3. 39 (d, 2H), 1.48 (s, 9H), 1.45 (s, 9H). For the latter: MS m/z 433 (M+l);'H NMR (CDCl3, 300 MHz) 8 8.39 (s, IH), 8.37 (d, 1H), 7.98 (d, 1H), 6.77 (s,

1H), 6.52 (d, 1H), 6.07 (m, IH), 4.23 (d, 2H), 4.12 (s, 2H), 3,69 (t, 2H), 3.40 (t, 2H), 1.52 (s, 9H), 1.45 (s, 9H).

EXAMPLE 97.4-f3- (4-tert-Butoxycarbonvlamino-pyridin-3-vl)-propvll-3-oxo-pipe razine-l-carboxylic acid tert-butvl ester A mixture of the two isomers from EXAMPLE 96, Part B. (0.11 g, 0.25 mmol) is dissolved in MeOH (7 ml), treated with with 10% Pd/C and is stirred under a balloon of hydrogen for 4 hours.

Filtration and concentration gives a white foam (80 mg, 0.18 mmol). El MS m/z 434 (M+);'H NMR (CDC13,300 MHz) 8 8.33 (d, 1H), 8.30 (s, IH), 8.05 (d, 1H), 4.08 (s, 2H), 3.64 (t, 2H), 3.50 (t, 2H), 3. 35 (t, 2H), 2.58 (t, 2H), 1.90 (m, 2H), 1.57 (s, 9H), 1.48 (s, 9H).

EXAMPLE 98.4- (Benzvloxvcarbonvl)-1- (2-pvrrolor3, 2-cpvridin-1-vlethyl)-piperazin-2-one 4- (Benzyloxycarbonyl)-1-(2-hydroxyethyl)-piperazin-2-one,(Benz yloxycarbonyl)-1-(2-hydroxyethyl)-piperazin-2-one, prepared as described in EXAMPLE 94, part A. (0.26 g, 0.94 mmol) in methylene chloride (6 mL) is treated with triphenyl phosphine (0.60 g, 2.3 mmol), imidazole (0.16 g, 2.3 mmol), and iodine (0.47 g, 1.9 mmol) for 0.5 h at 0 °C. The reactin mixture is partitioned between water and methylene chloride; the organic layer is concentrated and the residue is chromatographed (15 % EtOAc/methylene chloride) to give 4- (benzyloxycarbonyl)-1- (2-iodoethyl)-piperazin-2-one (0.24 g, 0.62 mmol). Pyrrolo [3,2-c] pyridine (0.073 g, g, 0.62 mmol) is dissolved in DMF (3 mL) and treated with 60 % sodium hydride (0.03 g, 0.74 mmol) and all of the 4- (benzyloxycarbonyl)-1-(2-iodoethyl)-piperazin-2-one from the previous step; the reaction mixture is stirred at r. t. for 16 g. The reaction mixture is concentrated to dryness and the residue is partitioned between water and methylene chloride. The organic layer is concentrated and subjected to chromatography (2-5 % MeOH/methylene chloride) to yield the title compound (0.028 g, 0.074 mmol) Ion Spray MS m/z: 379, [M+l] +.

EXAMPLE 99. ()-I- (3-Amino-4-cyano-benzvl)-4- (6-chloro-benzofblthiophene-2-sulfonvl)-6-oxo- piperazine-2-carboxvlic acid methyl ester. <BR> <BR> <P>A. ()-1- (3- (Benzhvdrylidene-amino)-4-cvano-benzyll-4- (6-chloro-benzofblthiophene-2-sulfonyl)-6- oxo-piperazine-2-carboxvlic acid methyl ester A solution containing (+)-I- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-6-oxo-piperazine-2- carboxylic acid methyl ester (55 mg, 0.12 mmol) in CH, CI= (1 mL) is cooled to 0°C. DIPEA (24 mg, 0.18 mmol) is then added followed by the addition of 6-chloro-benzo [b] thiophene-2-sulfonyl chloride (32 mg, 0.12 mmol), EXAMPLE 1. The reaction mixture is warmed to ambient temperature. After 16 h, the reaction mixture is absorbed directly onto silica gel and chromatographed (CH, CI, to 2% MeOH/

CH2CI2) to provide 60 mg (73%) of the title compound.'H NMR (300 MHz, CDCI3) å 2.77 (dd, J = 12. 3,3.4 Hz, 1H), 3.50-3.72 (m, 3H), 3.79 (s, 3H), 4.15 (dd, J = Hz, 1H), 4.24 (d, J = 16.9 Hz, 1H), 5.41 (d, J = 15.3 Hz, IH), 6.50 (s, 1H), 6.76 (dd, J = 7.9,1.4 Hz, 1H), 7.11-7.86 (m, 15H) ppm; MS (ISP loop): m/z 683 (M+H).

B. ()-I- (3-Amino-4-cvano-benzyl)-4- (6-chloro-benzoflthiophene-2-sulfonyl)-6-oxo-piperazine-2- carboxvlic acid methyl ester Concentrated HC1 (12M, one drop) is added at 0°C to a mixture containing ()-1- [3- <BR> <BR> <BR> <BR> (benzhydrylidene-amino)-4-cyano-benzyl]-4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine- 2-carboxylic acid methyl ester (60 mg, 0.08 mmol) in MeOH (5 mL). Added THF (2 mL) followed by a second drop of 12M HCI and warmed reaction mixture to ambient temperature. The reaction is quenched by pouring the reaction mixture onto a 1: I mixture of CH2CI2/aqueous NaHCO3 and the layers are separated. The aqueous phase is washed with CH2Cl2 and then the combined organic phase is washed with brine, dried over anhydrous MgS04, filtered and concentrated. The crude residue is chromatographed on silica gel (CH, C12 to 4% MeOH/CH, C12) to provide 42 mg (93%) of the title compound.'H NMR (300 MHz, CDC13) 8 2.98 (dd, J = 12.5,3.5 Hz, 1H), 3.60 (d, J= 16.8 Hz, 1H), 3.69 (d, J = 15.3 Hz, 1H), 3.79 (s, 3H), 3.98 (m, 1H), 4.21-4.31 (m, 2H), 4.44 (br s, 2H), 5. 36 (d, J = 15. 3 Hz, 1H), 6.47 (dd, J = 8.0,1.4 Hz, 1H), 6.54 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.45 (dd, J = 8.5,1.8 Hz, 1H), 7.80-7.86 (m, 3H) ppm; MS (ISP loop): m/z 519 (M+H).

EXAMPLE 100. ()-1- (3-Amino-4-cyano-benzyl)-4- (6-chloro-benzofblthiophene-2-sulfonvl)-6-oxo- piperazine-2-carboxvlic acid.

Water (5 drops) is added to a solution containing ()-I- (3-amino-4-cyano-benzyl)-4- (6-chloro- benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid methyl ester (30 mg, 0.05 mmol), EXAMPLE 99, in a 1: 1 mixture of THF/MeOH (2 mL). At ambient temperature, LiOH monohydrate (7 mg, 1.66 mmol) is then added. After 16 h, the reaction mixture is diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 10 mg (34%) of the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 8 3.18 (dd, J = 12.1,3.5 Hz, 1H), 3.61 (d, J = 16.0 Hz, 1H), 3.77 (d, J = 16.0 Hz, 1H), 3.95 (d, J = 16.0 Hz, 1H), 4.06 (d, J = 12.1 Hz, 1H), 4.14 (m, 1H), 6.40 (d, J = 8.0 Hz, 1H), 6.54 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.57 (dd, J = 8.6,1.9 Hz, 1H), 8.06 (d, J = 8.6 Hz, 1H), 8.18 (s, 1H), 8. 33 (s, IH) ppm; MS (ISP loop): m/z 505 (M+H).

EXAMPLE 101.4-r4- (6-Chlorobenzofblthiophene-2-sulfonvi)-2-oxo-piperazine-I- lmethvllbenzamidine.

To a solution of 4- (2-oxopiperazin-1-ylmethyl) benzamidine bistrifluoroacetate (0.38 g, 0.83mmol), EXAMPLE 66, in CH2CI2 (5 mL) is added Et3N (0. 35 mL, 2.6 mmol) and 6-chloro- benzo [b] thiophene-2-sulfonyl chloride (0.23 g, 0.85 mmol, EXAMPLE 1. After 6 hours, the solution is concentrated. The product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O(0.1% TFA) to 70% CH3CN/H2O (0. 1 % TFA). The appropriate collected fractions are lyophilized to afford the title compound as a white solid (0.37 g, 0.65 mmol). 1H NMR (d6-DMSO, 300MHz) # 9.33 (bs, 2H), 8.96 (bs, 2H), 8. 30 (s, 1H), 8.18 (s, 1H), 8.04 (d, 1H), 7.70 (m, 2H), 7.50 (m, 1H), 7.28 (m, 2H), 4.55 (s, 2H), 3.86 (s, 2H), 3.44 (m, 2H), 3.22 (m, 2H).

The following compounds are prepared from 1- (4-Aminoquinazol ine-7-ylmethyl)-3-ethyl- piperazine-2-one, Example 77, and the appropriate sulfonyl chloride using the method of Example 101. Example # Name m/z (M+H) 102 4- [4- (4-Methoxy-benzenesulfonyl)-2-oxo-piperazin-1-ylmethyl]-403 benzamidine 103 4- [4- (5-Chloro-thieno [3,2-b] pyridine-2-sulfonyl)-2-oxo-piperazin- 463,465 1-ylmethyl]-benzamidine 104 4- [4- (6-Chloro-thieno [2,3-b] pyridine-2-sulfonyl)-2-oxo-piperazin- 464,466 1-ylmethyl]-benzamidine Cl pattern 105 4- [2-Oxo-4- (thieno [2,3-c] pyridine-2-sulfonyl-piperazin-1- 430 ylmethyl]-benzamidine 106 4- [4- (7-Chloro-thieno [2,3-c] pyridine-2-sulfonyl)-2-oxo-piperazin- 464,466 1-ylmethyl]-benzamidine Cl pattern 107 4-[4-(5'-Chloro- [2,2'] bithiophenyl-5-sulfonyl)-2-oxo-piperazin-1-495, 497 ylmethyl]-benzamidine Cl pattern 108 4- [4- (4-Chloro-thieno [3,2-c] pyridine-2-sulfonyl)-2-oxo-piperazin- 464,466 1-ylmethyl]-benzamidine Cl pattern 109 4- [2-Oxo-4- (toluene-4-sulfonyl)-piperazin-I-ylmethyl]-3387 benzamidine 110 4- [4- (Benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-ylmethyl]- 429 benzamidine 478,4801114-Amino-3-[4-(6-chloro-benzo[b]thiophene-2-sulfony l)-2-oxo- piperazin-I-ylmethyl]-benzamidine Cl pattern 112 3- [2-Oxo-4- (toluene-4-sulfonyl)-piperazin-1-ylmethyl]-387 benzamidine 113 3- [4- (6-Fluoro-benzo [b] th iophene-2-sulfonyl)-2-oxo-piperazin-1-447 ylmethyl]-benzamidine 114 3- [4- (4-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1- 463, 465 ylmethyl]-benzamidine Cl pattern 115 3- [4- (5-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1- 463, 465 ylmethyl]-benzamidine Cl pattern 4531163-[4-(6-Methoxy-naphthalene-2-sulfonyl)-2-oxo-piperazi n-1- ylmethyl]-benzamidine 117 3- {4- [5- (5-Nitro-pyridine-2-sulfonyl)-thiophene-2-sulfonyl]-2-oxo- 565 piperazin-I-ylmethyl}-benzamidine 118 3- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-l- 463,465 ylmethyl]-benzamidine Cl pattern 119 3-14- [2- (3-Chloro-phenyl)-ethenesulfonyl]-2-oxo-piperazin-l- 433, 435 ylmethyl}-benzamidine Cl pattern 120 3- [2-Oxo-4- (4-phenylazo-benzenesulfonyl)-piperazin-1-ylmethyl]-477 benzamidine 121 3- [4- (Benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-ylmethyl]-429 benzamidine

EXAMPLE 4-[4-(6-Chloro-1H-benzoimidazol-2-ylmethyl)-2-oxo-piperazin- 1-ylmethyl]- benzamidine.

Hydrogen chloride gas is bubbled into an ice-cooled solution of 4-[4-(6-chloro-1H- benzoimidazol-2-ylmethyl)-2-oxo-piperazin-1-ylmethyl]-benzon itrile (100 mg, 0.264 mmol), (prepared by deprotecting 4- (4-cyanobenzyl)-3-oxopiperazine-1-carboxylic acid benzyl ester, EXAMPLE 66, Part A, followed by alkylation with 6-chloro-2-chloromethylbenzimidazole) in 15 mL of methanol. The solution contained 3A molecular sieves. The reaction mixture is stored at-30°C. The methanol is removed on the rotovap. Fresh methanol (20 ml) is added folowed by a stream of ammonia gas. The resulting mixture is heated to reflux for three hours. The reaction mixture is filtered at room temperature. The mother liquor is condensed and the resulting residue is purified by reverse phase HPLC (0-50 % ACN/H2O). The product is isolated as a white solid with a melting point of 91-95°C.

MS C20H21ClN6O m/z: 397,399. Anal. cald. for C20H2, CIN, 0-3C, HF102: C, 42.26; H, 3.27; N, 11.37.

Found C, 42.20; H, 3.44; N, 11. 36.

EXAMPLE 123. 4- 4-r3- (5-Chloro-thiophen-2-vl)- (E)-acrvlovll-2-oxopiperazin-1- vlmethvlbenzam idine.

To a solution of 4- (2-oxopiperazin-I-ylmethyl) benzamidine bistrifluoroacetate (75 mg, 0.16 mmol), EXAMPLE 66, in 1.5 mL of DMF is added N, N-diisopropylethylamine (0.14 mL, 0.80 mmol).

After stirring 10 min at room temperature, 3- (5-chloro-thiophen-2-yl)- (E)-acrylic acid (32 mg, 0.17 mmol), EXAMPLE 25, is added, followed by 2- (lH-benzotriazol-l-yl)-1, 1, 3,3-tetramethyluronium tetrafluoroborate (TBTU) (55 mg, 0. 17 mmol). The resulting mixture is stirred at room temperature for 16 h and the solution is concentrated. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H20 (0. 1% TFA) to 70% CH3CN/H20 (0. % TFA) and the appropriate product fractions are combined and lyopholized to provide the title compound (77 mg, 0.15 mmol) as a white solid.

'H NMR (d6-DMSO, 300 MHz) 8 9.27 (bs, 2H), 9.10 (bs, 2H), 7.77 (d, 2H), 7.65 (d, 1H), 7.49 (dd, 2H), 7.39 (m, 1H), 7.15 (d, 1H), 6.89 (d, 1H), 4.65 (s, 2H), 4.45,4.21 (m, 2H, rotamers), 3.80 (m, 2H), 3.35 (m, 2H). ESI MS, [M+H]+=403, 405 (Cl pattern).

EXAMPLE 124.3-i4-r3- (5-Chloro-thiophen-2-vl)- (E)-acrvlovll-2-oxopiperazin-1- vlmethylbenzamidine.

The title compound is prepared as described in EXAMPLE 123 using 3- (5-chloro-thiophen-2- yl)- (E)-acrylic acid (EXAMPLE 25) and 3- (2-oxopiperazin-1-ylmethyl) benzamidine bistrifluoroacetate (prepared from 3-bromomethyl toluylnitrile as described in EXAMPLE 66).'H NMR (DMSO-d6,300 MHz) 8 9.32 (bs, 2H), 9.16 (bs, 2H), 7.65 (m, 5H), 7. 39 (m, 1H), 7.15 (d, 1H), 6.89 (d, 1H), 4.64 (s, 2H), 4.44,4.21 (m, 2H, rotamers), 3.93,3.79 (m, 2H, rotamers), 3. 36 (m, 2H). ESI MS, [M+H]'=403,405 (Cl pattern).

EXAMPLE 125.3-f4- (6-Chloro-IH-benzoimidazol-2-vlmethvl)-2-oxo-piperazin-1-vlm ethvll- benzamidine.

A white solid (13.0 mg, 13%). C2oH21CIN60MS m/z: 397,399 Anal. cald. for C, OH, ICIN60- 3C, HF302: C, 42.26; H, 3.27; N, 11.37. Found C, 43.70; H, 3.71; N, 11.95.

EXAMPLE 126.1- (2-Aminoquinolin-6-vlmethyl)-4- (5'-chloro- (2, 2'lbithiophenyl-5-sulfonvl) piperazin- 2-one.

The title compound is prepared as described in Example 101 using 1- (2-aminoquinolin-6- ylmethyl) piperazin-2-one, EXAMPLE 67, and 5'-chloro- [2,2'] bithiophenyl-5-sulfonyl chloride, EXAMPLE 2. The crude product is triturated in CH, C1, and filtered to provide the title compound as a white solid.'H NMR (d6-DMSO, 300 MHz) 8 7.82 (d, 1H), 7.68 (d, 1H), 7.42 (m, 3H), 7. 36 (d, lH),

7.25 (d, 1H), 7.20 (d, 1H), 6.70 (d, 1H), 6.43 (bs, 2H), 4.53 (s, 2H), 3.78 (s, 2H), 3. 31 (m, 4H). MS (ion spray) m/z 519,521, (M+H), Cl pattern.

EXAMPLE 127. 6-[4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazin-1 -ylmethyl]-1H- quinolin-2-one.

The title compound is prepared as described in EXAMPLE 101, using 6-(2-oxopiperazin-1- ylmethyl)-lH-quinolin-2-one, minor product from EXAMPLE 67, Part D, and 6-chlorobenzo [b] thiophene-2-sulfonyl chloride, EXAMPLE 1. The crude product is triturated in CL, CIL and filtered to provide the title compound as a white solid. 1H NMR (d6-DMSO, 300 MHz) # 11. 72 (bs, IH), 8. 33 (s, 1H), 8.18 (s, 1H), 8.07 (d, lH), 7.78 (d, lH), 7.58 (dd, IH), 7.45 (s, IH), 7.30 (dd, IH), 7.18 (d, 1H), 6.46 (d, 1H), 4.52 (s, 2H), 3.86 (s, 2H), 3.43 (m, 2H), 3. 31 (m, 2H). MS (ion spray) m/z 488, 490, (M+H), Cl pattern.

The following compounds are prepared using starting materials prepared as described in Examples 67,68 and 73 and the appropriate carboxylic acid according to the method of Example 123. Example # Name m/z (M+H) 128 4-(Chloro-benzo [b] thiophene-2-sulfonyl)-I-thieno [2,3-c] pyridin-478, 480 3-ylmethyl-piperazin-2-one Cl pattern 129 1- (2-Amino-quinoxalin-6-ylmethyl)-4- (6-chloro- benzo [b] thiophene-2-sulfonyl)-piperazin-2-one 130 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-thieno [2,3-c] pyridin-478,480 2-ylmethyl-piperazin-2-one Cl pattern 131 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-thieno [3,2-c] pyridin-478,480 2-ylmethyl-piperazin-2-one Cl pattern 132 1- (2-Amino-quinolin-6-ylmethyl)-4- (6-chloro-thieno [2,3-488,490 b]pyridine-2-sulfonyl)-piperazin-2-one Cl pattern 133 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(1-hydroxy- 488, 490 isoquinolin-6-ylmethyl)-piperazin-2-one Cl pattern 506,5081344-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-chl oro- isoquinolin-6-ylmethyl)-piperazin-2-one CI pattern 135 7- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-4488,490 patternylmethyl]-2H-isoquinolin-1-oneCl 506,5081364-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-(1-chl oro- isoquinolin-7-ylmethyl)-piperazin-2-one Cl pattern 137 1- (7-Amino-thieno [2,3-c] pyridin-2-ylmethyl)-4-(6-chloro- 493, 495 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one Cl pattern 138 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(2-chloro-quinolin-6- 506, 508 ylmethyl)-piperazin-2-one Cl pattern 139 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-quinolin-6-ylmethyl-472, 474 patternpiperazin-2-oneCl 140 7- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1- 488, 490 ylmethyl]-I H-quinolin-2-one Cl pattern 141 1- (2-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-487,489 2-sulfonyl)-piperazin-2-one Cl pattern 142 1- (4-Amino-thieno [3,2-c] pyridin-2-ylmethyl)-4- (6-chloro- 493,495 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one CI pattern 143 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)- 1- (1,2,3,4-tetrahydro-475,477 patternisoquinolin-6-ylmethyl)-piperazin-2-oneCl 144 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-l-isoquinolin-6- 472, 474 ylmethyl-piperazin-2-one Cl pattern 145 1- (2-Amino-quinolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene-487,489 2-sulfonyl)-piperazin-2-one Cl pattern 146 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(decahydro- 482, 484 isoquinolin-6-ylmethyl)-piperazin-2-one Cl pattern 487,4891471-(1-Amino-isoquinolin-6-ylmethyl)-4-(6-chloro- patternbenzo[b]thiophene-2-sulfonyl)-piperazin-2-oneCl 148 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(decahydro- 482, 484 isoquinolin-7-ylmethyl)-piperazin-2-one Cl pattern 149 487,489 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one Cl pattern 150 1- (4-Amino-thieno [3,2-c] pyridin-3-ylmethyl)-4-(6-chloro-493,495 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one Cl pattern 151 (+/-)- [1-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-3-oxo-4- 536, 538 Clpatternthieno[3,2-c]pyridin-2-ylmethyl-piperazin-2-yl]-ace ticacid 152 538536, thieno [2,3-c] pyridin-2-ylmethyl-piperazin-2-yl]-acetic acid Cl pattern 153 1- (1-Amino-isoquinolin-6-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)-471, 473 (E)-acryloyl]-3-(S)-methoxymethyl-piperazin-2-one Cl pattern 154 477475, yloxy)-acetyl]-3-(S)-methoxymethyl-piperazin-2-one Cl pattern 155 496,494, yloxy)-acetyl]-3-methoxymethyl-piperazin-2-one 498, Cl2pattern 156 (3S)-I- (7-Chloro-isoquinolin-3-ylmethyl)-4- [3- (5-chloro-thiophen- 490,492, 2-yl)- (E)-acryloyl]-3-methoxymethyl-piperazin-2-one 494, Cl2 pattern 157 458456, quinolin-7-ylmethyl)-piperazin-2-one Cl pattern 427,4291581-(2-Amino-quinolin-6-ylmethyl)-4-[3-chloro-thioph en-2-yl)- (E)-acryloyl]-piperazin-2-one Cl pattern

The following compounds are prepared from starting materials prepared as described in Example 67 and the appropriate aryl-methyl bromide or allyl-methyl bromide using a K, CO,-mediated alkylation reaction. Example # Name m/z (M+H) 3771591-(2-Aminoquinolin-6-ylmethyl)-4-(4-methoxybenzyl)pipe razin-2- one 160 1- (2-Aminoquinolin-6-ylmethyl)-4-6-chlorobenzo [b] thiophen-2- 436,438 ylmethyl) piperazin-2-one Cl pattern 161 417 benzoimidazol-2-ylmethyl) piperazin-2-one 162 1- (2-Aminoquinolin-6-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl-5- 469,471 ylmethyl) piperazin-2-one Cl pattern 163 1- (2-Aminoquinolin-6-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 413, 415 allyl]-piperazin-2-one Cl pattern 164 1- (2-Aminoquinolin-6-ylmethyl)-4- [3- (3, 5-dibromo-4-methoxy- 601,603, phenyl)- [1,2,4] oxadiazol-5-y) methy) jpiperazin-2-one 605 Br2 pattern 165 3- [4- (2-Aminoquinolin-6-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- 431 7-fluoro-I H-quinolin-2-one 166 1- (2-Aminoquinolin-6-ylmethyl)-4- (6-chloro-naphthalen-2- 430 ylmethyl)-piperazin-2-one

The following compounds are prepared from starting materials prepared as described in Examples 66,67,68 and 73 and the appropriate aryl-methyl bromide or allyl-methyl bromide using a K2CO3-mediated alkylation reaction. Example # Name m/z (M+H) 3991673-(4-Biophenyl-3-ylmethyl-3-oxo-piperazin-1-ylmethyl)- benzamidine 439,4411684-(5-Chloro-1H-indol-2-ylmethyl)-1-(4-chloro-quino lin-7- ylmethyl)-piperazin-2-one Cl pattern 4271691,4-Bis-(5-chloro-1H-indol-2-ylmethyl)-piperazin-2-one 170 I- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- (7-chloro- 439,441 patternisoquinolin-3-ylmethyl)-piperazin-2-oneCl 171 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4-(6-chloro- 444, 446 patternbenzo[b]thiophen-2-ylmethyl)-piperazin-2-oneCl 172 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- [3- (5-chloro- 420,422 thiophen-2-yl)-allyl]-piperazin-2-one Cl pattern 173 401 yl)-alkyl]-piperazin-2-one 174 I- (3-Amino- I H-indazol-6-yimethyl)-4- (6-chloro- 426 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one 175 1- (4-Amino-thieno [2, 3-d]pyrimidin-6-ylmethyl)-4-(6-chloro- 443 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one 176 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2-oxo-piperazin- 413,415 1-ylmethyl]-benzamidine Cl pattern 177 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-3-oxo-piperazin- 413, 415 1-ylmethyl]-benzamidine Cl pattern 178 4- (4-Cyclohexylmethyl-2-oxo-piperazin-1-ylmethyl)- 329 benzamidine 437,4391791-(1-Amino-isoquinolin-6-ylmethyl)-4-(6-chloro- patternbenzo[b]thiophen-2-ylmethyl)-piperazin-2-oneCl 180 1- (I-Amino-isoquinolin-6-yimethyl)-4- [3- (5-chloro-thiophen-2- 457,459 yl)-allyt]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 181 4- [3- (5-Chloro-thiophen-2-yl)-allyl]-1- [4- (6-methoxy-pyridin- 468 3-yl)-benzyl]-3-(S)-methyl-piperazin-2-one 182 4- [3- (5-Chloro-thiophen-2-yl)-allyl]-3- (S)-methyl-1- [4- (6-oxo- 454 1,6-dihydro-pyridin-3-yl)-benzyl]-piperazin-2-one 183 (S)-4- H-indol-2-ylmethyl)-1-(4-chloro-quinolin-7-483 ylmethyl)-3-methoxymethyl-piperazin-2-one 184 (S)-4- (5-Chloro-1H-indol-2-ylmethyl)-1- (4-chloro-quinolin-7- 453 ylmethyl)-3-methyl-piperazin-2-one

EXAMPLE 185. 1- (4-Aminoquinazolin-7-vlmethvl)-4- (6-chlorobenzofbthiophene-2- sulfonyl)piperazin-2-one, The title compound is prepared as described in EXAMPLE 101, substituting 1- (4- aminoquinazoline-7-ylmethyl) piperazine-2-one bishydrochloride, EXAMPLE 72, for 4- (2-oxopiperazin- I-ylmethyl)-benzamidine. The product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 70% CH3CN/H2O (0.1% TFA). The appropriate collected fractions are lyopholized to afford the title compound as a white solid. MS (ion spray) m/z 488,490, (M+H).'H NMR (d6-DMSO, 300 MHz) 8 9.65 (s, 2H), 8.80 (s, 1H), 8.30 (m, 2H), 8.20 (s, 1H), 8.05 (d, 1H), 7.60 (m, 3H), 4.70 (s, 2H), 3.85 (s, 2H), 3.50-3.20 (m, 4H).

EXAMPLE 186.4- (4-Amino-quinazolin-7-ylmethvl)-3-oxo-piperazine-l-sulfonic acid 3-chloro- benzvlamide.

To a solution of 1- (4-aminoquinazoline-7-ylmethyl) piperazine-2-one bishydrochloride, EXAMPLE 72, (0. 10g, 0.30mmol) is 9 mL of DMF is added 3-chlorobenzyl sulfamyl catechol (0.09g, 0.30mmol), EXAMPLE 4, Et3N (0.08g, 0.75 mmol) and DMAP (0.001 g, 0.12 mmol). The solution is heated to 60°C. After 16 h, the solution is concentrated. The crude product is purified by RP-HPLC eluting with a gradient of 10% CH3CN/-I, (0. 1% TFA) to 100% CH3CN. The product fractions are lyophilized to give the title compound (0.077g, 0.17 mmol) as the TFA salt.'H NMR (d6-DMSO, 300 MHz) 8 9.82 (bs, 2H), 8.98 (s, 1H), 8.52 (d, 1H), 8. 32 (d, IH), 7.60 (m, 2H), 7. 35 (m, 4H), 4.69 (AB, 2H), 4.11 (m, 2H), 3.77 (s, 2H), 3. 38 (m, 2H), 3.27 (m, 2H). MS (ion spray) m/z 461,463, (M+H), Cl pattern.

The following compounds are prepared from the compound of Example 72 and the appropriate sulfonyl choride using the method of Example 101. Example # Name m/z (M+H) 187 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2,3- 489, 491 b] pyridine-2-sulfonyl)-piperazin-2-one Cl pattern 188 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl- 520,522 5-sulfonyl)-piperazin-2-one CI pattern 189 4- ino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-sulfonic 460 acid 4-chloro-benzylamide 190 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-isoxazol-3-yl-thiophene- 471 2-sulfonyl)-piperazin-2-one 191 1- (4-Amino-quinazolin-7-ylmethyl)-4- (thieno [3,2-b] pyridine-2- 455 sulfonyl)-piperazin-2-one 192 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-sulfonic 474 acid [2- (3-chloro-phenyl)-ethyl]-amide 193 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-sulfonic 474 acid[2- (4-chloro-phenyl)-ethyl]-amide 194 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro- I H-472 benzoimidazole-2-sulfonyl)-piperazin-2-one 195 466464, ethenesulfonyl]-piperazin-2-one Cl pattern 196 4- (3-Amino-benzenesulfonyl)-1- (4-amino-quinazolin-7-ylmethyl)- 413 piperazin-2-one The following compounds are prepared from starting materials obtained as described in Examples 75-88 and the appropriate sulfonyl chloride using the method of Example 101. Example # Name m/z (M+H) 197 494492, ethenesulfonyl]-3-(S)-ethyl-piperazin-2-one Cl pattern 198 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-516,518 pattern2-sulfonyl)-3-(S)-ethyl-piperazin-2-oneCl 199 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2, 2] bithiophenyl- 548,550 5-sulfonyl)-3-(S)-ethyl-piperazin-2-one Cl pattern 200 I-(4-Amino-quinazolin-7-ylmethyl)-4-(5'-chloro-(4-Amino-quin azolin-7-ylmethyl)-4-(5'-chloro- [2,2'] bithiophenyl- 534, 536 5-sulfonyl)-3-(S)-methyl-piperazin-2-one Cl pattern 201 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene- 502, 504 2-sulfonyl)-3- (S)-methyl-piperazin-2-one Cl pattern 202 (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro- 502,504 benzo [b] thiophene-2-sulfonyl)-6-methyl-piperazin-2-one Cl pattern 203 (+/-)- [4- (4-Amino-quinazolin-7-ylmethyl)- 1- (6-chloro- 546,548 benzo [b] thiophene-2-sulfonyl)-3-oxo-piperazin-2-yl]-acetic acid Cl pattern

The following compounds are prepared from starting materials obtained as described in Examples 72 and 73 and the appropriate sulfonyl chloride according to the method of Example 101 or the appropriate carboxylic acid according to the method of Example 123. Example # Name m/z (M+H) 204 I- (4-Amino-thieno [3, 2-d]pyrimidin-6-ylmethyl)-4-[2-(5-chloro- 470, 472 thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one Cl pattern 205 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- (6-chloro- 493,495 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one Cl pattern 206 1- (4-Amino-thieno [2, 3-d]pyrimidin-6-ylmethyl)-4-(6-chloro- 494, 496 patternbenzo[b]thiophene-2-sulfonyl)-piperazin-2-oneCl 207 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (4-hydroxy- 489, 491 quinazolin-6-ylmethyl)-piperazin-2-one Cl pattern 208 1- (4-Amino-thieno [3, 2-d]pyrimidin-7-ylmethyl)-4-(6-chloro- 494, 496 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one Cl pattern 209 1- (4-Amino-quinazolin-6-ylmethyl)-4- (6-chloro-benzo [b] thiophene- 488,490 2-sulfonyl)-piperazin-2-one CI pattern 210 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(4-hydroxy- 489, 491 patternquinazolin-7-ylmethyl)-piperzine-2-oneCl 211 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4- [3- (4-bromo- 478,480 patternthiophen-2-yl)-acryloyl]-piperazin-2-oneBr 212 1- (4-Amino-thieno [3,2-d] pyrimidin-6-ylmethyl)-4-[3-(5-chloro- 434, 436 patternthiophen-2-yl)-acryloyl]-piperazin-2-oneCl 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(1H-pyrrolo[ 3,2-c]pyridin-2-EXAMPLE213. ylmethyl)piperazin-2-one.

A. 2- [2- (5-Chloro-thiophen-2-vl)-ethenesulfonvll-2-oxopiperazin-1-vl methvl clpvridine-1-carboxylic acid tert-butyl ester.

To a solution of 2- (2-oxopiperazin-1-ylmethyl) pyrrolo [3,2-c] pyridin-1-carboxylic acid tert-butyl ester (0.71 g, 2.1 mmol), EXAMPLE 69, in CH3CN (7 mL) is added triethylamine (0.60 mL, 4.3 mmol) followed by 2- (5-chloro-thiophen-2-yl)-ethenesulfonyl chloride, EXAMPLE 3, (0.57 g, 2.1 mmol). The mixture is stirred overnight, then concentrated to dryness. The residue is diluted with CH, CL, and washed with saturated sodium bicarbonate and brine. The organic layer is dried over MgSO4, filtered and concentrated in vacuo to give the title compound (1.2 g, 2.1 mmol) as a light yellow solid. The crude material can be used in the subsequent step without further purification.'H NMR (CDCI3,300 MHz) 8 8.80 (s, 1H), 8.42 (d, 1H), 7.88 (d, 1H), 7.55 (d, 1H), 7.14 (d, 1H), 6.98 (d, 1H), 6.41 (s, 1H), 6. 36 (d, 1H), 5.00 (s, 2H), 3.98 (s, 2H), 3.61 (m, 4H), 1.71 (s, 9H). Ion spray MS, [M+H]+= 537,539, Cl pattern.

B. 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-(1H-pyrrolo[ 3, 2-clpvridin-2-vlmethyl) piperazin-2- one.

Trifluoroacetic acid (2.2 mL, 28.6 mmol) is added dropwise to a slurry of 2- [4- (6- chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1-ylmethyl] pyrrolo [3,2-c] pyridine-I-carboxylic acid tert-butyl ester (1.32 g, 2.4 mmol) in CH2Cl2 (25 mL) at 0°C. After 1.5 hours, the ice bath is removed and the solution stirred at room temperature for 4 hours. The reaction mixture is diluted with methylene choride and washed with saturated sodium bicarbonate and brine. The organic layer is dried over MgS04, filtered and concentrated in vacuo to give the title compound as the free base. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H, O (0. 1% TFA) to 100% CH3CN and the appropriate product fractions are lyophilized to provide the title compound (1.29 g, 2.2 mmol) as <BR> <BR> <BR> a white solid.'H NMR (CDC13,300 MHz) 8 14.90 (bs, 1H), 12.81 (s, 2H), 9.12 (s, 1H), 8.41 (d, 1H), 7.89 (d, 1H), 7.60 (d, 1H), 7.50 (d, 1H), 7.20 (d, 1H), 7.12 (d, 1H), 6.95 (s, 1H), 4.80 (s, 2H), 3.98 (s, 2H), 3.48 (s, 4H). Ion spray MS, [M+H] += 437,439, Cl pattern. <BR> <BR> <BR> <BR> <BR> <BR> <P>EXAMPLE 214. 4- (6-Chlorobenzorblthiophene-2-sulfonvl)-1- ( H-pyrrolo 3, 2-clpvridin-2-<BR> <BR> <BR> <BR> <BR> vlmethylpiperazin-2-one.

A. 2-[4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazin-1 -ylmethyl]pyrrolo[3,2-c]pyridine-1- carboxylic acid tert-butyl ester.

'H NMR (CDCl3, 300 MHz) 8 8.7 (s, 1H), 8.41 (d, 1H), 7.9-7.8 (m, 3H), 7.45 (d, 1H), 7.25 (d, 1H), 6.31 (s, 1H), 4.95 (s, 2H), 3.98 (s, 2H), 3.65 (m, 2H), 3.55 (m, 2H), 1.68 (s, 9H). Ion spray MS, [M+H]"-561,563, Cl pattern.

B. 4-(6-Chlorobenzol blthiophene-2-sulfonyl)-1-(I H-pvrrolor3. 2-clpvridin-2-Ylmethyl) piperazin-2-one trifluoroacetate.

'H NMR (d6-DMSO, 300MHz) S 14.68 (bs, 1H), 12.6 (s, 1H), 9.1 (s, IH), 8.36 (d, 1H), 8.29 (d, 1H), 8.17 (s, IH), 8.05 (d, 1H), 7.82 (d, 1H), 7.56 (m, 2H), 6.83 (s, 1H), 4.1 (s, 2H), 3.84 (s, 2H), 3. 38 (m, 4H). Ion spray MS, [M+H] += 461,463, Cl pattern.

EXAMPLE 215. 4- (6-Chtorobenzorbithiophene-2-sulfonyl)-1- (5-oxv-1H-pvrrolor3, 2-clpvridin-2- vlmethvl) piperazin-2-one.

4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-1- ( H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2- one (0.06 g, 0.13 mmol) is dissolved in anhydrous methylene chloride (20 ml), treated with m- chloroperbenzoic acid (0.03 g, mmol) and stirred at room temperature for 4 hours. The solution is diluted with methylene chloride, washed with NaHCO3, dried (Na2SO4) and concentrated. The residue is purified by flash chromatography (5-10 % MeOH/CH2CI2) and converted to the TFA salt to provide the title compound (0.015 g, 0.032 mmol).'HNMR (CDC13, 300 MHz) 6 9.14 (bs, IH), 8.95 (d, 1H), 7.8-7.87 (m, 3H), 7.57 (d, 1H), 7.48 (dd, IH), 6.87 (s, 1H), 4.90 (s, 2H), 3.95 (s, 2H), 3.86 (s, 3H), 3.49 (s, 3H).

EI MS, [M+] = 474,476, Cl pattern. <BR> <BR> <P>EXAMPLE 216. 4- (6-Chlorobenzofblthiophene-2-sulfonvl)-1- (I-methvl-1H-pvrrolor3. 2-clpvridin-2- ylmethyl)piperazin-2-one.

4-(6-Chlorobenzo [b] thiophene-2-sulfonyl)-1-(I H-pyrrolo(6-Chlorobenzo [b] thiophene-2-sulfonyl)-1-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazin-2- one (0.59 g, 1.28 mmol), EXAMPLE 214, is dissolved in anhydrous DMF (30 ml), cooled in an ice bath, treated with 60 % sodium hydride (0.061 g, 1.53 mmol) and stirred at room temperature for 30 minutes.

The solution is treated with methyl iodide (83 mL, 1.33 mmol) and warmed to room temperature over 4 hours. The reaction is quenched with ammonium chloride solution, diluted with ethyl acetate and separated. The organic layer is washed with brine (3x), dried (Na2SO4) and concentrated. The residue is purified by flash chromatography (5-10 % MeOH/CH, Cl,) to provide the title compound (0.31 g, 0.65 mmol).'H NMR (CD30D, 300 MHz) 8 8.55 (d, 1H), 7.99 (dd, 1H), 7.82 (m, 3H), 7.49 (dd, 1H), 7.43 (d, 1H), 6.55 (s, 1H), 4.75 (s, 2H), 3.96 (s, 2H), 3.52 (m, 4H), 3.86 (s, 3H), 3.49 (s, 3H). Ion Spray MS, [M+H] +=477.

The following compounds are prepared from starting materials obtained as described in Example 69 and the appropriate sulfonyl chlorides according to the method of Example 101. m/zExample#Name (M+H) 217 4- (3-Chlorobenzo [b] thiophene-2-sulfonyl)-1- ( H-pyrrolo [3,2- 460 c] pyridin-2-ylmethyl) piperazin-2-one 218 4- (6-Chlorothieno [2,3-b] pyridine-2-sulfonyl)-1- ( H-pyrrolo [3,2-462,464 c] pyridin-2-ylmethyl) piperazin-2-one. Cl pattern 5052194-(6-Bromobenzo[b]thiophene-2-sulfonyl)-1-(1H-pyrrolo[ 3,2- c] pyridin-2-ylmethyl) piperazin-2-one 220 2- [3-Oxo-4- (l H-pyrrolo [3, 2-c]pyridin-2-ylmethyl)piperazine-1- 452 sulfonyl]-benzo [b] thiophene-6-carbonitrile 221 4- (5'-Chloro-[2, 2'] bithiophenyl-5-sulfonyl)-1-(I H-pyrrolo [3,2- 493 c] pyridin-2-ylmethyl) piperazin-2-one 4312224-[2-(4-Chlorophenyl)ethenesulfonyl]-1-(1H-pyrrolo[3,2 -c]pyridin- 2-ylmethyl) piperazin-2-one 223 {2-[4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazin- 1- 519,521 Cl ylmethyl] pyrrolo [3,2-c] pyridin-I-yl} acetic acid pattern 224 4-(5-Pyridin-4-ylthiophene-2-sulfonyl)-1-(1H-pyrrolo[3, 2-c] pyridin- 454 2-ylmethyl) piperazin-2-one 225 {2- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1-547,549 Cl ylmethyl] pyrrolo [3,2-c] pyridin-1-yl} acetic acid ethyl ester pattern 226 4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-1-[1-(2-methoxyethyl)- 519, 520 1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl] piperazin-2-one 227 4-(6-Chlorothieno [3,2-b] pyridine-2-sulfonyl)-I- (IH-pyrrolo [3,2-462,464 c] pyridin-2-ylmethyl) piperazin-2-one 228 {2-[4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxopiperazin- I-533, 535 ylmethyl] pyrrolo [2,3-c] pyridin-1-yl} acetic acid methyl ester 229 2-[3-Oxo-4-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl) piperazine-1-452 sulfonyl] benzo [b] thiophene-5-carbonitrile 230 4- (5-Aminomethylbenzo [b] thiophene-2-sulfonyl)-I- ( H-pyrrolo [3,2- 456 c] pyridin-2-ylmethyl) piperazin-2-one 231 2- {2- [4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin-1- 518, 520 ylmethyl] pyrrolo [3,2-c] pyridin-1-yl} acetamide 232 4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-1- [1- (2-hydroxyethyl)- 505 1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl] piperazin-2-one 233 4-(6-Chloro-I H-benzoimidazole-2-sulfonyl)-1-(I H-pyrrolo(6-Chloro-I H-benzoimidazole-2-sulfonyl)-1-(I H-pyrrolo [3,2-445,447 c] pyridin-2-ylmethyl)-piperazin-2-one 234 4- (1H-Benzoimidazole-2-sulfonyl)-1-(1H-pyrrolo [3,2-c] pyridin-2- 411 ylmethyl)-piperazin-2-one 235 4- (6-Aminomethyl-benzo [b] thiophene-2-sulfonyl)- I- (I H-456 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 236 1- (1 H-Pyrrolo [3,2-c] pyridin-2-ylmethyl)-4- (thieno [2,3-b] pyridine-2- 428 sulfonyl)-piperazin-2-one 237 428 sulfonyl)-piperazin-2-one 2384-[2-(5-Chloro-thiophen-2-yl)-ethanesulfonyl]-1-(1H-pyrro lo[3,2- 439,441 Cl c] pyridin-2-ylmethyl)-piperazin-2-one pattern 4532394-(2-Benzo[b]thiophen-2-yl-ethenesulfonyl)-1-(1H-pyrro lo[3,2- c] pyridin-2-ylmethyl)-piperazin-2-one 467,4692404-[2-(5-Chloro-4-methoxy-thiophen-2-yl)-ethenesulf onyl]-1-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 462,4642414-(6-Chloro-benzo[b]thiophene-2-sulfonyl-1-furo[3, 2-c]pyridin-2- ylmethyl-piperazin-2-one 242 4- (6-Fluoro-benzo [b] thiophene-2-sulfonyl)-1-furo [3,2-c] pyridin-2- 446 ylmethyl-piperazin-2-one 243 4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-1- ( H-pyrrolo [2,3-460,462 c] pyridin-2-ylmethyl) piperazin-2-one Cl pattern 244 4- (6-Chlorothieno [2,3-b] pyridine-2-sulfonyl)-1- (I H-pyrrolo [2,3-462,464 c] pyridin-2-ylmethyl) piperazin-2-one Cl pattern 245 {2-[4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1- 533,535 ylmethyl]-pyrrolo [2, 3-c]pyridin-1-yl}-acetic acid methyl ester Cl pattern 246 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (H-pyrrolo [3,2- 461,463 Cl b]pyridin-2-ylmethyl)-piperazin-2-onepattern

EXAMPLE 247. 1- (4-Amino-I H-pvrrolof3, 2-clpvridin-2-vlmethyl)-4- (6-chloro-benzorblthiophene-2- sulfonyl) piperazin-2-one.

A. tert-butylester.acid NaHMDS (61.7 mL, I. OM solution in THF) is rapidly added to a solution of 2-chloro-pyridin- ylamine (4.0 g, 30.9 mmol) amd BOC anhydride (6.74 g, 30.9 mmol) in THF (28 mL) at RT. The reaction mixture is cooled in an ice water bath (0°C) for I h then stirred for 3 hr at RT. The gelatinous mixture is concentrated in vacuo and diluted with ethyl acetate and saturated NH, C ! solution. The

organic layer is washed with 0.1N HCI, saturated NaHC03 and brine. The organic layer is then dried over MgS04, filtered and concentrated to dryness. The crude product is chromatographed eluting with 1% MeOH/CH, Cl, to yield the title product (5.57 g, 24.4 mmol) as a yellow solid. 1H NMR (CDCl3, 300 MHz) 8 8.18 (d, 1 H), 7.48 (d, 1H), 7.12 (dd, 1 H), 1.60 (s, 9H). El MS [M] +=228.

B. (2-Chloro-3-iodo-pvridin-4-yl)-carbamic acid tert-butvl ester. tert-Butyllithium (36.3 mL, 1.7M in pentane) is added dropwise to a solution of (2-chloro- pyridin-4-yl)-carbamic acid tert-butyl ester (6.00 g, 26.2 mmol) in THF (46 mL) at-78 °C under Ar. The yellow/orange mixture is stirred for 2 h at-78°C then warmed to-40 °C for 1 h then cooled to -78°C before dropwise addition of 1, (15.65 g, 61.7 mmol) in THF (49 mL). The reaction mixture is stirred for 1.5 h at-78°C then at-10°C for 30 minutes. The reaction is quenched with saturated NH4C' solution then diluted with CH2C12 and washed with saturated NH4CI, saturated sodium thiosulfate, water then brine. The organic layer is dried over MgS04, filtered and concentrated to dryness. The crude product is chromatographed eluting with 1-2% MeOH/CH, C12 to yield the title product (7.96 g, 22.5 mmol) as a bright yellow solid. 'H NMR (CDC13, 300 MHz) 6 8.14 (d, 1H), 8.02 (d, 1H), 7.32 (bs, 1H), 1.60 (s, 9H). EI MS [M]+=354, 356, Cl pattern.

C. 4-(4-Chloro-lH-pvrrolor3, 2-clpvridin-2-vlmethvl)-3-oXo-Piperazine-l-carboXvlic acid benzvl ester.

Trifluoroacetic acid (10 mL) is added to a solution of 2- (4-benzyloxycarbonyl-2-oxo-piperazin- I-ylmtheyl)-4-chloro-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (5.66 g, 11.3 mmol, prepared in the same manner as described previously) in CH2C12 (10 mL). The solution is stirred overnight then diluted with CH, C1, and washed with saturated NaHCO3 and brine. The organic layer is dried over MgS04, filtered and concentrated to dryness. The crude product is chromatographed eluting with 1-5% MeOH/CH, C12 to yield the title product (3.81 g, 9.56 mmol) as a foamy yellow solid.

'HNMR (CDCl3, 300MHz) 89.43 (bs, 1H), 8.08 (d, 1H), 7.38 (s, 5H), 7.18 (d, IH), 6.51 (s, 1H), 5.15 (s, 2H), 4.58 (s, 2H), 4.20 (s, 2H), 3.71 (m, 2H), 3.50 (m, 2H). Ion spray [M+H] += 399,401, Cl pattern.

D. 4-(1-Benzenesulfonyl-4-chloro-1H-pyrrolo[3,2-c]pyridin-2-ylm ethyl)-3-oxo-piperazine-1-carboxylic acid benzvl ester.

Powdered NaOH (0.96 g, 23.9 mmol) followed by nBu4NHSO4 (0.32 g, 0.96 mmol) and benzene sulfonyl chloride (1.8 mL, 14.1 mmol) is added to a solution of 4- (4-chloro-1H-pyrrolo [3, 2-c] pyridin-2- ylmethyl)-3-oxo-piperazine-1-carboxylic acid benzyl ester (3.81 g, 9.56 mmol) in CH, CL, (32 mL) at RT.

The resulting slurry is stirred for 3.5 h then diluted with CH, C12 and washed with saturated NaHCO3 and brine. The organic layer is dried over MgSO4, filtered and concentrated to dryness. The crude product is chromatographed eluting with 1-5% MeOH/CH, C12 to yield the title product (5. 06 g, 9. 38 mmol).'H

NMR (CDC13, 300 MHz) 8 8.23 (d, 1H), 7.97 (d, 1H), 7.84 (d, 2H), 7.61 (d, 1H), 7.51 (m, 2H), 7.38 (s, 5H), 6.50 (s, 1 H), 5.18 (s, 2H), 5.03 (s, 2H), 4.29 (s, 2H), 4.29 (s, 2H), 3.80 (m, 2H), 3.51 (m, 2H). Ion spray [M+H] += 539,541, Cl pattern.

E. I- (I-Benzenesulfonvl-4-chloro-1 H-pvrrolof 3. 2-clpvridin-2-vlmethyl)-piperazin-2-one.

TMSI (2.7 mL, 19.0 mmol) is added to a solution of 4-(1-benzenesulfonyl-4-chloro-1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-3-oxo-piperazine-1-carboxylic acid benzyl ester (5.06 g, 9. 38 mmol) in CH3CN (134 mL) at 0°C. The reaction mixture is warmed to RT and stirred for 5 hours. The reaction mixture is concentrated to dryness and the red residue is diluted with MeOH and concentrated to dryness (this is repeated twice). The mixture is diluted with CH, CL, and washed with saturated NaHC03 and brine. The organic layer is dried over MgSO4, filtered and concentrated to dryness. The crude product is chromatographed eluting with 1-5% MeOH/CH, C12 to yield the title product (0.70 g, 1.74 mmol) and unreacted starting material (3.58 g, 6.64 mmol). IH NMR (CDCI3,300 MHz) 8 8.20 (d, IH), 7.93 (d, 1H), 7.85 (d, 2H), 7.60 (d, 1H), 7.51 (m, 2H), 6.50 (s, 1H), 5.01 (s, 2H), 3.45 (m, 2H), 3.18 (m, 2H). Ion spray [M+H] += 405,407, Cl pattern.

F. 1-(4-Amino-1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-4-(6-chlorob enzo[b]thiophene-2- sulfonvl) piperazin-2-one.

Anhydrous ammonium acetate (0.56 g, 7.2 mmol), phenol (0.45 g, 4.8 mmol) and 1- (1- benzenesulfonyl-4-chloro-I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-4-(6-chloro-benzo [b] thiophene-2- sulfonyl)-piperazin-2-one (0.31 g, 0.48 mmol, prepared as described previously) are heated to 100°C for 3.5 days. The mixture is cooled to RT then the crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1 % TFA) to 100% CH3CN then the appropriate product fractions are lyophilized to provide the title compound (1.29 g, 2.2 mmol) as a white solid (22.4 mg, 0.038 mmol).'H NMR (DMSO-d6, 300 MHz) (bs,1H),12.00(bs,1H),8.31(d,1H),8.20(s,1H),8.06(d,1H),12.40 8.02 (bs, 2H), 7.57 (dd, 1H), 7.48 (m, IH), 6.89 (d, 1H), 6.81 (s, 1H), 4.60 (s, 2H), 3.81 (s, 2H), 3.40 (m, 4H). LR-FAB MS, [M+H] +=476,478.

4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-(~)-hydro xymethyl-1-(1H-EXAMPLE248. pvrroloF3.2-clpvridin-2-vlmethvl)-piperazin-2-one.<BR> <BR> <P>A.2- 4-r2- (5-Chloro-thiophen-2-vl)-ethenesulfonyll-2- ()-hvdroxvmethvl-6-oxo-piperazin-I- vlmethvl-pyrrolof3, 2-clpvridine-1-carboxylic acid tert-butvl ester.

Sodium borohydride (0.005 g, 0.13 mmol) is added to a solution of 2- {4- [2- (5-chloro-thiophen- 2-yl)-ethenesulfonyl]-2-(~)-methoxycarbonyl-6-oxo-piperazin- 1-ylmethyl}-pyrrolo[3,2-c]pyridine-1-

carboxylic acid tert-butyl ester (0.04 g, 0.07 mmol), (prepared from 2- (2- ()-methoxycarbonyl-6-oxo- piperazin-l-ylmethyl)-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester, EXAMPLE 71, and 2- (5- chloro-thiophen-2-yl)-ethenesulfonyl chloride, EXAMPLE 3, using the procedure described in EXAMPLE 214, Part A) in MeOH (3 mL) at RT. The reaction mixture is stirred for 6 h then quenched with water and concentrated in vacuo. The crude product (0.04 g) is taken onto the next step without further purification.

B.4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-(~)-hyd roxymethyl-1-(1H-pyrrolo[3,2-c]pyridin-2- vlmeth rl)-piperazin-2-one.

Trifluoroacetic acid (1.8 mL) is added to a solution of2- {4- [2- (5-chloro-thiophen-2-yl)- ethenesulfonyl]-2- ()-hydroxymethyl-6-oxo-piperazin-1-ylmethyl}-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (0.04 g) in CH2C12 (4.2 mL) at RT. The reaction mixture is stirred for 4 h then concentrated in vacuo. The title compound is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0. 1% TFA) to 100% CH3CN and lyophilizing the appropriate product fractions.'H NMR (DMSO-d6, 300 MHz) 5 9.10 (s, 1H), 8.46 (d, 1H), 7.82 (d, 1H), 7.50 (d, 1H), 7.43 (d, 1H), 7.14 (d, 1 H), 7.01 (d, 1H), 6.94 (s, 1H), 5.12 (bs, 1H), 4.80 (AB, 2H), 3.98 (d, 2H0, 3.90 (m, 1H), 3.40-3.50 (m, 4H).

APCI MS, [M+H]+=467, 469.

The following compounds are prepared from starting materials obtained using the methods of Examples 69,70 and 71 and the appropriate sulfonyl chorides according to the method of Example 101. Example # Name m/z 249 1- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-5-oxo-4- (1H-pyrrolo [3,2-519,521 c]pyridin-2-ylmethyl)-piperazine-2-(~)-carboxylic acid Clpatternester 250 1- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-oxo-4- (l H-495,497 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern methyl ester 251 1- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-5-oxo-5-(1H-pyrrolo [3,2-505,507 c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern 252 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-5- ()-hydroxymethyl-I-491,493 (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one Cl pattern The following enantiomerically pure compounds are obtained by chiral resolution on a CHIRACEL OD prep column. Example # Name % ee m/z 253 1- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5-oxo-4- ( 1 H-99% 495,497 pyrrolo[3,2-c] pyridin-2-ylmethyl)-piperazine-2-(-)-carboxylic (-) Cl pattern acid methyl ester 95%495,4972541-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-5 -oxo-4-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- (+)- (+) Cl pattern carboxylic acid methyl ester

EXAMPLE 255.4-r2- (5-Chloro-thiophen-2-vl)-ethenesuifonvil-6- (R)-hydroxvmethvl-1- ( H- pyrrolo 2-c1pvridin-2-v) methy))-piperazin-2-one.

A. 6- (R)- (tert-Butyl-dimethvl-silanvloxvmethvl)-4-r2- (5-chloro-thiophen-2-yl)-ethenesulfonvll-1- (1H- pvrrolof3, 2-cJpvridin-2-ylmethvl)-piperazin-2-one.

Trifluoroacetic acid (0.25 mL) is added to a solution of 2- {2-(R)-(tert-butyl-dimethyl- silanyloxymethyl)-4-[2-(5-chloro-thiophen-2-yl)-ethenesulfon yl]-6-oXo-piperazin-1-ylmethyl}- pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (0.025 g, 0.037 mmol) in CH, CI, (0.5 mL) at room temperature. The reaction mixture is stirred for 2 h then concentrated to dryness. The residue is diluted with CH2Cl2 and washed with saturated NaHCO3 and brine. The organic layer is dried over MgSO4, filtered and concentrated in vacuo. The crude product (0.019 g, 0.033 mmol) is used in the subsequent step without further purification.

B. 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-(R)-hydroxym ethyl-1-(1H-pyrrolo[3,2-c]pyridin-2- lthyl)-piperazin-2-one.

Glacial acetic acid (3 mL, 0.046 mmol) and tetrabutylammonium fluoride (92 mL, 0.092 mmol) is added to a solution of 6- (R)- (tert-butyl-dimethyl-silanyloxymethyl)-4- [2- (5-chloro-thiophen-2-yl)- ethenesulfonyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one (0.019 g, 0.033 mmol) in THF (0.5 mL). The resulting solution is stirred for 4 h then concentrated in vacuo. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 100% CH3CN and the appropriate product fractions are lyophilized to provide the title compound (0.009 g, 0.016 mmol) as a whitesolid. 'HNMR (DMSO-d6, 300MHz) o 14.50 (bs, IH), 12.60 (bs, 1H), 9.18 (s, 1H), 8.38 (d, 1H), 7.89 (d, 1H), 7.61 (d, 1H), 7.50 (d, 1H), 7.21 (d, 1H), 7.08 (d, 1H), 6.90 (s, 1H), 5.03 (s, 2H), 4.63 (d, 2H), 3.70-3.90 (AB, 2H), 3.75 (m, 1H), 3.21 (m, 2H). Ion spray MS, [M+H] +=467,469, Cl pattern.

The following compounds are prepared from starting materials obtained as described in Examples 69,70 and 71 and the appropriate sulfonyl chloride according to the method of Example 101. Example # Name m/z 491,4932564-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-6-(R)-hy droxymethyl-1- (I H-pyrrolo [3,2-c]pyridin-2-ylmethyl)-piperazin-2-one 495,4972574-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-ox o-1-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern methyl ester 258 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo- I- (I H-519,521 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern methyl ester 481,4832594-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6-ox o-1-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern 260 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-1-(1H- 505, 507 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern 261 4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-6- ()-hydroxymethyl-1- 491,493 (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one C ! pattern 262 4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-6- ()-hydroxymethyl- 467,469 1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one Cl pattern 504,5062634-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-6-oxo-1- (1H- pyrrolo[3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid Cl pattern amide 264 483481, methoxymethyl-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-pipera zin- 2-one 265 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-3-(S)-methoxymethyl-1-505,507 (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 266 4-(5'-Ch loro-[2, 2l] bithiophenyl-5-sulfonyl)-3-(S)-methoxymethyl-I-537,(5'-Ch loro-[2, 2l] bithiophenyl-5-sulfonyl)-3-(S)-methoxymethyl-I-537, 539 (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 267 4- [2- (4-Chloro-phenyl)-ethenesulfonyl]-3- (S)-methoxymethyl- I-475,477 (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one

EXAMPLE1-(4-Aminoquinazolin-7-ylmethyl)-4-(6-chlorobenzo[b]t hiophene-2- ylmethyl)piperazin-2-one.

To a solution of 1- (4-aminoquinazoline-7-ylmethyl) piperazine-2-one bishydrochloride (1.84 g, 5.73 mmol), EXAMPLE 72, in DMF (20 mL) is added 2-bromomethyl-6-chloro-benzo [b] thiophene, EXAMPLE 5, (1.5 g, 5.73 mmol) and K, C03 (4.0 g, 28.7 mmol). The solution is stirred for 16 hours.

After this time, the solution is diluted with water. The solution is acidified with trifluoroacetic acid. The product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H, O (0. 1% TFA) to 50% CH3CN/H2O (0. 1% TFA). The appropriate collected fractions are lyopholized to afford the title <BR> <BR> <BR> <BR> compound as a white solid. 'H NMR (d6-DMSO, 300MHz) 6 9.78 (bs, 3H), 8.82 (s, 1H), 8.34 (d, 1H), 8.07 (s, 1H), 7.81 (d, 1H), 7.63 (d, 1H), 7.51 (s, 1H), 7. 32 (m, 2H), 4.71 (s, 2H), 3.95 (s, 2H), 3.28 (m, 4H), 2.80 (m, 2H). <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>EXAMPLE 269. 1-(4-Aminoquinazolin-7-vlmethvl)-4-(6-chloro-I H-benzoimidazol-2-<BR> <BR> <BR> <BR> <BR> vlmethvl) piperazin-2-one.

A mixture of 1- (4-aminoquinazolin-7-ylmethyl) piperazin-2-one (50 mg, 0.15 mmol), EXAMPLE 72,6-chloro-2-chloromethylbenzimidazole (30.5 mg, 0.15 mmol) and potassium carbonate (83 mg, 0.6 mmol) in 2 mL of DMF is stirred at ambient temperature overnight. The mixture is purified on reverse phase HPLC (CH3CN/H2O/TFA) to give the trifluoroacetic acid salt of 1- (4-aminoquinazolin- 7-ylmethyl)-4- (6-chloro-lH-benzoimidazol-2-ylmethyl) piperazin-2-one(6-chloro-lH-benzoimidazol-2-ylmethyl) piperazin-2-one (25 mg) as a solid.'H NMR (CD30D, 300 MHz) 8 8.69 (s, 1H), 8. 33 (d, 1H), 7.79 (s, 1H), 7.75-7.69 (m, 3H), 7.57-7.54 (m, 1H), 4.86 (s, 2H), 4.22 (s, 2H), 3. 31 (m, 4H), 2.99 (m, 2H). MS m/z 422 (M+H).

EXAMPLE 270. I- (4-Amino-quinazolin-7-vimeth(6-chloro-benzothioazol-2-vlmeth yl)-piperazin- 2-one.

To a solution of 1- (4-amino-quinazolin-7-ylmethyl)-piperazin-2-one (76 mg, 0.23 mmol), EXAMPLE 72, in 2 mLof DMF is added potassium carbonate (127 mg, 0.92 mmol) followed by 6- chloro-2-chloromethyl-benzothiazole (prepared according to the procedure of B. L. Mylari, Synthesis Comm. 1989,16,2921) (50 mg, 0.23 mmol). The resulting mixture is stirred overnight at room temperature. The undissolved potassium carbonate is removed by filtration and the mother liquor is purified by reverse phase HPLC (10-100% CH3CN/H2O). The desired is product is obtained as a white solid with a melting point of 123-126°C. C, H, 9C1N60S MS m/z: 439,441. Anal. cald. for C21H19ClN6OS#2C2HF3O2 : C, 45.02; H, 3. 17 N, 12.60. Found C, 44.15; H, N, 11.79.

EXAMPLE 271. 1- (4-Amino-quinazolin-7-vlmethyl)- (6-chloro-benzooxazol-2-ylmethyl)-piperazin-2- one.

The desired product (10.0 mg, 7 %) is isolated as a white solid. C21H19ClN6O2 MS m/z: 423,425.

EXAMPLE 272. 1- (4-Amino-quinazolin-7-vlmethYl)-4- (5-chloro-benzothioazol-2-vlmethvl)-piperazin- 2-one.

The desired product (19.0 mg, 22%) is obtained as a white solid. C,, HlgCIN, OS MS m/z: 438,440. Anal. cald. for C,, H, gCIN, OS-2C, HF302 : C, 45.02; H, 3.17 N, 12.60. Found C, 43. 35; H, 3.26; N, 12.65. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>EXAMPLE 273. 3-r4- (4-Aminoquinazoline-7-vlmethvl)-3-oxopiperazin-1-vlmethvll-7 -chloro-IH-<BR> <BR> <BR> <BR> <BR> <BR> <BR> guinolin-2-one.

The title compound is prepared as described in EXAMPLE 268, substituting 3-bromomethyl-7- chloro-1H-quinoline-2-one, EXAMPLE 8, for 2-bromomethyl-6-chlorobenzo [b] thiophene. The product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0. 1% TFA) to 50% CH3CN/H2O (0. 1% TFA). The appropriate collected fractions are lyopholized to afford the title compound as a white solid.

'HNMR (d6-DMSO, 300MHz) 6 12.18 (bs, 1H), 9.75 (m, IH), 8.86 (s, IH), 8.40 (m, 1H), 8.11 (d, 1H), 8.10 (s, 1H), 7.78 (m, 1H), 7.69 (m, 2H), 7.37 (m, 1H), 4.80 (s, 2H), 4.10 (m, 2H), 3.47 (m, 4H), 3.30 (m, 2H). MS (ion spray) m/z 449, (M+H).

1-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-1H-indol-6- ylmethyl)-piperazin-2-EXAMPLE274. one.

A. 1- (4-Amino-quinazolin-7-vlmethyl)-4- (3-chloro-1- (toluene-4-sulfonvl)-1H-indol-6-vlmethyl)- piperazin-2-one.

The title compound is prepared as described in EXAMPLE 268 using 6-bromomethyl-3-chloro- 1- (toluene-4-sulfonyl)-IH-indole, EXAMPLE 16, in place of 2-bromomethyl-6-chloro- benzo [b] thiophene. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H20 (0.1% TFA) to 80% CH3CN/H, O (0.1% TFA) and the appropriate product fractions are combined and lyopholized to give a white solid. 'H NMR (DMSO-d6,300 MHz) 8 9.75 (bs, 2H), 8.82 (s, 1H), 8.40 (d, 1H), 7.64 (m, 2H), 7.60 (m, 2H), 7.40 (d, 1H), 7.23 (m, 1H), 7.19 (m, 2H), 6.99 (d, 2H), 5.09 (s, 2H), 4.78 (s, 2H), 4.10 (m, 2H), 3.40 (m, 4H), 2.49 (s, 3H).

B. 1- (4-Amino-quinazolin-7-vlmethvl)-4- (3-chloro-IH-indol-6-vlmethvl) -piperazin-2-one.

To a solution of 1- (4-amino-quinazolin-7-ylmethyl)-4- (3-chloro-1- (toluene-4-sulfonyl)-lH- indol-6-ylmethyl)-piperazin-2-one ditrifluoroacetate (31 mg, 0.04 mmol) in 2 mL of MeOH is added 0.3 mL of IN NaOH solution. The solution is heated at 100°C for 3 hours. After this time, the solution is diluted with water/acetonitrile and neutralized with trifluoroacetic acid. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H, O (0. 1% TFA) to 60% CH3CN/H20 (0. 1% TFA) and

the appropriate product fractions are combined and lyopholized to give the title compound (21 mg, 0.03 <BR> <BR> <BR> <BR> mmol) as a white solid.'H NMR (DMSO-d6,300 MHz) 6 9.71 (bs, 2H), 8.81 (s, 1H), 8.40 (d, 1H), 7.63 (m, 3H), 7.53 (d, 1H), 7.50 (s, 1H), 7.20 (d, IH), 4.78 (s, 2H), 4.30-3.10 (m, 8H). ESI MS, [M+H]+=421, 423 (Cl pattern).

EXAMPLE 275.1- (4-Amino-quinazolin-7-ylmethyl)-4-r3- (5-chloro-thiophen-2-vl)- (E)-allvll-piperazin- 2-one.

To a solution of 1- (4-amino-quinazolin-7-yimethyl)-piperazin-2-one bishydrochloride (100 mg, 0.31 mmol), EXAMPLE 72, in 3 mL of DMF is added 2- (3-bromo- (E)-propenyl)-5-chloro-thiophene (73 mg, 0. 31 mmol), prepared as described in EXAMPLE 17., and K, C03 (0.21 g, 1.54 mmol). The solution is stirred at room temperature for 16 hours. After this time, the solution is diluted with water/acetonitrile and neutralized with trifluoroacetic acid. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1 % TFA) to 60% CH, CN/H, O (0. 1 % TFA) and the appropriate product fractions are combined and lyopholized to give the title compound (80 mg, 0.12 mmol) as a white solid.

'H NMR (DMSO-d6,300 MHz) 8 9.76 (bs, 2H), 8.81 (s, 1H), 8.40 (d, 1H), 7.70 (s, 1H), 7.62 (dd, 1H), 7.10 (m, 2H), 6.90 (d, 1H), 6.05 (dt, 1H), 4.80 (s, 2H), 3.77 (m, 4H), 3.50 (m, 2H), 3.37 (m, 2H). ESI MS, [M+H]+=414, 416 (Cl pattern). Anal. (C2oH2oCIN5OS2. 0TFA l. lH2O) C, H, N.

EXAMPLE 276. 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2- yl)-but-2-(E)-enyl]- piperazin-2-one ditrifluoroacetate.

'H NMR (DMSO-d,, 300 MHz) 6 9.70 (bs, 2H), 8.82 (s, 1H), 8.40 (d, 1H), 7.68 (s, 1H), 7.61 (d, 1H), 7.10 (m, 2H), 5.88 (t, 1H), 4.79 (s, 2H), 3.75 (m, 4H), 3.49 (m, 2H), 3.29 (m, 2H), 2.09 (s, 3H). El MS, [M+H] +=427,429 (Cl pattern).

EXAMPLE 277.1- (4-Amino-quinazolin-7-vlmethvl)-4-r3- (5-chloro-thiophen-2-vl)-2-methvl- (E)-allvll- piperazin-2-one ditrifluoroacetate.

1H NMR (DMSO-d6, 300 MHz) # 9. 80 (bs, 2H), 8.85 (s, 1H), 8.41 (d, IH), 7.70 (s, 1H), 7.68 (d, 1H), 7.06 (d, 1H), 7.05 (d, 1H), 6.70 (bs, 1H), 4.80 (s, 2H), 4. 30 (bs, 2H), 3.45 (m, 4H), 3.10 (m, 2H), 1.99 (s, 3H). ESI MS, [M+H] +=428,430 (Cl pattern).

EXAMPLE 278.1- (4-Amino-quinazolin-7-vimethyl)-4-r3- (4-bromo-furan-2-yi)- (E)-alivil-piperazin-2- one.

To a solution of 1- (4-amino-quinazolin-7-ylmethyl)-piperazin-2-one (50 mg, 0.20 mmol), EXAMPLE 72. in 3 mL of acetonitrile is added 3- (4-bromo-furan-2-yl)- (E)-propenal (43 mg, 0.22 mmol), prepared as described in EXAMPLE 18,2 drops of HOAc and sodium triacetoxyborohydride (62

mg, 0.29 mmol). The solution is stirred at room temperature for 16 hours. After this time, the solution is diluted with water/acetonitrile. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0. 1% TFA) to 80% CH3CN/H2O (0. 1 % TFA) and the appropriate product fractions are combined and lyopholized to give the title compound (48 mg, 0.07 mmol) as a white solid.'H NMR (DMSO-d6,300 MHz) 8 9.75 (bs, 2H), 8.85 (s, 1H), 8.60 (d, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.62 (d, 1H), 6.80 (s, 1H), 6.65 (d, 1H), 6.19 (dt, 1H), 4.80 (s, 2H), 3.70 (m, 4H), 3.50 (m, 2H), 3.28 (m, 2H). ESI MS, [M+H]'-441,443 (Br pattern).

EXAMPLE 279. 1- (4-Amino-quinazolin-7-vlmethvl)-4-f3- (6-methoxy-pyridin-3-vl)- (E)-allvll- piperazin-2-one.

Nitrogen (g) is bubbled through a solution of 1- (4-amino-quinazolin-7-ylmethyl)-piperazin-2- one (100 mg, 0. 39 mmol), EXAMPLE 72, in 2 mL of CH3CN. After 5 min, acetic acid 3- (6-methoxy- pyridin-3-yl)-(E)-allyl ester (75 mg, 0. 36 mmol, prepared as described in EXAMPLE 19 in 2 mL of CH3CN, palladium (II) acetate (catalytic amount), triphenylphosphine (catalytic amount), 2 mL of H, O and 0.5 mL of triethylamine are added to the solution. The mixture is heated at 80°C for 1 hours. At this time, the mixture is cooled, filtered and concentrated in vacuo. The crude material is purified by RP- HPLC eluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 60% CH3CN/H, O (0. 1 % TFA) and the appropriate product fractions are combined and lyopholized to give the title compound (44 mg, 0.07 mmol) as a white solid.'H NMR (DMSO-d6,300 MHz) 8 9.86 (s, 1H), 9.79 (s, 1H), 8.83 (s, 1H), 8.40 (d, IH), 8.25 (s, 1H), 7.95 (d, 1H), 7.75 (s, 1H), 7.63 (d, 1H), 6.86 (d, 1H), 6.82 (d, 1H), 6.32 (dt, 1H), 4.78 (s, 2H), 3.98 (s, 2H), 3.93 (m, 2H), 3.85 (s, 3H), 3.53 (m, 4H). ESI MS, [M+H] +=405.

EXAMPLE 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2- yl)-(E)-allyl]-4-oxy- piperazin-2-one.

To a solution of I- (4-amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- (E)-allyl]- piperazin-2-one ditrifluoroacetate (0.60 g, 0.94 mmol), prepared as described in EXAMPLE 275, in 25 mL of CH2CI2 is added m-chloroperoxybenzoic acid (0. 30 g, 0.96 mmol, 55% pure grade). The mixture is stirred at room temperature for 3 h and then concentrated in vacuo. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1 % TFA) to 60% CH, CN/H, O (0. 1 % TFA) and the appropriate product fractions are combined and lyopholized to give the title compound (0.5 mg, 0.76 <BR> <BR> <BR> <BR> mmol) as a white solid.'H NMR (DMSO-d6,300 MHz) 6 9.68 (bs, 2H), 8.79 (s, 1H), 8.39 (d, IH), 7.68 (s, 1H), 7.60 (d, 1H), 7.17 (d, 1H), 7.12 (d, 1H), 7.06 (d, 1H), 6.17 (dt, 1H), 4.84 (s, 2H), 4.53 (m, 2H), 4.50 (AB, 2H), 4.04 (m, 2H), 3.78 (m, 1H), 3.60 (m, 1H). ESI MS, [M+H] +=430,432 (Cl pattern).

Anal. (C2oH2oCIN502S 2. OTFA 1.4H20) C, H, N.

EXAMPLE 281. I- (4-Amino-quinazolin-7ylmethyl)-4-r3 (5-chloro-thiophen-2-yl)-prop-2-ynvll- piperazin-2-one.

The title compound is prepared as described in EXAMPLE 275 using 2- (3-bromo-prop-1-ynyl)- 5-chloro-thiophene (prepared as described in EXAMPLE 20) in place of 2- (3-bromo- (E)-propenyl)-5- chloro-thiophene. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H, O (0. 1% TFA) to 70% CH3CN/H2O (0. 1% TFA) and the appropriate product fractions are combined and lyopholized to give the title compound as a white solid.'H NMR (DMSO-d6,300 MHz) 8 9.77 (bs, 2H), 8.83 (s, IH), 8. 38 (d, 1H), 7.63 (d, 1H), 7.58 (s, 1H), 7.25 (d, 1H), 7.13 (d, 1H), 4.74 (s, 2H), 3.74 (s, 2H), 3. 32 (m, 4H), 2.85 (m, 2H). ESI MS, [M+H]+=412, 414 (Cl pattern).

EXAMPLE 282. 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2- yl)-propyl]-piperazin- 2-one The title compound is prepared as described in EXAMPLE 278 using 3- (5-chloro-thiophen-2- yl)-propionaldehyde (EXAMPLE 28, Part A) in place of 3- (4-bromo-furan-2-yl)- (E)-propenal. The crude material is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H, O (0. 1% TFA) to 60% CH3CN/H2O (0.1% TFA) and the appropriate product fractions are combined and lyopholized to give the title compound as a white solid.'H NMR (DMSO-d6,300 MHz) 8 9.77 (bs, 2H), 8.81 (s, 1H), 8.39 (d, 1H), 7.71 (s, 1H), 7.60 (d, 1H), 6.95 (d, 1H), 6.77 (d, 1H), 4.78 (s, 2H), 3.88 (m, 2H), 3.50 (m, 2H), 3.42 (m, 2H), 3.05 (m, 2H), 2.80 (t, 2H), 1.96 (m, 2H). ESI MS, [M+H]+=416, 418 (Cl pattern).

EXAMPLE 283. 1-(4-Amino-quinazolin-7-ylmethyl)-4-prop-2-ynyl-piperazin-2- one, A. 1-(4-Amino-quinazolin-7-vlmethvl)-4-prop-2-ynyl-piperazin-2- one.

Propargyl bromide (0.29 g, 1.95 mmol) is added to a solution containing 1- (4-amino-quinazolin- 7-ylmethyl)-piperazin-2-one (0.5 g, 1.95 mmol), EXAMPLE 72, and K2CO3 (0.40 g, 2.93 mmol) in DMSO (10 mL) at ambient temperature. After 15 min, the reaction mixture is partitioned between aqueous NaHC03 (100 mL) and CH2CI2 (100 mL) and the layers are separated. The aqueous phase is subsequently saturated with NaCI and extracted three times with CHCl3 (50 mL). The combined organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated. The residue is purified by flash silica gel chromatography (CH, C12 to 10% MeOH/CH2CI2) to provide 390 mg (68%) of the title compound as a white solid.'H NMR (300 MHz, CDC13) 8 2.68 (m, 1H), 3.13-3.37 (m, 6H), 4.07 (app q, J = 5.2 Hz, 1H), 4.63 (s, 2H), 7.28 (dd, J = 8.4,1.4 Hz, 1 H), 7.42 (s, 1H), 7.72 (br s, 2H), 8.14 (d, J = 8.4 Hz, 1H), 8. 34 (s, 1H) ppm; MS (ISP loop): m/z 296 (M+H).

EXAMPLE 284.1-(4-Amino-quinazol in-7-vlmethvl)-4-(3-biphenvl-2-el-prop-2-vnvl)-piperazin-2-o ne.

A solution containing 1- (4-amino-quinazolin-7-ylmethyl)-4-prop-2-ynyl-piperazin-2-on e (50 mg, 0.17 mmol), EXAMPLE 283,2-bromobiphenyl (44 mg, 0.19 mmol), Et3N (69 mg, 0.68 mmol), (Ph3P), PdCI, (6 mg, 0.008 mmol), and Cul (I mg, 0.005 mmol) in anhydrous DMF (2 mL) is warmed at 80°C for 1 hours. The reaction mixture is cooled to 50 °C and the solvent is removed over 16 h under a stream of nitrogen. The crude residue is purified by flash silica gel chromatography (CH, Cl, to 10% MeOH CH, CI,) to afford a colorless gum which is triturated with ethyl alcohol to provide 4 mg (5%) of <BR> <BR> <BR> the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 8 3.03 (s, 2H), 3.14 (m, 2H), 3. 31 (m, 2H), 3.50 (s, 2H), 7.21-7.55 (m, 11H), 7.76 (br s, 2H), 8.18 (d, J = 8.6 Hz, 1H), 8.36 (s, IH) ppm; MS (ion spray): m/z 448 (M+H). <BR> <BR> <BR> <BR> <BR> <BR> <P>EXAMPLE 285. 1- (4-Amino-quinazolin-7-vlmethyl)-4- (1H-pvrrolof3, 2-clpvridin-2-vlmethvl)-<BR> <BR> <BR> <BR> <BR> pperazin-2-one.

A. (3- {3-f4- (4-Amino-ouinazolin-7-vlmethyl)-3-oxo-piperazin-l-vn-prop-l- vnvl}-pvridin-4-yl)- carbamic acid tert-butvl ester.

A solution containing 1- (4-amino-quinazolin-7-ylmethyl)-4-prop-2-ynyl-piperazin-2-on e (100 mg, 0.34 mmol), EXAMPLE 283, (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester, EXAMPLE 69, Part B, (108 mg, 0.34 mmol), Et3N (140 mg, 1.36 mmol), (Ph3P) 4PdCI2 (12 mg, 0.017 mmol), and Cul (2 mg, 0.01 mmol) in anhydrous DMF (5 mL) is stirred at ambient temperature. After 5 h, the reaction mixture is diluted with EtOAc (50 mL) and water (50 mL) and the layers are separated. The aqueous layer is extracted twice with EtOAc (25 mL) and the combined organic phase is washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude residue is purified by flash silica gel chromatography (CH2CI2 to 10% MeOH CH, C12) to provide 59 mg (36%) of SC34 as a colorless oil.'H NMR (300 MHz, CDCl3) 8 1.49 (s, 9H), 2.84 (m, 2H), 3.35 (m, 2H), 3.44 (s, 2H), 3.71 (s, 2H), 4.75 (s, 2H), 6.19 (br s, 2H), 7.24 (d, J = 5.5 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.66 (s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 5.5 Hz, 1H), 8.37 (s, 1H), 8.49 (s, 1H), 8.58 (s, 1H) ppm; MS (ISP loop): m/z 488 (M+H).

B. 2-r4-(4-Amino-quinazolin-7-vlmethvl)-3-oxo-piperazin-1-ylmet hvll-pvrrolo [32-cloYridine-1- carboxylic acid tert-butyl ester.

1,8-Diazabicyclo [5.4.0] undec-7-ene (37 mg, 0.24 mmol) is added to a suspension containing (3- <BR> <BR> <BR> <BR> {3- [4- (4-amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-I-yl]-prop-I -ynyl}-pyridin-4-yl)-carbamic acid tert-butyl ester (59 mg, 0.12 mmol) in anhydrous CH3CN (5 mL) and the mixture is warmed to 50 °C.

Dimethylformamide (I mL) is added to solubilize and the homogeneous solution is maintained for 5 h at 50°C. The reaction mixture is diluted with EtOAc (50 mL) and water (50 mL) and the layers are

separated. The aqueous layer is extracted twice with EtOAc (25 mL) and the combined organic phase is washed with brine, dried over anhydrous NaSO, filtered and concentrated to provide 50 mg of the product as a crude solid which is used directly without further purification.'H NMR (300 MHz, CDCl3) 8 1.64 (s, 9H), 2.78 (m, 2H), 3.30 (m, 2H), 3. 37 (s, 2H), 3.95 (s, 2H), 4.74 (s, 2H), 6.24 (br s, 2H), 6.63 (s, 1H), 7.40 (dd, J = 8.5,1.6 Hz, 1H), 7.64 (s, 1H), 7.81 (d, J = 5.8 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.99 (s, 1H), 8.39 (d, J = 5.8 Hz, 1H), 8.58 (s, 1H), 8.77 (s, 1H) ppm.

C. 1- (4-Amino-quinazolin-7-ylmethyl)-4- ( I H-pvrrolor3, 2-clp, vridin-2-vlmethyl)-piperazin-2-one.

To a solution containing 2- [4- (4-amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]- pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (50 mg, 0.12 mmol) in CH, CI, (5 mL) is added TFA (I mL) at ambient temperature. After 16 h, the reaction mixture is concentrated to dryness, diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/ 0.1 % TFA; Gradient: 0% B to 45% B over 30 min] to provide 34 mg (73%, two steps) of the title compound as a white, lyophilized solid.'H NMR (300 MHz, CDCl3) 8 2.77 (s, 3H), 3.23 (s, 2H), 3.31 (m, 2H), 3.89 (s, 2H), 4.00 (br s, 3H), 4.71 (s, 2H), 6.94 (s, iH), 7.60 (m, 2H), 7.84 (d, J = 6.5 Hz, 1H), 8.36 (m, 2H), 8.81 (s, 1H), 9.18 (s, 1H), 9.73 (br s, 2H), 12.87 (s, 1H) ppm; MS (ion spray): m/z 388 (M+H).

The following compounds are prepared from the compound of Example 72 using the procedures described above. Example# Name m/z (M+H) 286 I- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2- 418, 420 yloxy)-ethyl]-piperazin-2-one Cl pattern 287 I-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1-methyl-I H-435,(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1-methyl-I H-435, 437 indoi-2-ylmethyl)-piperazin-2-one Cl pattern 288 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2- 414, 416 yl)-allyl]-piperazin-2-one Cl pattern 289 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (6-chloro- 464,466 benzo [b] thiophen-2-yl)-allyl]-piperazin-2-one Cl pattern 290 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-4-methyl- 428,430 thiophen-2-yl)-allyl]-piperazin-2-one Cl pattern 291 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzofuran-2- 422,424 ylmethyl)-piperazin-2-one Cl pattern 421,4232921-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-1H-i ndol-5- ylmethyl)-piperazin-2-one Cl pattern 293 423421, ylmethyl)-piperazin-2-one Cl pattern 455,4572941-(4-Amino-quinazolin-7-ylmethyl)-4-(5,7-dichloro- 1H-indol- 2-ylmethyl)-piperazin-2-one CI pattern 421,4232951-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-1H-i ndol-2- ylmethyl)-piperazin-2-one Cl pattern 296 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-p-tolyl-prop-2-ynyl)- 386 piperazin-2-one 297 I- (4-Amino-quinazolin-7-ylmethyl)-4- (3-m-tolyl-prop-2-ynyl)- 386 piperazin-2-one 298 408406, prop-2-ynyl]-piperazin-2-one Cl pattern 299 I- (4-Amino-quinazolin-7-ylmethyt)-4- [3- (3-chloro-phenyl)- 406,408 prop-2-ynyl]-piperazin-2-one Cl pattern 300 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (2-chloro-phenyl)- 406 prop-2-ynyl]-piperazin-2-one 4483011-(4-Amino-quinazolin-7-ylmethyl)-4-(3-biphenyl-4-yl-p rop-2- ynyl)-piperazin-2-one 302 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4, 5-dibromo- 536,538,540 thiophen-2-yl)-allyl]-piperazin-2-one Br, pattern 303 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-biphenyl-3-yi-prop-2- 448 ynyl)-piperazin-2-one 446,4483041-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(2,5-dichlo ro- thiophen-3-yl)-prop-2-ynyl]-piperazin-2-one Cl pattern 305 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-chloro-phenyl)- 410, 412 propyl]-piperazin-2-one Cl pattern 306 415 307 1- (4-Amino-quinazolin-7-ylmethyl)-4-(1H-pyrrolo [2,3- 388 c]pyridin-2-ylmethyl)-piperazin-2-one 308 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-nitro-thiophen-2- 425 yl)-allyl]-piperazin-2-one 309 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (6-chloro-pyridin-3- 409, 41 1 yl)-allyl]-piperazin-2-one C ! pattern 310 1-(4-Amino-quinazolin-7-ylmethyl)-4-(1H-pyrrolo [3,2- 388 c]pyridin-2-ylmethyl)-piperazin-2-one 311 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-3- 414,416 yl)-allyl]-piperazin-2-one Cl pattern 312 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-furan-2-yl)- 442,444 allyl]-piperazin-2-one Br pattern 313 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (5-methyl-thiophen-2- 420 yl)-penta-2,4-dienyl]-piperazin-2-one 314 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro- 438,440 benzo [b] thiophen-5-ylmethyl)-piperazin-2-one Cl pattern 315 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-methyl-thiophen-2- 394 yl)-allyl]-piperazin-2-one 316 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-methoxy-thiophen- 410 2-yl)-allyl]-piperazin-2-one 448,4503174-(1-Amino-7-chloro-isoquinolin-3-ylmethyl)-1-(4-a mino- patternquinazolin-7-ylmethyl)-piperazin-2-oneCl 318 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]-431 N- (5-chloro-thiophen-2-yl)-acetamide 319 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3- 433,435 patternylmethyl)-piperazin-2-oneCl 320 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (3-chloro-phenyl)-2- 412, 414 (S)-hydroxy-ethyl]-piperazin-2-one Cl pattern 321 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (3-chloro- 428,430 phenylsulfanyl)-ethyl]-piperazin-2-one Cl pattern 322 470 2, 3-dihydro-1H-11 6-benzo [b] thiophen-3-yl)-piperazin-2-one 323 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-nitro-phenyl)- 419 allyl]-piperazin-2-one 438,4403241-(4-Amino-quinazolin-7-ylmethyl)-4-(2-chloro- benzo [b] thiophen-6-ylmethyl)-piperazin-2-one Cl pattern 325 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]- 425, 427 N- (4-chloro-phenyl)-acetamide Cl pattern 326 1- (4-Amino-quinazolin-7-ylmethyl)-4- [1- (4-chloro-phenyl)- 437,439 pyrrolidin-3-yl]-piperazin-2-one Cl pattern 327 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2- 402,404 yl)-ethyl]-piperazin-2-one Cl patten 410,4123281-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-chloro-p henyl)- propyl]-piperazin-2-one Cl pattern 329 2- [4- (4-Aminoquinazoiine-7-ylmethyl)-3-oxo-piperazin-1--452,454 ylmethyl]-3- (4-chlorophenyl)-acrylic acid Cl pattern 330 451449, isoquinolin-3-ylmethyl)-piperazin-2-one Cl pattern 331 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 432, 434 ylmethyl)-piperazin-2-one Cl pattern 3993321-(4-Amino-quinazolin-7-ylmethyl)-4-isoquinolin-3-ylme thyl- piperazin-2-one 437,4393331-(4-Amino-quinazolin-7-ylmethyl)-4-[1-(3-chloro-p henyl)- pyrrolidin-3-yl]-piperazin-2-one Cl pattern 334 t- (4-Amino-quinazolin-7-ylmethyl)-4- (t, 7-dichloro- 467,469 isoquinolin-3-ylmethyl)-piperazin-2-one Cl pattern 335 4- (2-Amino-7-chloro-quinolin-3-ylmethyl)-1- (4-amino- 448,450 quinazolin-7-ylmethyl)-piperazin-2-one Cl pattern 336 I- (4-Aminoquinazolin-7-ytmethyl)-4- (5-chloro- 438,440 benzo [b] thiophene-2-ylmethyl) piperazin-2-one. Cl pattern 428,4303371-(4-Amino-quinazolin-7-ylmethyl)-4-[2-(4-chloro- phenylsulfanyl)-ethyl]-piperazin-2-one Cl pattern 338 454452, benzo [b] thiophen-2-yl)-ethyl]-piperazin-2-one Cl pattern 339 414412, ethyl]-piperazine-2-one Cl pattern 340 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1--469, 471 ylmethyl]-6-chloro-4H-benzo [1,4] thiazin-3-one Cl pattern -dichloro-quinolin-3-467,4693411-(4-Amino-quinazolin-7-ylmet hyl)-4-(2,7 ylmethyl)-piperazin-2-on pattern 342 482480, (4-chloro-phenyl)-methyl]-acrylic acid ethyl ester Cl pattern 343 482480, yimethyl]-3- (4-chloro-phenyl)-acrylic acid ethyl ester Cl pattern 408,4103441-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-chloro-p henyl)- patternallyl]-piperazin-2-oneCl 345 1- (4-Amino-quinazolin-7-yimethyl)-4- [3- (3-chloro-phenyl)- 408,410 allyl]-piperazin-2-one Cl pattern 346 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2- 458,460 patternyl)-allyl]-piperazin-2-oneBr 347 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2- 458,460 yl)-allyl]-piperazin-2-one Br pattern 348 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-I-433 ylmethyl]-7-fluoro-I H-quinolin-2-one 349 452450, ylmethyl]-6-chloro-1 H-quinoxalin-2-one Cl pattern 350 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-1-methyl-I H-436, 438 benzoimidazol-2-ylmethyl)-piperazin-2-one Cl pattern 351 2- [4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1- 492, 494 ylmethyl]-6-chloro-3H-quinazolin-4-one Cl pattern 352 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-thiophen-2-yl- 382 propyl)-piperazin-2-one 353 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-quinolin-3- 432, 434 ylmethyl)-piperazin-2-one Cl pattern 354 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1- 483,485 patternylmethyl]-5,7-dichloro-1H-quinolin-2-oneCl 355 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6, 7-dichloro- 472,474 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one CI, pattern 356 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-l- 449,451 ylmethyl]-5-chloro-I H-quinolin-2-one Cl pattern 357 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro- 470,472 [2,3'] bithiophenyl-5'-ylmethyl)-piperazin-2-one Cl pattern 358 4- (6-Amino-benzo [b] thiophen-2-ylmethyl)-1- (4-amino- 419 quinazolin-7-ylmethyl)-piperazin-2-one 359 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro-quinolin-6- 433,435 ylmethyl)-piperazin-2-one Cl pattern 466,4683601-(4-Amino-quinazolin-7-ylmethyl)-4-[6-bromo-1H- benzoimidazol-2-ylmethyl)-piperazin-2-one Br pattern 361 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-nitro- 449 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one 362 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (3-chloro-phenyl)- 464,466 thiophen-2-ylmethyl]-piperazin-2-one 363 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-3-methoxy- 468,470 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 364 3- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1- 449, 451 ylmethyl]-6-chloro-I H-quinolin-2-one Cl pattern 3653 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-trifluoromethyl-1H-456 benzoimidazol-2-ylmethyl)-piperazin-2-one 366 450 [2,2']bithiophenyl-5-ylmethyl)-piperazin-2-one 367 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-methyl- 418 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one 368 500498, [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one Cl pattern 602,604,6063691-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(3,5-di bromo-4- methoxy-phenyl)- [1,2,4joxadiazol-5-ylmethyl]-piperazin-2-one Br, pattern 370 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-methyl- 418 benzo[b] thiophen-2-ylmethyl)-piperazin-2-one 371 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-methyl- 418 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one 372 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro- 438,440 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 373 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro-3'-methyl- 484,486 [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one Cl pattern 374 388 ylmethyl)-piperazin-2-one 375 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-bromo- 514,516 [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one Br pattern 376 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (2, 3-dihydro- 473 benzo [1,4] dioxin-6-yl)-oxazol-2-ylmethyl]-piperazin-2-one 377 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5, 6-dichloro- 472,474 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 378 1- (4-Amino-quinazolin-7-yfmethyl)-4- (4, 5-dichioro- 472,474 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 379 1- (4-Amino-quinazolin-7-yimethyl)-4- (5-chloro-benzooxazol- 423,425 2-ylmethyl)-piperazin-2-one Cl pattern 380 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-5-fluoro- 456,458 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 381 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-chloro-5-fluoro- 456,458 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 484,4863821-(4-Amino-quinazolin-7-ylmethyl)-4-(5'-chloro-3-m ethyl- [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one Cl pattern 383 1- (4-Amino-quinazolin-7-ylmethyt)-4- (5-chloro-thieno [3,2- 439, 441 b] pyridin-2-ylmethyl)-piperazin-2-one Cl pattern 384 I-(4-Amino-quinazolin-7-ylmethyl)-4-(5, 6-dichloro-I H-456 benzoimidazol-2-ylmethyl)-piperazin-2-one 385 I- (4-Amino-quinazolin-7-ylmethyl)-4- (3-benzooxazol-2-yl- 464 benzyl)-piperazin-2-one 386 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (4-chloro-phenyl)- 464,466 thiophen-2-ylmethyl]-piperazin-2-one Cl pattern 387 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-methyl- I H-402 benzoimidazol-2-ylmethyl)-piperazin-2-one 388 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2,2'] bithiophenyl-5- 435 ylmethyl-piperazin-2-one 4223891-(4-Amino-quinazolin-7-ylmethyl)-4-(4-fluoro- benzo [b] thiophen-2-ylmethyl)-piperazin-2-one 390 1- (4-Aminoquinazolin-7-ylmethyl)-4- (6-fluoro- 422 benzo [b] thiophene-2-ylmethyl) piperazin-2-one. 391 501 methyl-1H-pyrazol-3-yl)-thiophen-2-ylmethyl]-piperazin-2-one 392 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3, 4-dimethyl- 438 thieno [2,3-b] thiophen-2-ylmethyl)-piperazin-2-one 452,4543931-(4-Amino-quinazolin-7-ylmethyl)-4-(4-chloro-3-me thyl- benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 452,4543941-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-3-me thyl- benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 395 1- (4-Amino-quinazolin-7-yimethyl)-4- [5- (2-methyl-5- 502 trifluoromethyl-2H-pyrazol-3-yl) thiophen-2-ylmethyl] piperazin-2-one 396 1- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (3-nitro-phenyl)- 459 furan-2-ylmethyl]-piperazin-2-one 397 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-thieno [3,2-439,441 b) pyridin-6-ylmethyl)-piperazin-2-one Cl pattern 398 I- (4-Amino-quinazolin-7-ylmethyl)-4- [5- (4-methoxy-phenyl)- 460 thiophen-2-ylmethyl]-piperazin-2-one 399 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-hydroxy-2-pyridin-2- 443 y-pyrimidin-5-ylmethyl)-piperazin-2-one 400 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-fluoro-phenoxy)- 458 benzyi]-piperazin-2-one 401 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (4-chloro-phenyl)- 465,467 thiazol-4-ylmethyl]-piperazin-2-one Cl pattern 402 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-bromo- 482,484 benzo [bjthiophen-2-ylmethyl)-piperazin-2-one Br pattern 403 1- (4-Amino-quinazolin-7-ylmethyl)-4-benzo [b] thiophen-2- 404 ylmethyl-piperazin-2-one 404 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- 470,472 [2,2'] bithiophenyl-5-ylmethyl)-piperazin-2-one Cl pattern 405 I- (4-Amino-quinazolin-7-ylmethyl)-4- (3, 5-bis-trifluoromethyl- 488 benzyl)-piperazin-2-one 406 1- (4-Amino-quinazolin-7-ylmethyl)-4-biphenyl-4-ylmethyl- 423 (M+) piperazin-2-one 407 I- (4-Amino-quinazolin-7-ylmethyl)-4-naphthalen-2-ylmethyl- 397 (M+) piperazin-2-one 408 1- (4-Amino-quinazolin-7-yimethyl)-4- (5-chloro- 438,440 benzo [b] thiophen-3-ylmethyl)-piperazin-2-one Cl pattern 409 1- ino-quinazolin-7-ylmethyl)-4- (6-chloro-thieno [2, 3-438, 440 (M+), b] pyridin-2-ylmethyl)-piperazin-2-one Cl pattern

EXAMPLE 1-(4-Aminoquinazolin-7-ylmethyl)-4-[3-(5-chloro-thiophen-2-y l)-(E)- acrvloyllpiperazin-2-one.

The title compound is prepared as described in EXAMPLE 123 using 1- (4-aminoquinazoline-7- ylmethyl) piperazine-2-one bishydrochloride, EXAMPLE 72, in place of 4- (2-oxopiperazin-1- ylmethyl) benzamidine bistrifluoroacetate.'H NMR (d6-DMSO, 300 MHz) 8 9.77 (bs, 2H), 8.83 (s, 1H), 8.40 (dd, 1H), 7.68 (d, 1H), 7.65 (s, 1H), 7.58 (d, 2H), 7.15 (d, 2H), 4.80 (s, 2H), 4.33,4.15 (m, 2H, rotamers), 3.70 (m, 2H), 3.49 (m, 2H). ESI MS, [M+H]+=456, 458 (Br pattern).

The following compounds are prepared from the compound of Example 72 using the methods described above. Examplem/z[M+H]Name 411 1- (4-Amino-quinazolin-7-ylmethyl)-4- (4-chloro-thiophene-2- 402, 404 carbonyl)-piperazin-2-one Cl pattern 412 4- [3- (3-Amino-4-chloro-phenyl)- (E)-acryloyl]- 1- (4-amino- 437,439 quinazolin-7-ylmethyl)-piperazin-2-one Cl pattern 413 437435, carbonyl)-piperazin-2-one Cl pattern 414 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 432,434 yloxy)-acetyl] piperazin-2-one Cl pattern 415 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-bromo-thiophen-2-yl)- 472,474 (E)-acryloyl]-piperazin-2-one Br pattern 416 5-Chloro-thiophene-2-carboxylic acid {2- [4- (4-amino-quinazolin-7- 459,461 ylmethyl)-3-oxo-piperazin-1-yl]-2-oxo-ethyl}-amide Cl pattern 417 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)- 428,430 (E)-acryloyl]-piperazin-2-one Cl pattern 418 437435, carbonyl)-piperazin-2-one Cl pattern 419 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (6-chloro- 478,480 benzo [b] thiophen-2-yl)-(E)-acryloyl]-piperazin-2-one Cl pattern 420 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- 472,474 (E)-acryloyl]-piperazin-2-one Br pattern 421 5-Chloro-thiophene-2-carboxylic acid {2-[4-(4-amino-quinazolin-7 473, 475 ylmethyl)-3-oxo-piperazin-1-yl]-I-methyl-2-oxo-ethyl}-amide Cl pattern 422 5-Chloro-thiophene-2-carboxylic acid {3- [4- (4-amino-quinazolin-7- 473,475 ylmethyl)-3-oxo-piperazin-1-yl]-3-oxo-propyl}-amide Cl pattern 423 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenoxy)-acetyl]- 426,428 piperazin-2-one Cl pattern 424 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-2-methyl- 440,442 phenoxy)-acetyl]-piperazin-2-one Cl pattern 425 486484, 5-carbonyl)-piperazin-2-one Cl pattern 426 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 430,432 propionyl]-piperazin-2-one Cl pattern 427 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-chloro-phenyl)- (E)- 422,424 acryloyl]-piperazin-2-one Cl pattern 428 N- [2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-yl]-l- 428,430 pattern(5-chloro-thiophen-2-ylmethyl)-2-oxo-ethyl]-benzamide Cl 429 N- [I- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1- 549,550 carbonyl]-2- (5-chloro-thiophen-2-yl)-vinyl]-benzamide Cl pattern 430 N- [I- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-I- 485, 487 patterncarbonyl]-2-(5-chloro-thiophen-2-yl)-vinyl]-acetamide Cl 431 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)- (E)- 422,424 acryloyl]-piperazin-2-one Cl pattern 432 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yl)- 415, 417 acetyl]-piperazin-2-one Cl pattern 433 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro- 451,453 benzo [b] thiophene-2-carbonyl)-piperazin-2-one Cl pattern 434 2- [4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1--483,485 carbonyl]-6-chloro-4H-benzo [1,4] thiazin-3-one Cl pattern 435 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(6-chloro-benzo [b] thiophen-466,468 2-yl)-acetyl]-piperazin-2-one Cl pattern

EXAMPLE 436. 4- (4-Aminoquinazolin-7-vlmethvl)-3-oxopiperazine-1-carboxvlic acid 4-chloro-<BR> <BR> benzylamide.

To a solution of 1- (4-aminoquinazoline-7-ylmethyl) piperazine-2-one (25 mg, 0.097 mmol), EXAMPLE 72, in 1 mL of DMF is added 4-chloro-benzyl isocyanate (22 mg, 0.13 mmol, prepared as described in EXAMPLE 37). After stirring 1 h at room temperature, the solution is concentrated. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 80%

CH3CN/H, O (0. 1% TFA) and the appropriate product fractions are combined and lyopholized to provide<BR> <BR> <BR> <BR> the title compound (36 mg, 0.067 mmol) as a white solid.'H NMR (d6-DMSO, 300 MHz) 8 9.76 (bs, 2H), 8.83 (s, 1H), 8.28 (d, 1H), 7.64 (d, 1H), 7.60 (s, 1H), 7.34 (d, 2H), 7. 31 (m, IH), 7.26 (d, 2H), 4.75 (s, 2H), 4.22 (d, 2H), 4.08 (s, 2H), 3.60 (m, 2H), 3. 35 (m, 2H). ESI MS, [M+H]+=425, 427 (Cl pattern).

EXAMPLE 437. 4- (4-Aminoquinazolin-7-ylmethvl)-3-oxopiperazine-I-carboxvlic acid (5-chloro- thiophen-2-vlmethvl) amide.

To a solution of (5-chloro-thiophen-2-yi)-acetic acid (0.18 g, 1.04 mmol), prepared as described in EXAMPLE 27 in 6 mL of dry CH, CI, is added Et3N (0.15 mL g, 1.04 mmol) and diphenylphosphoryl azide (0.24 mL, 1.04 mmol). The mixture is stirred at room temperature for 2.5 h, then heated at 50°C for 2 hours. To the solution is added 1- (4-aminoquinazoline-7-ylmethyl) piperazine-2-one (0.10 g, 0.41 mmol), EXAMPLE 72, and Et, N (0.15 mL g, I. 04 mmol) and the mixture is heated at 50°C for 2 h, then stirred at room temperature for 16 hours. The resulting mixture is concentrated. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H, O (0. 1 % TFA) to 60% CH3CN/H2O (0.1 % TFA) and the appropriate product fractions are combined and lyopholized to provide the title compound <BR> <BR> <BR> (10 mg, 0.02 mmol) as a white solid.'H NMR (d6-DMSO, 300 MHz) 8 9.69 (bs, 2H), 8.80 (s, IH), 8.48 (d, 1H), 7.61 (d, 1H), 7.60 (s, 1H), 7.41 (t, 1H), 6.90 (d, 1H), 6.80 (d, 1H), 4.77 (d, 2H), 4.30 (d, 2H), 4.10 (s, 2H), 3.61 (m, 2H), 3. 38 (m, 2H). ESI MS, [M+H] +=431,433 (Cl pattern).

EXAMPLE 438. 4- (4-Aminoquinazolin-7-vlmethel)-3-oxopiperazine-1-carboxYlic( 4-Aminoquinazolin-7-vlmethel)-3-oxopiperazine-1-carboxYlic acid (5-chloro- thiophen-2-vl) amide.

A mixture of 5-chloro-thiophene-2-carbonyl azide (55 mg, 0.29 mmol, prepared as described in EXAMPLE 38) and 1- (4-aminoquinazoline-7-ylmethyl) piperazine-2-one (50 mg, 0.20 mmol), EXAMPLE 72, in 3 mL of dry toluene is heated at 105°C for 1 hours. The resulting mixture is concentrated in vacuo. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H20 (0.1% TFA) to 60% CH3CN/H20 (0. 1% TFA) and the appropriate product fractions are combined and lyopholized to provide the title compound (35 mg, 0.02 mmol) as a white solid.'H NMR (DMSO-d6,300 MHz) 8 10.04 (s, 1H), 9.71 (bs, 2H), 8.81 (s, 1H), 8.38 (dd, 1H), 7.64 (d, 1H), 7.61 (s, 1H), 6.77 (d, 1H), 6.42 (d, 1H), 4.76 (s, 2H), 4.21 (s, 2H), 3.73 (m, 2H), 3.40 (m, 2H). ESI MS, pattern).[M+H]+=417,419(Cl The following compounds are prepared from the compound of Example 72 using the methods described above. Example # Name m/z [M+H] 439 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c 417,419 acid (4-chloro-thiophen-2-yl)-amide Cl pattern 440 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c 461, 463 acid (5-bromo-thiophen-2-yl)-amide Br pattern 441 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c 426,428 acid patternCl 442 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c 455, 457 acid (4-bromo-phenyl)-amide Br pattern 443 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c 411, 413 acid (4-chloro-phenyl)-amide Cl pattern 444 4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxy lic 407 acid (4-methoxy-phenyl)-amide 445 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxyli c 445, 447 acid (3,4-dichloro-phenyl)-amide Cl2 pattern

EXAMPLE 446. 4- (4-Amino-quinazolin-7-vlmethvl)-3-oxo-piperazine-1-carboxyli c acid 5-chloro- thiophen-2-ylmethvl ester.

To a solution of 5-chloro-2-thiophene-methanol (0. 10 g, 0.67 mmol, prepared by NaBH4 reduction of 5-chloro-2-thiophene-carboxaldehyde) in 6 mL of CH2CI2 is added l, l'-carbonyldiimidazole (0.11 g, 0.67 mmol). The mixture is stirred at room temperature for 3 hours. Then 1- (4- aminoquinazoline-7-ylmethyl) piperazine-2-one (0.17 g, 0.67 mmol, EXAMPLE 72) and a catalytic amount of DMAP is added to the solution and the resulting mixture is heated at 35°C for 18 hours. The mixture is dissolved in water/MeOH and the crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H20 (0.1% TFA) to 100% CH3CN. The appropriate fractions are combined and lyopholized to provide the title compound as a white solid. ESI MS, [M+H] +=432,434 (Cl pattern).

The following compounds are prepared from the compound of Example 72 using the methods described above. Example # Name m/z [M+H] 447 4-(4-Amino-quinazolin-7-vlmethvl)-3-oxo-piperazin-1-carboxvl ic 467,469 acid 6-chloro-benzooxazol-2-vlmethyl ester Cl pattern 448 4-(4-Amino-quinazolin-7-ylmethyl)-3-oxo-piperazine-1-carboxy l ic 481, 483

esterClpatternacid1-(3-chloro-henyl)-pyrrolidin-3-yl EXAMPLE 449.1- (4-Amino-quinazolin-7-vimethvl)-4- 7-chloro-isoguinolin-3-vimethyl)-3- (S)-methyl- piperazin-2-one.

To a solution of 1- (4-amino-quinazoline-7-ylmethyl)-3-methyl-piperazine-2-one, EXAMPLE 80, (0.06g, 0.2mmol) in 2 mL of DMF is added 3-bromomethyl-7-chloroisoquinoline, EXAMPLE 11, 0.052g, 0.20mmol), and K2CO3 (0.08 g, 0.06 mmol). After 16 h, the reaction mixture is concentrated to dryness. The crude product is purified by RP-HPLC eluting with a gradient of 5% CH, CN/H, O (0.1% TFA) to 50% CH3CN/H, O (0.1% TFA). The product fractions are lyophilized to give the title compound as a tristrisfluoroacetic acid salt (0.06g, 0.08 mmol) as a white solid.'H NMR (d6-DMSO, 300 MHz) 5 9.79 (bs, 2H), 9.40 (s, 1H), 8.73 (s, 1H), 8.33 (d, 1H), 8.25 (s, 1H), 8.06 (s, 1H), 8.00 (d, 1H), 7.79 (d, 1H), 7.60 (m, 2H), 4.80 (AB, 2H), 4.72 (AB, 2H), 4.28 (m, 1H), 3.54 (m, 4H), 1.96 (d, 3H). MS (ion spray) 447,449, (Cl pattern). Elemental analysis C$H25CIF6N606-3CF3CO, H 0. 28H, 0, cal C=45.38%, H=3.35%, N=10.58%; found C=45. 38, H=3.35%, N=10.63%.

4-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-1H-indol-6- ylmethyl)-3-(S)-methyl-EXAMPLE450. piperazin-2-one.

The title compound is prepared as described in EXAMPLE 274 using 1- (4-amino-quinazoline-7- ylmethyl)-3-methyl-piperazine-2-one, EXAMPLE 80.'H NMR (DMSO-d6,300 MHz) # 9. 79 (bs, 2H), 8.82 (s, 1H), 8.39 (d, 1H), 7.61 (m, 3H), 7.57 (d, 1H), 7.52 (d, 1H), 7.49 (d, 1H), 7.20 (d, 1H), 7.10 (d, 1H), 4.75 (AB, 2H), 4.57 (m, 1H), 4.23 (m, 1H), 3.97 (m, 1H), 3.50 (m, 3H), 1.65 (d, 3H). ESI MS, [M+H]+= 435,437 (Cl pattern). Anal. (C23H23ClN6O@2.15TFA@0.25H2O) C, H, N.

The following compounds are prepared from the compound of Example 80 using the methods described above. Example # Name m/z [M+H] 451 I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)- 428, 430 allyl]-3-(S)-methyl-piperazin-2-one Cl pattern 452 I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (6-chloro- 478,480 benzo [b] thiophen-2-yl)-allyl]-3-(S)-methyl-piperazin-2-one Cl pattern 453 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 429,431 patternpropyl]-3-(S)-methyl-piperazin-2-oneCl 454 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-I H-indol-2-435, 437 ylmethyl)-3-(S)-methyl-piperazin-2-one Cl pattern 455 I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 442,444 but-2-enyl]-3-(S)-methyl-piperazin-2-one Cl pattern 456 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl- 483 (M+) 5-ylmethyl)-3- (S)-methyl-piperazin-2-one (EI) 457 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro- I H-benzoimidazol-536, 538 2-ylmethyl)-3-(S)-methyl-piperazin-2-one Cl pattern 458 I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 428, 430 patternallyl]-3-(S)-methyl-piperazin-2-oneCl 459 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 446, 448 ylmethyl)-3- (S)-methyl-piperazin-2-one Cl pattern 453,4554601-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-thie no[2,3- patternb]pyridin-2-ylmethyl)-3-(S)-methyl-piperazin-2-oneCl 461 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen- 452, 454 2-ylmethyl)-3-(S)-methyl-piperazin-2-one Cl pattern 462 ~ (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-benzo [b] thiophen-452,454 2-ylmethyl)-3-(S)-methyl-piperazin-2-one Cl pattern 463 1- (4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-benzo[b]thiophen - 452, 454 2-ylmethyl)-3-(R)-methyl-piperazin-2-one Cl pattern 464 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-452,454 2-ylmethyl)-3-(R)-methyl-piperazin-2-one Cl pattern

EXAMPLE 465 1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-chloro-thiophen-2- yl)-acryloyl]-3-(S)- methvl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 123, using 1- (4-amino-quinazoline-7- ylmethyl)-3-methyl-piperazine-2-one, EXAMPLE 80, and 3- (4-chloro-thiophen-2-yl)- (E)-acrylic acid, EXAMPLE 26. 'H NMR (d6-DMSO, 300 MHz) 6 9.74 (bs, 2H), 8.82 (s, 1H), 8.40 (d, 1H), 7.62 (m, 5H), 7.05 (d, 1H), 4.92 (m, 1H), 4.80 (m, 2H), 4.73 (m, 1H), 4.50 (m, 1H), 3.40 (m, 2H), 1.42 (m, 3H).

ESI MS, (Clpattern).444 The following compounds are prepared from the compound of Example 80 using the methods described above. Example # [M+H]m/z 466 448446, yloxy)-acetyl]-3-(S)-methyl-piperazin-2-one Cl pattern 467 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2- 446,448 patternyloxy)-acetyl]-3-(S)-methyl-piperazin-2-oneCl 486,4884681-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-bromo-th iophen-2-yl)- acryloyl]-3-(S)-methyl-piperazin-2-one Br pattern 469 I-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-I H-indole-6-449, 451 patterncarbonyl)-3-(S)-methyl-piperazin-2-oneCl 470 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinoline-3- 461,463 carbonyl)-3-(S)-methyl-piperazin-2-one Cl pattern 471 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 446,448 yloxy)-acetyl]-3-(S)-methyl-piperazin-2-one Cl pattern 472 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- 486,488 patternacryloyl]-3-(S)-methyl-piperazin-2-oneBr 473 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenoxy)-acetyl]- 440, 442 3-(S)-methyl-piperazin-2-one Cl pattern 474 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5'-chloro- [2,2'] bithiophenyl- 498,500 pattern5-carbonyl)-3-(S)-methyl-piperazin-2-oneCl 475 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 456,458 but-2-enoyl]-3-(S)-methyl-piperazin-2-one Cl pattern 476 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro- 466,468 benzo [b] thiophene-2-carbonyl)-3-(S)-methyl-piperazin-2-one Cl pattern 477 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 442, 444 patternacryloyl]-3-(S)-methyl-piperazin-2-oneCl

EXAMPLE 478.1- (4-Amino-quinazolin-7-vlmethvl)-4-f3- (5-chloro-thiophen-2-vl)-propvll-3- (S)-ethyl- piperazin-2-one.

The title compound is prepared as described in EXAMPLE 278 using 1- (4-aminoquinazoline-7- ylmethyl)-3-ethyl-piperazine-2-one, EXAMPLE 77 and 3- (5-chloro-thiophen-2-yl)-propionaldehyde, EXAMPLE 28.'H NMR (d6-DMSO + I drop TFA, 300 MHz) 8 9.80 (bs, 2H), 8.79 (s, 1H), 8.32 (d, 1H), 7.58 (m, 2H), 6.88 (d, 1H), 6.70 (d, 1H), 4.72 (AB, 2H), 4.00 (m, I H), 3.72 (m, 1H), 3.48 (m, 2H), 3.23 (m, 3H), 2.72 (m, 2H), 1.96 (m, 4H), 0.98 (m, 3H). MS (ion spray), m/z, (M+H) = 444,446 (Cl pattern).

The following compounds are prepared from the compound of Example 77 using the methods described above. Example # Name m/z [M+H] 479 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)- 442,444 allyl]-3-(S)-ethyl-piperazin-2-one Cl pattern 480 t- (4-Amino-quinazolin-7-yimethyl)-4- [3- (5-chloro-thiophen-2-yl)- 456,458 patternbut-2-enyl]-3-(S)-ethyl-piperazin-2-oneCl 461,4634811-(4-Amino-quinazolin-7-ylmethyl)-4-[7-chloro-isoq uinolin-3- ylmethyl)-3- (S)-ethyl-piperazin-2-one Cl pattern 482 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 442,444 patternallyl]-3-(S)-ethyl-piperazin-2-oneCl 483 1- (4-Amino-quinazoiin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 460, 462 ylmethyl)-3- (S)-ethyl-piperazin-2-one Cl pattern 484 1- (4-Amino-quinazolin-'7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-466,468 2-ylmethyl)-3- (S)-ethyl-piperazin-2-one CI pattern 485 i-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-thieno(4-Amino -quinazolin-7-ylmethyl)-4-(6-chloro-thieno [2,3-467,469 b] pyridin-2-ylmethyl)-3-(S)-ethyl-piperazin-2-one C l pattern

EXAMPLE 486.1- (4-Amino-quinazolin-7-vimethvl)-4-3- (5-chloro-thiophen-2-vl)-acrvlovll-3- (S)- ethvl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 123, using 1- (4-aminoquinazoline-7- ylmethyl)-3-ethyl-piperazine-2-one, EXAMPLE 77 and 3- (5-chloro-thiophen-2-yl)- (E)-acrylic acid, EXAMPLE 25. 1H NMR (d6-DMSO + I drop TFA, 300 MHz) 8 9.78 (bs, 2H), 8.79 (s, 1H), 8.37 (d, 1H), 7.65 (m, 2H), 7.50 (s, 1H), 7.41 (m, 1H), 7.11 (d, 1H), 6.98 (d, 1H), 4.88 (m, 2H), 4.60 (m, 1H), 4. 31 (m, 1H), 3.52 (m, 1H), 3. 30 (m, 2H), 1.96 (m, 2H), 0.88 (m, 3H). MS (ion spray), m/z, (M+H) = 456,458 (Cl pattern). Elemental analysis, cal C22H22ClN5O2S#1.5C2HF3O2 % C=47.89, % H=3.78, % N=11.17; found % C=47.34, % H=4.00, % N=11.12.

The following compounds are prepared from the compound of Example 77 using the methods described above. Example # Name m/z [M+H] 487 1-? (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2- 460,462 yloxy)-acetyl]-(S)-3-ethyl-piperazin-2-one Cl(S)-3-ethyl-piperazin-2-one Cl pattern 488 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3- 460, 462 yloxy)-acetyl]-(S)-3-ethyl-piperazin-2-one Cl(S)-3-ethyl-piperazin-2-one Cl pattern 489 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-3-yl)- 456,458 acryloyl]- (S)-3-ethyl-piperazin-2-one CI pattern 490 2- (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-ethyl-3-oxo- 517,519 patternpiperazin-1-yl]-2-oxo-ethoxy}-5-chloro-thiophen-3-yl) -acetamideCl 491 (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-ethyl-3-oxo- 518,520 piperazin-I-yt]-2-oxo-ethoxy}-5-chloro-thiophen-3-yl)-acetic acid Cl pattern 492 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2, 3-dichloro- 514,516, benzo[b]thiophene-6-carbonyl)-(S)-3-ethyl-piperazin-2-one518 Cl2 pattern 493 482480, benzo [b] thiophene-6-carbonyl)- (S)-3-ethyl-piperazin-2-one Cl pattern 494 (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-ethyl-3-oxo- 546,548 Clpatternpiperazin-1-yl]-2-oxo-ethoxy}-5-chloro-thiophen-3-y l)-aceticacid ethyl ester 495 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3, 5-dichloro-thiophen-2- 494,496 patternyloxy)-acetyl]-(S)-3-ethyl-piperazin-2-oneCl 496 534532, piperazin-1-yl]-2-oxo-ethoxy}-5-chloro-thiophen-3-yl)-acetic acid Cl pattern methyl ester 463,4654971-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-1H-i ndole-6- carbonyl)- (3S)-ethyl-piperazin-2-one 498 477475, carbonyl)-3- (S)-ethyl-piperazin-2-one Cl pattern 499 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 460,462 yloxy)-acetyl]-3- (S)-ethyl-piperazin-2-one Cl pattern 500,5025001-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-bromo-th iophen-2-yl)- acryloyl]-3- (S)-ethyl-piperazin-2-one Br pattern 456,4585011-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-chloro-t hiophen-2-yl)- acryloyl]-3- (S)-ethyl-piperazin-2-one Cl pattern 500,5025021-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(4-bromo-th iophen-2-yl)- acryloyl]-3- (S)-ethyl-piperazin-2-one Br pattern 503 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 458,460 propionyl]-3- (S)-ethyl-piperazin-2-one CI pattern 504 1- (4-Amino-quinazolin-7-ylmethyl)-4-[1-(4-chloro-phenyl)-1H- 489, 491 patternpyrrole-2-carbonyl]-3-(S)-ethyl-piperazin-2-oneCl 505 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenylsulfanyl)- 470, 472 acetyl]-3-(S)-ethyl-piperazin-2-one Cl pattern 470,4725061-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-t hiophen-2-yl)- but-2-enoyl]-3-(S)-ethyl-piperazin-2-one Cl pattern 507 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(4-chloro-phenoxy)-acet yl]-454,(4-Amino-quinazolin-7-ylmethyl)-4-[(4-chloro-phenoxy )-acetyl]-454, 456 3-(S)-ethyl-piperazin-2-one Cl pattern 508 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)- 450,452 acryloyl]-3-(S)-ethyl-piperazin-2-one Cl pattern 509 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-I H-indole-2-463, 465 carbonyl)-3-(S)-ethyl-piperazin-2-one Cl pattern 510 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)- 452,454 patternpropionyl]-3-(S)-ethyl-piperazin-2-oneCl 511 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-ethyl-4- [3- (4-methoxy- 448 phenyl)-propionyl]-piperazin-2-one 512 1- (4-Amino-quinazolin-7-yimethyl)-4- (6-chloro- 480,482 benzo [b] thiophene-2-carbonyl)-3- (S)-ethyl-piperazin-2-one Cl pattern

EXAMPLE 513. 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-2-yl oxy)-acetyl]-3-(S)- propvl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 123, using 1- (4-aminoquinazoline-7- ylmethyl)-3-propyl-piperazine-2-one, EXAMPLE 78 and 5-chloro-2-thienyloxyacetic acid, EXAMPLE 24. 1H NMR (d6-DMSO, 300 MHz) # 9. 78 (bs, 2H), 8.81 (s, 1H), 8.35 (d, 1H), 7.60 (m, 2H), 7.51 (s, 1H), 6.69 (m, 1H), 6.21 (d, 1H), 4.91 (AB, 2H), 4.72 (m, 2H), 3.84 (m, 1H), 3.52 (m, 2H), 3.23 (m, 1H), 1.80 (m, 2H), 1.24 (m, 2H), 0.82 (m, 3H). MS (ion spray), m/z, 474,476, (M+H) (Cl pattern).

Elemental analysis, cal C22H22ClN5O2S#C2HF3O2#1.15H2O % C=47.31, % H=4.52, % N=11.50; found % C=47.39, % H=4.140, % N=11. 19.

EXAMPLE 514.4-f3- (6-Amino-pyridin-3-vl)-acrylovll-I- (4-amino-quinazolin-7-vlmethvl)-3- (S)- propvl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 123, using 1- (4-aminoquinazoline-7- ylmethyl)-z-propyl-piperazine-2-one, EXAMPLE 78 and 3-(6-amino-pyridin-3-yl)-acrylic acid,

EXAMPLE 36.'H NMR (d6-DMSO, 300 MHz) 8 9.73 (bs, 2H), 8.81 (s, 1H), 8. 36 (m, 2H), 8.22 (m, 3H), 7.62 (d, 1H), 7.52 (m, 1H), 7.39 (m, 1H), 7.21 (m, 1H), 6.91 (d, 1H), 5.00 (m, 1H), 4.78 (m, 1H), 4.60 (m, 2H), 4.34 (m, IH), 3. 30 (m, 2H), 1.87 (m, 2H), 1.24 (m, 2H), 0.90 (m, 3H). MS (ion spray), m/z, 446,448 (M+H), (Cl pattern).

The following compounds are prepared from the compound of Example 78 using the methods described above. Example m/z[M+H]Name 515 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (2, 5-dichloro-thiophen-3- 508,509,511, yloxy)-acetyl]-3- (S)-propyl-piperazin-2-one C1 pattern 516 1- (4-Amino-quinazolin-7-yimethyl)-4- [ (4-chloro-thiophen-2- 474,476 yloxy)-acetyl]-3-(S)-propyl-piperazin-2-one Cl pattern 517 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2- 514,516 yl)-acryloyl]-3-(S)-propyl-piperazin-2-one Br pattern 518 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2- 470,472 patternyl)-acryloyl]-3-(S)-propyl-piperazin-2-oneCl 519 I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenoxy)- 468, 470 acetyl]-3-(S)-propyl-piperazin-2-one Cl pattern 520 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3- 474, 476 yloxy)-acetyl]-3-(S)-propyl-piperazin-2-one Cl pattern 521 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-5-methoxy- 498,500 phenoxy)-acetyl]-3-(S)-propyl-piperazin-2-one C1 pattern 522 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-3- 470,472 yl)-acryloyl]-3-(S)-propyl-piperazin-2-one Cl pattern 523 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- 470, 472 yl)-acryloyl]-3-(S)-propyl-piperazin-2-one Cl pattern

EXAMPLE 524.1- (4-Amino-quinazolin-7-vlmethvl)-4-r3- (5-chloro-thiophen-2-yl)-allYll3 (S)- methoxvmethvl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 278 using 1- (4-amino-quinazoline-7- ylmethyl)-3-methoxymethyl-piperazine-2-one, EXAMPLE 75 and 2- (3-bromo- (E)-propenyl)-5-chloro- thiophene EXAMPLE 17.'H NMR (d6-DMSO, 300 MHz) 8 9.74 (bs, 2H), 8.80 (s, 1H), 8. 38 (d, 1H), 7.69 (m, 2H), 7.02 (dd, 1H), 6.84 (d, 1H), 6.02 (m, 1H), 4.76 (AB, 2H), 3.86 (m, 4H), 3. 30 (s, 3H), 3.23 (m, 2H), 3.02 (m, 2H). MS (ion spray), m/z, 458,460, (M+H) (Cl pattern). Elemental analysis, cal

C22H24ClN5O2S#2C2HF3O2#1.45H2O % C=43.85, % H=4.09, % N=9.83; found % C=43.92, % H=3.61, % N=9.63.

The following compounds are prepared from the compound of Example 75 using the methods described above. Example # Name m/z [M+H] 525 I-(4-Amino-quinazolin-7-ylmethyl)-4-(3-chloro-I H-indol-6-465, 467 ylmethyl)-3- (S)-methoxymethyl-piperazin-2-one 446,4485261-(4-Amino-quinazolin-7-ylmethyl)-4-[2-(5-chloro-t hiophen-2- yloxy)-ethyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 527 1- (4-Amino-quinazoiin-7-ylmethyl)-4- (5-chloro-IH-indol-2- 446,448 ylmethyl)-3-(S)-methoxymethyl-piperazin-2-one Cl(S)-methoxymethyl-piperazin-2-one Cl pattern 528 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3- 477,479 ylmethyl)-3- (R)-methoxymethyl-piperazin-2-one Cl pattern 477,4795291-(4-Amino-quinazolin-7-ylmethyl)-4-(7-chloro-isoq uinolin-3- ylmethyl)-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 530 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 476,478 ylmethyl)-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 531 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophen-482, 484 2-ylmethyl)-3- (S)-methoxymethyl-piperazin-2-one Cl pattern EXAMPLE 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thiophen-2-yl oxy)-acetyl]-3-(S)- methoxvmethvl-piperazin-2-one.

To a solution of 4- (4-amino-quinazoline-7-ylmethyl)-2-methoxymethyl-3-oxo-piper azine-1- carboxylic acid benzyl ester, EXAMPLE 75, (0.69g, 2.29mmol) in 9mL of DMF is added N, N- diisopropylethyl amine (0.89g, 6. 87mmol), TBTU (0.76g, 2. 36mmol), and 5-chloro-2-thienyloxyacetic acid, EXAMPLE 24, (0.40g, 2.08mmol). The solution is stirred for 16 hours. After this time the solution is concentrated. The crude material is purified by RP-HPLC eluting with a gradient of 10% CH3CN/H2O (0.1% TFA) to 80% CH3CN/H, O (0. 1% TFA). The product fractions are lyophilized to give the product as a white solid (1. 0g, 1. 57mmol).'H NMR (d6-DMSO, 300MHz) 8 9.70 (bs, 2H), 8.78 (s, IH), 8.29 (m, 1H), 7.55 (m, 2H), 6.72 (m, 1H), 6.22 (m, 1H), 4.80 (m, 4H), 3.78 (m, 4H), 3.59 (m, 3H), 3.3 land 3. 2 (s, 3H rotational isomers). MS (ion spray) M+H=476. Elemental Analysis: C21H22CIN504S-1. 4CF3C02H cal: C=45.03%, H=3.68%, N=11.04%; found C=44.98%, H=3.71%, N=11.02%.

EXAMPLE 533. 1-(4-Am ino-guinazol in-7-vlmethvl)-4-(6-chloro-I H-benzoimidazole-2-carbonvl)-3- (S)-methoxvmethvl-piperazin-2-one.

To a solution of 4- (4-amino-quinazoline-7-ylmethyl)-2-methoxymethyl-3-oxo-piper azine-1- carboxylic acid benzyl ester, EXAMPLE 75, (20 mg, 0.066 mml) in 1.5 mL of DMF is added TBTU (923.4 mg, 0.073 mmol), diisopropylethylamine (0.013 ml, 0.073 mmol) and 6-chloro-1H- benzoimidazole-2-carboxylic acid (prepared from literature in Eur. J. med. Chem. 1993,28,71) (14.3 mg, 0.073 mmol). The resulting mixture is left to stir at room temperature overnight. The crude mixture is directly purified by reverse phase HPLC (10-70% ACN/H2O). The product (30.1 mg, 55%) is isolated as a white powder. C23H22ClN7O3 MS m/z: 480,481. Anal. cald. for C23H22ClN7O3#2C2HF3O2: C, H, 3.42; N, 13.85. Found C, 45.19; H, 3.59; N, 13.76.

The following compounds are prepared from the compound of Example 75 using the methods described above. Example # Name m/z [M+H] 534 1- (4-Amino-quinazolin-7-yimethyl)-4- [ (4-chloro-thiophen-2- 476,478 yloxy)-acetyl]-3-(S)-methoxymethyl-piperazin-2-one Cl pattern 535 4- [3- (4-Amino-phenyl)-acryloyl]-I- (4-amino-quinazolin-7- 447 ylmethyl)-3-(S)-methoxymethyl-piperazin-2-one 536 1- (4-Amino-quinazolin-7-ylmethyl)-4- (3-3H-imidazol-4-yi- acryloyl)-3- (S)-methoxymethyl-piperazin-2-one 537 510,512, yloxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2-one C I, pattem 538 (1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-IH- 480,482 patternbenzoimidazole-2-carvonyl)-3-(S)-methoxymethyl-pipera zin-2-oneCl 539 1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-thiophene-2- 446,448 patterncarbonyl)-3-(S)-methoxymethyl-piperazin-2-oneCl 500,5025401-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-bromo-fu ran-2-yl)- acryloyl]-3- (S)-methoxymethyl-piperazin-2-one Br pattern 541 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-phenyl)- 510,512 acryloyl]-3- (S)-methoxymethyl-piperazin-2-one Br pattern 542 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-phenyl)- 466,468 acryloyl]-3- (S)-methoxymethyl-piperazin-2-one CI pattern 543 I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (3-bromo-phenyl)- 576,578 acryloyl]-3- (S)-methoxymethyl-piperazin-2-one Br pattern 544 468466, acryloyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 545 578576, acryloyl]-3- (S)-methoxymethyl-piperazin-2-one Br pattern 546 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3- 476, 478 yloxy)-acetyl]-3- (S)--methoxymethyl-piperazin-2-one Cl pattern 547 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-pyridin-3-yloxy)- 471, 473 patternacetyl]-3-(S)-methoxymethyl-piperazin-2-oneCl 548 474472, acetyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 549 4- [3- (6-Amino-pyridin-3-yl)-acryloyl]-I- (4-amino-quinazolin-7- 448 ylmethyl)-3- (S)-methoxymethyl-piperazin-2-one 550 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-5-methoxy- 500, 502 phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 551 474472, acryloyl]-3-(S)-methoxymethyl-piperazin-2-one Cl(S)-methoxymethyl-piperazin-2-one Cl pattern 552 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(2,5-dichloro-phenoxy)- 504, 506,508 patternacetyl]-3-(S)-methoxymethyl-piperazin-2-oneCl2 553 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-fluoro-thiophen-2- 460 yloxy)-acetyl]-3- (S)- methoxymethyl-piperazin-2-one 554 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-fluoro-phenoxy)-acetyl]- 453 3- (S)-methoxymethyl-piperazin-2-one 555 1- (4-Amino-quinazolin-7-ylmethyl)-4- [2- (3-chloro-phenoxy)- 484, 486 propionyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 556 1-(4-Amino-quinazolin-7-ylmethyl)-4-[(6-chloro-pyridin-3-ylo xy)-471, 473 acetyl]-3-(S)-methoxymethyl-piperazin-2-one Cl(S)-methoxymethyl-piperazin-2-one Cl pattern 557 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-methoxymethyl-4- [ (4- 536 trifluoromethylsulfanyl-phenoxy)-acetyl]-piperazin-2-one 558 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenylamino)- 469, 471 patternacetyl]-3-(S)-methoxymethyl-piperazin-2-oneCl 559 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenylamino)- 469, 471 acetyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 560 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenoxy)- 471,473 patternacetyl]-3-(S)-methoxymethyl-piperazin-2-oneCl 561 (2- {2- [4- (4-Amino-quinazolin-7-ylmethyi)-2- (S)-methoxymethyl- 534,536 3-oxo-piperazin-1-yl]-2-oxo-ethoxy}-5-chloro-thiophen-3-yl)- Cl pattern acetic acid 562 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 492,494 ylsulfanyl)-acetyl]-3-(S)-methoxymethyl-piperazin-2-one Cl(S)-methoxymethyl-piperazin-2-one Cl pattern 470,4725631-(4-Amino-quinazolin-7-ylmethyl)-4-[(6-chloro-pyr idin-3- patternylamino)-acetyl]-3-(S)-methoxymethyl-piperazin-2-oneC l 564 2- (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)- 533,535 methoxymethyl-3-oxo-piperazin-I-yl]-2-oxo-ethoxy}-5-chloro-C I pattern thiophen-3-yl)- 565 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2-chloro- 496,498 benzo [b] thiophene-6-carbonyl)-3- (S)-methoxymethyl-piperazin-2- Cl pattern one 566 1- (4-Amino-quinazolin-7-ylmethyl)-4- (2, 3-dichloro- 530,532,534 benzo [b] thiophene-6-carbonyl)-3-(S)-methoxymethyl-piperazin-2-Cl2 pattern one 567 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3, 5-dichloro-thiophen-2- 510, 512, 514 patternyloxy)-acetyl]-3-(S)-methoxymethyl-piperazin-2-oneCl2 568 (2- {2- [4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl- 548,550 3-oxo-piperazin-1-yi]-2-oxo-ethoxy}-5-chloro-thiophen-3-yl)- Cl pattern acetic acid methyl ester 569 (2- {2-[4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-methoxymethyl- 562, 564 3-oxo-piperazin-1-yl]-2-oxo-ethoxy}-5-chloro-thiophen-3-yl)- Cl pattern acetic acid ethyl ester 470,4725701-(4-Amino-quinazolin-7-ylmethyl)-4-[(2-chloro-pyr idin-3- ylamino)-acetyl]-3-(S)-methoxymethyl-piperazin-2-one Cl(S)-methoxymethyl-piperazin-2-one Cl pattern 571 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (2, 3-dichloro-phenoxy)- 504, 506, 508 patternacetyl]-3-(S)-methoxymethyl-piperazin-2-oneCl2 572 I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-fluoro-phenoxy)-acetyl]- 454 3- (S)-methoxymethyl-piperazin-2-one 573 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-2-methyl- 484,486 phenoxy)-acetyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern 574 I-(4-Amino-quinazolin-7-ylmethyl)-4- [(2, 4-dichloro-phenoxy)-504, 506, 508 acetyl]-3- (S)-methoxymethyl-piperazin-2-one Cl, pattern 575 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinoline-3- 491,493 carbonyl)-3-(S)-methoxymethyl-piperazin-2-one Cl pattern 576 (1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-516,518 patternyl)-acryloyl]-3-(S)-methoxymethyl-piperazin-2-oneBr 577 t- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-chloro-thiophen-2-yl)- 472, 474 acryloyl]-3- (S)-methoxymethyl-piperazin-2-one CI pattern 578 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 472,474 acryloyl]-3-(R)-methoxymethyl-piperazin-2-one Cl pattern 472,4745791-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-t hiophen-2-yl)- acryloyl]-3-(S)-methoxymethyl-piperazin-2-one Cl pattern 580 498496, benzo [b] thiophene-2-carbonyl)-3- (S)-methoxymethyl-piperazin-2- Cl pattern one 581 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-phenoxy)- 470, 472 acetyl]-3- (S)-methoxymethyl-piperazin-2-one Cl pattern

EXAMPLE 582. 1- (4-Amino-quinazolin-7-ylmethvl)-4-r (6-chloro-pvridin-3-vloxy)-acetyll-3- (S)- ethoxymethvl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 123, using 1- (4-aminoquinazoline-7- ylmethyl)-3-ethoxymethyl-piperazine-2-one, EXAMPLE 79 and, (6-chloro-pyridin-3-yloxy)-acetic acid, prepared similary to the procedure descibed in EXAMPLE 29.'H NMR (d6-DMSO, 300 MHz) 8 9.73 (bs, 2H), 8.81 (s, 1H), 8.37 (m, IH), 8.10 (m, 1H), 7.61 (m, 2H), 7.40 (m, 2H), 4.98 (m, 2H), 4.65 (m, 2H), 4.50 (m, 1H), 3.91 (m, 1H), 3.75 (m, 1H), 3.59 (m, 2H), 3. 31 (m, 2H), 1.07 (m, 3H). MS (ion spray), m/z, 485,487 (M+H), (Cl pattern).

The following compounds are prepared from the compound of Example 79 using the methods described above. Example # Name m/z [M+H] | 583 1- (4-Amino-quinazolin-7-yimethyl)-3- (S)-ethoxymethyl-4- [ (3- 454 fluoro-phenoxy)-acetyl]-piperazin-2-one 584 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 486, 488 patternacryloyl]-3-(S)-ethoxymethyl-piperazin-2-oneCl 585 I-(4-Amino-quinazolin-7-ylmethyl)-4- [(2-chloro-pyridin-3-484, 486 patternylamino)-acetyl]-3-(S)-ethoxymethyl-piperazin-2-oneCl 586 1- (4-Amino-quinazolin-7-ylmethyl)-4-[(6-chloro-pyridin-3- 484, 486 patternylamino)-acetyl]-3-(S)-ethoxymethyl-piperazin-2-oneCl 490,4925871-(4-Amino-quinazolin-7-ylmethyl)-4-[(5-chloro-thi ophen-2-yloxy)- acetyl]-3-(S)-ethoxymethyl-piperazin-2-one Cl pattern The following compounds are prepared from the compounds of Examples 81-85 using the methods described above. Example # Name m/z [M+H] 588 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- [3- (5-chloro- 518,520 thiophen-2-y )-acryloyl]-piperazin-2-one Cl pattern 589 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- (6-chloro- 542,544 benzo [b] thiophene-2-carbonyl)-piperazin-2-one pattern 590 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- [3- (5-chloro- 504,506 thiophen-2-yl)-allyl]-piperazin-2-one Cl pattern 59I 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- (6-chloro- 528,530 benzo [b] thiophen-2-ylmethyl)-piperazin-2-one Cl pattern 516,5185921-(4-Amino-quinazolin-7-ylmethyl)-3-(S)-benzyl-4-[ (4-chloro- phenoxy)-acetyl]-piperazin-2-one C I pattem 593 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- (6-chloro- 522,524 naphthalen-2-ylmethyl)-piperazin-2-one Cl pattern 594 1- (4-Amino-quinazolin-7-ylmethyl)-3- (S)-benzyl-4- [3- (5-chloro- 506,508 patternthiophen-2-yl)-propyl]-piperazin-2-oneCl 595 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)- 490, 492 patternacetyl]-3-(S)-((R)-1-methoxy-ethyl)-piperazin-2-oneCl 596 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 472, 474 pattetnallyl]-3-(S)-((R)-1-methoxy-ethyl)-piperazin-2-oneCl 597 488486, patternacryloyl]-3-(S)-((R)-1-methoxy-ethyl)-piperazin-2-one Cl 598 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- 530, 532 acryloyl]-3-(S)-((R)-I-methoxy-ethyl)-piperazin-2-one Br pattern 599 1- (4-Amino-quinazolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3- 491,493 ylmethyl)-3-(S)-((R)-I-methoxy-ethyl)-piperazin-2-one Cl pattern 600 1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo [b] thiophen-2-480,482 ylmethyl)-3-(S)-isopropyl-piperazin-2-one Cl, pattern 601 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophen-2-466.468 ylmethyl)-3,3-dimethyl-piperazin-2-one Cl pattern 602 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 442,444 patternallyl]-3,3-dimethyl-piperazin-2-oneCl 603 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 456,458 acryloyl]-3,3-dimethyl-piperazin-2-one CI pattern 604 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-480,482 2-carbonyl)-3, 3-dimethyl-piperazin-2-one Cl pattern 605 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)- 490,492 patternacetyl]-3-(S)-(2-methoxy-ethyl)-piperazin-2-oneCl 606 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)- (2-methoxy-ethyl)-3-oxo- 469,471 piperazine-I-carboxylic acid (4-chloro-phenyl)-amide Cl pattern 607 492490, acetyl]-3-(S)-(2-methoxy-ethyl)-piperazin-2-one Cl pattern 608 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-510,512 pattern2-carbonyl)-3-(S)-(2-methoxy-ethyl)-piperazin-2-oneCl

EXAMPLE 609. 1- (4-Amino-quinazolin-7-vlmethvl)-4- (6-chloro-naphthalen-2-vlmethyl)-3- (S)- methoxvmethvl-6- (S)-methyl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 268, using 1- (4-amino-quinazoline-7- ylmethyl)-3-methoxymethyl-6-methyl-piperazine-2-one, EXAMPLE 87, and 2-bromomethyl-6- chloronaphthalene, EXAMPLE 12. 'H NMR (CDC13, 300 MHz) 8 8.59 (s, 1H), 7.79 (d, 1H), 7.70-7.12 (m, 3H), 7.68-7.67 (m, 2H), 7.55 (d, 1H), 7.39 (d, 1H), 4.78 (d, 2H), 3.98 (d, 2H), 3.44 (s, 3H), 3. 38 (t, 1H), 2.64 (m, 2H), 1.26 (d, 3H). MS (ISP) 490,492, (M+H), Cl pattern.

The following materials are prepared from starting materials obtained as described in Example 87 using the methods described above. Example # Name m/z [M+H] 610 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 458, 460 patternpropyl]-3-(S)-ethyl-6-methyl-piperazin-2-oneCl 611 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 490,492 patternylmethyl)-3-(S)-methoxymethyl-6-(R)-methyl-piperazin- 2-oneCl 612 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 472,474 allyl]-3-(S)-methoxymethyl-6-methyl-piperazin-2-one Cl pattern 613 (1- (4-Amino-quinazolin-7-ytmethyl)-4- (7-chloro-isoquinolin-3- 490, 492 patternylmethyl)-3-(S)-methoxymethyl-6-methyl-piperazin-2-on eCl 614 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 491,493 allyl]-3-(S)-6-dimethyl-piperazin-2-one Cl pattern 615 1- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 442, 446 ylmethyl)-6-methyl-piperazin-2-one Cl pattern 616 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 428,430 allyl]-6-methyl-piperazin-2-one Cl pattern

EXAMPLE 617. 1- (4-Amino-quinazolin-7-vlmethvl)-4-f (5-chloro-thiophen-2-vloxy)-acetyll-3 (S)-<BR> methoxvmethvl-6-methyl-piperazin-2-one.

The title compound is prepared as described in EXAMPLE 123 using 1- (4-amino-quinazoline-7- ylmethyl)-3-methoxymethyl-6-methyl-piperazine-2-one, EXAMPLE 87, and 5-chloro-2-thienyloxyacetic acid, EXAMPLE 24.'H NMR (CD30D300 MHz) 8 8.68 (s, 1H), 8.27 (d, 1H), 7.62 (m, 2H), 6.54 (d, 1H), 6.18 (m, 1H), 7. 39 (d, 1H), 4.94 (m, 4H), 4.15 (m, 2H), 3.76 (m, 2H), 3.44 (s, 3H), 3.10 (m, 2H), 1.28 (d, 3H).

The following compounds are prepared from compounds obtained as described Examples 75-87 using the methods described above. Example # Name m/z [M+H] 618 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (4-chloro-thiophen-2-yloxy)- 490, 492 patternacetyl]-(S)-3-methoxymethyl-6-methyl-piperazin-2-oneC l 619 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-3-yloxy)- 490, 492 acetyl]- (S)-3-methoxymethyl-6-methyl-piperazin-2-one Cl, pattern 620 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-4-fluoro-phenoxy)- 502, 504 acetyl]-3(S)-methoxymethyl-6-methyl-piperazin-2-one Cl, pattern 621 1- (4-Amino-quinazolin-7-yimethyl)-4- [ (3, 5-dichloro-phenoxy)- 502,504 acetyl]-3 (S)-methoxymethyl-6-methyl-piperazin-2-one Cl pattern 622 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (2, 5-dichloro-phenyl)- 514 acryloyl]-3 (S)-methoxymethyl-6-methyl-piperazin-2-one 623 500498, phenoxy)-acetyl]-3 (S)-methoxymethyl-6-methyl-piperazin-2-one Cl2 pattern 624 1- ino-quinazolin-7-ylmethyl)-4- [(2, 5-dichloro-phenoxy)-518 acetyl]-3 (S)-methoxymethyl-6-methyl-piperazin-2-one 625 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (3-chloro-phenoxy)-acetyl]- 484 3- (S)-methoxymethyl-6-methyl-piperazin-2-one 626 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 472, 474 propionyl]-3 (S)-ethyl-6-methyl-piperazin-2-one Cl pattern 627 1- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)- 474 acetyl]-3 (S)-ethyl-6-methyl-piperazin-2-one 628 1- (4-Amino-quinazolin-7-ylmethyt)-4- [3- (4-bromo-thiophen-2-yl)- 514,516 acryloyl]-3 (S)-ethyl-6-methyl-piperazin-2-one Br pattern 629 472470, acryloyl]-3 (S)-ethyl-6-methyl-piperazin-2-one Cl pattern 630 (S)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- 486,488 yl)-acryloyl]-3-methoxymethyl-6-methyl-piperazin-2-one CI pattern 631 (S)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2- 530,532 patternyl)-acryloyl]-3-methoxymethyl-6-methyl-piperazin-2-on eBr 632 1- (4-Amino-quinazolin-7-yimethyl)-4- (6-chloro-benzo [b] thiophene- 480 2-carbonyl)-3 (S)-6-dimethyl-piperazin-2-one Cl pattern 633 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- 500,502 patternacryloyl]-3(S)-6-dimethyl-piperazin-2-oneBr 634 1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 456,458 acryloyl]-3 (S)-6-dimethyl-piperazin-2-one Cl pattern 635 444442, acryloyl]-6-methyl-piperazin-2-one Cl pattern

EXAMPLE 636. 4- (4-Amino-quinazolin-7-vlmethvl)-2- (S)-methoxvmethyl-3-oxo-niperazine-1- carboxvlic acid (4-chloro-phenvl)-amide.

The title compound is prepared as described in EXAMPLE 436 using 1- (4-amino-quinazoline-7- ylmethyl)-3-methoxymethyl-piperazine-2-one, EXAMPLE 75, and 4-chlorophenyl isocyanate.'H NMR (DMSO-d6,300 MHz) 8 9.77 (bs, 2H), 8.81 (s, 1H), 8.70 (s, 1H), 8.40 (d, 1H), 7.64 (d, 1H), 7.61 (s, 1H),

7.49 (d, 2H), 7.28 (d, 2H), 4.88 (m, 1H), 4.80 (AB, 2H), 4.19 (m, 1H), 3.96 (m, 1H), 3.74-3.42 (m, 4H), 3.28 (s, 3H). ESI MS, [M+H]"=455,457 (Cl pattern). Anal. (CHC!N.OTFA!.5HO)C,H,N. <BR> <BR> <BR> <BR> <BR> <P>EXAMPLE 637.4- (4-Amino-quinazolin-7-vlmethyl)-2- (S)-methvl-3-oxo-piperazine-1-carboxylic acid<BR> <BR> <BR> <BR> (5-chloro-thiophen-2-vl)-amide.

The title compound is prepared as described in EXAMPLE 438 using 1- (4-amino-quinazoline-7- ylmethyl)-3-methyl-piperazine-2-one (EXAMPLE 80) and 5-chloro-thiophene-2-carbonyl azide (EXAMPLE 38).'H NMR (DMSO-d6,300 MHz) 8 10.01 (s, 1H), 9.73 (bs, 2H), 8.83 (s, IH), 8.39 (d, IH), 7.65 (d, IH), 7.58 (s, IH), 6.79 (d, 1H), 6.44 (d, 1H), 4.85 (d, 1H), 4.71 (m, IH), 4.69 (d, IH), 4.17 (d, IH), 3.50 (m, 3H), 1.45 (d, 3H). ESI MS, [M+H]'=431, 433 (Cl pattern). Anal.

(C,, H,, CtN, 0, STFA 1. 9H, 0) C, H, N.

EXAMPLE 638. 4-(4-Amino-quinazolin-7-ylmethyl)-(2S)-methoxymethyl-3-oxo-p iperazine-l- carboxylic acid (5-chloro-thiophen-2-vl)-amide.

The title compound is prepared as described in EXAMPLE 439 using 1- (4-amino-quinazoline-7- ylmethyl)-3-methoxymethyl-piperazine-2-one (EXAMPLE 75) and 5-chloro-thiophene-2-carbonyl azide (EXAMPLE 38).'H NMR (DMSO-d6,300 MHz) 8 10.00 (s, 1H), 9.73 (bs, 2H), 8.82 (s, IH), 8.40 (d, 1H), 7.65 (d, 1H), 7.60 (s, 1H), 6.80 (d, 1H), 6.42 (d, 1H), 4.86 (d, 1H), 4.80 (m, 1H), 4.70 (d, 1H), 4.18 (d, IH), 3.96 (dd, IH), 3.60 (m, 4H), 3.30 (s, 3H). ESI MS, [M+H] +=461, 463 (Cl pattern). Anal.

(C20H,, CIN603STFA I. lH2O) C, H, N.

The following compounds are prepared using the methods described above. Example # Name m/z [M+H] 639 4- (4-Amino-quinazolin-7-ylmethyl)-2 (S)- (2-methoxy-ethyl)-3-oxo- 469 piperazine-I-carboxylic acid (4-chloro-phenyl)-amide 640 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-butyl-3-oxo-piperazine-1- 467,469 carboxylic acid (4-chloro-phenyl)-amide Cl pattern 641 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo- 505,507 piperazine-1-carboxylic acid (5-bromo-thiophen-2-yl)-amide 642 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo- 461,463 piperazine-1-carboxylic acid (5-chloro-thiophen-3-yl)-amide 643 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo- 461 piperazine-l-carboxylic acid (4-chloro-thiophen-2-yl)-amide 644 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-(S)-2-propyl-piperazin e- 453, 455 I-carboxylic acid (4-chloro-phenyl)-amide Cl pattern 645 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo- 499 piperazine-l-carboxylic acid (3-bromo-phenyl)-amide 646 461459, carboxylic acid (4-chloro-thiophen-2-yl)-amide 647 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo- (S)-2-propyl-piperazine- 483,485 (5-chloro-2-methoxy-phenyl)-amideClpattern1-carboxylicacid 648 535533, piperazine-1-carboxylic acid (4-bromo-2-chloro-phenyl)-amide 649 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo- 505 piperazine-l-carboxylic acid (4-trifluoromethoxy-phenyl)-amide 650 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo- 439 piperazine-1-carboxylic acid (4-fluoro-phenyl)-amide 651 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo- 489,491 piperazine-1-carboxylic acid (2,4-dichloro-phenyl)-amide 652 4- (4-Amino-quinazolin-7-ylmethyl)-2- (S)-methoxymethyl-3-oxo- 457 piperazine-1-carboxylic acid (2,4-difluoro-phenyl)-amide 653 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo- 455 (3-chloro-phenyl)-amidepiperazine-1-carboxylicacid 654 4- (4-Amino-quinazolin-7-ylmethyl)-3-oxo-(2S)-propyl-piperazine -1- 459, 460 carboxylic acid (5-chloro-thiophen-2-yl)-amide C) pattern 655 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methyl-3-oxo-piperazine- 426,428 1-carboxylic acid (6-chloro-pyridin-3-yl)-amide 656 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methoxymethyl-3-oxo- 499,501 piperazine-1-carboxylic acid (4-bromo-phenyl)-amide 657 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methyl-3-oxo-piperazine- 486,488 1-carboxylic acid (4-bromo-phenyl)-amide 658 471469, methyl-3-oxo-piperazine-1-carboxylic acid (4-chloro-phenyl)-amide 659 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-ethyl-3-oxo-piperazine-l- 483,485 carboxylic acid (4-bromo-phenyl)-amide 660 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-methyl-3-oxo-piperazine- 425,427 (4-chloro-phenyl)-amide1-carboxylicacid 661 4- (4-Amino-quinazolin-7-ylmethyl)- (2S)-ethyl-3-oxo-piperazine-1- 439, 441 carboxylic acid (4-chloro-phenyl)-amide 662 4- (4-Amino-quinazolin-7-ylmethyl)- (S)-2-methoxymethyl-3-oxo- 491,493 piperazine-I-carboxylic acid (5-chloro-4-methoxy-thiophen-2-yl)-Cl pattern amide

EXAMPLE 663. (3S, 5RS)-I-S4-Amino-quinazolin-7-vlmethvl)-4- (6-chloro-benzofblthiophen-2- ylmethyl)-3,5-dimethyl-piperazin-2-one.

(3S, 5RS)-1- (4-Amino-quinazolin-7-ylmethyl)-3, 5-dimethyl-piperazin-2-one (260 mg, 0.56 mmol), EXAMPLE 88, is dissolved in 5 mL of DMF. Potassium carbonate (193.4 mg, 1.4 mmol) is added followed by the addition of 2-bromomethyl-6-chloro-benzo [b] thiophene (218 mg, 0.84 mmol), EXAMPLE 5. Reaction is left to stir overnight. The crude mixture is purified by reverse phase HPLC (10-70% ACN/H, O) to afford the product (27 mg, 6%) as a clear wax with a melting point of 130-131 °C. CHCINsOS MS m/z: 466,468.

EXAMPLE 664. (3S, 5S)-I- (4-Amino-quinazolin-7-vlmethyl)-4-r3- (5-chloro-thiophen-2-yl)-allvl-13. 5- dimethvl-piperazin-2-one. and EXAMPLE 665. (3S, 5R)-I- (4-Amino-quinazolin-7-vlmethvl)-4-r3- (5-chloro-thiophen-2-vl)-allvll-3,5- dimethvl-piperazin-2-one.

(3S, 5RS)-1- (4-Amino-quinazolin-7-ylmethyl)-3, 5-dimethyl-piperazin-2-one (60 mg, 0.13 mmol) is dissolved in 1 mL of DMF. Potassium carbonate (53 mg, 0.39 mmol) is added followed by the addition of 3-bromoallyl-5-chloro-thiophene (75 mg, 0.32 mmol). Reaction is left to stir overnight. The two epimers are separated by reverse phase HPLC (10-70% ACN) in 43% yield.

The major epimer is assigned as (3S, 5S)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- yl)-allyl]-3,5-dimethyl-piperazin-2-one trifluoroacetic acid salt (30.8 mg) and is isolated as a yellow solid with a melting point of 69-72°C. C22H24CIN5OS MS m/z: 442,444.

The minor epimer is assigned as (3S,5R)-1-(4-Amino-quinazolin-7-ylmethyl)-4-[3-(5-chloro-thi ophen- 2-yl)-allyl]-3,5-dimethyl-piperazin-2-one trifluoroacetic acid salt (13.1 mg) with a melting point of 67- 70 °C. C22H24CIN5OS MS m/z: 442,444. I H NMR (CD30D) 6: 8.67 (s, I H); 8.31 (d, 1H, J = 8.56 Hz); 7.83 (s, IH); 7.74 (d, 2H, J = 8.56 Hz); 7.14 (d, 1H, J = 15.6 Hz); 6.92 (d, 1H), J = 3.74 Hz); 6.10-6.03 (m, 1H), ; 5.0-4.74 (m, 2H); 4.25-3.63 (m, 6 H); 1.78 (d, 3H, J = 7.03 Hz); 1.50 (d, 3H, J = 6.47 Hz).

EXAMPLE 666. (3S, 5R)-l- (4-Amino-quinazolin-7-vlmethvl)-4-f2- (5-chloro-thiophen-2-vl)- ethenesulfonvll-3,5-dimethvl-piperazin-2-one.

(3S, 5R)-1- (4-Amino-quinazolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one (43 mg, 0.123 mmol), minor epimer fromEXAMPLE 88, Part D, is taken up in methylene chloride to this is added triethylamine (0.034 mi, 0.25 mmol) followed by 2- (5-chloro-thiophen-2-yi)-ethenesulfonyl chloride (40 mg, 0.16 mmol), EXAMPLE 3. The reaction is stirred overnight, and the crude material is purified by preparative thin layer chromatography (15 % methanol/CH2CI2). The product (1.4 mg, 2. 3%) is isolated as a yellow wax. C21H22ClN5O3S2 MS m/z: 492,494. IH NMR (CD30D) õ 8. 36 (s, I H); 8.03 (d, I H, J = 7.5 Hz); 7.61 (s, 1H); 7.49-7.44 (m, 2H); 7.19 (d, 1H, J = 3.83 Hz); 6.98 (d, 1H, J = 3.75 Hz); 6.76 (d, IH, J = 15.1 Hz); 4.86-4.71 (m, 2H); 4. 45-4.39 (m, 1H) ; 4.13-4.09 (m, 1H); 3.64-3.7 (m, 2H); 1.63 (d, 3H, J = 7. 09 Hz); 1.33 (d, 3H, J = 6. 80 Hz).

EXAMPLE 667. (3S. SS)-1- (4-Amino-quinazolin-7-vlmethyl)-4-r2- (5-chloro-thiophen-2-vl)- ethenesulfonvll-3. 5-dimethvl-piperazin-2-one.

The product (7 mg, 9.4 %) is isolated as a yellow solid with a melting point of 218-221 °C.

C,, H"CIN503S, MS m/z : 492,494. IH NMR (CD30D) 6 8.37 (s, 1H), ; 8.10 (d, IH, J = 8. 57 Hz); 7.61- 7.45 (m, 3H); 7.24 (d, 1H, J = 3.94 Hz); 6.98 (d, 1H, J = 3.85 Hz); 6.71 (d, 1H, J = 15.1 Hz); 4.76 (s, 2H); 4.32 (m, 1H) ; 3.71 (m, 1H); 3.36 (m, 2H); 1.62 (d, 3H, J = 7.06 Hz); 1.20 (d, 3H, J = 6.63 Hz).

EXAMPLE 668. (3S, 5S)-1- (4-Amino-quinazolin-7-vlmethvl)-4- (6-chloro-benzofblthiophen-2- sulfonvl)-3, 5-dimethyl-piperazin-2-one.

The desired product (5.4 mg, 8.5 %) is isolated as yellow solid with a melting point of 224-226° C. C23H22ClN5O3S2 MS m/z: 516,518.

EXAMPLE 669. (3S, 5S)-I- (4-Amino-quinazolin-7-vlmethvl)-4 3- (5-chloro-thiophen-2-vl)-acrylovll- 3,5-dimethvl-piperazin-2-one.

To a solution of (3S, 5S)-I- (4-amino-quinazolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one (42 mg, 0.147 mmol), major epimer from EXAMPLE 88, Part D, in 2 mL of DMF is added TBTU (52 mg, 0.162 mmol), triethylamine (0.02 mL, 0.162 mmol) and 3- (5-chloro-thiophen-2-yi)-acrylic acid (28 mg, 0.15 mmol), EXAMPLE 25. After stirring for two hours, the reaction mixture is directly purified by reverse phase HPLC (10-70 % ACN/H2O). The product (35.5 mg, 36%) is isolated as a yellow solid with a melting point of 116-120°C. C22H22ClN5O2S: MS m/z: 456,458. Anal. calcd. for C"H22CIN5O2S* C2HF302: C, 50.57; H, 4.07; N, 12.29. Found: C, 46.48; H, 3.64; N, 11.04.

EXAMPLE 670. 5R)-4-(4-Amino-quinazolin-7-ylmethyl)-2,6-dimethyl-oxo-piper azine-1- carboxvlic acid (4-bromo-phenvl)-amide.

4-Bromo-phenyl isocyanate (20.8 mg, 0.105 mmol) is added to solution of (3S,5R)-1-(4-amino- quinazolin-7-ylmethyl)-3,5-dimethyl-piperazin-2-one (30 mg, 0.105 mmol), minor epimer from EXAMPLE 88, Part D, in 1 mL of DMF. The reaction is stirred for two hours at room temperature. The product (21.4 mg, 33%) is isolated from reverse phase HPLC (10-70% ACNIH, O) as white solid. The melting of the compound is 142-144 °C. C22H23BrN602 MS m/z: 483, 485. Anal. cald. for C22H23BrN602 #2C2HF3O2 : C, 43.90; H, 3.54; N, 11.81. Found: C, 44.52; H, 3.86; N, 12.44.

EXAMPLE 671. (3S, 5S)-4- (4-Amino-quinazolin-7-vlmethvl)-2, 6-dimethvl-oxo-piperazine-1-carboxvlic acid(4-bromo-phenvl)-amide.

The desired product (35 mg, 47%) is isolated as a white solid with a melting point of 142-144°C . C22H23BrN6O2MS m/z : 483,485. Anal. cald. for C,, H23BrN60, 92CHF30,: C, 43.90; H, 3.54; N, 11.81.

Found: C, 44.73; H, N, 12. 38.

EXAMPLE 672. (3S, 5S)-4- (4-Amino-quinazolin-7-vlmethvl)-2, 6-dimethyl-oxo-piperazine-1- carboxvlic acid (4-chloro-phenvl)-amide.

The product (24.7 mg, 50%) is obtained as a white solid with a melting point of 123-125 °C.

C, 2H23CIN60, MS m/z: 439,441. Anal. cald. for C22H23ClN6O2#2C2HF3O2 : C, 46.82; H, 3.78; N, 12.60.

Found: C, 47.69; H, 4. 33; N, 13. 32.

EXAMPLE 673.1- (4-Aminoguinolin-7-vlmethvl)-4- (6-chlorobenzofblthiophen-2-sulfonvl)-piperazin- 2-one.

A.1- (4-Chloroquinolin-7-vlmethvl)-4- (6-chlorobenzorblthiophen-2-sulfonvl)-piperazin-2-one.

1- (4-chloroquinolin-7-ylmethyl)-3- (S)-methylpiperazin-2-one hydrochloride (0.49 g, 1.4 mmol), EXAMPLE 89, is treated with acetonitrile (20 mL), triethyl amine (1.2 ml, 8.4 mmol) and a solution of 6-chlorobenzo [b] thiophen-2-sulfonyl chloride (0.41 g, 1.54 mmol), EXAMPLE 1, in acetonitrile (10 mL) at 0°C. After 2 h the solution is poured into water and extracted with ethyl acetate. The organic layer is washed with water, dried over sodium sulfate and concentrated to yielded the title compound (0.45 g, 0.95 mmol). MS m/z: 506, [M+l] + ;'H NMR (CD30D, 300 MHz) 8 8.8 (d, IH), 8.15 (d, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.4-7.5 (m, 2H), 6.8 (s, 1H), 4.8 (s, 2H), 4.0 (s, 2H), 3.4-3.45 (m, 4H).

B.1-(4-Azidoquinolin-7-ylmethyl)-4-(6-chlorobenzo[b]thiop hen-2-sulfonyl)-piperazin-2-one 1- (4-Chloroquinolin-7-ylmethyl)-4- (6-chlorobenzo [b] thiophen-2-sulfonyl)-piperazin-2-one (0.52 g, 1.03 mmol) is dissolved in DMF (15 mL), treated with sodium azide (0.52 g, 8.0 mmol), tetrabutyl ammonium chloride (0.1 g, 0.36 mmol) and heated to 65 °C overnight. The reaction mixture is cooled,

poured into water and extracted with ethyl acetate. The organic layer is washed with water, dried (sodium sulfate) and concentrated to give the title compound (0.5 g, 1.04 mmol).'H NMR (CD30D, 300 MHz) 8 9.0 (d, I H), 8.2 (d, I H), 8.0 (s, I H), 7.9 (d, 2H), 7.8 (d, lH), 7.6 (d, 1H), 7.5 (d, lH), 6.9 (s, I H), 4.85 (s, 2H), 4.0 (s, 2H), 3.5-3.7 (m, 4H).

C. I- (4-AminoQuinolin-7-vlmethyl)-4- (6-chlorobenzofblthiophen-2-sulfonvl)-piperazin-2-one.

A suspension of 1- (4-azidoquinolin-7-ylmethyl)-4- (6-chlorobenzo [b] thiophen-2-sulfonyl)- piperazin-2-one (0.50 g, 1.04 mmol) in 100 mL of acetic acid/methanol (~ 1: 10) is treated with 10% Pd/C (0.15 g) and stirred under hydrogen for 1.5 hours. The resulting solution is filtered through Celite and the filtrate is evaporated in vacuo. The organic layer is concentrated and the residue is purified by reverse phase HPLC (gradient elution of 30 % of 0.1 % aqueous TFA/acetonitrile to 100 % acetonitrile) and lyopholized to give the title compound (0.39 g, 0.86 mmol). MS (ISP) m/z 487,489, (M+H), Cl pattern.

The following compounds are prepared from the compound of Example 89 or 91 using the methods described above. Example # Name m/z [M+H] 674 1- (4-Amino-quinolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2-yl) 463,465 ethenesulfonyl]-piperazin-2-one 675 (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene- 501,503 2-sulfonyl)-3-methyl-piperazin-2-one 676 (3S, 5S)-1- (4-Amino-quinolin-7-ylmethyt)-4- [2- (5-chloro-thiophen-2- 491,493 yl)-ethenesulfonyl]-3,5-dimethyl-piperazin-2-one 677 (3S, 5R)-I- (4-Amino-quinolin-7-ylmethyl)-4- [2- (5-chloro-thiophen-2- 491, 493 yl)-ethenesulfonyl]-3, 5-dimethyl-piperazin-2-one 678 (S, R)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro- 531,533 benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid 679 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2- 544 sulfonyl)-6-oxo-piperazine-2-carboxylic acid methylamide 680 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2- 558 sulfonyl)-6-oxo-piperazine-2-carboxylic acid ethylamide 681 1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2- 558 sulfonyl% 6-oxo-piperazine-2-carboxylic acid dimethylamide 682 I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene-2- 600 sulfonyl)-6-(morphoRine-4-carbonyl)-piperazin-2-one

EXAMPLE 683. (S)-1-(4-Aminoquinolin-7-vlmethvl)-4-F3-(5-chlorothioPhen-2- vl)-allvll-3-<BR> methvlpiperazin-2-one.

A. (S)-I- (4-Chloroquinolin-7-vlmethvl)-4- [3- (5-chlorothiophen-2-vi)-allvll-3-methvlperazin-2-one.

(S)-1- (4-chloroquinolin-7-ylmethyl)-3-methylpiperazin-2-one hydrochloride (0. 25 g, 1.0 mmol), EXAMPLE 91, is treated with 2- (3-Bromo- (E)-propenyl)-5-chloro-thiophene (0. 35 g 1.2 mmol), EXAMPLE 17, and potassium carbonate (0.5 g, 3 mmol). The resulting suspension is sonicated for 10 minutes then stirred vigorously for 16 h at ambient temperature. The reaction mixture is poured into water and extracted with ethyl acetate (2 X 150 mL). The organic layer is washed with water (4 X 200 mL), dried over sodium sulfate and concentrated. The residue is chromatographed (3 % methanol/methylene chloride) to give the title compound (0.31 g, 0.73 mmol).

B. (S)-1- (4-Aminoquinolin-7-vlmethvl)-4-j3- (5-chlorothiophen-2-yl)-allvll-3-methvlpiperazin-2-one.

(S)-1- (4-Chloroquinolin-7-ylmethyl)-4- [3- (5-chlorothiophen-2-yi)-allyl]-3-methylpiperazin-2- one (0. 35 g, 0.82 mmol) is treated with phenol (2 g) and ammonium acetate (0.7 g, 9.1 mmol) and heated to 120 °C in a sealed vessel for 1 hour. Upon cooling, the solution is partitioned between 2 N NaOH and ethyl acetate. The organic layer is separated and washed with fresh 2 N NaOH (3 X 100 mL) and water.

The organic layer is concentrated and the residue is purified by reverse phase HPLC to give the title compound as a white solid (0.15 g, 0.35 mmol). MS (ISP) m/z 427,429, (M+H), Cl pattern.

The following compounds are prepared from starting materials prepared as described in Examples 61-64,89 or 91 using the methods described above. Example # Name m/z [M+H] 684 I- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 413,415 allyl]-piperazin-2-one 685 (3S, 467465, benzo [b] thiophen-2-ylmethyl)-3, 5-dimethyl-piperazin-2-one 686 (3 S, 5 S)-I-(4-Amino-quinolin-7-ylmethyl)-4-(6-chloro-464 benzo [b] thiophen-2-ylmethyl)-3,5-dimethyl-piperazin-2-one 687 (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3- 446,448 ylmethyl)-3-methyl-piperazin-2-one 688 (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 444 ylmethyl)-3-methyl-piperazin-2-one 689 443441, 2-yl)-allyl]-3,5-dimethyl-piperazin-2-one 690 443441, 2-yl)-allyl]-3, 5-dimethyl-piperazin-2-one 691 I-(4-Amino-quinolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-ylmethyl)-420, 422 piperazin-2-one 692 (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro-naphthalen-2- 458 ylmethyl)-3-ethyl-piperazin-2-one 693 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 470 allyl]-(S)-3-((R)-I-methoxy-ethyl)-piperazin-2-one 694 1- (4-Amino-quinolin-7-ylmethyl)-4- (7-chloro-isoquinolin-3- 489 ylmethyl)-(S)-3-((R)-1-methyoxy-ethyl)-piperazin-2-one 695 (S)-1-(4-Amino-quinolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-464, 466 ylmethyl)-3-methoxymethyl-piperazin-2-one 696 436434, ylmethyl)-3-methyl-piperazin-2-one 697 464 quinolin-7-ylmethyl]-piperazin-2-one 698 (S)-4- H-indol-2-ylmethyl)-1-(4-ethylamino-quinolin-7-462 ylmethyl)-3-methyl-piperazin-2-one 699 (S)-4- H-indol-2-ylmethyl)-1-(4-ethylamino-quinolin-7-492 ylmethyl)-3-methoxymethyl-piperazin-2-one 700 (S)-4- H-indol-2-ylmethyl)-3-methyl-1-(4-methylamino-448 quinolin-7-ylmethyl)-piperazin-2-one 701 (S)-4-(5-Chloro-1H-indol-2-ylmethyl)-3-methoxymethyl-1-(4- 478 methylamino-quinolin-7-ylmethyl)-piperazin-2-one 702 443 allyl]-3-methyl-4-oxy-piperazin-2-one EXAMPLE 703. (S)-1- (4-Aminoquinolin-7-vlmethyl)-4-r3- (4-bromothiophen-2-vl) acrylovll-3-methvl- piperazin-2-one.

A. (S)-I- (4-Chloroquinolin-7ylmethyl)-4-f3- (4-bromothiophen-2-vl) acrviovll-3-methvl piperazin-2- one.

(S)-1-(4-chloroquinolin-7-ylmethyl)-3-methylpiperazin-2-one hydrochloride (0.35 g, 1.4 mmol), EXAMPLE 91, is treated with DMF (20 mL), 3- (4-bromothiophen-2-yl)- (E)-acrylic acid (0. 32 g, 1.4 mmol), prepared according to EXAMPLE 26, using 4-bromothiophene-2-carboxaldehyde, triethyl amine (0.21 ml, 1.4 mmol) and 2- (lH-benzotriazol-l-yl) 1, 1, 3,3-tertamethyluronium tetrafluoroborate (0.45 g, 1.4 mmol) and heated to 50 °C for 5 minutes. The reaction mixture is stirred at ambient temperature for 16 h then partitioned between ethyl acetate and water. The organic layer is concentrated and the residue is chromatographed (5% methanol/methylene chloride) to give crude title compound (0.5 g, 0.9 mmol).

MS m/z: [M+H] + = 504. 1H NMR (CDCl3, 300 MHz) # 8. 9 (d, I H), 2H), 8.0 (s, 1H), 7.7-7.8 (m, 1H), 7.4 (s, 1H), 7.3-7.4 (m, 1H), 6.7-6.8 (m, 1H), 6.6 (d, 1H), 5.1-5.2 (m, 1H), 4.6-4.7 (m, 2H), 3.4- 3.6 (m, 2H), 3.0-3.3 (m, 2H), 1.5 (d, 3H).

B. (S)-I- inoquinol in-7-ylmethvl)-4-13- (4-bromothioPhen-2-vl acrvloyl1-3-methvl-piperazin-2- one.

(S)-I- (4-Chloroquinolin-7-yimethyl)-4- [3- (4-bromothiophen-2-yl) acryloyl]-3-methyl piperazin- 2-one (0.50 g, 0.9 mmol) is treated with phenol (-2 g) and ammonium acetate (0.5 g, 6.4 mmol) and heated to 120 °C in a sealed vessel for I hour. Upon cooling, the solution is partitioned between 2 N NaOH and ethyl acetate. The organic layer is separated and washed with fresh 2 N NaOH (3 X 100 mL) and water. The organic layer is concentrated and the residue is purified by reverse phase HPLC (gradient elution of 10 % of 0.1 % aqueous TFA/acetonitrile to 100 % acetonitrile) to give the title compound <BR> <BR> <BR> (0.22 g, 0.56 mmol). MS m/z: [M+H] t = 485,487, Cl pattern.'H NMR (CD30D, 300 MHz) 6 8.2-8.4 (m, 2H), 7.7-7.8 (m, 2H), 7.6 (d, 1H), 7.5 (s, 1H), 7.3 (s, 1H), 6.9-7.0 (m, 1H), 6.7 (d, IH), 5.0-5.1 (m, 1H), 4.9 (q, 2H), 4. 3-4.4 (m, 1H), 3.5-3.7 (m, 2H), 3.3-3.4 (m, 2H), 1.5 (d, 3H).

The following compounds are prepared from starting materials prepared as described in Examples 75-87 using the methods described above. Example # Name m/z [M+H] 704 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 469 acryloyl]-3 (S)-ethyl-6-methyl-piperazin-2-one Cl pattern 705 4- [3- (5-Chloro-th iophen-2-yi)-acryloyl]- (S)-3-ethyl-1- (4- 471,473 hydroxyamino-quinolin-7-ylmethyl)-piperazin-2-one 706 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 427,429 acryloyl]-piperazin-2-one 707 (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 454 acryloyl]-3-ethyl-piperazin-2-one 708 441,443 acryloyl]-3-methyl-piperazin-2-one 709 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- 471,473 acryloyl]-piperazin-2-one 710 (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 470 acryloyl]-3-methoxymethyl-piperazin-2-one 711 (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [3- (4-bromo-thiophen-2-yl)- 498 acryloyl]-3-ethyl-piperazin-2-one 712 (S)-I- (4-Amino-quinolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 458 yloxy)-acetyl]-3-ethyl-piperazin-2-one 713 (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 488 yloxy)-acetyl]-3-methoxymethyl-6-methyl-piperazin-2-one 714 1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 484 acryloyl]-(S)-3-(1-(R)-methoxy-ethyl)-piperazin-2-one 715 1- (4-Aminoquinolin-7-ylmethyl)-4- [3- (4-bromothiophen-2-yl)-acryl- 528 oyl]-3-(S)-(I-(R)-methoxyethyl)-piperazin-2-one(S)-(I-(R)-me thoxyethyl)-piperazin-2-one trifluoroacetate 716 1- (4-Aminoquinolin-7-ylmethyl)-4- [ (5-chlorothiophen-2-yioxy- 488 acetyl]-3- (S)- (1- (R)-methoxyethyl)-piperazin-2-one trifluoroacetate 717 (S)-1- (4-Amino-quinolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2-yl)- 454 acryloyl]-3-ethyl-piperazin-2-one

EXAMPLE 718. 1- (4-Aminocinnolin-7-vlmethyl)-4-f2- (5-chlorothiophen-2-vl)-ethenesulfonvll- piperazin-2-one.

A. 1-(4-Chlorocinnolin-7-ylmethyl)-4-[2-(5-chlorothiophen-2-yl) -ethenesulfonyl]-piperazine-2-one 1- (4-chlorocinnolin-7-ylmethyl)-piperazin-2-one hydrochloride (0.14 g, 0.4 mmol), EXAMPLE 90, is treated with acetonitrile (20 mL), triethylamine (2 mL, 14 mmol) and 2- (5-chlorothiophen-2- yl) ethene-sulfonyl chloride (0.097 g, 0.4 mmol), EXAMPLE 3, at 0°C. The solution is warmed to ambient temperature over 1.5 h and diluted with ethyl acetate. The solution is washed with 10 % sodium bicarbonate solution and water, dried (sodium sulfate) and concentrated to yield the title compound (0.17 g, 0.35 mmol). MS m/z: [M+H]+= 483;'H NMR (CDC13, 300 MHz) 8 9.4 (s, 1H), 8.4 (s, 1H), 8.3 (d,

I H) 7.85 (d, 1H), 7.7 (d, 1H), 7.1 (d, 1H), 6.95 (d, 1H), 6.35 (d, 1H), 4.9 (s, 2H), 4.0 (s, 2H), 3.4-3.5 (m, 4H).

B. 1-(4-Aminocinnolin-7-ylmethyl)-4-[2-(5-chlorothiophen-2-yl)- ethenesulfonyl]-piperazin-2-one 1- (4-Chlorocinnolin-7-ylmethyl)-4- [2- (5-chlorothiophen-2-yl)-ethenesulfonyl]-piperazin-2-one (0.06 g, 0.12 mmol) is treated with phenol (0.20 g) and ammonium acetate (0.2 g, 2.6 mmol) and heated to 120 °C for 45 minutes. The reaction mixture is cooled, diluted with ethyl acetate and washed with 1 N NaOH (3 X 100 mL) and water. The organic layer is concentrated and the residue is purified by reverse phase HPLC (20 % aqueous TFA (0.1 %)/acetonitrile to 100 % acetonitrile). Fractions containing the desired product are lyophilized to obtain the title compound (0.02 g, 0.043 mmol). MS m/z: [M+H] + = 464;'H NMR (CD30D, 300 MHz) 8 8.6 (s, 1H), 8.4 (d, IH), 7.75 (d, 1H, 7.65 (d, 1H), 7.35 (d, 1H), 7.1 (d, lH), 6.8 (d, 1H), 4.9 (s, 2H), 4.05 (s, 2H), 3.6 (m, 4H).

EXAMPLE 719.4- 3-blpyridine-2-sulfonvl)-I-l 2-(Pvridin-4-vlam ino)-ethvll- <BR> <BR> <BR> piperazin-2-one.<BR> <BR> <BR> <BR> <P> 1- [2- (Pyridin-4-ylamino)-ethyl]-piperazin-2-one (0.20 mmol), EXAMPLE 90, is dissolved in MeCN (5 mL) and treated with 4-methylmorphorline (0.055 ml, 0.50 mmol). 6-Chloro-thieno [2,3- b] pyridine-2-sulfonyl chloride (54 mg, 0.20 mmol) in MeCN (2 mL) is added dropwise. The reaction mixture is stirred at r. t. for 1.5 h, then subjected to HPLC purification, to give the title compound as white solid (0.021 g, 0.037 mmol). MS m/z 452,454 (M+l);'H NMR (CD30D, 300 MHz) 8 8. 37 (d, 1H), 8. 30 (b, 1H), 8.12 (d, 1H), 8.02 (s, 1H), 7.97 (d, 1H), 7.57 (d. 1H), 6.98 (d, 1H), 6.88 (d, 2H), 3.73 (s, 2H), 3.60-3.48 (m, 8H).

EXAMPLE 720.4- (6-Chloro-benzorblthiophene-2-sulfonvl)-1-f2- (methvl-nvridin-4-vl-amino)-ethvll- piperazin-2-one.

A portion (-50%) of the crude 1-[2-{(Methyl)-(pyridin-4-yl)-amino}-ethyl]-piperazin-2-one, EXAMPLE 93 is reacted with 6-chloro-benzo [b] thiophene-2-sulfonyl chloride (54 mg, 0.20 mmol), EXAMPLE 1, using same procedure as described in EXAMPLE 719. The residue obtained after HPLC purification is subjected to silica gel chromatography using NH4OH/MeOH/CH, CI, (1: 4: 95) as eluant to give title compound (30 mg, 0.064 mmol) as a white solid. MS m/z 465,457 (M+1) ;'H NMR (CDCl3, 300 MHz) 8 8.15 (d, 2H), 7.88 (s, IH), 7.85 (d, IH), 7.79 (s, 1H), 7.47 (d, 1H), 6.47 (d. 2H), 3.80 (s, 2H), 3.50 (m, 4H), 3.43 (d, 2H), 3.30 (d, 2H), 2.98 (s, 3H). <BR> <BR> <P>EXAMPLE 721. 4-2- (5-Chloro-thiophen-2-vl)-ethenesulfonvll-1-r2- (3-methvl-pvridin-4-vlamino)-<BR> <BR> <BR> <BR> <BR> ethyl]-piperazin-2-one.

1- [2- (3-Methylpyridin-4-yl-amino)-ethyl]-piperazin-2-one (38 mg, 0.16 mmol), EXAMPLE 94, is reacted with 2- (5-chloro-thiophen-2-yl)-ethenesulfonyl chloride (40 mg, 0.16 mmol), EXAMPLE 3, using the same procedure as described in EXAMPLE 719. Reverse phase HPLC purification gives the title compound (29 mg, 0.052 mmol) as a white solid. MS m/z 441,443 (M+H);'H NMR (CD30D, 300 MHz) S 8.08 (d, 1H), 7.98 (s, 1H), 7.56 (d, 1H), 7.30 (d, 1H), 7.02 (s, 1H), 7.00 (d. 1H), 6.78 (d, 1H), 3.87 (s, 2H), 3.70-3.50 (m, 8H), 2.15 (s, 3H).

The following compounds are prepared from starting materials obtained as described in Examples 92-97 using the methods described above. Example # Name m/z [M+H] 722 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- [2-(pyridin-4-520 (M+) ylamino)-ethyl]-piperazin-2-one 723 1- [2- (Pyridin-4-ylamino)-ethyl]-4- (thieno [2,3-b] pyridine-2-417 sulfonyl)-piperazin-2-one 724 4- (5'-Chloro- [2,2'] biothiophenyl-5-sulfonyl)-1-[2-(pyridin-4- 483, 485 ylamino)-ethyl]-piperazin-2-one 725 I- [2-(Pyridin-4-ylamino)-ethyl]-4-(thieno [3,2-b] pyridine-2-418 sulfonyl)-piperazin-2-one 427,4297264-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-[2 -(pyridin-4- ylamino)-ethyl]-piperazin-2-one 4417274-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-[2-(me thylpyridin- 4-ylamino)-ethyl]-piperazin-2-one 4437284-(2-Benzo[b]thiophen-2-yl-ethenesulfonyl)-1-[2-(pyrid in-4- ylamino)-ethyl]-piperazin-2-one 729 4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- [2- (3-methyl-pyridin- 465,467 4-ylamino)-ethyl]-piperazin-2-one 730 4- [2- (5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1- (2-pyrrolo [3,2-450,452 c] pyridin-I-yl-ethyl)-piperazin-2-one 731 1- [2- (2-Amino-3-chloro-pyridin-4-ylamino)-ethyl]-4- [2- (5-chloro- 476,478 thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one 732 1- [2- (2-Amino-5-chloro-pyridin-4-ylamino)-ethyl]-4- [2- (5-chloro- 476,478 thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one 733 4-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonyl]-1-[2-(2, 3,5,6-563,565, tetrachloro-pyridin-4-ylamino)-ethyl]-piperazin-2-one 567,569 734 1- [2- (2-Amino-3,5,6-trichloro-pyridin-4-ylam ino)-ethyl]-4-[2-(5-544, 546, chloro-thiophen-2-yl)-ethenesulfonyl]-piperazin-2-one 548 735 4- [3- (5-Chloro-thiophen-2-yl)-acryloyl]-]- [2- (pyridin-4-ylamino)- 391,393 ethyl]-piperazin-2-one

EXAMPLE 736.4- (6-Chloro-benzofblthiophene-2-sulfonvl)-I-r2- (pvridazin-4-yl-amino)-eth piperazin-2-one.<BR> <P> 1- [2- (Pyridazin-4-ylamino)-ethyl]-piperazin-2-one hydrochloride (0.5 g, 1.7 mmol), EXAMPLE 95, is reacted with 6-chloro-benzo [b] thiophene-2-sulfonyl chloride (0.40 g, 1.5 mmol), EXAMPLE 1, using essentially the same procedure as described in EXAMPLE 719. Reverse phase HPLC purification gives the title compound (0.34 g, 0.75 mmol) as a white solid. MS m/z (M+H= 452);'H NMR (CD30D, 300 MHz) 8 8.6 (d, 1H), 8.4 (d, 1H), 8.05 (s, 1H), 8.05 (s, 1H), 7.9 (d, 1H), 7.5 (d, 1H), 7.2 (d, 1H), 3.8 (s, 2H), 3.4-3.7 (m, 8H).

EXAMPLE 737. -f3- (4-Amino-pvridin-3-propenytl-4-f2- (5-chloro-thiophen-2-vl)-ethenesulfonvll- piperazin-2-one.<BR> <P> 4- [3- (4-tert-Butoxycarbonylamino-pyridin-3-yi)-propenyl]-3-oxo-pi perazine- I-carboxylic acid tert-butyl ester from EXAMPLE 96, Part B (45 mg, 0.10 mmol) is dissolved in 20% TFA/CH2CI2 and stirred at r. t. for 2 hours. The solution is concentrated to residue. The residue is dissolved in MeCN (2.5 ml) and treated with 4-methylmorphorline (0.027 ml, 0.25 mmol). 2- (5-Chloro-thiophen-2-yl)- ethenesulfonyl chloride (24 mg, 0.10 mmol), EXAMPLE 3, in MeCN (1 mL) is then added dropwise.

The reaction mixture is stirred at r. t. for 1 h, then subjected to reverse phase HPLC purification, to give the title compound as white solid (0.040 g, 0.037 mmol). MS m/z 439,441 (M+H);'H NMR (CD30D, 300 MHz) 8 8.20 (br, 1H), 8.10 (s, 1H), 8.08 (d, 1H), 7.60 (d, 1H), 7.53 (d. 1H),735 (d, IH), 7.21 (d, IH), 7.07 (d, lH), 6.82 (d, IH), 5.27 (m, 1H), 3.88 (s, 2H), 3.60-3.50 (m, 4H), 3.30 (d, 2H).

The following compounds are prepared from starting materials obtained as described in Examples 92-97 using the methods described above. ExampleExample# Name m/z [M+H] 738 1- [3- (4-Amino-pyridin-3-yl)-propenyl]-4- (6-chloro- 463,465 benzo [b] thiophene-2-sulfonyl)-piperazin-2-one 739 1- [3- (4-Amino-pyridin-3-yl)-allyl]-4- (6-chloro-benzo [b] thiophene-2- 463,465 sulfonyl)-piperazin-2-one 740 1- [3- (4-Amino-pyridin-3-yi)-allyll-4- [2- (5-chloro-thiophen-2-yi)- 439, 441 ethenesulfonyl]-piperazin-2-one 741 1- [3- (4-Amino-pyridin-3-yi)-propyl]-4- (6-chloro-benzo [b] thiophene- 465,467 2-sulfonyl)-piperazin-2-one 742 1- [3- (4-Amino-pyridin-3-yi)-propyl]-4- [2- (5-chloro-thiophen-2-yl)- 441,443 ethenesulfonyl]-piperazin-2-one

EXAMPLE 743.4-f2-(5-Chlorothiophen-2-vl)-ethenesulfonvll-1-(2-pvrrol oF3. 2-clpvridin-1-vlethvl)- piperazin-2-one.

4-(Benzyloxycarbonyl)-1-(2-pyrrolo(Benzyloxycarbonyl)-1-(2-p yrrolo [3,2-c] pyridin-1-ylethyl)-piperazin-2-one (0.028 g, 0.074 mmol), EXAMPLE 98, is treated with 4 % HCOH/MeOH (5 mL) and a catalytic amount of Pd black for 5 minutes. The reaction mixture is filtered washed with methanol and the filtrate is concentrated to a residue. The residue is treated with acetonitrile (3 mL) excess N-methylmorpholine (0.04 mL) and 2- (5- chlorothiophen-2-yl) ethene-sulfonyl chloride (0.018 g, 0.074 mmol), EXAMPLE 3, and processed as usual (EXAMPLE 719). Further chromatographic purification (NH4OH/MeOH/CH2CI2: 1/4/95) yields the title compound: MS m/z 451,453 (M+H);'H NMR (CDCl3, 300 MHz) 8 8.93 (bs, 1H), 8.24 (bs, 1H), 7.41 (d, 1H), 7.23 (d, 1H), 7.14 (m, 2H), 6.94 (d, 1H), 6.68 (d. 1H), 6.18 (d, 1H), 4.43 (t, 2H), 3.67 (t, 2H), 2.88 (t, 2H), 2.66 (t, 2H).

EXAMPLE 744. 4-Prop-2-ynyl-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-pipera zin-2-one, <BR> <BR> A. 2- (2-Oxo-4-prop-2-vnyl-piperazin-l-vlmethel)-pyrrolo [392-clpvridine-l-carboXvlic acid tert-butyl ester.

A solution containing 2-(2-oxo-piperazin-1-ylmethyl)-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (4.3 g, 13.0 mmol), EXAMPLE 69, in CH3CN (250 mL) is cooled to 0°C. Potassium carbonate (1.98 g, 14.3 mmol) is added to the reaction mixture followed by propargyl bromide (1.55g, 13.0 mmol). The mixture is slowly warmed to ambient temperature and maintained until complete consumption of starting material is observed by TLC (approx. 8 h). The mixture is concentrated to dryness and then partitioned between aqueous NaHC03 (200 mL) and CH2C12 (200 mL) and the layers are separated. The aqueous phase is extracted twice with CH2Cl2 (100 mL) and the combined organic phase is washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude residue is purified by flash silica gel chromatography (CH2CI2 to 5% MeOH/CH2Cl2) to provide 3. 38 g (70%) of the title compound as a pale yellow solid.'H NMR (300 MHz, CDCI3) 5 1.69 (s, 9H), 2. 34 (t, J = 2.4 Hz, 1H), 2.89 (m, 2H), 3.42 (s, 2H), 3.45 (d, J = 2.4 Hz, 2H), 3.52 (m, 2H), 4.95 (d, J = 1.4 Hz, 2H), 6.42

(br s, 1H), 7.88 (dd, J = 5.8,0.8 Hz, 1H), 8.41 (d, J = 5.8 Hz, 1H), 8.78 (d, J = 0.8 Hz, I H) ppm; MS (EI): m/z 368 (M+).

B.4-Prop-2-ynyl-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-p iperazin-2-one.

To a solution containing 2- (2-oxo-4-prop-2-ynyl-piperazin-1-ylmethyl)-pyrrolo [3,2-c] pyridine- I-carboxylic acid tert-butyl ester (1.3 g, 3.53 mmol) in CH, CL, (100 mL) is added TFA (20 mL) at 0 °C.

After 6 h, the reaction mixture is concentrated to dryness and then partitioned between aqueous NaHCO3 (500 mL) and CH2CI2 (200 mL) and the layers are separated. The aqueous phase is extracted four times with CH2Cl2(100 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, SO4, filtered and concentrated. The crude residue is purified by flash silica gel chromatography (CH, CI, to 10% MeOH/CH, CI,) to provide 616 mg (65%) of the title compound as a pale yellow solid. <BR> <BR> <BR> <BR> <P>'H NMR (300 MHz, CDCI3) 5 2.27 (app t, J = 2.4 Hz, 1H), 2.76 (m, 2H), 3.33 (s, 2H), 3.83 (d, J = 2.4 Hz, 2H), 3.45 (m, 2H), 4.57 (s, 2H), 6.47 (s, 1 H), 723 (d, J = 5.7 Hz, 1H), 8.28 (d, J = 5.7 Hz, 1H), 8.85 (d, J = 0.9 Hz, IH), 9. 34 (br s, 1H) ppm; MS (El): m/z 268 (M+).

EXAMPLE (1H-pvrrolo (3, 2-clpvridin-2-vlmethvl)-piperazin-2-one.

A. 2-{4-[3-(4-tert-Butoxycarbonylamino-pyridin-3-yl)-prop-2-yny l]-2-oxo-piperazin-1-ylmethyl}- pyrrolor3, 2-clpyridine-1-carboxvlic acid tert-butvl ester.

A solution containing 2-(2-oxo-4-prop-2-ynyl-piperazin-1-ylmethyl)-pyrrolo [3,2-c] pyridine-1- carboxylic acid tert-butyl ester (100 mg, 0. 27 mmol), EXAMPLE 743, (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester (87 mg, 0.27 mmol), EXAMPLE 69, Part B, Et, N (110 mg, 1.08 mmol), (Ph3P) 4PdC12 (10 mg, 0.013 mmol), and Cul (1 mg, 0.008 mmol) in anhydrous DMF (5 mL) is stirred at ambient temperature. After 5 h, the reaction mixture is diluted with EtOAc (50 mL) and water (50 mL) and the layers are separated. The aqueous layer is extracted twice with EtOAc (25 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated.

The crude residue is purified by flash silica gel chromatography (CH, C12 to 10% MeOH CHCl) to provide 77 mg (51%) of SC41 as a colorless oil.'HNMR (300 MHz, CDCI3, ~2: 1mixture of rotamers) major rotamer: 5 1.53 (s, 9H), 1.69 (s, 9H), 2.98 (m, 2H), 3.49 (s, 2H), 3.56 (m, 2H), 3.78 (s, 2H), 4.98 (s, 2H), 6.43 (s, 1H), 7.89 (m, 1H), 8.09 (m, 2H), 8.34 (m, 1H), 8.41 (m, 1H), 8.75 (m, 1H), ppm; MS (ISP loop): m/z 561 (M+H).

B. 2-[4-(1-tert-Butoxycarbonyl-1H-pyrrolo[3,2-c]pyridin-2-ylmet hyl)-2-oxo-piperazin-1-ylmethyl]- pyrrolo[3, 2-clpyridine-1-carboxylic acid tert-butyl ester.

1,8-Diazabicyclo [5.4.0] undec-7-ene (42 mg, 0.27 mmol) is added to a suspension containing 2- {4-[3-(4-tert-butoxycarbonylamino-pyridin-3-yl)-prop-2-ynyl] -2-oxo-piperazin-1-ylmethyl}-pyrrolo[3,2- c] pyridine-1-carboxylic acid tert-butyl ester (SC41,77 mg, 0.14 mmol) in anhydrous CH3CN (10 mL) and the mixture is warmed to 50 °C. After 4 h, the reaction mixture is concentrated to dryness and the residue is partitioned between CH, CL (50 mL) and water (50 mL) and the layers are separated. The aqueous layer is extracted twice with CH, CL, (25 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, SO,, filtered and concentrated to provide 85 mg of the title compound as a crude solid which is used directly without further purification.'H NMR (300 MHz, CDCI3) 6 1.68 (s, 9H), 1.70 (s, 9H), 2.91 (m, 2H), 3.41 (s, 2H), 3.49 (m, 2H), 4.26 (s, 2H), 4.95 (d, J = 1.1 Hz, 2H), 6. 39 (d, J = 0.7 Hz, 1H), 6.68 (d, J = 0.7 Hz, 1H), 7.86 (m, IH), 8.41 (m, 1H), 8.76 (br s, 1H), 8.82 (br s, IH) ppm; MS (El): m/z 561 (M+H).

C.1,4-Bis-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin -2-one.

To a solution containing 2- [4- (1-tert-Butoxycarbonyl-lH-pyrrolo [3,2-c] pyridin-2-ylmethyl)-2- oxo-piperazin-l-ylmethyl]-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (85 mg, 0.14mmol) in CH, CI, (5 mL) is added TFA (1 mL) at 0°C and the solution is allowed to slowly warm to ambient temperature. After 16 h, the reaction mixture is concentrated to dryness, diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/0.1 % TFA; Gradient: 0% B to 45% B over 30 min] to provide 35 mg (36%, two steps) of SC43 as a pale yellow, lyophilized solid.

'H NMR (300 MHz, db DMSO) 8 2.80 (m, 2H), 3. 25 (s, 2H), 3.37 (m, 2H), 3.93 (s, 2H), 4.76 (s, 2H), 6.88 (s, 1H), 6.94 (s, 1H), 7.85 (d, J = 6.6 Hz, 1H), 7.89 (d, J = 6.6 Hz, IH), 8. 37 (d, J = 6.7 Hz, 1H), 8.38 (d, J = 6.7 Hz, I H), 9.17 (s, 1H), 9.19 (s, 1H), 12.80 (s, 1H), 12.96 (s, IH), 14.91 (br s, 2H) ppm; MS (ion spray): m/z 361 (M+H). CHCIN. OS MS m/z: 441,443.

The following compounds are prepared from starting materials obtained as described in Examples 69-71 using the methods described above. Example # Name m/z [M+H] 746 4- H-benzoimidazol-2-ylmethyl)-1- (I H-pyrrolo [3,2-395,397 c] pyridin-2-ylmethyl)-piperazin-2-one 747 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-1- ( H-pyrrolo [3, 2- 443,445 c] pyridin-2-ylmethyl)-piperazin-2-one 748 4- [3- (5-Chloro-thiopheD-2-yl)-allyi]- I- (I H-pyrrolo [3,2-c] pyridin-2- 386,388 ylmethyl)-piperazin-2-one 749 4-(5-Chloro-I H-indol-2-ylmethyl)-1-(1 H-pyrrolo(5-Chloro-I H-indol-2-ylmethyl)-1-(1 H-pyrrolo [3,2-c] pyridin-2-394,396 ylmethyl)-piperazin-2-one 750 4-(6-Chloro-naphthalen-2-ylmethyl)-1-(I H-pyrrolo(6-Chloro-naphthalen-2-ylmethyl)-1-(I H-pyrrolo [3,2-c] pyridin-2- 405,407 ylmethyl)-piperazin-2-one 751 4-(7-Chloro-isoquinolin-3-ylmethyl)-1-(1H-pyrrolo [3,2-c] pyridin-2- 406,408 ylmethyl)-piperazin-2-one 752 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-6-oxo-1- ( H-501,503 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- ()-carboxylic acid methyl ester 753 1- H-indol-2-ylmethyl)-5-oxo-4- (1 H-pyrrolo [3,2-452,454 c] pyridin-2-ylmethyl)-piperazme-2- ()-carboxylic acid methyl ester 754 1-[(5-Chloro-thiophen-2-yloxy)-acetyl]-5-oxo-4-(1H-pyrrolo [3,2-463,465 c] pyridin-2-ylmethyl)-piperazine-2-carboxylic acid methyl ester 755 1- (6-Chloro-benzo [b] thiophene-2-carbonyl)-5-oxo-4-(1H- 483, 485 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2-carboxylic acid methyl ester 756 554,556 oxo-4- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazine-2- carboxylic acid methyl ester 757 1- (1H-Pyrrolo [3,2-c] pyridin-2-ylmethyl)-4- H-pyrrolo [2,3- 361 c] pyridin-2-ylmethyl)-piperazin-2-one 758 4-(3-Phenyl-prop-2-ynyl)-1-(I H-pyrrolo(3-Phenyl-prop-2-ynyl)-1-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- 345 piperazin-2-one 3847594-[3-(5-Chloro-thiophen-2-yl)-prop-2-ynyl]-1-(1H-pyrro lo[3,2- c] pyridin-2-ylmethyl)-piperazin-2-one The following compounds are prepared from 3- (S)-methoxymethyl-l-(lH-pyrrolo [3,2-c] pyridin- 2-ylmethyl)-piperazin-2-one using the procedures described above. Example # Name m/z [M+H] 760 4- [3- (5-Chloro-thiophen-2-yl)-allyl]-3- (S)-methoxymethyl-l- (II-H-431,433 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 761 438,440 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 762 4- (5'-Chloro- [2,2'] bithiophenyl-5-ylmethyl)-3- (S)-methoxymethyl- 487,489 1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one 763 4-(6-Chloro-benzo [b] thiophene-2-carbonyl)-3-(S)-methoxymethyl-469, 471 1- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 764 4- [I- (3, 5-Dichloro-phenyl)-2, 5-dimethyl-IH-pyrrole-3-carbonyl]-3- 540, 542 (S)-methoxymethyl-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)- piperazin-2-one 439,4417654-[3-(4-Chloro-phenyl)-(E)-acryloyl]-3-(S)-methoxy methyl-1-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 766 (S)-2-Methoxymethyl-3-oxo-4- H-pyrrolo [3,2-c] pyridin-2-428,430 ylmethyl)-piperazine-l-carboxylic acid (4-chloro-phenyl)-amide 767 (S)-4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-3-methoxymethyl- 445,447 1- (1 H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one

EXAMPLE 768. 4-(6-Chloro-benzo[b]thiophene-2-carbonyl)-1-(1H-pyrrolo[3,2- c]pyridin-2- vlmethvl) piperazin-2-one.

A. 2-r4-(6-Chloro-benzol blthiophene-2-carbonvl)-2-oxopiperazin-1-vlmethvll-(pvrrolol 3 2-clpvridin-1- carboxylic acid tert-butyl ester.

The title compound is prepared as described in EXAMPLE 123 using 6-chloro- benzo [b] thiophene-2-carboxylic acid, EXAMPLE 1 and 2- (2-oxopiperazin-1-ylmethyl)-pyrrolo [3,2- c] pyridin-I-carboxylic acid tert-butyl ester EXAMPLE 69. The mixture is stirred overnight, then concentrated to dryness. The residue is diluted with CH, CL, and washed with saturated sodium bicarbonate and brine. The organic layer is dried over MgS04, filtered and concentrated in vacuo to give the title compound as a solid. The crude material can be used in the subsequent step without further purification.

B. 4-(6-Chloro-benzo[b]thiophene-2-carbonyl)-1-(1H-pyrrolo[3,2- c]pyridin-2-ylmethyl)-piperazin-2 one.

Trifluoroacetic acid (0.5 mL) is added dropwise to a solution of 2- [4- (6-chloro- benzo [b] thiophene-2-carbonyl)-2-oxopiperazin-1-ylmethyl]-(pyrrolo [3,2-c] pyridin-1-carboxylic acid tert-butyl ester (0.14 g, 0.27 mmol) in 6 mL CH, CI, at 0°C. After 1 h, the ice bath is removed and the solution stirred at room temperature for 2 hours. The reaction mixture is concentrated in vacuo. The crude residue is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H20 (0.1 % TFA) to 100% CH3CN and the appropriate product fractions are combined and lyophilized to provide the title compound (0.07 g, 0.13 mmol) as a white solid. ESI MS, [M+H] +=425,427 (Cl pattern).

The following compounds are prepared using starting materials obtained as described in Example 69 using the methods described above. Example # Name m/z [M+H] 769 4-[3-(6-Chloro-benzo [b] thiophen-2-yl)-(E)-acryloyl]-I-(I H-451,453 pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 770 4-[(5-Chloro-thiophen-2-yloxy)-acetyl]-1-(I H-pyrrolo[(5-Chloro-thiophen-2-yloxy)-acetyl]-1-(I H-pyrrolo [3,2-c] pyridin- 405,407 2-ylmethyl)-piperazin-2-one 497,4997714-[1-(3,5-Dichloro-phenyl)-2,5-dimethyl-1H-pyrrole -3-cqarbonyl]-1- (I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 772 4- (5'-Chloro- [2,2'] bithiophenyl-5-carbonyl)-1- ( H-pyrrolo [3,2-457,459 c] pyridin-2-ylmethyl)-piperazin-2-one 773 4-(5-Chloro-1H-indole-2-carbonyl)-1-(1H-pyrrolo [3,2-c] pyridin-2-364,366 ylmethyl)-piperazin-2-one 774 4- [4- (6-Methoxy-pyridin-3-yl)-benzoyl]-1- ( H-pyrrolo [3,2- 442 c] pyridin-2-ylmethyl)-piperazin-2-one 775 4-(4-Pyridin-3-yl-benzoyl)-1-(I H-pyrrolo(4-Pyridin-3-yl-benzoyl)-1-(I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)- 412 piperazin-2-one 776 4- [3- (4-Bromo-thiophen-2-yl)- (E)-acryloyl]- I- (I H-pyrrolo [3,2- 446 c] pyridin-2-ylmethyl)-piperazin-2-one 777 4- [3- (5-Chloro-thiophen-2-yl)-propionyl]-1- ( H-pyrrolo [3,2-403,405 c] pyridin-2-ylmethyl)-piperazin-2-one 453,4557784-[(5-Chloro-3-methyl-benzo[b]thiophen-2-yl)-acety l]-1-(1H- pyrrolo [3,2-c] pyridin-2-ylmethyl)-piperazin-2-one 779 4- [2- (4-Chloro-phenyl)-2-methyl-propionyl]-1- ( H-pyrrolo [3,2- 411, 413 c] pyridin-2-ylmethyl)-piperazin-2-one 780 4- [3- (3, 4-Dichloro-phenyl)- (E)-acryloyl]- I- (I H-pyrrolo [3,2-431,433 c] pyridin-2-ylmethyl)-piperazin-2-one 781 4-[(4-Chloro-phenyl)-acetyl]-1-(1H-pyrrolo [3,2-c] pyridin-2-383,385 ylmethyl)-piperazin-2-one 782 4- [3- (4-Chloro-phenyl)- (E)-acryloyl]- I- (I H-pyrrolo [3,2-c] pyridin-2- 395,397 ylmethyl)-piperazin-2-one 783 4-[3-(5-Chloro-thiophen-2-yl)-(E)-acryloyl]-1-(1H-pyrrolo [3,2-400,402 c] pyridin-2-ylmethyl)-piperazin-2-one

EXAMPLE 784. (~)-1-(4-Amino-quinazoln-7-ylmethyl)-4-(5-chloro-1H-indol-2- ylmethyl)-6-oxo- piperazine-2-carboxvlic acid methyl ester.

A. ()-4-f3- (Benzhvdrylidene-amino)-4-cyano-benzvll-5-oxo-piperazine-l. 3-dicarboxYiic acid I-allvl ester 3-methyl ester.

To a solution containing (S)-5-oxo-piperazine-1,3-dicarboxylic acid l-allyl ester 3-methyl ester (0.43 g, 1.77 mmol), EXAMPLE 56, and 2- (benzhydrylidene-amino)-4-bromomethyl-benzonitrile (0.66 g, 1.77 mmol), EXAMPLE 13, in anhydrous DMF (5 mL) at 0°C is added 60% NaH (78 mg, 1.95 mmol). After 30 min, the reaction mixture is warmed to ambient temperature and maintained for 6 hours. The reaction mixture is carefully quenched with water and then diluted with water and diethyl ether. The layers are separated and the organic phase is washed twice with water, brine, dried over anhydrous Na. SO,, filtered and concentrated. The crude residue is chromatographed on silica gel (2: 1 hexane/ethyl acetate to 1: 1 hexane/ethyl acetate) to provide 0. 37 g (39%) of the title compound as a glassy solid. <BR> <BR> <BR> <P>'HNMR (300 MHz, CDC1,) 8 3.01-3.22 (m, 2H), 3.58 (m, 2H), 3.73 (s, 3H), 3.86-3.92 (m, 1H), 4.42- 4.58 (m, 4H), 5.25 (m, 2H), 5.93 (m, 1H), 6.57 (br s, 1H), 6.85 (d, J = 8.2 Hz, 1 H), 7.17-7.51 (m, 9H), 7.76 (m, 2H) ppm; MS (ion spray): m/z 537 (M+H).

B. ()-I-r3- (Benzhvdrvlidene-amino)-4-cyano-benzyll-6-oxo-piperazine-2-c arboxylic acid methyl ester.

Tetrakis (triphenylphosphine) palladium (0) (237 mg, 0.2 mmol) is added to a solution containing ()-4- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-5-oxo-piperazine-1, 3-dicarboxylic acid 1-allyl ester 3-methyl ester (1.10 g, 2.05 mmol) and morpholine (894 mg, 10.2 mmol) in CH2CI2 (30 mL). After-5 min, the reaction mixture is absorbed onto silica gel and chromatographed (CH, Cl, to 10% MeOH/ CH2CI2) to provide 900 mg (97%) of the title compound as a viscous yellow oil.'H NMR (300 MHz, CDCI3) 8 1.83 (br s, 1H), 2.95 (dd, J = 13.5,4.3 Hz, 1H), 3.27 (br d, J = 13.5 Hz, 1H), 3.46-3.72 (m, 4H), 3.73 (s, 3H), 5.40 (d, J = 15.3 Hz, IH), 6.57 (br s, 1H), 6.83 (dd, J = 8.0,1.2 Hz, 1H), 7.17-7.50 (m, 9H), 7.75-7.77 (m, 2H) ppm; MS (ion spray): m/z 453 (M+H).

C. ()-2- 4-F3- (Benzhydrvlidene-amino)-4-cvano-benzyll-3-methoxvcarbonvl-5- oxo-piperazin-1- elmethell-5-chloro-indole-1-carboxvlic acid tert-butvl ester.

To a mixture of ()-I- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-6-oxo-piperazine-2- carboxylic acid methyl ester (630 mg, 1. 39 mmol) and K, CO, (380 mg, 2.78 mmol) in anhydrous CH3CN (5 mL) at 0 °C is added 2-bromomethyl-5-chloro-indole-1-carboxylic acid tert-butyl ester (720 mg, 2.09

mmol), EXAMPLE 21, in CH3CN (4 mL). The reaction mixture is allowed to warm to ambient temperature then maintained for 16 hours. The reaction mixture is diluted with diethyl ether/water and the layers are separated. The organic phase is washed twice with water, brine, dried over anhydrous Na, S04, filtered and concentrated. The crude residue is chromatographed on silica (CFLCL, to 2% MeOH/CH, Cl,) to provide 550 mg (55%) of the title compound which is used directly in the next reaction without further characterization.

D. (~)-2-[4-(3-Amino-4-cyano-benzyl)-3-methoxycarbonyl-5-oxo-pi perazin-1-ylmethyl]-5-chloro- indole-1-carboxylic acid tert-butyl ester.

Partially-purified ()-2- {4- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-3-methoxycarbonyl-5- oxo-piperazin-l-ylmethyl}-5-chloro-indole-1-carboxylic acid tert-butyl ester (550 mg, 0.76 mmol) is suspended in reagent grade MeOH (20 mL). To the heterogeneous mixture is added 12M HCI (5 drops) and the reaction mixture is maintained at ambient temperature until homogeneous (-30 min). The reaction mixture is partitioned between diethyl ether and water containing excess NaHCO3 (500 mL).

The layers are separated and the organic phase is washed with brine, dried over anhydrous Naos04, filtered and concentrated. The crude residue is chromatographed on silica gel (CH, CI, to 2% MeOH/ CH, Cl,) to provide 400 mg (94%) of the title compound which is used directly in the next reaction. MS (ISP loop): 532 (M+H).

E.(~)-2-[4-(4-Amino-quinazolin-7-ylmethyl)-3-methoxycarbo nyl-5-oxo-piperazin-1-ylmethyl]-5- chloro-indole-1-carboxylic acid tert-butvl ester.

A solution containing ()-2- [4- (3-amino-4-cyano-benzyl)-3-methoxycarbonyl-5-oxo-piperazin- 1-ylmethyl]-5-chloro-indole-1-carboxylic acid tert-butyl ester (100 mg, 0.18 mmol), 1,3,5-triazine (146 mg, 1.81 mmol), and glacial HOAc (99 mg, 1.81 mmol) in absolute EtOH (10 mL) is maintained at reflux for 16 hours. A second portion of 1,3,5-triazine (146 mg, 1.81 mmol) and glacial HOAc (99 mg, 1.81 mmol) is added and the reaction mixture is maintained at reflux for an additional 16 hours. The reaction mixture is concentrated in vacuo and the crude product is diluted with water/CH3CN and purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/0.1 % TFA; Gradient: 0% B to 60% B over 30 min] to provide 26 mg (20%) of the title compound as a white solid which is used directly in the next reaction without further characterization.

F. (+)-I-(4-Amino-quinazolin-7-vlmethvl)-4-(5-chloro-I H-indol-2-vlmethvl)-6-oxo-Piperazine-2- carboxylic acid methyl ester.

To a solution containing ()-2- [4- (4-amino-quinazolin-7-ylmethyl)-3-methoxycarbonyl-5-oxo- piperazin-l-ylmethyl]-5-chloro-indole-1-carboxylic acid tert-butyl ester (26 mg, 0.03 mmol) in CH2CI2

(4 mL) is added trifluoroacetic acid (ImL) at ambient temperature. After 4 h, the reaction mixture is concentrated in vacuo and then dissolved in water/CH3CN and purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/0. I % TFA; Gradient: 0% B to 60% B over 30 min] to provide 10 mg (47%) of the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 8 2.62 (m, 1H), 3.05-3.51 (m, 4H), 3.59 (s, 3H), 3.81 (d, J = 14.0 Hz, 1H), 4.26 (m, IH), 4 69 (ABq, AAB = 310 Hz, JAB = 16.4 Hz, 2H), 6.26 (s, 1H), 7.02 (dd, J = 8.6,2.0 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.52 (s, 1H), 7.61 (d, J = 8.7 Hz, 1H), 8. 30 (d, J = 8.6 Hz, 1H), 8.47 (s, 1H), 8.77 (s, 1H), 9.69 (br s, 2H), 11.17 (s, 1H), ppm; MS (ion spray): m/z 479 (M+H).

EXAMPLE 785. ()-1- (4-Amino-quinazolin-7-vlmethvl)-4- (5-chloro-1H-indol-2-vlmethvl)-6-oxo- piperazine-2-carboxvlic acid.

A. (~)-1-(3-Amino-4-cyano-benzyl)-4-(5-chloro-1H-indol-2-ylmeth yl)-6-oxo-piperazine-2-carboxylic acid.

LiOH monohydrate (380 mg, 9.06 mmol) is added at ambient temperature to a solution containing ()-2- [4- (3-amino-4-cyano-benzyl)-3-methoxycarbonyl-5-oxo-piperazin-1 -ylmethyl]-5- chloro-indole-I-carboxylic acid tert-butyl ester (1.0 g, 1.81 mmol), EXAMPLE 784, Part E, in 1: 1: 1 THF/MeOH/water (30 mL). After 16 h, HOAc (0.5 mL) is added and the reaction mixture is concentrated in vacuo. The residue is dissolved in CH3CN/water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 378 mg (48%) of the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 6 3.03 (m, 1H), 3.48 (m, 1H), 3.51 (ABq, AAB = 69.2 Hz, JAB = 16.4 Hz, 2H), 3.78 (d, J = 15.9 Hz, 1H), 4.05- 4.09 (m, 2H), 5.04 (d, J = 15.9 Hz, 1H), 6.41 (m, 2H), 6.58 (s, 1H), 7.04 (dd, J = 8.6,2.0 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.51, d, J = 2.0 Hz, 1H), ppm; MS (ISP loop): m/z 438 (M+H).

B. (+)-I-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1 H-indol-2-vlmethvl)-6-oxo-pinerazine-2- carboxylic acid A solution containing (+)-1-(3-amino-4-cyano-benzyl)-4-(5-chloro-lH-indol-2-ylmeth yl)-6-oxo- piperazine-2-carboxylic acid (200 mg, 0. 30 mmol), 1,3,5-triazine (244 mg, 3.00 mmol), and glacial HOAc (180 mg, 3.00 mmol) in absolute EtOH (20 mL) is maintained at reflux for 16 hours. The reaction mixture is cooled to ambient temperature and the solid is collected on a Buchner funnel and washed with EtOH followed by diethyl ether. Oven-drying in vacuo provided 13 mg (76%) of the title compound as an off-white solid.'H NMR (300 MHz, d,-DMSO) 8 2.63 (m, 1H), 3.06 (d, J = 16.4 Hz, 1H), 3.24-3.42 (m, 4H), 3.68 (ABq, #AB = 34.5 Hz, JAB = 14.1 Hz, 2H), 3.96 (m, 1H), 4. 63 (ABq, #AB = 400 Hz, JAB =

15.8 Hz, 2H), 6.27 (s, 1H), 6.99 (dd, J = 8.6,2.0 Hz, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.40 (s, 1H), 7.46 (s, 1 H), 7.69 (br s, 2H), 8.10 (d, J = 8.5 Hz, I H), 8.32 (s, I H), 11.20 (s, I H) ppm; MS (ion spray): m/z 465 (M+H).

EXAMPLE 786. (~)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1H-indol-2 -ylmethyl-6-oxo- piperazine-2-carboxylic acid methylamide To a solution containing ()-1- (4-amino-quinazolin-7-ylmethyl)-4- (5-chloro-lH-indol-2- ylmethyl)-6-oxo-piperazine-2-carboxylic acid (25 mg, 0.03 mmol), EXAMPLE 785, and N-methylmorpholine (36 mg, 0.36 mmol) in anhydrous DMF (I mL) is added methylamine hydrochloride (10 mg, 0.14 mmol) followed by HATU (40 mg, 0.10 mmol) at ambient temperature.

After 3 h, the solvent is removed under high vacuum and the residue is dissolved in CH3CN/water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 22 mg (88%) of the title compound as a white solid.

'H NMR (300 MHz, d6-DMSO) 5 2.57 (d, J = 4.4 Hz, 3H), 2.70 (m, IH), 3.0 (m, 1H), 3.66 (d, J = 14. 2 Hz, 1H), 3.77 (d, J = 14.2 Hz, 1H), 3.85 (m, 1H), 4.03 (d, J = 16.3 Hz, 1H), 5.18 (d, J = 16.3 Hz, 1H), 6.28 (s, 1H), 7.02 (dd, J = 8.5,2.0 Hz, 1H), 7. 31 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.51 (s, 1H), 7.58 (d, J = 8. 6 Hz, IH), 7.97 (m, 1H), 8. 31 (d, J = 8.6 Hz, 1H), 8.79 (s, 1H), 9.72 (br s, 2H), 11.18 (s, 1H) ppm; MS (ISP loop): m/z 478 (M+H).

Table 1: Amide Analogs Derived From C-6 Carboxylic Acid. Example # Name m/z [M+H] 787 (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- (5-chloro-I H-indol-2-492 ylmethyl)-6-oxo-piperazine-2-carboxylic acid ethylamide 788 492 ylmethyl)-6-oxo-piperazine-2-carboxylic acid dimethylamide 789 (+/-)-I-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-1 H-indol-2-554 ylmethyl)-6-oxo-piperazine-2-carboxylic acid benzylamide 790 (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-508 ylmethyl)-6-oxo-piperazine-2-carboxylic acid (2-hydroxy-ethyl)- amide 791 (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-552 ylmethyl)-6-oxo-piperazine-2-carboxylic acid bis-(2-hydroxy-ethyl)- amide 792 (+/-)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-534 ylmethyl)-6- (morpholine-4-carbonyl)-piperazin-2-one 793 (+/-)-I-(4-Amino-quinazolin-7-ylmethyl)-4-(5-chloro-I H-indol-2-535 ylmethyl)-6-oxo-piperazine-2-carboxylic acid methylcarbamoylmethyl-amide The following compounds are prepared using the procedures described above. Example # Name m/z [M+H] 794 (+/-)-1- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- 458 yl)-allyl]-6-oxo-piperazine-2-carboxylic acid 795 (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- 472 yl)-allyl]-6-oxo-piperazine-2-carboxylic acid methyl ester 796 (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- 457 yl)-allyl]-6-oxo-piperazine-2-carboxylic acid amide 797 (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [3- (5-chloro-thiophen-2- 458 yl)-allyl]-6-oxo-piperazine-2-carboxylic acid ethylamide 798 540 yl)-allyl]-6- (4-methyl-piperazine-1-carbonyl)-piperazin-2-one

EXAMPLE 799. ()-1- (4-Amino-quinazolin-7-vlmethvl)-4-(6-chloro-benzorblthiophen e-2-sulfonvl)-6- oxo-piperazine-2-carboxvlic acid methyl ester.

A solution containing (+)-1-(3-amino-4-cyano-benzyl)-4-(6-chloro-benzo [b] thiophene-2- sulfonyl)-6-oxo-piperazine-2-carboxylic acid methyl ester (42 mg, 0.08 mmol), EXAMPLE 99,1,3,5- triazine (40 mg, 0.48 mmol), and glacial HOAc (30 mg, 0.48 mmol) in absolute EtOH (I mL) is maintained at reflux for 16 hours. The reaction mixture is concentrated and then dissolved in water/CH3CN and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/ 0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 17 mg (32%) of the title compound as a white solid.

'HNMR (300MHz, d6-DMSO) a3.47 (m, 1H), 3.67 (s, 3H), 3.71 (d, J= 16.1 Hz, 1H), 4.00 (d, J=16.5 Hz, 1H), 4.05 (m, 1H), 4.52 (m, 1H), 4.72 (ABq, #AB = 248 Hz, JAB = 16.5 Hz, 2H), 7.57 (m, 2H), 8.05 (d, J = 8.6 Hz, 1H), 8.20 (s, 1H), 8.23 (d, J = 8.5 Hz, IH), 8. 35 (d, J = 1.9 Hz, 1H), 8.49 (s, 1H), 8.72 (s, 1H), 9.57 (br s, 2H) ppm; MS (ion spray): m/z 546 (M+H).

EXAMPLE 800. ()-I- (4-Amino-quinazolin-7-vlmethyl)-4- (6-chloro-benzofblthiophene-2-sulfonvl)-6- oxo-piperazine-2-carboxylic acid.

Water (1 mL) is added to a solution containing ()-1- (4-amino-quinazolin-7-ylmethyl)-4- (6- chloro-benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid methyl ester (20 mg, 0.03 mmol), EXAMPLE 799, in a 1: 1 mixture of THF/MeOH (2 mL). At ambient temperature, LiOH monohydrate (15 mg, 0.35 mmol) is then added. After 16 h, the reaction mixture is diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 12 mg (63%) of the title compound as a white solid.

'HNMR (300MHz, d6-DMSO) ã3.69 (d, J 16. 0 Hz, 1H), 3.97 (d, J= 16.0Hz, lH), 4.08 (d, J= 11.7 Hz, 1H), 4.18 (d, J =16. 2 Hz, IH), 4.31 (d, J = 2. 7 Hz, 1 H), 5.20 (d, J =16. 2 Hz, 1 H), 7.47 (d, J = 8. 7 Hz, 1H), 7.52 (s, 1H), 7.58 (dd, J = 8.6,1.9 Hz, 1H), 8.06 (d, J = 8. 7 Hz, IH), 8.16 (d, J=8. 6Hz, 1H), 8.19 (s, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.54 (s, IH), 8.77 (br s, IH) ppm; MS (ion spray): m/z 532 (M+H).

EXAMPLE 801. (~)-1-(4-Amino-quinazolin-7-ylmethyl)-4-(6-chloro-benzo[b]th iophene-2-sulfonyl)-6- oxo-piperazine-2-carboxylic acid amide To a mixture containing ()-1- (4-amino-quinazolin-7-ylmethyl)-4- (6-chloro-benzo [b] thiophene- 2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid (45 mg, 0.08 mmol), EXAMPLE 800, N- methylmorpholine (18 mg, 0.18 mmol), and HATU (35 mg, 0.09 mmol) in anhydrous DMF (1 mL) is added NH3 (7N in MeOH, 2 drops, approx. 0.5 mmol). The heterogeneous mixture is stirred 16 h at ambient temprature and then concentrated to dryness. The residue is dissolved in water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1 % TFA; Gradient: 0% B to 60% B over 30 min] to provide 25 mg (46%) of the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 5 3.63 (d, J = 16.0 Hz, 1H), 4.01 (m, 4H), 5.17 (d, J = 16.6 Hz, 1H), 7.58 (m, 3H), 8.08 (d, J = 8.6 Hz, 1H), 8.17 (s, IH), 8.26 (d, J = 8.6 Hz, IH), 8. 34 (d, J = 1.9 Hz, 1H), 8.74 (s, 1H), 9.63 (br s, 2H) ppm; MS (ISP loop): m/z 531 (M+H).

The following compounds are prepared using the procedures described above. Example # Name m/z [M+H] 802 (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- (6-chloro- 560 benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid ethyl ester 803 (+/-)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro- 531 benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid 804 (+/_) _1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro- 544 benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid methylamide 805 (+/-)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro- 558 benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid ethylamide 806 (+/-)-I- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro- 558 benzo [b] thiophene-2-sulfonyl)-6-oxo-piperazine-2-carboxylic acid dimethylamide 807 (+/-)-1- (4-Amino-quinolin-7-ylmethyl)-4- (6-chloro- 600 benzo [b] thiophene-2-sulfonyl)-6- (morpholine-4-carbonyl)- piperazin-2-one

EXAMPLE 808. ()-I- (4-Amino-quinazolin-7-vlmethvl)-4-j (5-chloro-thiophen-2-vloxv)-acetl-6-oxo- piperazine-2-carboxvlic acid methyl ester.

A. ()-I-f3- (Benzhvdrvlidene-amino)-4-cvano-benzvll-4-f (5-chloro-thiophen-2-yloxv)-acetvll-6-oxo- piperazine-2-carboxvlic acid methyl ester.

To a solution containing ()-1- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-6-oxo-piperazine-2- carboxylic acid methyl ester (1.17 g, 2.6 mmol), EXAMPLE 784, Part B, 5-chlorothiophen-2-yloxyacetic acid (0.5 g, 2.6 mmol), EXAMPLE 24, and N-methylmorpholine (0.58 g, 5.72 mmol) in anhydrous DMF (10 mL) is added HATU (1.09 g, 2.86 mmol) at ambient temperature. After 1.5 h, the reaction mixture is diluted with CHCI (100 mL) and aqueous NaHCO3 (100 mL) and the layers are separated. The aqueous phase is washed four times with CH2CI2 (100 mL) and the combined organic phase is washed once with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude amide is purified by flash silica gel chromatography (hexane/EtOAc, 4: 1 to 1: 2) to afford 1.5 g of the title compound which is used directly in the next reaction.'H NMR (300 MHz, CDCl3, #2 : 1 mixture of rotomers) major rotomer: 8 3.55 (d, J = 15.2 Hz, 1H), 3.60 (m, 1H), 3.69 (m, 5H), 4.37 (d, J = 17.7 Hz, 1H), 4.62 (m, 2H), 4.79 (d, J = 13.3 Hz, 1H), 5. 35 (d, J = 15.2 Hz, 1H), 6.05 (d, J = 3.9 Hz, 1H), 6.52 (m. 2H), 6.84 (d, J = 8.1 Hz, 1H), 7.18-7.49 (m, 11H), 7.76 (m, 1H) ppm; MS (ISP loop): m/z 627 (M+H).

B. ()-1- (3-Amino-4-cvano-benzvl)-4-f (5-chloro-thiophen-2-vloxy)-acetvll-6-oxo-piperazine-2- carboxylic acid methyl ester.

Concentrated HCI (12M, 0.5 mL) is added at 0 °C to a solution containing ()-1- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-4-[(5-chloro-thiophe n-2-yloxy)-acetyl]-6-oxo-piperazine-2- carboxylic acid methyl ester (1.5 g, 2. 39 mmol) in 4: 1 MeOH/THF (25 mL). After 1.5 h, the reaction

mixture is concentrated to dryness and then partitioned between a 1: I mixture of EtOAc/aqueous NaHCO3 (200 mL) and the layers are separated. The aqueous phase is extracted with EtOAc and then the combined organic phase is washed with brine, dried over anhydrous Na, SO4, filtered and concentrated. The crude residue is chromatographed on silica gel (hexane/EtOAc, 4: 1 to 1: 2) to provide 934 mg (84%, two steps) of the title compound.'H NMR (300 MHz, CDCI3, ~2: 1 mixture of rotomers) selected peaks: 8 3.16 (app. dd, J 14.0,3.8 Hz, 1H), 3.68 (s, 3H), 3.96 (app. dd, J = 3.8,2.0 Hz, 1H), 4.17 (d, J = 17. 7 Hz, IH), 4.45 (br s, 2H), 4.62 (m, 2H), 4.87 (d, J = 14.1 Hz, 1H), 5.21 (d, J = 15. 1 Hz, IH), 6.07 (m, 1H), 6.51 (d, J = 3.8 Hz, 1H), 6.57 (d, J = 7.9 Hz, 1H), 6.62 (br s, 1H), 7.35 (d, J = 7.9 Hz, 1H), ppm; MS (ISP loop): m/z 463 (M+H).

C. ()-I- (4-Amino-quinazoiin-7-vlmethyl)-4- (5-chloro-thiophen-2-vloxy)-acetvll-6-oxo-piperazine-2- carboxvlic acid methyl ester.

A solution containing ()-1- (3-amino-4-cyano-benzyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-6- oxo-piperazine-2-carboxylic acid methyl ester (110 mg, 0.25 mmol), 1,3,5-triazine (207 mg, 2.55 mmol), and glacial HOAc (157 mg, 2.55 mmol) in absolute EtOH (5 mL) is maintained at reflux for 16 hours. The reaction mixture is concentrated to dryness and then purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 50 mg (32%) of the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 8 3. 34- 3.89 (m, 2H), 3.60 (s, 3H), 4.14-4.54 (m, 3H), 4.64 (br d, J = 14.4 Hz, 1H), 4.78-5.11 (m, 3H), 6.19 (d, J = 4.1 Hz, 1H), 6.73 (d, J = 4.1 Hz, 1H), 7.64 (s, 1H), 7.65 (d, J = 9.0 Hz, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.79 (s, 1H), 9.71 (br s, 2H) ppm; MS (ion spray): m/z 490 (M+H).

EXAMPLE 809. ()-I- (4-Amino-quinazolin-7-vlmethvl)-4- (5-chloro-thiophen-2-vloxv)-acetl-6-oxo- piperazine-2-carboxylic acid methylamide.

Water (I mL) is added to a solution containing ()-1- (4-amino-quinazolin-7-ylmethyl)-4- [ (5- chloro-thiophen-2-yloxy)-acetyl]-6-oxo-piperazine-2-carboxyl ic acid methyl ester (20 mg, 0.03 mmol), EXAMPLE 808, in a 1: 1 mixture of THF/MeOH (2 mL). At ambient temperature, LiOH monohydrate (3 mg, 0.07 mmol) is then added. After 16 h, the reaction mixture is diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 25 mg (> 100 %) of the associated acid as a white solid after lyophilization which is used directly in the next reaction. To a mixture containing (+/-)-1- (4-amino- quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]-6-oxo-piperazine-2-carbo xylic acid (12 mg, 0.02 mmol), N-methylmorpholine (19 mg, 0.19 mmol), and HATU (22 mg, 0.05 mmol) in anhydrous DMF (1 mL) is added MeNH2 hydrochloride (5 mg, 0.19 mmol). The reaction mixture is stirred I h at ambient temperature and then concentrated to dryness. The residue is dissolved in water

and purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/0.1 % TFA; Gradient: 0% B to 60% B over 30 min] to provide 7 mg (58%) of the title compound as a white solid.

'H NMR (300 MHz, d6-DMSO) mixture of rotamers: 8 2.51 (m, 3H), 4.07-4.54 (m, 6H), 4.87 (m, 2H), 5.10 (m, IH), 6.18 (m, IH), 6.74 (m, IH), 7.62 (m, 2H), 8.06 (br s, IH), 8. 32 (br d, J = 8. 8 Hz, IH), 8.78 (s, 1H), 9.61 (br s, 2H) ppm; MS (ISP loop): 489 (M+H).

The following compound is prepared using the procedures described above. Example # Name m/z [M+H] 810 (+/-)-I- (4-Amino-quinazolin-7-ylmethyl)-4- [ (5-chloro-thiophen-2- 503 yloxy)-acetyl]-6-oxo-piperazine-2-carboxylic acid ethylamide EXAMPLE 811. (+/-)-1-(4-Amino-quinazolin-7-vlmethyl)-4-r (5-chloro-thiophen-2-yloxy)-acetyll-6 oxo-piperazine-2-carboxylic acid.

Water (0.5 mL) is added to a solution containing ()-1- (3-amino-4-cyano-benzyl)-4- [ (5-chloro- thiophen-2-yloxy)-acetyl]-6-oxo-piperazine-2-carboxylic acid methyl ester (35 mg, 0.08 mmol), EXAMPLE 808, Part B, in a 1: 1 mixture of THF/MeOH (I mL). At ambient temperature, LiOH monohydrate (4 mg, 0.10 mmol) is then added. After 16 h, an additional portion of LiOH monohydrate (4 mg, 0.10 mmol) is added and the reaction mixture is stirred for another 2 h then diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1 % TFA; Buffer B: CH3CN w/0.1 % TFA; Gradient: 0% B to 60% B over 30 min] to provide 40 mg (95%) of the associated acid as a white solid after lyophilization which is used directly in the next reaction. MS (ISP loop): m/z 449 (M+H).

A solution containing (+/-)-1- (3-amino-4-cyano-benzyl)-4- [ (5-chloro-thiophen-2-yloxy)-acetyl]- 6-oxo-piperazine-2-carboxylic acid (20 mg, 0.03 mmol), 1,3,5-triazine (28 mg, 0. 34 mmol), and glacial HOAc (20 mg, 0. 34 mmol) in absolute EtOH (6 mL) is maintained at reflux for 16 hours. The reaction mixture is concentrated to dryness and then purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 15 mg (75%) of the title compound as a white solid.'H NMR (300 MHz, d6-DMSO) 8 3.75-4.38 (m, 5H), 4.67 (d, J = 14.8 Hz, 1H), 4.79 (d, J = 15.3 Hz, 1H), 4.95 (m, 1H), 5.09 (br d, J = 16.0 Hz, 1H), 6.18 (m, 1H), 6.71 (m, 1H), 7.64 (m, 2H), 8.31 (d, J = 8.5 Hz, 1H), 8.75 (s, 1H), 9.64 (br s, 2H) ppm; MS (ISP loop): m/z 476 (M+H).

EXAMPLE 812.4-Prop-2-vn-I- (I H-pyrrolo [3, 2-clpvridin-2-ylmethvl)-piperazin-2-one.

A. 2- (2-Oxo-4-prop-2-ynvl--piperazin-1-vlmethvl).-pvrrolof3, 2-clpvridine-l-carboxvlic acid tert-butyi ester.

A solution containing 2-(2-oxo-piperazin-1-ylmethyl)-pyrrolo [3,2-c] pyridine-I-carboxylic acid tert-butyl ester (4.3 g, 13.0 mmol), EXAMPLE 69, in CH3CN (250 mL) is cooled to 0°C. Potassium carbonate (1.98 g, 14.3 mmol) is added to the reaction mixture followed by propargyl bromide (1.55g, 13.0 mmol). The mixture is slowly warmed to ambient temperature and maintained until complete consumption of starting material is observed by TLC (approx. 8 h). The mixture is concentrated to dryness and then partitioned between aqueous NaHCO3 (200 mL) and CL, CI (200 mL) and the layers are separated. The aqueous phase is extracted twice with CH, C12 (100 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated. The crude residue is purified by flash silica gel chromatography (CH, CI, to 5% MeOH/CH, Cl,) to provide 3. 38 g (70%) of the title compound as a pale yellow solid.'H NMR (300 MHz, CDCl3) 8 1.69 (s, 9H), 2. 34 (t, J = 2.4 Hz, 1H), 2.89 (m, 2H), 3.42 (s, 2H), 3.45 (d, J = 2.4 Hz, 2H), 3.52 (m, 2H), 4.95 (d, J = 1.4 Hz, 2H), 6.42 (br s, 1H), 7.88 (dd, J = 5.8,0.8 Hz, 1H), 8.41 (d, J = 5.8 Hz, 1H), 8.78 (d, J = 0.8 Hz, 1H), ppm; MS (EI) : m/z 368 (M+).

B.4-Prop-2-ynyl-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-p iperazin-2-one.

To a solution containing 2-(2-oxo-4-prop-2-ynyl-piperazinm-1-ylmethyl)-pyrrolo [3,2-c] pyridine- 1-carboxylic acid tert-butyl ester (1.3 g, 3.53 mmol) in CH, CL, (100 mL) is added TFA (20 mL) at 0 °C.

After 6 h, the reaction mixture is concentrated to dryness and then partitioned between aqueous NaHCO3 (500 mL) and CH, CL, (200 mL) and the layers are separated. The aqueous phase is extracted four times with CH, CT, (100 mL) and the combined organic phase is washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude residue is purified by flash silica gel chromatography (CH2CI2 to 10% MeOH/CH, CI,) to provide 616 mg (65%) of the title compound as a pale yellow solid.

'H NMR (300 MHz, CDC13) 8 2.27 (app t, J = 2.4 Hz, I H), 2.76 (m, 2H), 3.33 (s, 2H), 3.83 (d, J = 2.4 Hz, 2H), 3.45 (m, 2H), 4.57 (s, 2H), 6.47 (s, 1H), 7.23 (d, J = 5.7 Hz, 1H), 8.28 (d, J = 5.7 Hz, 1H), 8.85 (d, J = 0.9 Hz, 1H), 9. 34 (br s, 1H), ppm; MS (EI) : m/z 268 (M+).

EXAMPLE 813. 1,4-Bis-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-on e.

A. 2- {3- (4-tert-Butoxycarbonylamino-pyridin-3-yl)-prop-2-ynvll-2-oxo -piperazin-l-vlmethvl- tert-butylester.pyrrolo[3,2-c]pyridine-1-carboxylicacid A solution containing 2-(2-oxo-4-prop-2-ynyl-piperazin-1-ylmethyl)-pyrrolo [3,2-c] pyridine-1- carboxylic acid tert-butyl ester (100 mg, 0.27 mmol), EXAMPLE 812, (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester (87 mg, 0.27 mmol), EXAMPLE 69, Part B, Et3N(110 mg, 1.08 mmol),

(Ph3P) 4PdCI2 (10 mg, 0.013 mmol), and Cul (1 mg, 0.008 mmol) in anhydrous DMF (5 mL) is stirred at ambient temperature. After 5 h, the reaction mixture is diluted with EtOAc (50 mL) and water (50 mL) and the layers are separated. The aqueous layer is extracted twice with EtOAc (25 mL) and the combined organic phase is washed with brine, dried over anhydrous Na2SO4, filtered and concentrated.

The crude residue is purified by flash silica gel chromatography (CH2Cl2 to 10% MeOH CH2CI2) to provide 77 mg (51%) of SC41 as a colorless oi).'H NMR (300 MHz, CDC,-2 : lmixture ofrotamers) major rotamer: 5 1.53 (s, 9H), 1.69 (s, 9H), 2.98 (m, 2H), 3.49 (s, 2H), 3.56 (m, 2H), 3.78 (s, 2H), 4.98 (s, 2H), 6.43 (s, 1H), 7.89 (m, 1H), 8.09 (m, 2H), 8. 34 (m, 1H), 8.41 (m, 1H), 8.75 (m, IH) ppm; MS (ISP loop): m/z 561 (M+H).

B. 2-14-(1-tert-Butoxvcarbonvl-I H-pvrroloF3, 2-clpvridin-2-vlmethvl)-2-oxo-piperazin-1-vlmethvll- pvrrolof3, 2-clpvridine-1-carboxylic acid tert-butyl ester.

1,8-Diazabicyclo [5.4.0] undec-7-ene (42 mg, 0.27 mmol) is added to a suspension containing 2- {4-[3-(4-tert-butoxycarbonylamino-pyridin-3-yl)-prop-2-ynyl] -2-oxo-piperazin-1-ylmethyl}-pyrrolo[3,2- c] pyridine-l-carboxylic acid tert-butyl ester (SC41,77 mg, 0.14 mmol) in anhydrous CH3CN (10 mL) and the mixture is warmed to 50 °C. After 4 h, the reaction mixture is concentrated to dryness and the residue is partitioned between CH2CI2 (50 mL) and water (50 mL) and the layers are separated. The aqueous layer is extracted twice with CH2C12 (25 mL) and the combined organic phase is washed with brine, dried over anhydrous Na, S04, filtered and concentrated to provide 85 mg of SC42 as a crude solid which is used directly without further purification.'H NMR (300 MHz, CDC13) â 1.68 (s, 9H), 1.70 (s, 9H), 2.91 (m, 2H), 3.41 (s, 2H), 3.49 (m, 2H), 4.26 (s, 2H), 4.95 (d, J = 1.1 Hz, 2H), 6. 39 (d, J = 0.7 Hz, 1H), 6.68 (d, J = 0.7 Hz, 1H), 7.86 (m, 1H), 8.41 (m, 1H), 8.76 (br s, 1H), 8.82 (br s, 1H), ppm; MS (EI) : m/z 561 (M+H).

C. 1,4-Bis-(1H)-pyrrolo[3,2-c]pyridin-2-vlmethyl)-piperazin-2-o ne.

To a solution containing 2- [4- (l-tert-Butoxycarbonyl-I H-pyrrolo [3,2-c] pyridin-2-ylmethyl)-2- oxo-piperazin-l-ylmethyl]-pyrrolo [3, 2-c] pyridine-I-carboxylic acid tert-butyl ester (85 mg, 0.14mmol) in CH2CI2 (5 mL) is added TFA (1 mL) at 0 °C and the solution is allowed to slowly warm to ambient temperature. After 16 h, the reaction mixture is concentrated to dryness, diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1 % TFA; Gradient: 0% B to 45% B over 30 min] to provide 35 mg (36%, two steps) of SC43 as a pale yellow, lyophilized solid.

'H NMR (300 MHz, d,-DMSO) 8 2.80 (m, 2H), 3.25 (s, 2H), 3.37 (m, 2H), 3.93 (s, 2H), 4.76 (s, 2H), 6.88 (s, 1H), 6.94 (s, 1H), 7.85 (d, J = 6.6 Hz, 1H), 7.89 (d, J = 6.6 Hz, 1H), 8. 37 (d, J = 6.7 Hz, 1H), 8. 38 (d, J = 6.7 Hz, 1H), 9.17 (s, 1H), 9.19 (s, 1H), 12.80 (s, 1H), 12.96 (s, 1H), 14.91 (br s, 2H) ppm; MS (ion spray): m/z 361 (M+H). Cz3H25CIN4OS MS m/z: 441,443.

EXAMPLE 2-Amino-4-[4-(6-chloro-1H-benzoimidazol-2-ylmethyl)-2-oxo-pi peridin-1-ylmethyl]- benzonitrile.

A. f3-benzhydrylidene-amino)-4-cyano-benzyll-2-oxo-piperidin-4- yl}-acetic acid ethvl ester: Sodium hydride (140 mg, 3.51 mmol) is added to a cooled solution of (2-oxo-piperidin-4-yl)- acetic acid ethyl ester (500 mg, 2.70 mmol) in 10 mL of THF. After stirring for forty five minutes, 2- (benzhydrylidene-amino)-4-bromomethyl-benzonitrile (1.43 g, 3.82 mmol), EXAMPLE 13, is added, and the reaction is left to stir overnight. THF is removed, and the residue is taken up in 250 mL of ethyl acetate. Excess sodium hydride is quenched with 5 mL of water, and normal aqueous work-up followed.

The crude product is chromatographed on silica gel (50% EtOAc/Hexane) to give {I- [3-benzhydrylidene- amino)-4-cyano-benzyl]-2-oxo-piperidin-4-yl}-acetic acid ethyl ester (732 mg, 57%) as a light yellow solid. C30H29N303 MS m/z: 480,482. Anal cald. for C10H29N3O3:C, 75.13; H, 6.09; N, 8.76. Found C, 73.01 ; H, 6.02; N, 8.46.

B. {l-f3-benzhvdrvlidene-amino)-4-cvano-benzvll-2-oxo-piperidin -4-vl-acetic acid To a solution of {1- [3-benzhydrylidene-amino)-4-cyano-benzyl]-2-oxo-piperidin-4- yl}-acetic acid ethyl ester (732 mg, 1.53 mmol) in 5 mL of THF is added IN sodium hydroxide (1.53 ml, 1.53 mmol). After stirring for four hours, the THF is removed and EtOAc (500 mL) is added. The reaction mixture is acidified to a pH of 6 and normal aqueous work-up followed. The desired carboxylic acid (571 mg, 83% yield) is isolated as a white solid. <BR> <BR> <BR> <BR> <BR> <BR> <P>C. N- (2-amino-5-chloro-phenyl)-2- 1-f3- (benzhydrvlidene-amino)-4-cyano-benyl1-2-oxo-piperidin-4-< ;BR> <BR> <BR> <BR> <BR> vl}-acetamide To a slurry of the {I- [3- (benzhydrylidene-amino)-4-cyano-benzyl]-2-oxo-piperidin-4-yl }-acetic acid (190 mg, 0.422 mmol) in THF (5 mL) and methylene chloride (3 mL) is added triethylamine (0.09 ml, 0.633 mmol). The solution is cooled to 0 °C, and 1M isopropyl chloroformate in toluene (0.422 mL, 0.422 mmol) is added. The homogenous mixture is allowed to warm to room temperature, and 4-chloro- 1,2-phenylene-diamine (150 mg, 1.06 mmol) is added. The reaction is stirred at room temperature overnight. The volatile solvents are removed, and the resulting residue is chromatographed (SiO2, 5% MeOH/EtOAc) to give N- (2-amino-5-chloro-phenyl)-2- { 1- [3- (benzhydrylidene-amino)-4-cyano- benyl]-2-oxo-piperidin-4-yl}-acetamide (200 mg, 82% yield). C34H30CIN502 MS m/z: 576,578.

D. 2- (Benzhvdrvlidene-amino)-4-f4- (6-cloro-1 H-benzoimidazol-2-Iyl)-2-oxo-piperidin-1- vlmethvl}-benzonitrile

The acetamide (200 mg, 0.35 mmol) is dissolved in 2 mL of acetic acid and refluxed for three hours. The acetic acid is removed, and the residue taken up in ethyl acetate and washed with saturated sodium bicarbonate. Concentration of the solvent afforded 2- (benzhydrylidene-amino)-4- [4- (6-cloro- lH-benzoimidazol-2-ylmethyl)-2-oxo-piperidin-1-ylmethyl}-ben zonitrile (200 mg, 100% yield) which is used without further purification. Cg4H28CIN5O5 MS m/z: + 558,560.

E. 2-Amino-4-f4- (6-chloro-1 H-benzoimidazol-2-yimethvl)-2-oxo-piperidin-llmethvll-benzon itrile hydrochloric acid salt The above benzonitrile (220 mg, 0. 36 mmol) is dissolved in 5 ml of methanol. Hydrochloric acid is bubbled into the ice-cooled methanol solution followed by three drops of water. After stirring at room temperature for one hour, the MeOH is removed. The resulting white solid is titurated with EtOAc. After drying under high vacuum, 2-amino-4-[4-(6-chloro-1H-benzoimidazol-2-ylmethyl)-2-oxo- piperidin-1-ylmethyl]-benzonitrile hydrochloric acid salt (145.6 mg, 87% yield) is obtained as a white solid. C,, H20CIN5O: MS m/z: 394,396.

EXAMPLE 4-[4-(6-Chloro-1H-benzoimidazol-2-ylmethyl)-2-ylmethyl)-2-ox o-piperidin-1-ylmethyl]- benzamidine Hydrochloric acid is bubbled into an ice cooled solution of 4- [4- (6-chloro-1H-benzoimidazol-2- ylmethyl)-2-oxo-piperidin-1-ylmethyl]-benzonitrile (127 mg, 0.336 mmol) in 10 mL of methanol. The solution also contained 3A molecular sieves. The reaction is stored at-30 for forty-eight hours. The methanol is condensed on the rotovap. Fresh methanol (15 mL) is added followed by a stream of ammonia gas. The reaction is heated to reflux for two and half hours. The reaction mixture is filtered at room temperature. Methanol is removed from the mother liquor. The resulting residue is purified by reverse phase HPLC (0-50 % ACN/H, O). The product is isolated as a white solid with a melting point of 105-110-C. C, IH22CIN, OMSm/z: 396,398. Anal. cald. for C2, H22CIN5O 2C2HF302: C, 48.13; H, 3.88; N, 11.22. Found: C, 45.05; H, 3.52; N, 9.89.

EXAMPLE 816.1- ino-quinazolin-7-vlmethlv)-4-(6-chloro-I H-benzoimidazol-2-ylmethvl)- piperidin-2-one.

To a solution of 2-Amino-4- [4- (6-chloro- I H-benzoimidazol-2-yimethyl)-2-oxo-piperidin-I- ylmethyl]-benzonitrile hydrochloric acid salt (143 mg, 0. 308 mmol), EXAMPLE 814, Part E, in 2 mL of ethanol is added triethylamine (0.05 mL, 0.366 mmol), glacial acetic acid (0.02mL, 0.366 mmol) and triazine (15 mg, 0.183 mmol). The resulting mixture is refluxed overnight. The volatile solvents are removed on the rotovap, and the residue is purified by reverse phase HPLC (0-50% Acetonitrile/H, O).

The desired product (110 mg, 55% yield) is isolated as a white powder with a melting point of 128-132

°C. C22H21ClN6O MS m/z: 421,423. Anal. calcd. for C22H2, CIN6O: C, 48.12; H, 3.57; N, 12.95. Found: C, 45.79; H, 3.68; N, 11. 94. H NMR (CD30D) 6: 8.67 (s, 1 H); 8.31 (d, I H, J = 4.0 Hz); 7.83-7.55 (m, 5H); 4.93-4.73 (m, 2H); 3.48-3.42 (m, 2H); 3. 31-3.21 (m, 2H); 2.71-2.58 (m, 2H); 2.43-2. 33 (m, 1H); (m, 1H) ; (m, 1H).

EXAMPLE 4-(6-Chloro-1H-benzoimidazol-2-ylmethyl)-1-(2,4-diamino-quin azolin-7-ylmethyl)- piperidin-2-one<BR> 2-Amino-4- [4- (6-chloro-1 H-benzoimidazol-2-ylmethyl)-2-oxo-piperidin-1-ylmethyl]- benzonitrile hydrochloric acid salt (70 mg, 0.15 mmol), EXAMPLE 814, Part E, pyridine (1.0 mL) and freshly made chloroformamide hydrochloride (150 mg, 1. 33 mmol) are placed in a sealed tube and heated to 200 °C. The resulting mixture is heated for twenty four hours. The crude reaction mixture is directly purified by reverse phase HPLC (0-50% ACN/H, O). The product (53 mg, 45% yield) is isolated as a tanish solid. C,, H,, CIN, O MS m/z: 436,438. Anal. calcd. for C22H22ClN7O: C, 43.23; H, 3.24; N, 12.60. Found: C, 43.16; H, 3.44; N, 13.40.

EXAMPLE 818. 1- (4-Amino-2-methvl-quinazolin-7-vlmethly)-4- (6-chloro-1H-benzoimidazol-2- ylmethyl)-piperidin-2-one.

A stream of hydrogen chloride gas is bubbled intermittently through an ice-cold mixture of 2- amino-4- [4- (6-chloro-1 H-benzoimidazol-2-ylmethyl)-2-oxo-piperidin-1-ylmethyl]-benz onitrile hydrochloric acid salt (57 mg, 0.123 mmol), EXAMPLE 814, Part E, and acetonitrile (0.03 mL, 0.93 mmol) in 1.5 mL of dioxane for six hours. The dioxane is removed; the residue is purified by reverse phase HPLC (0-40 % ACN/H2O). The desired product (9.5 mg, 12% yield) is isolated as a clear wax.

C23H23CIN6O MS m/z: 435,437.

The following compounds are prepared using the methods described above. Example # Name m/z [M+H] 819 (3S, SR)-4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-3,5-dimethyl- 441,443 2-oxo-piperazin-I-ylmethyl]-benzamidine 820 (3S, 5S)-4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-3,5-dimethyl- 441,443 2-oxo-piperazin-I-ylmethyl]-benzamidine 821 4- {4- [3- (5-Chloro-thiophen-2-yl)-acryloyl]-3, 5-dimethyl-2-oxo- 431,433 piperazin-I-ylmethyl}-benzamidine 822 (3R, 5S)-4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-3, 5-dimethyl- 441,443 2-oxo-piperazin-1-ylmethyl]-benzamidine

EXAMPLE 823. 2-[4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazin-1 -yl]-N-[2-(3H- imidazol-4-yl)-ethvllacetamide.

A. 4-tert-Butoxvcarbonvlmethvl-3-oxo-piperazine-l-carboxvlic acid benzvl ester.

To a solution of 3-oxopiperazine-I-carboxylic acid benzyl ester (4.68g, 20mmol) in 20 mL of DMF at) 0°C is added sodium hydride (60%, 880 mg, 22 mmol). The suspension is stirred at ambient temperature for one t-butyl bromoacetate (4.68 g, 24 mmol) is added. The resulting mixture is stirred at ambient temperature overnight. After dilution with ethyl acetate (200 mL), the mixture is washed with brine (3 x 50 mL). The crude residue obtained from concentration of the organic phase is chromatographied on silica gel (30% ethyl acetate/Hexane) to give 5.57 g (80%) of 4-tert- butoxycarbonylmethyl-3-oxopiperazine-1-carboxylic acid benzyl ester as a white solid.

B. (2-Oxo-piperazin-I-vl) acetic acid tert-butvl ester.

4-tert-Butoxycarbonylmethyl-3-oxopiperazine-1-carboxylic acid benzyl ester (2.0g, 5.75 mmol) is dissolved in 20 mL of methanol and 2 mL of acetic acid. Palladium (5%) on carbon (100 mg) is added, and the reaction mixture is stirred in an atmosphere of hydrogen overnight. The mixture is filtered and concentrated. Ethyl acetate is added, and the mixture is neutralized to pH 7 using IN NaOH.

The organic layer is concentrated to give (2-oxo-piperazin-1-yl) acetic acid tert-butyl ester (1.22g).

C. r4- (6-Chlorobenzofblthiophene-2-sulfonvl)-2-oxopiperazine-1acet ic acid tert-butyl ester.

To a solution of (2-oxo-piperazin-1-yl) acetic acid tert-butyl ester (1.22 g, 5.7 mmol) in 10 ml of methylene chloride is added triethylamine (1.2 mL, 8.55 mmol) and 6-chlorobenzothiophenesulfonyl chloride (1.52 g, 5.7 mmol). The reaction mixture is stirred overnight at ambient temperature. Flash column chromatography (50 % ethyl acetate/hexane) affords 2.3 g (92%) of [4- (6- chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazine-1-yl] acetic acid tert-butyl ester.

D. r4- (6-Chlorobenzofblthiophene-2-sulfonvl)-2-oxopiperazine-1-vll -acetic acid.

[4- (6-Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazine-1-yl] acetic acid tert-butyl ester (500 mg, 1.13 mmol) is dissolved in 1 mL of trifluoroacetic acid and 3 mL of CH2C12. The solvents are azeotropically removed with toluene. [4- (6-chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazine-1- yl] acetic acid (438 mg) is isolated as a white solid. \ E. 2-r4- (6-Chlorobenzorblthiophene-2-sulfonyl)-2-oxopiperazin-I-yl1- N-r2- ( H-im idazol-4-vl)- ethvllacetamide.

To a slurry of [4- (6-chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazine-1-yl] acetic acid (47 mg, 0.12 mmol) in 2 mL of tetrahydrofuran is added Et3N (0.025 mL, 0.18 mmol). The mixture is cooled to 0°C, and 1M solution of isopropyl chloroformate in toluene (0.12 mL, 0.12mmol) is added.

The mixture is stirred for fifteen minutes and histamine (13.3 mg, 0.12 mmol) is added. The mixture is stirred overnight at room temperature. Reverse phase HPLC (AcCN/H, O/TFA) affords 2- [4- (6- Chlorobenzo [b] thiophene-2-sulfonyl)-2-oxopiperazin- 1-yl]-N- [2- (3H-imidazol-4-yl)-ethyl] acetamide trifluoroacetic acid salt (17 mg, 25%) as a solid. mp 77-82°C; MS m/z 482 (M+H).

The followin compounds are prepared from the appropriate starting materials using the method of EXAMPLE 823. Example # Name m/z [M+H] 824 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 465, 467 N-pyridin-4-yt-acetamide 825 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 479, 481 N-pyridin-3-ylmethyl-acetamide 826 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 471,473 N-piperidin-4-yi-acetamide 513,515827N-(1-Carbamimidoyl-piperidin-4-yl)-2-[4-(6-chloro- benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- ide 828 5- (2- {2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-554,556 piperazin-I-yl]-acetylamino}-ethyl)-imidazole-I-carboxylic acid ethyl ester 829 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yi]- 466, 468 N-pyrimidin-4-yl-acetamide 830 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 464,466 N-phenyl-acetamide 831 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 506, 508 N-(9H-purin-6-yl)-acetamide 509,511832N-(4-Amino-2-methyl-pyrimdin-5-ylmethyl)-2-[4-(6-c hloro- benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-acetamide 496,4988332-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo -piperazin-1-yl]- N- (3-imidazol-1-yl-propyl)-acetamide 834 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-I-yl]-496, 498 N-[2-(1-methyl-1H-imidazol-4-yl)-ethyl]-acetamide 835 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 493, 495 N- (2-pyridin-4-yl-ethyl)-acetamide 836 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl- 496, 498 N- [2- (3-methyl-3H-imidazol-4-yl)-ethyl]-acetamide 837 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 493, 495 N-(2-pyridin-2-yl-ethyl)-acetamide 838 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 493,495 N- (2-pyridin-3-yi-ethyl)-acetamide 839 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-482, 484 N-(2-imidazol-1-yl-ethyl)-acetamide 840 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 495, 497 N-[2-(1-methyl-I H-pyrrol-2-yl)-ethyl]-acetamide 841 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 496, 498 N- [2- (5-methyl-1 H-imidazol-4-yl)-ethyl]-acetamide 842 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yi]- 510, 512 N-(4-dimethylamino-[1,3,5]triazin-2-yl)-acetamide 843 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 479, 481 N-methyl-N-pyridin-4-yl-acetamide 844 N- [2- (2-Amino-pyridin-4-yl)-ethyl]-2- [4- (6-chloro- 508, 510 benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-acetamide 845 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-513, 515 N- [2- (4-methyl-thiazol-5-yl)-ethyl]-acetamide 499,5018462-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo -piperazin-1-yl]- N-(2-thiazol-4-yl-ethyl)-acetamide 847 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-yi]-487, 489 N- (3-guanidino-propyl)-acetamide trifluoroacetic acid salt 848 N- (3-Amino-propyl)-2- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)- 445,447 2-oxo-piperazin-1-yl]-acetamide 849 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 14, 516 N- [2- (2-mercapto-I H-imidazol-4-yl)-ethyl]-acetamide 850 N- [2- (2-Amino-thiazol-4-yl)-ethyl]-2- [4- (6-chloro- 514, 516 bezno[b]thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-acetamid e 851 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 507,509 N-methyl-N- (2-pyridin-4-yl-ethyl)-acetamide 852 2- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]- 528,530 N- [2- (2-methylsulfanyl-1 H-imidazol-4-yl)-ethyl]-acetamide

EXAMPLE 853. 4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-1-[3-(3H-imidazol- 4-yl)-propyl]-piperazin- 2-one.

A. 3-Oxo-4-r3- (3-trityl-3H-imidazol-4- lvl-piperazine-1-carboxylic acid benzvl ester.

3-Oxo-piperazin-l-carboxylic acid benzyl ester (702 mg, 3.0 mmol) is dissolved in dimethylformamide (10 mL) and cooled to 0°C. Sodium hydride (60%, 148 mg, 3.7 mmol) is added, followed by the addition of 5- (3-chloro-propenyl)-I-trityl-I H-imidazole (473 mg, 1.2 mmol). The resulting mixture is left to stir at room temperature overnight. Most of the dimethylformamide is removed on the high vacuum. The reaction mixture is diluted with ethyl acetate (250 mL) and quenched with water. The two layers are separated and ethyl acetate (2x 100 mL) is used to extract and dried over magnesium sulfate. The residue after filtration and concentration is chromatographed on silica gel (50% EtOAc/hexane) to give 3-oxo-4- [3- (3-trityl-3H-imidazol-4-yl)-ally (-piperazine-1-carboxylic acid benzyl ester (360 mg) as the desired product.

B. 4-r3- (3-tert-Butoxycarbony-3H-imidazol-4-vl)-allyll-3-oxo-piperaz ine-l-carboxylic acid benzvl ester.

3-Oxo-4- [3- (3-trityl-3H-imidazol-4-yl)-allyl-piperazine-1-carboxylic acid benzyl ester (360 mg, 0.62 mmol) is stirred vigorously in a 30% solution of trifluoroacetic acid and methylene chloride (10 mL). After stirring for three hours, the trityl group is removed. The volatile solvents are removed in vacuo, and the crude product is taken-up in methylene chloride (10 mL). Pyridine (0.5 ml) and Di-tert- butyl dicarbonate (176 mg, 0.81 mmol) is added to the solution, and the resulting mixture is left to stir overnight. The reaction mixture is condensed and purified by flash column (SiO,, 20% EtOAc/Hexane) to give 4- [3- (3-tert-butoxycarbonyl-3H-imidazol-4-yl)-allyl]-3-oxo-pipera zine-1-carboxylic acid benzyl ester (100 mg).

C. 5- {3-r4-(6-Chloro-benzorblthiophene-2-sulfonvl)-2-oxo-piperazi n-1-vll-propyl T-imidazol-I- carboxvlic acid tert-butvl ester.

Palladium on carbon (10 %, 15 mg) is added to a solution of 4- [3- (3-tert-butoxycarbonyl-3H- imidazol-4-yl)-allyl]-3-oxo-piperazine-1-carboxylic acid benzyl ester (50 mg, 0.114 mmol) in 5 mL of methanol. The reaction mixture is left to stir in an atmosphere of hydrogen overnight. The palladium is

filtered off, and the volatile solvents are removed on the rotovap. The crude product (50 mg, 0.114 mmol) is redissolved in methylene chloride (5 mL). Triethylamine (0.06 ml, 0.43 mmol) 6-chloro- benzo [b] thiophene-2-sulfonyl chloride (39 mg, 0.15 mmol) is added, and the resulting mixture is stirred overnight. The crude product is directly purified by flash column (SiO2, 30% EtOAc/Hexane) to afford 5- {3- [4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-propyl}-imidazol -l-carboxylic acid tert-butyl ester (30 mg).

D. 4- (6-Chloro-benzofblthiophene-2-sulfonvl)-1- 3- (3H-imidazol-4-vl)-propvll-piperazin-2-one: 5- {3- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oXo-piperazin-1-yl]-propyl}-imidazol -I- carboxylic acid tert-butyl ester (30 mg, 0.055 mmol) is stirred vigorously in a 30 % solution of trifluoroacetic acid and methylene chloride (2 mL). The reaction is complete after stirring for three hours. The volatile solvents are removed on the rotovap, and the gummy solid is titurated with ether several times to afford 4- (6-chloro-benzo [b] thiophene-2-sulfonyl)-1- [3- (3H-imidazol-4-yl)-propyl]- piperazin-2-one trifluoroacetic acid salt (30 mg) as a yellow solid. C18H19ClN4O3S2 (m/z) +: 439,441.

Anal cald. for Cl8H, 9CIN403S2 C2HF302 : C, 43.44; H, 3.65; N, 10.13. Found C, 42.03; H, 3.55; N, 8. 26.

The following compounds are prepared using the methods described above. Example # Name m/z [M+H] 854 4- [4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin- I-470,472 ylmethyl]-piperidine-I-carboxamidine Cl pattern 855 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(3-piperazin-1-yl- 457, 459 propyl)-piperazin-2-one Cl pattern 856 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (3-pyridin-4-yl- 450,452 propyl)-piperazin-2-one Cl pattern 857 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-I- (4-piperidin-4-yl- 470,472 butyl)-piperazin-2-one Cl pattern 858 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(2-piperidin-4-yl- 442 ethyl)-piperazin-2-one 859 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)-1- (3-piperidin-4-yl- 456 propyl)-piperazin-2-one 4-[(5-Chloro-thiophen-2-yloxy)-acetyl]-3-(S)-methoxymethyl-1 -[4-(6-methoxy.EXAMPLE860. pvridin-3-yl)-benzyll-piperazin-2-one.

A. 3-Methoxvmethvl-4- [4- (6-methoxy-pvridin-3-yl)-benzvll-3-oxo-piperazine-l-carboxyl ic acid benzvl ester.

The title compound is prepared by the method in EXAMPLE 66, Part A, substituting 5- (4- bromomethyl-phenyl)-2-methoxy-pyridine for 4-bromomethyl tolynitrile and 2-methoxymethyl- 3oxopiperazin-1-carboxylic acid benzyl ester for 3-oxopiperazin-1-carboxylic acid benzyl ester.

MS (ISP) m/z 476, (M+H). <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>4-f (5-Chloro-thiophen-2-vloxv)-acetvll-3- (S)-methoxvmethvl-l-F4- (6-methoxy-pyridin-3-vl)-benzvll- piperazin-2-one The title compound is prepared by deprotecting 3-methoxymethyl-4- [4- (6-methoxy-pyridin-3- yl)-benzyl]-3-oxo-piperazine-1-carboxylic acid benzyl ester as described in EXAMPLE 75, Part C. The crude amine is then coupled as described in EXAMPLE 123 with 3- (5-chloro-thiophen-2-yl)- (E)-acrylic acid, EXAMPLE 25. MS (ISP) m/z 516,518, (M+H), Cl pattern.

The following compounds are prepared according to the method of Example 860. Example Name m/z [M+H] 861 4'-[4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-2-oxo-piperazin-1-522,524 ylmethyl]-biphenyl-2-carbonitrile Cl pattern 862 4-(6-Chloro-benzo [b] thiophene-2-sulfonyl)-1-(4-chloro-3-hydroxy-471, 473 patternbenzyl)-piperazin-2-oneCl 863 1-Benzyl-4-(6-chloro-benzo [b] thiophene-2-sulfonyl)-piperazin-2-one 421,423 Cl pattern 864 4- (6-Chloro-benzo [b] thiophene-2-sulfonyl)- 1- (4-chloro-benzyi)- 455,457 piperazin-2-one Cl pattern 865 4- [ (4-Chloro-thiophen-2-yloxy)-acetyl]-3- (S)-methoxymethyl- 1- [4- 516,518 (6-methoxy-pyridin-3-yl)-benzyl]-piperazin-2-one Cl pattern 866 4- [ (5-Chloro-thiophen-3-yloxy)-acetyl]-1- [4- (6-hydroxy-pyridin-3- 502,504 yl)-benzyl]-3-(S)-methoxymethyl-piperazin-2-one Cl pattern 867 4- [ (5-Chloro-thiophen-3-yloxy)-acetyl]-3- (S)-methoxymethyl-1- [4- 516,518 (6-methoxy-pyridin-3-yl)-benzyl]-piperazin-2-one Cl pattern 868 4- [ (5-Chloro-thiophen-2-yloxy)-acetyl]-I- [4- (6-hydroxy-pyridin-3- 502,504 patternyl)-benzyl]-3-(S)-methoxymethyl-piperazin-2-oneCl 869 4- [3- (5-Chloro-thiophen-2-yi)- (E)-acryloyl]- I- [4- (6-methoxy- 482 pyridin-3-yl)-benzyl]-3-(S)-methyl-piperazin-2-one 870 4- [3- (5-Chloro-thiophen-2-yi)- (E)-acryloyl]-3- (S)-methyl- 1- [4- (6- 468 oxo-1,6-dihydro-pyridin-3-yl)-benzyl]-piperazin-2-one 871 1-Biphenyl-4-yimethyl-4- [3- (5-chloro-thiophen-2-yi)- (E)-acryloyi]- 3(S)-ethyl-6-methyl-piperazin-2-one 872 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-I- [4- (6-hydroxy- 498,500 patternpyridin-3-yl)-benzyl]-3-(S)-methoxymethyl-piperazin-2 -oneCl 873 4- [3- (5-Chloro-thiophen-2-yl)- (E)-acryloyl]-3- (S)-methoxymethyl-l- 512, 514 pattern[4-(6-methoxy-pyridin-3-yl)-benzyl]-piperazin-2-oneCl

EXAMPLE 874. 1- H-indazol-6-vlmethvl)-4-(6-chloro-benzorblthiophen-2-vlmethy l)- piperazin-2-one.

A. 2-Amino-4-(2-oxo-piperazin-1-ylmethyl)-benzonitrile.

To a solution of 4- (3-Amino-4-cyano-benzyl)-3-oxo-piperazine-1-carboxylic acid benzyl ester hydrochloride (4.0 g, 10.0mmol) in CH30H (45 ml) and CH2C12 (10 ml) is added 10% Pd on carbon (0.6 g). The mixture is stirred under an atmosphere of H, for 2 hours then is filtered through a pad of celite.

The filtrate is concentrated and the residue purified by column chromatography eluting with 10% 7M NH3 in CH30H/CH2CI2 to yield the title compound (1.62 g, 7.0 mmol).'H NMR (DMSO, 300MHz) b 7. 34 (d, 1H), 6.64 (s, 1H), 6.46 (d, 1H), 6.04 (bs, 2H), 4.40 (s, 2H), 3.28 (s, 2H), 3.14 (m, 2H), 2.87 (m, 2H), 2.77 (bs, 1H), MS (ion spray): m/z 231 (M+H) t. <BR> <BR> <P>B.2-Amino-4-r4-(6-chloro-benzorblthiophen-2-ylmethv l)-2-oxo-piperazin-l-ylmethyll-benzonitrile.

To a cooled solution (0° C) of 2-Amino-4-(2-oxo-piperazin-I-ylmethyl)-benzonitrile (0. 345 g, 1.5 mmol) in DMF (2 ml) is added finely powdered anhydrous K2CO3 (0.311 g, 2.25 mmol) and allowed to stir for 20 minutes. To this mixture is added a solution of 2-bromomethyl-benzo [b] thiophene (0. 392 g, 1.5 mmol) in DMF (3 ml), the cold bath removed and allowed to stir for 2 hours. The reaction mixture is concentrated under high vacuum and the residue purified by column chromatography eluting with 55% EtOAc/5% CH30H/hexane to yield the title compound (0.477 g, 1.16 mmol) as a white solid.'H NMR (DMSO, 300MHz) 5 8.06 (d, 1H), 7.78 (d, 1H), 7.37 (m, 3H), 6.64 (s, 1H), 6.44 (d, 1H), 6.09 (bs, 2H), 4.42 (s, 2H), 3.88 (s, 2H), 3.21 (m, 4H), 2.72 (m, 2H). MS (ion spray): m/z 411,413 (M+H)+, Cl pattern.

C. 1- (3-Amino-1 H-indazol-6-vlmethyl)-4- (6-chloro-benzorblthiophen-2-vlmethyl)-piperazin-2-one.

To a cooled solution (0° C) of 2-Amino-4- [4- (6-chloro-benzo [b] thiophen-2-ylmethyl)-2-oxo- piperazin-1-ylmethyl]-benzonitrile (0.365 g, 0.89 mmol) in concentrated HCl (2.1 ml) is added dropwise a solution of sodium nitrite (0.068 g, 0.98 mmol) in H, O (0.2 ml). The reaction mixture is added to a cooled solution (0° C) of tin (II) chloride dihydrate (1.61 g, 7.12 mmol) in concentrated HCI (0.62 mi) and H, O (3 ml). The precipitate is collected by vacuum filtration and dried under high vacuum. The crude solid is purified by column chromatography eluting with 10% 7M NH3 in CH30H/CH2CI to yield the title compound (0.144 g, 0.34 mmol) as a yellow soild. 1H NMR (DMSO, 300MHz) # 11. 35 (bs, 1H), 8.05 (d, 1H), 7.78 (d, 1H), 7.64 (d, 1H), 7.37 (m, 2H), 7.08 (s, 1H), 6.78 (d, 1H), 5.75 (s, 1H), 5.40 (bs, 1H), 4.58 (s, 2H), 3.88 (s, 2H), 3.20 (m, 4H), 2.70 (bt, 2H). MS (ion spray): m/z 426 (M+H) +. Anal. cald. for C21 H, oN50SCI; (H2O)0.25: C, 58.6; H, 4.8; N, 16. 3. Found C, 58.6; H, 4.7; N, 15.9. M. P. = 246- 248°C.

1-(3-Amino-1H-indazol-6-ylmethyl)-4-[3-(5-chloro-thiophen -2-yl)]-piperazin-2-one.EXAMPLE875.

A. 2-Amino-4- {4-r3-(5-chloro-thiophen-2-vl)-allvll-2-oxo-piperazin-1-vlme thyl}-benzonitrile.

Using essentially the same procedure as in EXAMPLE 874, Part B using 2- (3-bromo-propenyl)- 5-chloro-thiophene is obtained the title compound. MS (EI) : m/z 386,388 (M+), Cl pattern.

B. 1-(3-Amino-1H-indazol-6-ylmethyl)-4-[3-(5-chloro-thiophen-2- yl)]-piperazin-2-one.

Using essentially the same procedure as in EXAMPLE 874, Part C there is obtained the title compound.'H NMR (DMSO, 300MHz) 8 11.32 (bs, IH), 7.62 (d, 1H), 7.06 (s, 1H), 7.02 (d, 1H), 6.96 (d, 1H), 6.78 (d, 1H), 6.67 (d, 1H), 5.96 (m, IH), 5. 32 (bs, 2H), 4.57 (s, 2H), 3.19 (bt, 2H), 3.12 (m, 4H), 2.64 (bt, 2H). MS (EI) : m/z 401,403 (Mt), Cl pattern. Anal. cald. for C, H20CIN5OS: C, 56.8; H, 5.0; N, 17.4. Found C, 56.6; H, 4.8; N, 17.2. M. P. = 167-169°C EXAMPLE 876.1-3-Amino-1H-indazol-6-vlmethyl)-4- (6-chloro-benzorblthiophene-2-sulfonvl)- piperazin-2-one.

A. 2-Amino-4-r4- (6-chloro-benzof bthiophene-2-sulfonyl)-2-oxo-piperzin-I-vlmethvll-benzonitri le.

Using essentially the same procedure as in EXAMPLE 874, Part B except using 6-chloro- benzo [b] thiophene-2-sulfonyl chloride, EXAMPLE 1, is obtained the title compound. MS (ion spray): m/z 461,463 (M+H) +, Cl pattern.

B. 1- (3-Amino-1 H-indazol-6-vlmethvl)-4- (6-chloro-benzofblthiophene-2-sulfonyl)-piDerazin-2-one.

Using essentially the same procedure as in EXAMPLE 874, Part C there is obtained the title compound.'HNMR (DMSO, 300MHz) 8 11.29 (s, IH), 8. 35 (s, 1H), 8.18 (s, 1H), 8.08 (d, 1H), 7.58

(m, 2H), 7.05 (s, IH), 6.70 (d, 1H), 5.30 (bs, 2H), 4.56 (s, 2H), 3.84 (s, 2H), 3.40 (m, 2H), 3. 30 (m, 2H).

MS (ion spray): m/z 476,478 (M+H) +, Cl pattern. Anal. cald. for C20H, 8CIN503S2 : C, 50.5; H, 3.8; N, 14.7. Found C, 50.3; H, 3.6; N, 14.5. M. P. =274-276°C.

The following compounds are prepared using the procedures described above. Example # Name m/z 877 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2- (S)-methyl-3, 6- 441,443 dioxo-piperazin-I-ylmethyl]-benzamidine Cl pattern 878 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2- (R)-methyl-3, 6- 441,443 dioxo-piperazin-l-ylmethyl]-benzamidine Cl pattern 879 3- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2, 5-dioxo-piperazin- 427,429 I-ylmethyl]-benzamidine Cl pattern 880 4- [4- (6-Chloro-benzo [b] thiophen-2-ylmethyl)-2, 5-dioxo-piperazin-427,429 1-ylmethyl]-benzamidine Cl pattern Inhibition of Factor Xa The compounds described herein inhibit blood coagulation by virtue of their ability to inhibit the penultimate enzyme in the coagulation cascade, controlling the activity of Factor Xa. Both the activity of free Factor Xa and Factor Xa assembled in the prothrombinase complex (Factor Xa, Factor Va, calcium and phospholipid) are inhibited by compounds of formula 1. The inhibition of the Factor Xa activity is obtained by direct complex formation between the inhibitor and the enzyme and is therefore independent of the plasma co-factor antithrombin III. Effective inhibition of the Factor Xa activity is achieved by administering the compounds either by oral administration, continuous intravenous infusion, bolus intravenous administration or any other parenteral route such that it achieves the desired effect of preventing the activity of Factor Xa induced formation of thrombin from prothrombin.

Anticoagulant therapy is indicated for the treatment and prophylaxis of a variety of thrombotic conditions of both the venous and arterial vasculature. In the arterial system, abnormal thrombus formation is primarily associated with arteries of the coronary, cerebral and peripheral vasculature. The diseases associated with thrombotic occlusion of these vessels principally include acute myocardial infarction (AMI), unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy and percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication and bypass grafting of the coronary (CABG) or peripheral arteries. Chronic anticoagulant therapy may also be beneficial in preventing the vessel luminal narrowing (restenosis) that

often occurs following PTCA and CABG, and in the maintenance of vascular access patency in long- term hemodialysis patients. With respect to the venous vasculature, pathologic thrombus formation frequently occurs in the veins of the lower extremities following abdominal, knee and hip surgery (deep vein thrombosis, DVT). DVT further predisposes the patient to a higher risk of pulmonary thromboembolism. A systemic, disseminated intravascular coagulopathy (DIC) commonly occurs in both vascular systems during septic shock, certain viral infections and cancer. This condition is characterized by a rapid consumption of coagulation factors and their plasma inhibitors resulting in the formation of life-threatening thrombin throughout the microvasculature of several organ systems. The indications discussed above include some, but not all, of the possible clinical situations where anticoagulant therapy is warranted. Those experienced in this field are well aware of the circumstances requiring either acute or chronic prophylactic anticoagulant therapy.

Accumulated experimental evidence has also reflected that prothrombin activation is only one of the biological activities of Factor Xa. EPR-1 (effector cell protease receptor-1, recognizing Factor Xa), is believed to mediate several of the vascular wall interactions by Factor Xa. It has been shown to be expressed on human umbilical vein endothelial cells, rat smooth muscle cells and platelets (CR McKenzie, et al., Arterioscler Thromb Vasc Biol 16 1285-91 (1996); also F Bono, et al., J Cell Physiol 172 36-43 (1997), AC Nicholson, et al., J Biol Chem 271 28407-13 (1996), J. M. Herbert, et al., J Clin Invest 101 993-1000 (1998)). This protease-receptor interaction could mediate not only prothrombinase- catalyzed thrombin generation, but also diverse cellular functions such as cell proliferation, release of PDGF and DNA syntheses. The mitogenic effect of Factor Xa has been reported to be dependent on Factor Xa enzymatic activity (F Bono, et al., J Cell Physiol 172 36-43 (1997), J. M. Herbert, et al., J Clin Invest 101 993-1000 (1998)). TAP for example inhibited the mitogenesis of human and rat cultured vascular smooth muscle cells (F Bono, et al., J Cell Physiol 172 36-43 (1997)). In a study of the rabbit carotid artery air-drying injury model, increased EPR-1 expression is detected after vascular injury.

Animals treated with the specific Factor Xa inhibitor, DX-9065a, exhibited less neointimal proliferation.

The important regulatory role of Factor Xa in the coagulation process coupled with its mitogenic effects points to Factor Xa's involvement in the formation of thrombin at the luminal surface of the vessel wall and contribution to the atherothrombotic process and abnormal proliferation of vascular cells resulting in restenosis or angiogenesis.

These compounds may be used alone or in combination with other diagnostic, anticoagulant, antiplatelet or fibrinolytic agents. For example adjunctive administration of inhibitors of the activity of Factor Xa with standard heparin, low molecular weight heparin, direct thrombin inhibitors (i. e. hirudin), aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and/or tissue plasminogen activator may result in greater antithrombotic or thrombolytic efficacy or efficiency. The compounds described herein may be administered to treat thrombotic complications in a variety of animals such as primates

including humans. Inhibition of factor Xa is useful not only in the anticoagulant therapy of individuals having thrombotic conditions but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, any inhibitor of Factor Xa activity can be added to or contacted with any medium containing or suspected of containing Factor Xa and in which it is desired that blood coagulation be inhibited.

In addition to their use in anticoagulant therapy, Factor Xa inhibitors may find utility in the treatment or prevention of other diseases in which the generation of thrombin has been implicated as playing a physiologic role. For example, thrombin has been proposed to contribute to the morbidity and mortality of such chronic and degenerative diseases as arthritis, cancer, atherosclerosis and Alzheimer's disease by virtue of its ability to regulate many different cell types through specific cleavage and activation of a cell surface thrombin receptor, mitogenic effects, diverse cellular functions such as cell proliferation, for example, abnormal proliferation of vascular cells resulting in restenosis or angiogenesis, release of PDGF and DNA syntheses. Inhibition of Factor Xa will effectively block thrombin generation and therefore neutralize any physiologic effects of thrombin on various cell types.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the Factor Xa activity, for example conditions as hereinbefore described, which comprises the administration to the patient of a therapeutically effective amount of compound of formula I or a composition containing a compound of formula I."Effective amount"is meant to describe an amount of compound of the present invention effective in inhibiting the activity of Factor Xa and thus producing the desired therapeutic effect.

The present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of formula I in association with a pharmaceutically acceptable carrier or coating.

In practice compounds of the present invention may generally be administered parenterally, intravenously, subcutaneously intramuscularly, colonically, nasally, intraperitoneally, rectally or orally.

The products according to the invention may be presented in forms permitting administration by the most suitable route and the invention also relates to pharmaceutical compositions containing at least one product according to the invention which are suitable for use in human or veterinary medicine. These compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can

contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, or stabilizers in order to obtain pharmaceutically acceptable preparations.

The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the product, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation or microfiltration.

Suitable compositions containing the compounds of the invention may be prepared by conventional means. For example, compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formula I.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound (s) that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. In the adult, the doses are generally from about 0.01 to about 100, preferably about 0.01 to about 10, mg/kg body weight per day by inhalation, from about 0.01 to about 100,

preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.01 to about 50, preferably 0.01 to 10, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The products according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally I to 4 times per day. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds within the scope of the present invention exhibit marked pharmacological activities according to tests described in the literature which tests results are believed to correlate to pharmacological activity in humans and other mammals. The following pharmacological test results are typical characteristics of compounds of the present invention.

Enzyme Assays: The ability of the compounds in the present invention to act as inhibitors of factor Xa, thrombin, trypsin, tissue-plasminogen activator (t-PA), urokinase-plasminogen activator (u-PA), plasmin and activated protein C is evaluated by determining the concentration of inhibitor which resulted in a 50% loss in enzyme activity (IC50) using purified enzymes.

All enzyme assays are carried out at room temperature in 96-well microtiter plates using a final enzyme concentration of I nM. The concentrations of factor Xa and thrombin are determined by active site titration and the concentrations of all other enzymes are based on the protein concentration supplied by the manufacturer. Compounds according to the invention are dissolved in DMSO, diluted with their respective buffers and assayed at a maximal final DMSO concentration of 1.25%. Compound dilutions are added to wells containing buffer and enzyme and pre-equilibrated for between 5 and 30 minutes. The enzyme reactions are initiated by the addition of substrate and the color developed from the hydrolysis of the peptide-p-nitroanilide substrates is monitored continuously for 5 minutes at 405 nm on a Vmax microplate reader (Molecular Devices). Under these conditions, less than 10% of the substrate is utilized in all assays. The initial velocities measured are used to calculate the amount of inhibitor which resulted in a 50% reduction of the control velocity (IC50). The apparent Ki values are then determined according to the Cheng-Prusoff equation (IC50 = Ki [1+ [S]/Km]) assuming competitive inhibition kinetics.

An additional in vitro assay may be used to evaluate the potency of compounds according to the invention in normal human plasma. The activated partial thromboplastin time is a plasma-based clotting assay that relies on the in situ generation of factor Xa, its assembly into the prothrombinase complex and the subsequent generation of thrombin and fibrin which ultimately yields the formation of a clot as the assay endpoint. This assay is currently used clinically to monitor the ex vivo effects of the commonly used anticoagulant drug heparin as well as direct acting antithrombin agents undergoing clinical evaluation. Therefore, activity in this in vitro assay is considered as a surrogate marker for in vivo anticoagulant activity.

Human Plasma Based Clotting Assav: Activated partial thromboplastin clotting times are determined in duplicate on a MLA Electra 800 instrument. A volume of 100 mi of citrated normal human pooled plasma (George King Biomedical) is added to a cuvette containing 100 in of a compound according to the invention in Tris/NaCI buffer (pH 7.5) and placed in the instrument. Following a 3 minute warming period the instrument automatically adds 100 ml of activated cephaloplastin reagent (Actin, Dade) followed by 100 ml of 0.035 M CaC12 to initiate the clotting reaction. Clot formation is determined spectrophotometrically and measured in seconds. Compound potency is quantitated as the concentration required to double a control clotting time measured with human plasma in the absence of the compound according to the invention.

A compound according to the invention may also be evaluated for their in vivo antithrombotic efficacy in two well established animal experimental models of acute vascular thrombosis. A rabbit model of jugular vein thrombosis and a rat model of carotid artery thrombosis are used to demonstrate the antithrombotic activity of these compounds in distinct animal model paradigms of human venous thrombosis and arterial thrombosis, respectively.

Experimental Plazma Protein Binding Assav Compounds are dissolved into DMSO to prepare a 10 mM stock. Serial dilutions of compounds are made in a buffer containing 0.05M Tris, 0.15M NaCI, 0.1% PEG-8000, PH 7.5.

Human FXa and the substrate, Spectrozyme FXa, are prepared in the aforementioned buffer containing human Albumin and fibrinogen at 3.45 mg/ml and 2.3 mg/ml, respectively. The FXa assay is carried out at room temperature in the 96-well microtiter plates with a final enzyme concentration and substrate concentration of 1nM and 200 u. M, respectively. Compound dilutions are added to the wells containing buffer and FXa and preincubated for 30 minutes. The enzyme reactions are initiated by the addition of substrate, Spectrozyme FXa, and the color

developed from the release of p-nitroanilide from each chromogenic substrate is monitored continuously for 5 minutes at 405 nm on a Thermomax microtiter plate reader (Molecular Devices, Sunnyvale, CA.). In the final reaction mixture, the concentration of albumin and fibeinogen is 3mg/ml and 2 mg/ml, respectively. Under the experimental conditions, less than 10% of the substrate is consumed in all assays. The initial velocities measured are used to determine the amount of inhibitor required to diminish 50% of the control velocity and defined as IC50 of the inhibitor. Assuming the kinetic mechanisms are competitive inhibition, the apparent Ki values are then calculated according to the Cheng-Prusoff equation, Ki = IC50/(1 + Experimental In Vivo Rabbit Venous Thrombosis Model: This is a well characterized model of fibrin rich venous thrombosis that is validated in the literature and shown to be sensitive to several anticoagulant drugs including heparin (Antithrombotic Effect of Recombinant Truncated Tissue Factor Pathway Inhibitor (TFPI 1-161) in Experimental Venous Thrombosis-a Comparison with Low Molecular Weight Heparin, J. Holst, B. Lindblad, D. Bergqvist, O.

Nordfang, P. B. Ostergaard, J. G. L. Petersen, G. Nielsen and U. Hedner. Thrombosis and Haemostasis, 71 214-219 (1994). The purpose of utilizing this model is to evaluate the ability of compounds to prevent the formation of venous thrombi (clots) in vivo generated at a site of injury and partial stasis in the juguiar vein.

Male and female New Zealand white rabbits weighing 1.5-2 kg are anesthetized with 35 mg/kg of ketamine and 5 mg/kg xylazine in a volume of 1 ml/kg (i. m.). The right jugular vein is cannulated for infusion of anesthetic (ketamine/xylazine 17/2.5 mg/kg/hr at a rate of approximately 0.5 ml/hr) and administration of test substances. The right carotid artery is cannulated for recording arterial blood pressure and collecting blood samples. Body temperature is maintained at 39°C with a GAYMAR T- PUMP. The left external jugular vein is isolated and all side branches along an exposed 2-3 cm of vessel are tied off. The internal jugular vein is cannulated, just above the bifurcation of the common jugular, and the tip of the cannula is advanced just proximal to the common jugular vein. A 1 cm segment of the vein is isolated with non-traumatic vascular clamps and a relative stenosis is formed by tying a ligature around the vein with an 18G needle just below the distal most clamp. This creates a region of reduced flow and partial stasis at the injury site. The isolated segment is gently rinsed with saline 2-3 times via the cannula in the internal jugular. Thereafter the isolated segment is filled with 0.5 ml of 0.5% polyoxyethylene ether (W-1) for 5 minutes. W-l is a detergent which disrupts the endothelial cell lining of the segment, thus providing a thrombogenic surface for initiating clot formation. After 5 minutes the W-l is withdrawn from the segment, and the segment is again gently rinsed with saline 2-3 times. The

vascular clamps are then removed, restoring blood flow through this portion of the vessel. Clot formation is allowed to form and grow for 30 minutes after which the vein is cut just below the stenotic ligature and inspected for blood flow (the absence of blood flow is recorded as complete occlusion). The entire isolated segment of vein is then ligated and the formed clot is removed and weighed (wet weight).

The effect of test agents on final clot weights is used as the primary end point. Animals are maintained for an additional thirty minutes to obtain a final pharmacodynamic measure of anticoagulation. Drug administration is initiated 15 minutes prior to vascular injury with W-I and continued through the period of clot formation and maturation. Three blood samples (3 ml ea.) are obtained for evaluation of hemostatic parameters: one just prior to administration of W-1; a second 30 minutes after removal of the vascular clamps and a third at the termination of the experiment. Antithrombotic efficacy is expressed as a reduction in the final clot weight in preparations treated with a compound according to the invention relative to vehicle treated control animals.

Experimental In Vivo Rat Arterial Thrombosis Model: The antithrombotic efficacy of factor Xa inhibitors against platelet-rich arterial thrombosis may be evaluated using a well characterized rat carotid artery FeC12-induced thrombosis model (Superior Activity of a Thromboxane Receptor Antagonist as Compared with Aspirin in Rat Models of Arterial and Venous Thrombosis, W. A. Schumacher, C. L. Heran, T. E. Steinbacher, S. Youssef and M. L. Ogletree.

Journal of Cardiovascular Pharmacologv, 22,526-533 (1993); Rat Model of Arterial Thrombosis Induced by Ferric Chloride, K. D. Kurtz, B. W. Main, and G. E. Sandusky. Thrombosis Research 60, 269-280 (1990); The Effect of Thrombin Inhibition in a Rat Arterial Thrombosis Model, R. J. Broersma, L. W. Kutcher and E. F. Heminger. Thrombosis Research 64,405-412 (1991). This model is widely used to evaluate the antithrombotic potential of a variety of agents including heparin and the direct acting thrombin inhibitors.

Sprague Dawley rats weighing 375-450 g are anesthetized with sodium pentobarbital (50 mg/kg i. p.). Upon reaching an acceptable level of anesthesia, the ventral surface of the neck is shaved and prepared for aseptic surgery. Electrocardiogram electrodes are connected and lead 11 is monitored throughout the experiment. The right femoral vein and artery are cannulated with PE-50 tubing for administration of a compound according to the invention and for obtaining blood samples and monitoring blood pressure, respectively. A midline incision is made in the ventral surface of the neck.

The trachea is exposed and intubated with PE-240 tubing to ensure airway patency. The right carotid artery is isolated and two 4-0 silk sutures are placed around the vessel to facilitate instrumentation. An electromagnetic flow probe mm lumen) is placed around the vessel to measure blood flow.

Distal to the probe a 4x4 mm strip of parafilm is placed under the vessel to isolate it from the surrounding muscle bed. After baseline flow measurements are made, a 2x5 mm strip of filter paper

previously saturated in 35% FeC12 is placed on top of the vessel downstream from the probe for ten minutes and then removed. The FeC12 is thought to diffuse into the underlying segment of artery and cause deendothelialization resulting in acute thrombus formation. Following application of the FeC12- soaked filter paper, blood pressure, carotid artery blood flow and heart rate are monitored for an observation period of 60 minutes. Following occlusion of the vessel (defined as the attainment of zero blood flow), or 60 minutes after filter paper application if patency is maintained, the artery is ligated proximal and distal to the area of injury and the vessel is excised. The thrombus is removed and weighed immediately and recorded as the primary end point of the study.

Following surgical instrumentation a control blood sample (BI) is drawn. All blood samples are collected from the arterial catheter and mixed with sodium citrate to prevent clotting. After each blood sample, the catheter is flushed with 0.5 ml of 0.9% saline. A compound according to the invention is administered intravenously (i. v.) starting 5 minutes prior to FeC12 application. The time between FeC12 application and the time at which carotid blood flow reached zero is recorded as time to occlusion (TTO). For vessels that did not occlude within 60 minutes, TTO is assigned a value of 60 minutes. Five minutes after application of FeC12, a second blood sample is drawn (B2). After 10 minutes of FeC12 exposure, the filter paper is removed from the vessel and the animal is monitored for the remainder of the experiment. Upon reaching zero blood flow blood a third blood sample is drawn (B3) and the clot is removed and weighed. Template bleeding time measurements are performed on the forelimb toe pads at the same time that blood samples are obtained. Coagulation profiles consisting of activated partial thromboplastin time (APTT) and prothrombin time (PT) are performed on all blood samples. In some instances a compound according to the invention may be administered orally. Rats are restrained manually using standard techniques and compounds are administered by intragastric gavage using a 18 gauge curved dosing needle (volume of 5 ml/kg). Fifteen minutes after intragastric dosing, the animal is anesthetized and instrumented as described previously. Experiments are then performed according to the protocol described above.

Experimental Canine intravenous and intragastric dosing experiments.

Beagle dogs (9-13 kg) of either sex are used to evaluate the pharmacodynamic effect of compounds of this invention after intravenous and intragastric dosing. Blood samples for these experiments are obtained via venipuncture of the cephalic vein. After discarding the first 0.5 ml of blood drawn, the control sample of 4.5 ml of blood is drawn into chilled plastic syringes containing 0.5 ml of trisodium citrate. After drug administration, 0.9 ml of blood is obtained at each time point (after discarding the first 0.5 mi of blood) by drawing the sample directly into chilled plastic syringes containing 0.1 mi trisodium citrate.

For the intravenous experiments, compounds are administered in the cephalic vein in the forelimb contralateral to that used for blood sampling. Compounds are dissolved in saline (0.5 ml/kg body weight) and administered as an i. v. bolus. Post-dosing blood samples are obtained at specific time points after dosing.

For the intragastric experiments, Compounds (in 0.5% methyl cellulose and 1 % polysorbate-80, 1 ml/kg dosing volume) are administered via an intragastric feeding tube. A pre-dosing control blood sample is obtained as above and post-dosing samples are obtained at specific time points after dosing.

Coagulation times. Platelet-poor plasma is used for determination of activated partial thromboplastin time (APTT) and prothrombin time (PT), which are measured using a Microsample Coagulation Analyzer (MCA210, Bio Data Corp, Horsham, PA) and Dade reagents (Thromboplastin-C Plus and Actin FS Activated PTT reagent, Baxter Diagnostics, Inc., Deerfield, IL).

Ex vivo inhibition of Factor Xa. Factor-Xa inhibitory activity is analyzed by chromogenic methods using reagents (bovine factor Xa and spectrozyme Xa) supplied by American Diagnostica (Greenwich, CT). The rate of change of optical density (Vmax, 405 nm) is measured using a SPECTRAmax microtiter plate spectrophotometer and Softmax Pro software (Molecular Devices Corp., Sunnyvale, CA). Inhibition of Xa activity is determined as follows: percent inhibition of Xa activity = 1- (Vmax of sample with inhibitor/Vmax of the pre-drug control sample) X 100.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects of the invention and obtain the ends and advantages mentioned, as well as those inherent therein. The compounds, compositions and methods described herein are presented as representative of the preferred embodiments, or intended to be exemplary and not intended as limitations on the scope of the present invention.